

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/00		A2	(11) International Publication Number: WO 99/61471 (43) International Publication Date: 2 December 1999 (02.12.99)
(21) International Application Number: PCT/US99/11904 (22) International Filing Date: 28 May 1999 (28.05.99) (30) Priority Data: 60/087,260 29 May 1998 (29.05.98) US 60/091,674 2 July 1998 (02.07.98) US 60/102,954 2 October 1998 (02.10.98) US 60/109,869 24 November 1998 (24.11.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 60/087,260 (CIP) Filed on 29 May 1998 (29.05.98) US 60/091,674 (CIP) Filed on 2 July 1998 (02.07.98) US 60/102,954 (CIP) Filed on 2 October 1998 (02.10.98) US 60/109,869 (CIP) Filed on 24 November 1998 (24.11.98) (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).		(72) Inventors; and (75) Inventors/Applicants (for US only): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). GORGONE, Gina, A. [US/US]; 1253 Pinecrest Drive, Boulder Creek, CA 95006 (US). KASER, Matthew, R. [GB/US]; 4793 Ewing Road, Castro Valley, CA 94546-1017 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). AU-YOUNG, Janice [US/US]; 1419 Kains Avenue, Berkeley, CA 94702 (US). (74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: HUMAN TRANSMEMBRANE PROTEINS			
(57) Abstract The invention provides human transmembrane proteins (HTMPN) and polynucleotides which identify and encode HTMPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HTMPN.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HUMAN TRANSMEMBRANE PROTEINS

TECHNICAL FIELD

5 This invention relates to nucleic acid and amino acid sequences of human transmembrane proteins and to the use of these sequences in the diagnosis, treatment, and prevention of immune, reproductive, smooth muscle, neurological, gastrointestinal, developmental, and cell proliferative disorders.

10 BACKGROUND OF THE INVENTION

Eukaryotic organisms are distinct from prokaryotes in possessing many intracellular organelle and vesicle structures. Many of the metabolic reactions which distinguish eukaryotic biochemistry from prokaryotic biochemistry take place within these structures. In particular, many cellular functions require very stringent reaction
15 conditions, and the organelles and vesicles enable compartmentalization and isolation of reactions which might otherwise disrupt cytosolic metabolic processes. The organelles include mitochondria, smooth and rough endoplasmic reticula, sarcoplasmic reticulum, and the Golgi body. The vesicles include phagosomes, lysosomes, endosomes, peroxisomes, and secretory vesicles. Organelles and vesicles are bounded by single or
20 double membranes.

Biological membranes are highly selective permeable barriers made up of lipid bilayer sheets composed of phosphoglycerides, fatty acids, cholesterol, phospholipids, glycolipids, proteoglycans, and proteins. Membranes contain ion pumps, ion channels, and specific receptors for external stimuli which transmit biochemical signals across the
25 membranes. These membranes also contain second messenger proteins which interact with these pumps, channels, and receptors to amplify and regulate transmission of these signals.

Plasma Membrane Proteins

Plasma membrane proteins (MPs) are divided into two groups based upon methods
30 of protein extraction from the membrane. Extrinsic or peripheral membrane proteins can be released using extremes of ionic strength or pH, urea, or other disruptors of protein interactions. Intrinsic or integral membrane proteins are released only when the lipid

bilayer of the membrane is dissolved by detergent.

Transmembrane proteins (TM) are characterized by an extracellular, a transmembrane, and an intracellular domain. TM domains are typically comprised of 15 to 25 hydrophobic amino acids which are predicted to adopt an α -helical conformation.

5 TM proteins are classified as bitopic (Types I and II) proteins, which span the membrane once, and polytopic (Types III and IV) (Singer, S.J. (1990) *Annu. Rev. Cell Biol.* 6:247-96) proteins which contain multiple membrane-spanning segments. TM proteins that act as cell-surface receptor proteins involved in signal transduction include growth and differentiation factor receptors, and receptor-interacting proteins such as *Drosophila*

10 pecanex and frizzled proteins, LIV-1 protein, NF2 protein, and GNS1/SUR4 eukaryotic integral membrane proteins. TM proteins also act as transporters of ions or metabolites, such as gap junction channels (connexins), and ion channels, and as cell anchoring proteins, such as lectins, integrins, and fibronectins. TM proteins are found in vesicle organelle-forming molecules, such as calveolins; or cell recognition molecules, such as

15 cluster of differentiation (CD) antigens, glycoproteins, and mucins.

Many membrane proteins (MPs) contain amino acid sequence motifs that serve to localize proteins to specific subcellular sites. Examples of these motifs include PDZ domains, KDEL, RGD, NGR, and GSL sequence motifs, von Willebrand factor A (vWFA) domains, and EGF-like domains. RGD, NGR, and GSL motif-containing

20 peptides have been used as drug delivery agents in targeted cancer treatment of tumor vasculature (Arap, W. et al. (1998) *Science*, 279:377-380). Membrane proteins may also contain amino acid sequence motifs that serve to interact with extracellular or intracellular molecules, such as carbohydrate recognition domains.

Chemical modification of amino acid residue side chains alters the manner in

25 which MPs interact with other molecules, for example, phospholipid membranes. Examples of such chemical modifications to amino acid residue side chains are covalent bond formation with glycosaminoglycans, oligosaccharides, phospholipids, acetyl and palmitoyl moieties, ADP-ribose, phosphate, and sulphate groups.

RNA-encoding membrane proteins may have alternative splice sites which give

30 rise to proteins encoded by the same gene but with different messenger RNA and amino acid sequences. Splice variant membrane proteins may interact with other ligand and protein isoforms.

G-Protein Coupled Receptors

G-protein coupled receptors (GPCR) are a superfamily of integral membrane proteins which transduce extracellular signals. GPCRs include receptors for biogenic amines, lipid mediators of inflammation, peptide hormones, and sensory signal mediators.

5 The structure of these highly-conserved receptors consists of seven hydrophobic transmembrane (serpentine) regions, cysteine disulfide bridges between the second and third extracellular loops, an extracellular N-terminus, and a cytoplasmic C-terminus. Three extracellular loops alternate with three intracellular loops to link the seven transmembrane regions. The most conserved parts of these proteins are the
10 transmembrane regions and the first two cytoplasmic loops. A conserved, acidic-Arg-aromatic residue triplet present in the second cytoplasmic loop may interact with G proteins. A GPCR consensus pattern is characteristic of most proteins belonging to this superfamily (ExPASy PROSITE document PS00237; and Watson, S. and S. Arkininstall (1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego,
15 CA, pp 2-6). Mutations and changes in transcriptional activation of GPCR-encoding genes have been associated with neurological disorders such as schizophrenia, Parkinson's disease, Alzheimer's disease, drug addiction, and feeding disorders.

Scavenger Receptors

Macrophage scavenger receptors with broad ligand specificity may participate in
20 the binding of low density lipoproteins (LDL) and foreign antigens. Scavenger receptors types I and II are trimeric membrane proteins with each subunit containing a small N-terminal intracellular domain, a transmembrane domain, a large extracellular domain, and a C-terminal cysteine-rich domain. The extracellular domain contains a short spacer domain, an α -helical coiled-coil domain, and a triple helical collagenous domain. These
25 receptors have been shown to bind a spectrum of ligands, including chemically modified lipoproteins and albumin, polyribonucleotides, polysaccharides, phospholipids, and asbestos (Matsumoto, A. et al. (1990) Proc. Natl. Acad. Sci. 87:9133-9137; and Elomaa, O. et al. (1995) Cell 80:603-609). The scavenger receptors are thought to play a key role in atherogenesis by mediating uptake of modified LDL in arterial walls, and in host
30 defense by binding bacterial endotoxins, bacteria, and protozoa.

Tetraspan family proteins

The transmembrane 4 superfamily (TM4SF) or tetraspan family is a multigene

family encoding type III integral membrane proteins (Wright, M.D. and Tomlinson, M.G. (1994) Immunol. Today 15:588). TM4SF is comprised of membrane proteins which traverse the cell membrane four times. Members of the TM4SF include platelet and endothelial cell membrane proteins, melanoma-associated antigens, leukocyte surface glycoproteins, colonal carcinoma antigens, tumor-associated antigens, and surface proteins of the schistosome parasites (Jankowski, S.A. (1994) Oncogene 9:1205-1211). Members of the TM4SF share about 25-30% amino acid sequence identity with one another.

A number of TM4SF members have been implicated in signal transduction, control of cell adhesion, regulation of cell growth and proliferation, including development and oncogenesis, and cell motility, including tumor cell metastasis. Expression of TM4SF proteins is associated with a variety of tumors and the level of expression may be altered when cells are growing or activated.

Tumor Antigens

Tumor antigens are surface molecules that are differentially expressed in tumor cells relative to normal cells. Tumor antigens distinguish tumor cells immunologically from normal cells and provide diagnostic and therapeutic targets for human cancers (Takagi, S. et al. (1995) Int. J. Cancer 61: 706-715; Liu, E. et al. (1992) Oncogene 7: 1027-1032).

Ion channels

Ion channels are found in the plasma membranes of virtually every cell in the body. For example, chloride channels mediate a variety of cellular functions including regulation of membrane potentials and absorption and secretion of ions across epithelial membranes. When present in intracellular membranes of the Golgi apparatus and endocytic vesicles, chloride channels also regulate organelle pH (see, e.g., Greger, R. (1988) Annu. Rev. Physiol. 50:111-122). Electrophysiological and pharmacological properties of chloride channels, including ion conductance, current-voltage relationships, and sensitivity to modulators, suggest that different chloride channels exist in muscles, neurons, fibroblasts, epithelial cells, and lymphocytes.

Many channels have sites for phosphorylation by one or more protein kinases including protein kinase A, protein kinase C, tyrosine kinase, and casein kinase II, all of which regulate ion channel activity in cells. Inappropriate phosphorylation of proteins in cells has been linked to changes in cell cycle progression and cell differentiation. Changes

in the cell cycle have been linked to induction of apoptosis or cancer. Changes in cell differentiation have been linked to diseases and disorders of the reproductive system, immune system, and skeletal muscle.

Proton pumps

- 5 Proton ATPases are a large class of membrane proteins that use the energy of ATP hydrolysis to generate an electrochemical proton gradient across a membrane. The resultant gradient may be used to transport other ions across the membrane (Na^+ , K^+ , or Cl^-) or to maintain organelle pH. Proton ATPases are further subdivided into the mitochondrial F-ATPases, the plasma membrane ATPases, and the vacuolar ATPases.
- 10 The vacuolar ATPases establish and maintain an acidic pH within various vesicles involved in the processes of endocytosis and exocytosis (Mellman, I. et al. (1986) *Ann. Rev. Biochem.* 55:663-700).

- Proton-coupled, 12 membrane-spanning domain transporters such as PEPT 1 and PEPT 2 are responsible for gastrointestinal absorption and for renal reabsorption of
- 15 peptides using an electrochemical H^+ gradient as the driving force. Another type of peptide transporter, the TAP transporter, is a heterodimer consisting of TAP 1 and TAP 2 and is associated with antigen processing. Peptide antigens are transported across the membrane of the endoplasmic reticulum by TAP so they can be expressed on the cell surface in association with MHC molecules. Each TAP protein consists of multiple
- 20 hydrophobic membrane spanning segments and a highly conserved ATP-binding cassette (Boll, M. et al. (1996) *Proc. Natl. Acad. Sci.* 93:284-289). Pathogenic microorganisms, such as herpes simplex virus, may encode inhibitors of TAP-mediated peptide transport in order to evade immune surveillance (Marusina, K. and Manaco, J.J. (1996) *Curr. Opin. Hematol.* 3:19-26).

25 ABC Transporters

- The ATP-binding cassette (ABC) transporters, also called the "traffic ATPases", comprise a superfamily of membrane proteins that mediate transport and channel functions in prokaryotes and eukaryotes (Higgins, C.F. (1992) *Annu. Rev. Cell Biol.* 8:67-113). ABC proteins share a similar overall structure and significant sequence homology. All
- 30 ABC proteins contain a conserved domain of approximately two hundred amino acid residues which includes one or more nucleotide binding domains. Mutations in ABC transporter genes are associated with various disorders, such as hyperbilirubinemia

II/Dubin-Johnson syndrome, recessive Stargardt's disease, X-linked adrenoleukodystrophy, multidrug resistance, celiac disease, and cystic fibrosis.

Membrane Proteins Associated with Intercellular Communication

Intercellular communication is essential for the development and survival of
5 multicellular organisms. Cells communicate with one another through the secretion and uptake of protein signaling molecules. The uptake of proteins into the cell is achieved by endocytosis, in which the interaction of signaling molecules with the plasma membrane surface, often via binding to specific receptors, results in the formation of plasma
10 membrane-derived vesicles that enclose and transport the molecules into the cytosol. The secretion of proteins from the cell is achieved by exocytosis, in which molecules inside of the cell are packaged into membrane-bound transport vesicles derived from the *trans*-Golgi network. These vesicles fuse with the plasma membrane and release their contents into the surrounding extracellular space. Endocytosis and exocytosis result in the removal and addition of plasma membrane components and the recycling of these components is
15 essential to maintain the integrity, identity, and functionality of both the plasma membrane and internal membrane-bound compartments.

Lysosomes are the site of degradation of intracellular material during autophagy and of extracellular molecules following endocytosis. Lysosomal enzymes are packaged into vesicles which bud from the *trans*-Golgi network. These vesicles fuse with
20 endosomes to form the mature lysosome in which hydrolytic digestion of endocytosed material occurs. Lysosomes can fuse with autophagosomes to form a unique compartment in which the degradation of organelles and other intracellular components occurs.

Protein sorting by transport vesicles, such as the endosome, has important consequences for a variety of physiological processes including cell surface growth, the biogenesis of
25 distinct intracellular organelles, endocytosis, and the controlled secretion of hormones and neurotransmitters (Rothman, J.E. and Wieland, F.T. (1996) *Science* 272:227-234). In particular, neurodegenerative disorders and other neuronal pathologies are associated with biochemical flaws during endosomal protein sorting or endosomal biogenesis (Mayer R.J. et al. (1996) *Adv. Exp. Med. Biol.* 389:261-269).

30 Peroxisomes are organelles independent from the secretory pathway. They are the site of many peroxide-generating oxidative reactions in the cell. Peroxisomes are unique among eukaryotic organelles in that their size, number, and enzyme content vary

depending upon organism, cell type, and metabolic needs. The majority of peroxisome-associated proteins are membrane-bound or are found proximal to the cytosolic or the luminal side of the peroxisome membrane (Waterham, H.R. and Cregg, J.M. (1997) *BioEssays* 19:57-66).

- 5 Genetic defects in peroxisome proteins which result in peroxisomal deficiencies have been linked to a number of human pathologies, including Zellweger syndrome, rhizomelic chondrodysplasia punctata, X-linked adrenoleukodystrophy, acyl-CoA oxidase deficiency, bifunctional enzyme deficiency, classical Refsum's disease, DHAP alkyl transferase deficiency, and acatalasemia (Moser, H.W. and Moser, A.B. (1996) *Ann. NY*
10 *Acad. Sci.* 804:427-441). In addition, Gartner, J. et al. (1991; *Pediatr. Res.* 29:141-146) found a 22 kDa integral membrane protein associated with lower density peroxisome-like subcellular fractions in patients with Zellweger syndrome.

- Normal embryonic development and control of germ cell maturation is modulated by a number of secretory proteins which interact with their respective membrane-bound
15 receptors. Cell fate during embryonic development is determined by members of the activin/TGF- β superfamily, cadherins, IGF-2, and other morphogens. In addition, proliferation, maturation, and redifferentiation of germ cell and reproductive tissues are regulated, for example, by IGF-2, inhibins, activins, and follistatins (Petraglia, F. (1997) *Placenta* 18:3-8; Mather, J.P. et al. (1997) *Proc. Soc. Exp. Biol. Med.* 215:209-222).

20 Endoplasmic Reticulum Membrane Proteins

- The normal functioning of the eukaryotic cell requires that all newly synthesized proteins be correctly folded, modified, and delivered to specific intra- and extracellular sites. Newly synthesized membrane and secretory proteins enter a cellular sorting and distribution network during or immediately after synthesis and are routed to specific
25 locations inside and outside of the cell. The initial compartment in this process is the endoplasmic reticulum (ER) where proteins undergo modifications such as glycosylation, disulfide bond formation, and assembly into oligomers. The modified proteins are then transported through a series of membrane-bound compartments which include the various cisternae of the Golgi complex, where further carbohydrate modifications occur.
- 30 Transport between compartments occurs by means of vesicles that bud and fuse in a manner specific to the type of protein being transported. Once within the secretory pathway, proteins do not have to cross a membrane to reach the cell surface.

Although the majority of proteins processed through the ER are transported out of the organelle, some are retained. The signal for retention in the ER in mammalian cells consists of the tetrapeptide sequence, KDEL, located at the carboxyl terminus of proteins (Munro, S. (1986) Cell 46:291-300). Proteins containing this sequence leave the ER but
5 are quickly retrieved from the early Golgi cisternae and returned to the ER, while proteins lacking this signal continue through the secretory pathway.

Disruptions in the cellular secretory pathway have been implicated in several human diseases. In familial hypercholesterolemia the low density lipoprotein receptors remain in the ER, rather than moving to the cell surface (Pathak, R.K. (1988) J. Cell Biol.
10 106:1831-1841). Altered transport and processing of the β -amyloid precursor protein (β APP) involves the putative vesicle transport protein presenilin, and may play a role in early-onset Alzheimer's disease (Levy-Lahad, E. et al. (1995) Science 269:973-977). Changes in ER-derived calcium homeostasis have been associated with diseases such as cardiomyopathy, cardiac hypertrophy, myotonic dystrophy, Brody disease, Smith-McCort
15 dysplasia, and diabetes mellitus.

Mitochondrial Membrane Proteins

The mitochondrial electron transport (or respiratory) chain is a series of three enzyme complexes in the mitochondrial membrane that is responsible for the transport of electrons from NADH to oxygen and the coupling of this oxidation to the synthesis of
20 ATP (oxidative phosphorylation). ATP then provides the primary source of energy for driving the many energy-requiring reactions of a cell.

Most of the protein components of the mitochondrial respiratory chain are the products of nuclear encoded genes that are imported into the mitochondria and the remainder are products of mitochondrial genes. Defects and altered expression of
25 enzymes in the respiratory chain are associated with a variety of disease conditions in man, including, for example, neurodegenerative diseases, myopathies, and cancer.

Lymphocyte and Leukocyte Membrane Proteins

The B-cell response to antigens, which is modulated through receptors, is an essential component of the normal immune system. Mature B cells recognize foreign
30 antigens through B cell receptors (BCR) which are membrane-bound, specific antibodies that bind foreign antigens. The antigen/receptor complex is internalized and the antigen is proteolytically processed. To generate an efficient response to complex antigens, the

BCR, BCR-associated proteins, and T cell response are all required. Proteolytic fragments of the antigen are complexed with major histocompatibility complex-II (MHCII) molecules on the surface of the B cells where the complex can be recognized by T cells. In contrast, macrophages and other lymphoid cells present antigens in association with MHCI molecules to T cells. T cells recognize and are activated by the MHCI-antigen complex through interactions with the T cell receptor/CD3 complex, a T cell-surface multimeric protein located in the plasma membrane. T cells activated by antigen presentation secrete a variety of lymphokines that induce B cell maturation and T cell proliferation and activate macrophages, which kill target cells.

10 Leukocytes have a fundamental role in the inflammatory and immune response and include monocytes/macrophages, mast cells, polymorphonucleoleukocytes, natural killer cells, neutrophils, eosinophils, basophils, and myeloid precursors. Leukocyte membrane proteins include members of the CD antigens, N-CAM, I-CAM, human leukocyte antigen (HLA) class I and HLA class II gene products, immunoglobulins, immunoglobulin
15 receptors, complement, complement receptors, interferons, interferon receptors, interleukin receptors, and chemokine receptors.

Abnormal lymphocyte and leukocyte activity has been associated with acute disorders, such as AIDS, immune hypersensitivity, leukemias, leukopenia, systemic lupus, granulomatous disease, and eosinophilia.

20 **Apoptosis-Associated Membrane Proteins**

A variety of ligands, receptors, enzymes, tumor suppressors, viral gene products, pharmacological agents, and inorganic ions have important positive or negative roles in regulating and implementing the apoptotic destruction of a cell. Although some specific components of the apoptotic pathway have been identified and characterized, many
25 interactions between the proteins involved are undefined, leaving major aspects of the pathway unknown.

A requirement for calcium in apoptosis was previously suggested by studies showing the involvement of calcium levels in DNA cleavage and Fas-mediated cell death (Hewish, D.R. and L.A. Burgoyne (1973) *Biochem. Biophys. Res. Comm.* 52:504-510; Vignaux, F. et al. (1995) *J. Exp. Med.* 181:781-786; Oshimi, Y. and S. Miyazaki (1995) *J.*
30 *Immunol.* 154:599-609). Other studies show that intracellular calcium concentrations increase when apoptosis is triggered in thymocytes by either T cell receptor cross-linking

or by glucocorticoids and cell death can be prevented by blocking this increase (McConkey, D.J. et al. (1989) J. Immunol. 143:1801-1806; McConkey, D.J. et al. (1989) Arch. Biochem. Biophys. 269:365-370). Therefore, membrane proteins such as calcium channels are important for the apoptotic response.

5 Tumorigenesis

Tumorigenesis is associated with the activation of oncogenes which are derived from normal cellular genes. These oncogenes encode oncoproteins which are capable of converting normal cells into malignant cells. Some oncoproteins are mutant isoforms of the normal protein and other oncoproteins are abnormally expressed with respect to
10 location or level of expression. The latter category of oncoprotein causes cancer by altering transcriptional control of cell proliferation. Five classes of oncoproteins are known to affect the cell cycle controls. These classes include growth factors, growth factor receptors, intracellular signal transducers, nuclear transcription factors, and cell-cycle control proteins. These proteins include those which are modified by glycosylation,
15 phosphorylation, glycosaminoglycan attachment, sulphation, and lipidation.

Modulation of factors which act in the coordination of the human cell division cycle may provide an important means to reduce tumorigenesis. An example of the metastasis-associated proteins is the lysosomal membrane glycoprotein P2B/LAMP-1 which is also expressed in normal tissues. (Heffernan, M. et al. (1989) Cancer Res.
20 49:6077-6084.) In addition, mammalian proteins homologous to the plant pathogenesis-related proteins have been identified in hyperplastic glioma. (Murphy, E.V. et al. (1995) Gene 159:131-135.)

The discovery of new human transmembrane proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful
25 in the diagnosis, prevention, and treatment of immune, reproductive, smooth muscle, neurological, gastrointestinal, developmental, and cell proliferative disorders.

SUMMARY OF THE INVENTION

30 The invention features substantially purified polypeptides, human transmembrane proteins, referred to collectively as "HTMPN" and individually as "HTMPN-1", "HTMPN-2", "HTMPN-3", "HTMPN-4", "HTMPN-5", "HTMPN-6", "HTMPN-7", "HTMPN-8", "HTMPN-9", "HTMPN-10", "HTMPN-11", "HTMPN-12", "HTMPN-13",

"HTMPN-14", "HTMPN-15", "HTMPN-16", "HTMPN-17", "HTMPN-18", "HTMPN-19", "HTMPN-20", "HTMPN-21", "HTMPN-22", "HTMPN-23", "HTMPN-24", "HTMPN-25", "HTMPN-26", "HTMPN-27", "HTMPN-28", "HTMPN-29", "HTMPN-30", "HTMPN-31", "HTMPN-32", "HTMPN-33", "HTMPN-34", "HTMPN-35",
5 "HTMPN-36", "HTMPN-37", "HTMPN-38", "HTMPN-39", "HTMPN-40", "HTMPN-41", "HTMPN-42", "HTMPN-43", "HTMPN-44", "HTMPN-45", "HTMPN-46", "HTMPN-47", "HTMPN-48", "HTMPN-49", "HTMPN-50", "HTMPN-51", "HTMPN-52", "HTMPN-53", "HTMPN-54", "HTMPN-55", "HTMPN-56", "HTMPN-57", "HTMPN-58", "HTMPN-59", "HTMPN-60", "HTMPN-61", "HTMPN-62", "HTMPN-63", "HTMPN-64", "HTMPN-65", "HTMPN-66", "HTMPN-67", "HTMPN-68",
10 "HTMPN-69", "HTMPN-70", "HTMPN-71", "HTMPN-72", "HTMPN-73", "HTMPN-74", "HTMPN-75", "HTMPN-76", "HTMPN-77", "HTMPN-78", and "HTMPN-79". In one aspect, the invention provides a substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2,
15 SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29,
20 SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID
25 NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, and SEQ ID NO:79 (SEQ ID NO:1-79), and fragments thereof.
30 The invention further provides a substantially purified variant having at least 90% amino acid identity to at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:1-79, and fragments thereof. The invention also provides an

isolated and purified polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-79, and fragments thereof. The invention also includes an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-79, and fragments thereof.

Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-79, and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1-79, and fragments thereof.

The invention also provides an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, and SEQ ID NO:158 (SEQ ID NO:80-158), and fragments thereof. The invention further provides an isolated and purified polynucleotide variant having at least

90% polynucleotide sequence identity to the polynucleotide sequence selected from the group consisting of SEQ ID NO:80-158, and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:80-158, and fragments thereof.

The invention also provides a method for detecting a polynucleotide in a sample containing nucleic acids, the method comprising the steps of (a) hybridizing the complement of the polynucleotide sequence to at least one of the polynucleotides of the sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide in the sample. In one aspect, the method further comprises amplifying the polynucleotide prior to hybridization.

The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-79, and fragments thereof. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide under conditions suitable for the expression of the polypeptide; and (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-79, and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide selected from the group consisting of SEQ ID NO:1-79, and fragments thereof. The invention also provides a purified agonist and a purified antagonist to the polypeptide.

The invention also provides a method for treating or preventing a disorder associated with decreased expression or activity of HTMPN, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a substantially purified polypeptide having the

amino acid sequence selected from the group consisting of SEQ ID NO:1-79, and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing a disorder associated with increased expression or activity of HTMPN, the method comprising
5 administering to a subject in need of such treatment an effective amount of an antagonist of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-79, and fragments thereof.

BRIEF DESCRIPTION OF THE TABLES

10 Table 1 shows nucleotide and polypeptide sequence identification numbers (SEQ ID NOs), clone identification numbers (clone ID), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding HTMPN.

Table 2 shows features of each polypeptide sequence including predicted transmembrane sequences, potential motifs, homologous sequences, and methods and
15 algorithms used for identification of HTMPN.

Table 3 shows the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis, diseases, disorders, or conditions associated with these tissues, and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which
20 Incyte cDNA clones encoding HTMPN were isolated.

Table 5 shows the programs, their descriptions, references, and threshold parameters used to analyze HTMPN.

DESCRIPTION OF THE INVENTION

25 Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the
30 appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise.

Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"HTMPN" refers to the amino acid sequences of substantially purified HTMPN obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and preferably the human species, from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which, when bound to HTMPN, increases or prolongs the duration of the effect of HTMPN. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of HTMPN.

An "allelic variant" is an alternative form of the gene encoding HTMPN. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding HTMPN include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polynucleotide the same as HTMPN or a polypeptide with at least one functional characteristic of

HTMPN. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding HTMPN, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding HTMPN.

- 5 The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent HTMPN. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of
- 10 HTMPN is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, positively charged amino acids may include lysine and arginine, and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine; glycine and alanine; asparagine and glutamine; serine and threonine; and phenylalanine and tyrosine.

- 15 The terms "amino acid" or "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. In this context, "fragments," "immunogenic fragments," or "antigenic fragments" refer to fragments of HTMPN which are preferably at least 5 to about 15 amino acids in length, most preferably at least 14 amino acids, and which retain
- 20 some biological activity or immunological activity of HTMPN. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

- 25 "Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

- The term "antagonist" refers to a molecule which, when bound to HTMPN, decreases the amount or the duration of the effect of the biological or immunological
- 30 activity of HTMPN. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of HTMPN.

The term "antibody" refers to intact molecules as well as to fragments thereof, such

as Fab, F(ab')₂, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind HTMPN polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit)
5 can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a
10 protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (given regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for
15 binding to an antibody.

The term "antisense" refers to any composition containing a nucleic acid sequence which is complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural
20 sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" can refer to the antisense strand, and the designation "positive" can refer to the sense strand.

The term "biologically active," refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically
25 active" refers to the capability of the natural, recombinant, or synthetic HTMPN, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" or "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the
30 complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules.

The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands, and in the design and use of peptide nucleic acid (PNA) molecules.

- 5 A "composition comprising a given polynucleotide sequence" or a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding HTMPN or fragments of HTMPN may be employed as hybridization probes.
- 10 The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

- "Consensus sequence" refers to a nucleic acid sequence which has been
- 15 resequenced to resolve uncalled bases, extended using XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly, such as the GELVIEW Fragment Assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to
- 20 produce the consensus sequence.

- The term "correlates with expression of a polynucleotide" indicates that the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding HTMPN, by northern analysis is indicative of the presence of nucleic acids encoding HTMPN in a sample, and thereby correlates with expression of the transcript
- 25 from the polynucleotide encoding HTMPN.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

- The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide
- 30 sequence can include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is

one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or probe will not hybridize to the second non-complementary target sequence.

The phrases "percent identity" or "% identity" refer to the percentage of sequence similarity found in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, e.g., by using the MEGALIGN program (DNASTAR, Madison WI) which creates alignments between two or more sequences according to methods selected by the user, e.g., the clustal method. (See, e.g., Higgins, D.G. and P.M. Sharp (1988) Gene 73:237-244.) The clustal algorithm groups sequences into clusters by examining the distances between all pairs. The clusters are aligned pairwise and then in groups. The percentage similarity between two amino acid sequences, e.g., sequence A and sequence B, is calculated by dividing the length of sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A and sequence B, times one hundred. Gaps of low or of no similarity between the two amino acid sequences are not included in determining percentage similarity. Percent identity between nucleic acid sequences can also be counted or calculated by other methods known

in the art, e.g., the Jotun Hein method. (See, e.g., Hein, J. (1990) *Methods Enzymol.* 183:626-645.) Identity between sequences can also be determined by other methods known in the art, e.g., by varying hybridization conditions.

“Human artificial chromosomes” (HACs) are linear microchromosomes which
5 may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

The term “humanized antibody” refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

10 “Hybridization” refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

The term “hybridization complex” refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or
15 formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words “insertion” or “addition” refer to changes in an amino acid or nucleotide
20 sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, to the sequence found in the naturally occurring molecule.

“Immune response” can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other
25 signaling molecules, which may affect cellular and systemic defense systems.

The term “microarray” refers to an arrangement of distinct polynucleotides on a substrate.

The terms “element” or “array element” in a microarray context, refer to hybridizable polynucleotides arranged on the surface of a substrate.

30 The term “modulate” refers to a change in the activity of HTMPN. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of HTMPN.

The phrases "nucleic acid" or "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to
5 any DNA-like or RNA-like material. In this context, "fragments" refers to those nucleic acid sequences which, when translated, would produce polypeptides retaining some functional characteristic, e.g., antigenicity, or structural domain characteristic, e.g., ATP-binding site, of the full-length polypeptide.

The terms "operably associated" or "operably linked" refer to functionally related
10 nucleic acid sequences. A promoter is operably associated or operably linked with a coding sequence if the promoter controls the translation of the encoded polypeptide. While operably associated or operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain genetic elements, e.g., repressor genes, are not contiguously linked to the sequence encoding the polypeptide but still bind to operator
15 sequences that control expression of the polypeptide.

The term "oligonucleotide" refers to a nucleic acid sequence of at least about 6 nucleotides to 60 nucleotides, preferably about 15 to 30 nucleotides, and most preferably about 20 to 25 nucleotides, which can be used in PCR amplification or in a hybridization assay or microarray. "Oligonucleotide" is substantially equivalent to the terms
20 "amplimer," "primer," "oligomer," and "probe," as these terms are commonly defined in the art.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers
25 solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding HTMPN, or fragments thereof, or HTMPN itself, may comprise a
30 bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" or "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody
5 is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "stringent conditions" refers to conditions which permit hybridization between polynucleotides and the claimed polynucleotides. Stringent conditions can be
10 defined by salt concentration, the concentration of organic solvent, e.g., formamide, temperature, and other conditions well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.

The term "substantially purified" refers to nucleic acid or amino acid sequences
15 that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

20 "Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

25 "Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being
30 transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an

autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of HTMPN polypeptides refers to an amino acid sequence that is altered by one or more amino acid residues. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). More rarely, a variant may have "nonconservative" changes (e.g., replacement of glycine with tryptophan). Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, LASERGENE software (DNASTAR).

The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to HTMPN. This definition may also include, for example, "allelic" (as defined above), "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

THE INVENTION

The invention is based on the discovery of new human transmembrane proteins (HTMPN), the polynucleotides encoding HTMPN, and the use of these compositions for the diagnosis, treatment, or prevention of immune, reproductive, smooth muscle, neurological, gastrointestinal, developmental, and cell proliferative disorders.

Table 1 lists the Incyte Clones used to derive full length nucleotide sequences encoding HTMPN. Columns 1 and 2 show the sequence identification numbers (SEQ ID

NOs) of the amino acid and nucleic acid sequences, respectively. Column 3 shows the Clone ID of the Incyte Clone in which nucleic acids encoding each HTMPN were identified, and column 4, the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones, their corresponding cDNA libraries, and shotgun sequences. The clones and shotgun sequences are part of the consensus nucleotide sequence of each HTMPN and are useful as fragments in hybridization technologies.

The columns of Table 2 show various properties of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3, potential phosphorylation sites; column 4, potential glycosylation sites; column 5, the amino acid residues comprising signature sequences and motifs; column 6, the identity of each protein; and column 7, analytical methods used to identify each protein through sequence homology and protein motifs. Hidden Markov Model analysis indicates the presence of one or more potential transmembrane motifs in each of SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO: 66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO: 75, SEQ ID NO:76, SEQ ID NO:77, and SEQ ID NO: 79; as well as the presence of one or more potential signal peptide motifs in each of SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:75, SEQ ID NO:77, and SEQ ID NO:79.

Motifs analysis indicates the presence of a potential ATP/GTP binding site in SEQ ID NO:68, a potential calcium-binding site also in SEQ ID NO:68, a potential leucine zipper gene regulatory motif in each of SEQ ID NO:68 and SEQ ID NO:73; and a potential microbody (single-membraned organelle) targeting signal site in SEQ ID NO:78. BLOCKS analysis indicates the presence of two potential PMP-22 integral membrane glycoprotein motifs and a trehalase motif, all in SEQ ID NO:77, as well as a potential protein-splicing motif in SEQ ID NO:66. PRINTS analysis indicates the presence of a potential G-protein coupled receptor motif in SEQ ID NO:79.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding HTMPN. The first column of Table 3 lists the nucleotide sequence identifiers. The second column lists tissue categories which express HTMPN as a fraction of total tissue categories expressing HTMPN. The

third column lists the diseases, disorders, or conditions associated with those tissues expressing HTMPN. The fourth column lists the vectors used to subclone the cDNA library. Of particular note is the expression of HTMPN in tissue involved in inflammation and the immune response and with cell proliferative conditions including cancer, and in
5 reproductive, gastrointestinal, fetal, smooth muscle, cardiovascular, urologic, endocrine, developmental, and nervous tissue.

The following fragments of the nucleotide sequences encoding HTMPN are useful in hybridization or amplification technologies to identify SEQ ID NO:121-158 and to distinguish between SEQ ID NO:121-158 and related polynucleotide sequences. The
10 useful fragments are the fragment of SEQ ID NO:121 from about nucleotide 151 to about nucleotide 189; the fragment of SEQ ID NO:122 from about nucleotide 280 to about nucleotide 318; the fragment of SEQ ID NO:123 from about nucleotide 505 to about nucleotide 558; the fragments of SEQ ID NO:124 from about nucleotide 1 to about nucleotide 21 and from about nucleotide 694 to about nucleotide 720; the fragment of SEQ
15 ID NO:125 from about nucleotide 331 to about nucleotide 378; the fragment of SEQ ID NO:126 from about nucleotide 1012 to about nucleotide 1047; the fragment of SEQ ID NO:127 from about nucleotide 1070 to about nucleotide 1106; the fragment of SEQ ID NO:128 from about nucleotide 133 to about nucleotide 186; the fragment of SEQ ID NO:129 from about nucleotide 432 to about nucleotide 482; the fragments of SEQ ID
20 NO:130 from about nucleotide 1745 to about nucleotide 1795 and from about nucleotide 1910 to about nucleotide 1979; the fragment of SEQ ID NO:131 from about nucleotide 322 to about nucleotide 375; the fragment of SEQ ID NO:132 from about nucleotide 147 to about nucleotide 203; the fragment of SEQ ID NO:133 from about nucleotide 557 to about nucleotide 613; the fragment of SEQ ID NO:134 from about nucleotide 509 to about
25 nucleotide 595; the fragment of SEQ ID NO:135 from about nucleotide 808 to about nucleotide 848; the fragment of SEQ ID NO:136 from about nucleotide 216 to about nucleotide 260; the fragment of SEQ ID NO:137 from about nucleotide 132 to about nucleotide 188; the fragment of SEQ ID NO:138 from about nucleotide 231 to about nucleotide 278; the fragment of SEQ ID NO:139 from about nucleotide 303 to about
30 nucleotide 350; the fragment of SEQ ID NO:140 from about nucleotide 507 to about nucleotide 550; the fragment of SEQ ID NO:141 from about nucleotide 433 to about nucleotide 477; the fragment of SEQ ID NO:142 from about nucleotide 266 to about

nucleotide 314; the fragment of SEQ ID:143 from about nucleotide 3 to about nucleotide 48; the fragment of SEQ ID NO:144 from about nucleotide 76 to about nucleotide 122; the fragment of SEQ ID NO:145 from about nucleotide 93 to about nucleotide 139; the fragment of SEQ ID NO:146 from about nucleotide 241 to about nucleotide 286; the
5 fragment of SEQ ID NO:147 from about nucleotide 43 to about nucleotide 89; the fragment of SEQ ID NO:148 from about nucleotide 219 to about nucleotide 265; the fragment of SEQ ID NO:149 from about nucleotide 619 to about nucleotide 663; the fragment of SEQ ID NO:150 from about nucleotide 25 to about nucleotide 69; the fragment of SEQ ID NO:151 from about nucleotide 175 to about nucleotide 221; the
10 fragment of SEQ ID NO:152 from about nucleotide 94 to about nucleotide 138; the fragment of SEQ ID NO:153 from about nucleotide 46 to about nucleotide 90; the fragment of SEQ ID NO:154 from about nucleotide 1081 to about nucleotide 1127; the fragment of SEQ ID NO:155 from about nucleotide 31 to about nucleotide 77; the fragment of SEQ ID NO:156 from about nucleotide 157 to about nucleotide 201; the
15 fragment of SEQ ID NO:157 from about nucleotide 216 to about nucleotide 259; and the fragment of SEQ ID NO:158 from about nucleotide 517 to about nucleotide 561. The polypeptides encoded by these fragments may be useful, for example, as antigenic polypeptides.

The invention also encompasses HTMPN variants. A preferred HTMPN variant is
20 one which has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% amino acid sequence identity to the HTMPN amino acid sequence, and which contains at least one functional or structural characteristic of HTMPN.

The invention also encompasses polynucleotides which encode HTMPN. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising
25 a sequence selected from the group consisting of SEQ ID NO:80-158, which encodes HTMPN.

The invention also encompasses a variant of a polynucleotide sequence encoding HTMPN. In particular, such a variant polynucleotide sequence will have at least about 80%, more preferably at least about 90%, and most preferably at least about 95%
30 polynucleotide sequence identity to the polynucleotide sequence encoding HTMPN. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:80-158 which

has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:80-158. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or
5 structural characteristic of HTMPN.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding HTMPN, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every
10 possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring HTMPN, and all such variations are to be considered as being specifically disclosed.

15 Although nucleotide sequences which encode HTMPN and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring HTMPN under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding HTMPN or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons.
20 Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding HTMPN and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable
25 properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode HTMPN and HTMPN derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available
30 expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding HTMPN or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:80-158 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and most preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and most preferably at least about 50% formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30°C, more preferably of at least about 37°C, and most preferably of at least about 42°C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 µg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42°C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50 % formamide, and 200 µg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

The washing steps which follow hybridization can also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include temperature of at least about 25°C, more preferably of at least about 42°C, and most preferably of at least about 68°C. In a preferred embodiment, wash steps will occur at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In

a more preferred embodiment, wash steps will occur at 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a most preferred embodiment, wash steps will occur at 68°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art.

5 Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading
10 exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the Hamilton MICROLAB 2200 (Hamilton, Reno NV), Peltier Thermal Cycler 200 (PTC200; MJ Research, Watertown MA) and the ABI CATALYST 800 (Perkin-Elmer). Sequencing is then carried out using either ABI 373 or 377 DNA
15 sequencing systems (Perkin-Elmer) or the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA). The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY,
20 pp. 856-853.)

The nucleic acid sequences encoding HTMPN may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to
25 amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988)
30 Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this

method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) *Nucleic Acids Res.* 19:3055-306).

5 Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth MN) or another appropriate

10 program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in

15 which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic

20 separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer

25 controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode HTMPN may be cloned in recombinant DNA molecules that direct expression of HTMPN, or fragments or functional equivalents thereof, in appropriate host

30 cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express HTMPN.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter HTMPN-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR
5 reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

In another embodiment, sequences encoding HTMPN may be synthesized, in
10 whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, and Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232.) Alternatively, HTMPN itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science
15 269:202-204.) Automated synthesis may be achieved using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of HTMPN, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid
20 chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY.)

In order to express a biologically active HTMPN, the nucleotide sequences
25 encoding HTMPN or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding
30 HTMPN. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding HTMPN. Such signals include the ATG initiation codon and adjacent sequences, e.g. the

Kozak sequence. In cases where sequences encoding HTMPN and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous
5 translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

10 Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding HTMPN and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding HTMPN. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA
20 expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

25 In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding HTMPN. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding HTMPN can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or pSPORT1 plasmid (Life Technologies).
30 Ligation of sequences encoding HTMPN into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be

useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of HTMPN are needed, e.g. for the production of antibodies, vectors which direct high level expression of HTMPN may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of HTMPN. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Grant et al. (1987) Methods Enzymol. 153:516-54; and Scorer, C. A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of HTMPN. Transcription of sequences encoding HTMPN may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding HTMPN may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses HTMPN in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g.,
5 Harrington, J.J. et al. (1997) Nat Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of HTMPN in cell lines is preferred. For example, sequences encoding HTMPN can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker
10 gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated
15 using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* or *apr*⁻ cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.)
20 Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides, neomycin and G-418; and *als* or *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol.
25 Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These
30 markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding HTMPN is inserted within a marker gene sequence, transformed cells containing sequences encoding HTMPN can be identified by the absence
5 of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding HTMPN under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding HTMPN and
10 that express HTMPN may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

15 Immunological methods for detecting and measuring the expression of HTMPN using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two
20 non-interfering epitopes on HTMPN is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul MN, Sect. IV; Coligan, J. E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols,
25 Humana Press, Totowa NJ).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding HTMPN include oligolabeling, nick translation, end-labeling, or
30 PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding HTMPN, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be

used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or
5 labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding HTMPN may be cultured under conditions suitable for the expression and recovery of the protein from cell
10 culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode HTMPN may be designed to contain signal sequences which direct secretion of HTMPN through a prokaryotic or eukaryotic cell membrane.

15 In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to specify protein targeting,
20 folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC, Bethesda MD) and may be chosen to ensure the correct modification and processing of the foreign protein.

25 In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding HTMPN may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric HTMPN protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for
30 inhibitors of HTMPN activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose

binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the HTMPN encoding sequence and the heterologous protein sequence, so that HTMPN may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled HTMPN may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract systems (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, preferably ³⁵S-methionine.

Fragments of HTMPN may be produced not only by recombinant production, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, supra, pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Various fragments of HTMPN may be synthesized separately and then combined to produce the full length molecule.

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of HTMPN and human transmembrane proteins. In addition, the expression of HTMPN is closely associated with tissue involved in inflammation and the immune response and with cell proliferative conditions including cancer, and in reproductive, gastrointestinal, fetal, smooth muscle, cardiovascular, developmental, and nervous tissue. Therefore, HTMPN appears to play a role in immune, reproductive, smooth muscle, neurological, gastrointestinal, developmental, and cell proliferative disorders. In the treatment of immune, reproductive, smooth muscle, neurological,

gastrointestinal, developmental, and cell proliferative disorders associated with increased HTMPN expression or activity, it is desirable to decrease the expression or activity of HTMPN. In the treatment of the above conditions associated with decreased HTMPN expression or activity, it is desirable to increase the expression or activity of HTMPN.

5 Therefore, in one embodiment, HTMPN or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of HTMPN. Examples of such disorders include, but are not limited to, an immune disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis,
10 anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis,
15 glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis,
20 thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a reproductive disorder such as a disorder of prolactin production; infertility, including tubal disease, ovulatory defects, and endometriosis; a disruption of the estrous cycle, a disruption of the menstrual cycle,
25 polycystic ovary syndrome, ovarian hyperstimulation syndrome, endometrial and ovarian tumors, uterine fibroids, autoimmune disorders, ectopic pregnancies, and teratogenesis; cancer of the breast, fibrocystic breast disease, and galactorrhea; disruptions of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the
30 male breast, and gynecomastia; a smooth muscle disorder such as angina, anaphylactic shock, arrhythmias, asthma, cardiovascular shock, Cushing's syndrome, hypertension, hypoglycemia, myocardial infarction, migraine, and pheochromocytoma, and myopathies

including cardiomyopathy, encephalopathy, epilepsy, Kearns-Sayre syndrome, lactic acidosis, myoclonic disorder, and ophthalmoplegia; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other

5 extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease; prion diseases including kuru,

10 Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome; fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders,

15 cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis; inherited, metabolic, endocrine, and toxic myopathies; myasthenia gravis, periodic paralysis; mental disorders including mood, anxiety, and schizophrenic disorders; akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid

20 psychoses, postherpetic neuralgia, and Tourette's disorder; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis,

25 cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, and acquired immunodeficiency syndrome (AIDS) enteropathy, cirrhosis, jaundice, cholestasis,

30 hereditary hyperbilirubinemia, hepatic encephalopathy, hepatorenal syndrome, hepatitis, hepatic steatosis, hemochromatosis, Wilson's disease, α_1 -antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and

thrombosis, passive congestion, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; a cell proliferative disorder such as actinic
5 keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast,
10 cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and a developmental disorder including, but not limited to, those listed above.

In another embodiment, a vector capable of expressing HTMPN or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated
15 with decreased expression or activity of HTMPN including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified HTMPN in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased
20 expression or activity of HTMPN including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of HTMPN may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of HTMPN including, but not limited to, those listed above.

In a further embodiment, an antagonist of HTMPN may be administered to a
25 subject to treat or prevent a disorder associated with increased expression or activity of HTMPN. Examples of such disorders include, but are not limited to, those described above. In one aspect, an antibody which specifically binds HTMPN may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express HTMPN.

30 In an additional embodiment, a vector expressing the complement of the polynucleotide encoding HTMPN may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of HTMPN including, but not

limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of HTMPN may be produced using methods which are generally known in the art. In particular, purified HTMPN may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind HTMPN. Antibodies to HTMPN may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with HTMPN or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to HTMPN have an amino acid sequence consisting of at least about 5 amino acids, and, more preferably, of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of HTMPN amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be

produced.

Monoclonal antibodies to HTMPN may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture.

These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci.* 80:2026-2030; and Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci.* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda, S. et al. (1985) *Nature* 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce HTMPN-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton D.R. (1991) *Proc. Natl. Acad. Sci.* 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci.* 86: 3833-3837; Winter, G. et al. (1991) *Nature* 349:293-299.)

Antibody fragments which contain specific binding sites for HTMPN may also be generated. For example, such fragments include, but are not limited to, F(ab')₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) *Science* 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are

well known in the art. Such immunoassays typically involve the measurement of complex formation between HTMPN and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering HTMPN epitopes is preferred, but a competitive binding assay may also be employed (Pound, 5 supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for HTMPN. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of HTMPN-antibody complex divided by the molar concentrations of free antigen and free 10 antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple HTMPN epitopes, represents the average affinity, or avidity, of the antibodies for HTMPN. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular HTMPN epitope, represents a true measure of affinity. High-affinity antibody 15 preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the HTMPN-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of HTMPN, preferably in active form, from the antibody 20 (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington, DC; Liddell, J. E. and Cryer, A. (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream 25 applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is preferred for use in procedures requiring precipitation of HTMPN-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan 30 et al. supra.)

In another embodiment of the invention, the polynucleotides encoding HTMPN, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect,

the complement of the polynucleotide encoding HTMPN may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding HTMPN. Thus, complementary molecules or fragments may be used to modulate HTMPN activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding HTMPN.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding HTMPN. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

Genes encoding HTMPN can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding HTMPN. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding HTMPN. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block

translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by
5 endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding HTMPN.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the
10 following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides
15 using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by
20 in vitro and in vivo transcription of DNA sequences encoding HTMPN. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

25 RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the
30 inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or
5 by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

10 An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of HTMPN, antibodies to HTMPN, and mimetics, agonists, antagonists, or inhibitors of HTMPN. The compositions may be administered alone or in
15 combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by
20 any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries
25 which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using
30 pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for

ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino

polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier
5 to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or
10 lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred
15 preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For
20 administration of HTMPN, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those
25 skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to
30 determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example HTMPN or fragments thereof, antibodies of HTMPN, and agonists, antagonists

or inhibitors of HTMPN, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the LD_{50}/ED_{50} ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about $0.1 \mu\text{g}$ to $100,000 \mu\text{g}$, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind HTMPN may be used for the diagnosis of disorders characterized by expression of HTMPN, or in assays to monitor patients being treated with HTMPN or agonists, antagonists, or inhibitors of HTMPN. Antibodies useful for diagnostic purposes may be prepared in the same manner

as described above for therapeutics. Diagnostic assays for HTMPN include methods which utilize the antibody and a label to detect HTMPN in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide
5 variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring HTMPN, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of HTMPN expression. Normal or standard values for HTMPN expression are established
10 by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to HTMPN under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, preferably by photometric means. Quantities of HTMPN expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values.
15 Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding HTMPN may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The
20 polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of HTMPN may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of HTMPN, and to monitor regulation of HTMPN levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting
25 polynucleotide sequences, including genomic sequences, encoding HTMPN or closely related molecules may be used to identify nucleic acid sequences which encode HTMPN. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low), will determine
30 whether the probe identifies only naturally occurring sequences encoding HTMPN, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and should

preferably have at least 50% sequence identity to any of the HTMPN encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:80-158 or from genomic sequences including promoters, enhancers, and introns of the HTMPN gene.

- 5 Means for producing specific hybridization probes for DNAs encoding HTMPN include the cloning of polynucleotide sequences encoding HTMPN or HTMPN derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides.
- 10 Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

- Polynucleotide sequences encoding HTMPN may be used for the diagnosis of disorders associated with expression of HTMPN. Examples of such disorders include, but
- 15 are not limited to, an immune disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic
- 20 dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis,
- 25 polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a reproductive disorder such as a
- 30 disorder of prolactin production; infertility, including tubal disease, ovulatory defects, and endometriosis; a disruption of the estrous cycle, a disruption of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, endometrial and ovarian

tumors, uterine fibroids, autoimmune disorders, ectopic pregnancies, and teratogenesis; cancer of the breast, fibrocystic breast disease, and galactorrhea; disruptions of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, and gynecomastia; a smooth muscle disorder such as angina, anaphylactic shock, arrhythmias, asthma, cardiovascular shock, Cushing's syndrome, hypertension, hypoglycemia, myocardial infarction, migraine, and pheochromocytoma, and myopathies including cardiomyopathy, encephalopathy, epilepsy, Kearns-Sayre syndrome, lactic acidosis, myoclonic disorder, and ophthalmoplegia; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease; prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome; fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis; inherited, metabolic, endocrine, and toxic myopathies; myasthenia gravis, periodic paralysis; mental disorders including mood, anxiety, and schizophrenic disorders; akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatoma, infectious

- colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, and acquired immunodeficiency syndrome (AIDS) enteropathy, cirrhosis, jaundice, cholestasis,
- 5 hereditary hyperbilirubinemia, hepatic encephalopathy, hepatorenal syndrome, hepatitis, hepatic steatosis, hemochromatosis, Wilson's disease, α_1 -antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, passive congestion, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of
- 10 pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including
- 15 adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and a developmental disorder including, but not limited to, those listed above.
- 20 The polynucleotide sequences encoding HTMPN may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered HTMPN expression. Such qualitative or quantitative methods are well known in the art.
- 25 In a particular aspect, the nucleotide sequences encoding HTMPN may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding HTMPN may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and
- 30 the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding HTMPN in the sample indicates the

presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of HTMPN, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding HTMPN, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding HTMPN may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding HTMPN, or a fragment of a polynucleotide complementary to the polynucleotide encoding HTMPN, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or

quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of HTMPN include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J.

5 Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.)

The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of
10 the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic
15 agents.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al.
20 (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

In another embodiment of the invention, nucleic acid sequences encoding HTMPN may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a
25 specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.)

30 Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in

various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) site. Correlation between the location of the gene encoding HTMPN on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of
5 the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another
10 mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to
15 a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

20 In another embodiment of the invention, HTMPN, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between HTMPN and the agent being
25 tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted
30 with HTMPN, or fragments thereof, and washed. Bound HTMPN is then detected by methods well known in the art. Purified HTMPN can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing

antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding HTMPN specifically compete with a test compound for binding HTMPN. In this manner, antibodies can be used to detect the
5 presence of any peptide which shares one or more antigenic determinants with HTMPN.

In additional embodiments, the nucleotide sequences which encode HTMPN may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base
10 pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

15 The entire disclosure of all applications, patents, and publications, cited above and below, and of US provisional applications 60/087,260 (filed May 29, 1998), 60/091,674 (filed July 2, 1998), 60/102,954 (filed October 2, 1998), and 60/109,869 (filed November 24, 1998) is hereby incorporated by reference.

EXAMPLES

20 I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine
25 isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega),
30 OLIGOTEX latex particles (QIAGEN, Valencia CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates

using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIP^T plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, *supra*, units 5.1-6.6). Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), pSPORT1 plasmid (Life Technologies), or pINCY (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids were recovered from host cells by *in vivo* excision, using the UNIZAP vector system (Stratagene) or cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the REAL Prep 96 plasmid kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a Fluoroskan II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

The cDNAs were prepared for sequencing using the ABI CATALYST 800 (Perkin-Elmer) or the HYDRA microdispenser (Robbins Scientific) or MICROLAB 2200 (Hamilton) systems in combination with the PTC-200 thermal cyclers (MJ Research). The cDNAs were sequenced using the ABI PRISM 373 or 377 sequencing systems (Perkin-Elmer) and standard ABI protocols, base calling software, and kits. In one alternative, cDNAs were sequenced using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics). In another alternative, the cDNAs were amplified and sequenced using the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer). In yet another alternative, cDNAs were sequenced using solutions and dyes from Amersham Pharmacia Biotech. Reading frames for the ESTs were determined using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA, extension, and shotgun sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the software programs, descriptions, references, and threshold parameters used. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides a brief description thereof, the third column presents the references which are incorporated by reference herein, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the probability the greater the homology). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS to acquire annotation, using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on

GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, Prosite, and

5 Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene families. (See, e.g., Eddy, S.R. (1996) *Cur. Opin. Str. Biol.* 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide

10 sequence fragments from SEQ ID NO:80-158. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a

15 transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, *supra*, ch. 7; Ausubel, 1995, *supra*, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ database

20 (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

25

100

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules are usually identified by selecting those which show product

30 scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding HTMPN occurred. Analysis involved the

categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation/trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

V. Extension of HTMPN Encoding Polynucleotides

Full length nucleic acid sequences of SEQ ID NOs:80-120 were produced by extension of the component fragments described in Table 1, column 5, using oligonucleotide primers based on these fragments. For each nucleic acid sequence, one primer was synthesized to initiate extension of an antisense polynucleotide, and the other was synthesized to initiate extension of a sense polynucleotide. Primers were used to facilitate the extension of the known sequence "outward" generating amplicons containing new unknown nucleotide sequence for the region of interest. The initial primers were designed from the cDNA using OLIGO™ 4.06 (National Biosciences, Plymouth, MN), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries (GIBCO BRL) were used to extend the sequence. If more than one extension is necessary or desired, additional sets of primers are designed to further extend the known region.

High fidelity amplification was obtained by following the instructions for the XL-PCR™ kit (The Perkin-Elmer Corp., Norwalk, CT) and thoroughly mixing the enzyme and reaction mix. PCR was performed using the PTC-200 thermal cycler (MJ Research, Inc., Watertown, MA), beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, with the following parameters:

30	Step 1	94° C for 1 min (initial denaturation)
	Step 2	65° C for 1 min
	Step 3	68° C for 6 min
	Step 4	94° C for 15 sec

	Step 5	65° C for 1 min
	Step 6	68° C for 7 min
	Step 7	Repeat steps 4 through 6 for an additional 15 cycles
	Step 8	94° C for 15 sec
5	Step 9	65° C for 1 min
	Step 10	68° C for 7:15 min
	Step 11	Repeat steps 8 through 10 for an additional 12 cycles
	Step 12	72° C for 8 min
10	Step 13	4° C (and holding)

A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a low concentration (about 0.6% to 0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products were excised from the gel, purified using QIAQUICK™ (QIAGEN Inc.), and trimmed of
15 overhangs using Klenow enzyme to facilitate religation and cloning.

After ethanol precipitation, the products were redissolved in 13 μ l of ligation buffer, 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase were added, and the mixture was incubated at room temperature for 2 to 3 hours, or overnight at 16° C. Competent *E. coli* cells (in 40 μ l of appropriate media) were transformed with 3 μ l of
20 ligation mixture and cultured in 80 μ l of SOC medium. (See, e.g., Sambrook, *supra*, Appendix A, p. 2.) After incubation for one hour at 37° C, the *E. coli* mixture was plated on Luria Bertani (LB) agar (See, e.g., Sambrook, *supra*, Appendix A, p. 1) containing carbenicillin (2x carb). The following day, several colonies were randomly picked from each plate and cultured in 150 μ l of liquid LB/2x carb medium placed in an individual well
25 of an appropriate commercially-available sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture was transferred into a non-sterile 96-well plate and, after dilution 1:10 with water, 5 μ l from each sample was transferred into a PCR array.

For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific
30 primers used for the extension reaction were added to each well. Amplification was performed using the following conditions:

	Step 1	94° C for 60 sec
	Step 2	94° C for 20 sec
	Step 3	55° C for 30 sec
35	Step 4	72° C for 90 sec
	Step 5	Repeat steps 2 through 4 for an additional 29 cycles
	Step 6	72° C for 180 sec

Step 7 4° C (and holding)

Aliquots of the PCR reactions were run on agarose gels together with molecular weight markers. The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid, and sequenced.

The full length nucleic acid sequences of SEQ ID NO:121-158 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and β -mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure

the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulphoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

In like manner, the nucleotide sequences of SEQ ID NO:80-158 are used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

VI. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:80-158 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-

art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ - 32 P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25
5 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to
10 nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT-AR film (Eastman Kodak, Rochester NY) is exposed to the blots to film for several hours, hybridization
15 patterns are compared visually.

VII. Microarrays

A chemical coupling procedure and an ink jet device can be used to synthesize array elements on the surface of a substrate. (See, e.g., Baldeschweiler, supra.) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface
20 of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element
25 on the microarray may be assessed through analysis of the scanned images.

Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the
30 nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal

and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

5 VIII. Complementary Polynucleotides

Sequences complementary to the HTMPN-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring HTMPN. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments.

- 10 Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of HTMPN. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the HTMPN-encoding
- 15 transcript.

IX. Expression of HTMPN

- Expression and purification of HTMPN is achieved using bacterial or virus-based expression systems. For expression of HTMPN in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that
- 20 directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express HTMPN upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG).
- 25 Expression of HTMPN in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding HTMPN by either homologous recombination or bacterial-mediated transposition involving transfer plasmid
- 30 intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection

of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, HTMPN is synthesized as a fusion protein with, e.g.,
5 glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His,
permitting rapid, single-step, affinity-based purification of recombinant fusion protein
from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum,
enables the purification of fusion proteins on immobilized glutathione under conditions
that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following
10 purification, the GST moiety can be proteolytically cleaved from HTMPN at specifically
engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification
using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman
Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on
metal-chelate resins (QIAGEN). Methods for protein expression and purification are
15 discussed in Ausubel (1995, supra, ch 10 and 16). Purified HTMPN obtained by these
methods can be used directly in the following activity assay.

X. Demonstration of HTMPN Activity

Given the chemical and structural similarity between the HTMPN and other
members of the transmembrane protein families, HTMPN is identified as a new member of
20 the membrane spanning proteins and is presumed to be involved in the regulation of cell
growth. To demonstrate that increased levels of HTMPN expression correlates with
decreased cell motility and increased cell proliferation, expression vectors encoding
HTMPN are electroporated into highly motile cell lines, such as U-937 (ATCC CRL
1593), HEL 92.1.7 (ATCC TIB 180) and MAC10, and the motility of the electroporated
25 and control cells are compared. Methods for the design and construction of an expression
vector capable of expressing HTMPN in the desired mammalian cell line(s) chosen are
well known to the art. Assays for examining the motility of cells in culture are known to
the art (cf Miyake, M. et al. (1991) J. Exp. Med. 174:1347-1354 and Ikeyama, S. et al.
(1993) J. Exp. Med. 177:1231-1237). Increasing the level of HTMPN in highly motile cell
30 lines by transfection with an HTMPN expression vector inhibits or reduces the motility of
these cell lines, and the amount of this inhibition is proportional to the activity of HTMPN
in the assay.

Alternatively, the activity of HTMPN may be measured using an assay based upon the property of MPs to support in vitro proliferation of fibroblasts and tumor cells under serum-free conditions. (Chiquet-Ehrismann, R. et al. (1986) Cell 47:131-139.) Wells in 96 well cluster plates (Falcon, Fisher Scientific, Santa Clara, CA) are coated with HTMPN by
5 incubation with solutions at 50-100 µg HTMPN/ml for 15 min at ambient temperature. The coating solution is aspirated, and the wells washed with Dulbecco's medium before cells are plated. Rat fibroblast cultures or rat mammary tumor cells are prepared as described. (Chiquet-Ehrismann, R. et al. supra.) and plated at a density of 10^4 - 10^5 cells/ml in Dulbecco's medium supplemented with 10% fetal calf serum.

10 After three days the medium is removed, and the cells washed three times with phosphate-buffered saline (PBS), pH 7.0, before addition of serum-free Dulbecco's medium containing 0.25 mg/ml bovine serum albumin (BSA, Fraction V, Sigma Chemical Company, St. Louis, MO). After 2 days the medium is aspirated, and 100 µl of [³H]thymidine (NEN) at 2 µCi/ml in fresh Dulbecco's medium containing 0.25 mg/ml
15 BSA is added. Parallel plates are fixed and stained to determine cell numbers. After 16 hr, the medium is aspirated, the cell layer washed with PBS, and the 10% trichloroacetic acid-precipitable radioactivity in the cell layer determined by liquid scintillation counting (normalized to relative cell numbers; Chiquet-Ehrismann, R. et al. supra). The amount of radioisotope-labeled DNA incorporated into chromatin under serum-free conditions is
20 proportional to the activity of HTMPN.

Alternatively, HTMPN, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent (See, e.g., Bolton et al. (1973) Biochem. J. 133:529). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled HTMPN, washed, and any wells with labeled HTMPN complex are assayed. Data
25 obtained using different concentrations of HTMPN are used to calculate values for the number, affinity, and association of HTMPN with the candidate molecules.

XI. Functional Assays

HTMPN function is assessed by expressing the sequences encoding HTMPN at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned
30 into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter.

5-10 μ g of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP, and to evaluate properties, for example, their apoptotic state. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of HTMPN on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding HTMPN and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding HTMPN and other genes of interest can be analyzed by northern analysis or microarray techniques.

XII. Production of HTMPN Specific Antibodies

HTMPN substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard

protocols.

Alternatively, the HTMPN amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill
5 in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides 15 residues in length are synthesized using an ABI 431A Peptide Synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-
10 Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for anti-peptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-
15 iodinated goat anti-rabbit IgG.

XIII. Purification of Naturally Occurring HTMPN Using Specific Antibodies

Naturally occurring or recombinant HTMPN is substantially purified by immunoaffinity chromatography using antibodies specific for HTMPN. An immunoaffinity column is constructed by covalently coupling anti-HTMPN antibody to an
20 activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing HTMPN are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of HTMPN (e.g.,
25 high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/HTMPN binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and HTMPN is collected.

XIV. Identification of Molecules Which Interact with HTMPN

HTMPN, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent (See, e.g., Bolton et al. (1973) Biochem. J. 133:529). Candidate
30 molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled HTMPN, washed, and any wells with labeled HTMPN complex are assayed. Data

obtained using different concentrations of HTMPN are used to calculate values for the number, affinity, and association of HTMPN with the candidate molecules.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and
5 spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following
10 claims.

Table 1

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
1	80	153831	THIP1P1.B02	153831 (THIP1P1.B02), 2700741111 (OVAR1UT10), 881348R1 (THYRN0202), 1856588F6 (PROSNOT18)
2	81	350629	LVENNOT01	350629 and 350629T6 (LVENNOT01), 3499109H1 (PROSTUT13)
3	82	729171	LUNGNOT03	729171 and 729171R6 (LUNGNOT03), 1645343111 (HEARFET01), 680519X2 and 680519X1 (UTRSNOT02), 625051R6 (PGANNOT01), 1459466F1 (COLNFET02), 1225759T1 (COLNNOT01), 2590526H1 (LUNGNOT22), 2807811H1 (BLADTUT08)
4	83	1273641	TESTTUT02	1273641 and 1273641F6 (TESTTUT02), 1308181F6 and 1308181F1 (COLNFET02), 1427606F1 (SINTBST01), 756171H1 (BRAITUT02), 2416518F6 (HINT3AZT01), 4242346H1 (SYNWDIT01)
5	84	1427389	SINTBST01	1427389 (SINTBST01), 3097151H1 (CERVNOT03), 723779R1 (SYNOOAT01)
6	85	1458357	COLNFET02	1458357 (COLNFET02), SAOA01955F1, SAOA03146F1, SAOA03356F1, SAOA00213F1
7	86	1482837	CORPNOT02	1482837 and 1482837T6 (CORPNOT02), 869453H1 (LUNGAST01), 3564972F6 (SKINNOT05), 663983H1 (SCORNOT01), 1315073F6 (BLADTUT02), 3809242H1 (CONTTUT01), 311459T6 (LUNGNOT02), 1798893F6 (COLNNOT27)
8	87	1517434	PANCTUT01	1517434 (PANCTUT01), 2848842H1 (BRSTTUT13), 586843X1 (UTRSNOT01), 1261245R1 (SYNORAT05), 1554505F1 (BLADTUT04)
9	88	1536052	SPLNNOT04	1536052 and 1531447T6 (SPLNNOT04), 1729124T6 (BRSTTUT08)
10	89	1666118	BRSTNOT09	1666118 (BRSTNOT09), 907075R2 (COLNNOT08), 1524914T1 (UCMCI.5T01), 1283459F6 (COLNNOT16)
11	90	1675560	BLADNOT05	1675560 and 1675560T6 (BLADNOT05)
12	91	1687323	PROSTUT10	1687323 and 1687323F6 (PROSTUT10), 2292356R3 (BRAINON01)
13	92	1692236	PROSTUT10	1692236 (PROSTUT10), 2786557F6 (BRSTNOT13), 602869R6 and 602869T6 (BRSTTUT01), 2258230H1 (OVAR1UT01), 780083T1 (MYOMNOT01), 2057230T6 (BEPINOT01), 288105R1 (EOSIIHET02)
14	93	1720847	BLADNOT06	1720847, 1722250F6, and 1722250T6 (BLADNOT06)

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
15	94	1752821	LIVRUT01	1752821 (LIVRUT01), 3180328H1 (TLYNOT01), 1969457T6 (BRSTNOT04), 2608504H1 (BONTNOT01), 2455688T6 and 2455688F6 (ENDANOT01), 1816354F6 (PROSNOT20)
16	95	1810923	PROSTUT12	1810923 and 1810923T6 (PROSTUT12), 3221260H1 (COLNNON03)
17	96	1822315	GBLATUT01	1822315 (GBLATUT01), 1841726H1 (COLNNOT07), 1598582T6 (BLADNOT03), 1264125R1 (SYNORAT05), 645048H1 (BRSTTUT02), 1474782H1 (LUNGNOT03), 352739F1 (LVENNOT01), 876001R1 (LUNGAST01)
18	97	1877777	LEUKNOT03	1877777 (LEUKNOT03), 1219656H1 (NEUTGMT01), 1471553T1 (LUNGNOT03)
19	98	1879819	LEUKNOT03	1879819 (LEUKNOT03), 1734538H1 (COLNNOT22), 1428615F6 (SINTBST01), 3558710H1 (LUNGNOT31), 1996096R6 (BRSTTUT03)
20	99	1932945	COLNNOT16	1932945 (COLNNOT16), 2383333H1 (ISL'TNOT01), 2706050F6 (PONSAT01),
21	100	2061026	OVARNOT03	2061026 (OVARNOT03)
22	101	2096687	BRAITUT02	2096687 (BRAITUT02), 2204640H1 (SPLNFET02)
23	102	2100530	BRAITUT02	2100530 (BRAITUT02), 2740969F6 (BRSTTUT14)
24	103	2357636	LUNGNOT20	2357636 (LUNGNOT20), 2693537H1 (LUNGNOT23), 1794235T6 (PROSTUT05), 235425R6 (SINTNOT02), 760091R1 (BRAITUT02), 887877R1 (PANCNOT05)
25	104	2365230	ADRENOT07	2365230 (ADRENOT07), 2921195H1 (SININOT04)
26	105	2455121	ENDANOT01	2455121 and 2455121F6 (ENDANOT01)
27	106	2472514	THPINOT03	2472514 (THPINOT03), 3212904H1 (BLADNOT08)
28	107	2543486	UTRSNOT11	2543486 (UTRSNOT11), 2374764H1 (ISL'TNOT01), 1359576F1 (LUNGNOT12), 1357170H1 (LUNGNOT09)
29	108	2778171	OVARUT03	2778171 (OVARUT03), 1822045H1 (GBLATUT01), 1692535F6 (COLNNOT23), 1905275F6 (OVARNOT07)

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
30	109	2799575	PIENCNOT01	2799575 (PIENCNOT01), 874115111 (LUNGNOT01), 967837R1 (BRSTNOT05), 3235248T6 and 3235248F6 (COLNUCT03)
31	110	2804955	BLADTUT08	2804955 (BLADTUT08), 732534H1 (LUNGNOT03), 402168R1 (TMLR3D01), 3481814H1 (KIDNNOT31), 1485989F1 (CORPNOT02)
32	111	2806395	BLADTUT08	2806395 (BLADTUT08), 1579109H1 (DUODNOT01), 1533572F1 (SPLNNOT04), 1889837F6 and 1889837T6 (BLADTUT07), 2414178F6 (HINT3AZT01)
33	112	2836858	TYMNOT03	2836858 and 2836858CT1 (TYMNOT03), 2127516H1 (KIDNNOT05)
34	113	2844513	DRGLNOT01	2844513 and 2844513T6 (DRGLNOT01), 388885T6 (THYMNOT02), 287344F1 (EOSIHET02), 3867626H1 (BMARNOT03)
35	114	3000380	TYMNOT06	3000380 (TYMNOT06), 1930658H1 (COLNTUT03), 2395295F6 (THPIAZT01), 1242456R6 (LUNGNOT03)
36	115	182532	PLACNOB01	062374111, 062962R6, 064457R6, and 182532111 (PLACNOB01), 3144248X12F1 (HINT2AZS07)
37	116	239589	HIPONOT01	239589H1 and 239589X13 (HIPONOT01), 264805R6 (HINT2AGT01), 552683X17 (SCORNOT01), 1595053F1 (BRAINT04)
38	117	1671302	BMARNOT03	399804H1 (PITUNOT02), 1458549H1 (COLNFEET02), 1671302F6 and 1671302H1 (BMARNOT03), 2093453R6 (PANCNOT04), 2498385F6 and 2498385T6 (ADRETUT05)
39	118	2041858	HIPONON02	063184R1 (PLACNOB01), 1294823F1 (PGANNOT03), 1303974F1 (PLACNOT02), 1648770F6 (PROSTUT09), 2041858H1 (HIPONON02)
40	119	2198863	SPLNFET02	1880470F6 (LEUKNOT03), 1888946F6 (BLADTUT07), 2198863F6 and 2198863H1 (SPLNFET02)
41	120	3250703	SEMVNOT03	1317728H1, 1318433H1, 1319354H1, 1319380F1, 1320494H1, and 1320812F1 (BLADNOT04), 3247874H1, 3249188H1, 3249385H1, and 3250703H1 (SEMVNOT03)
42	121	350287	LVENNOT01	062018F1 (PLACNOB01), 350287H1 (LVENNOT01), 869320R1 (LUNGAST01), 1416927F6 (BRAINT02), 3083789H1 (OVARUTUN01)
43	122	1618171	BRAITUT12	1618171F6 and 1618171H1 (BRAITUT12), 3316315F6 (PROSBPT03)

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
44	123	1625863	COLNPOT01	1625863H1 and 1625863T6 (COLNPOT01), 2100364R6 (BRAITUT02)
45	124	1638353	UTRSNOT06	1638353H1 (UTRSNOT06), 3733085H1 (SMCCNOS01), 3882774T6 (SPLNNOT11), 1626195T6 (COLNPOT01), 1495745H1 (PROSNON01)
46	125	1726843	PROSNOT14	826000T1 (PROSNOT06), 1726843F6 and 1726843H1 (PROSNOT14), 2225762F6 (SEMVNOT01), 2480248H1 (SMCANOT01), 2600692F6 (UTRSNOT10), 2728257F6 (OVARUT05)
47	126	1754506	LIVRTUT01	907854R2 (COLNNOT09), 1354345F1 (LUNGNOT09), 1359472F1 (LUNGNOT12), 1397284F1 (BRAITUT08), 1557921F1 (BLADTUT04), 1754506F6 and 1754506H1 (LIVRTUT01)
48	127	1831378	THP1AZT01	441541R1 (MPHGNOT03), 712292R6 (SYNORAT04), 1311835F1 (COLNFET02), 1555765F6 (BLADTUT04), 1831378H1 (THP1AZT01), 1865502F6 (PROSNOT19), 3077521H1 (BONEUNT01), 3555043H1 (SYNONOT01), 3774618H1 (BRSTNOT25)
49	128	1864943	PROSNOT19	714070F1 (PROSTUT01), 736327R1 (TONSNOT01), 1864943H1 (PROSNOT19), 2672921F6 (KIDNNOT19)
50	129	1911316	CONNTUT01	777070F1 (COLNNOT05), 1911316H1 and 1911316T6 (CONNTUT01)
51	130	1943120	HIPONOT01	1516263F1 (PANCUTUT01), 1943120H1 (HIPONOT01), 2469009F6 (THYRNOT08), 2522459F6 (BRAITUT21), 3202972F6 (PENCNOT02), 4383679H1 (BRAVUTT02)
52	131	2314236	NGANNOOT01	2314236H1 (NGANNOOT01), 2812085F6 (OVARNOT10), 3949704T6 (DRGCNOT01)
53	132	2479409	SMCANOT01	2479409F6 and 2479409H1 (SMCANOT01)
54	133	2683149	SINIUCT01	760389H1 (BRAITUT02), 1634372F6 (COLNNOT19), 1695052F6 (COLNNO123), 1736429F6 (COLNNOT22), 2048429F6 (LIVRFET02), 2683149H1 (SINIUCT01), 3282234F6 (STOMFET02)
55	134	2774051	PANCNOT15	1852505F6 (LUNGFET03), 2774051F6 and 2774051H1 (PANCNOT15)
56	135	2869038	THYRNOT10	536017R6 (ADRENOT03), 2770632F6 (COLANOT02), 2795420F6 (NPOLNOT01), 2869038F6 and 2869038H1 (THYRNOT10), 3323992H1 (PTHYNOT03)
57	136	2918334	THYMFET03	2918334H1 (THYMFET03), SBNA01788F1

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
58	137	2949916	KIDNFET01	2949916H1 (KIDNFET01), SBMA00738F1
59	138	2989375	KIDNFET02	437481R6 and 437481T6 (THYRN0T01), 2989375H1 (KIDNFET02)
60	139	3316764	PROSBPT03	1328462F1 (PANCNOT07), 1691807F6 (PROSTUT10), 1851237F6 (LUNGFET03), 3316764H1 (PROSBPT03), 5092348H1 (UTRSTMR01)
61	140	3359559	PROSTUT16	943684 and 943564 (ADREN0T03), 1697079F6 (COLNNO123), 2717735H1 (THYRN0T09), 2792705H1 (COLNTUT16), 3359559H1 (PROSTUT16)
62	141	4289208	BRABDIR01	3990421R6 (LUNGNON03), 4289208H1 (BRABDIR01)
63	142	2454013	ENDANOT01	014571R1 (THP1PLB01), 1303790T1 (PLACNOT02), 1342791T1 (COLNTUT03), 1351680F1 (LATRTUT02), 1359607T1 (LUNGN0T12), 2454013F6 and 2454013H1 (ENDANOT01)
64	143	2454048	ENDANOT01	551329R1 and 2056675R6 (BEPINOT01), 819281R1 (KERANOT02), 2454048H1 (ENDANOT01), 3143588H1 (HNT2AZS07)
65	144	2479282	SMCANOT01	873307R1 (LUNGAST01), 2479282H1 and 2479282T6 (SMCANOT01), 2610082F6 (COLNTUT15), SANA03636F1
66	145	2483432	SMCANOT01	940455T1 (ADREN0T03), 1863558T6 (PROSN0T19), 2483432H1 (SMCANOT01), 2641345H1 (LUNGUTUT08), 3245089T6 (BRAINO119), SBCA02765F1
67	146	2493824	ADRETUT05	489685F1 (HNT2AGT01), 530794H1 (BRAINO103), 735826R1 (TONSN0T01), 2056809R6 (BEPINOT01), 2493824H1 (ADRETUT05), 2763162F6 (BRSTN0T12), 2812426H1 (OVARNOT10)
68	147	2555823	THYMN0T03	1266972F6 (BRAINO109), 1335461T1 (COLNNO13), 1900947F6 (BLADTUT06), 1942256T6 (HIPONOT01), 2555823H1 (THYMN0T03), SARB01019F1, SARB01303F1
69	148	2598242	OVARUTUT02	320268F1 (EOSIHET02), 738915R1 (PANCNOT04), 1250161F1 (LUNGFET03), 2598242F6 and 2598242H1 (OVARUTUT02), 5020793H1 (OVARNON03), SASA00178F1
70	149	2634120	COLNTUT15	1398694F1 (BRAITUT08), 1506594F1 (BRAITUT07), 2120954F6 (BRSTN0T07), 2634120F6 and 2634120H1 (COLNTUT15), 2761586H1 (BRAINOS12), 2806841F6 (BLADTUT08)

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
71	150	2765411	BRSTNOT12	2765236F6 and 2765411H1 (BRSTNOT12), 4058218H1 (SP1NNOT13)
72	151	2769412	COLANOT02	1715480F6 (UCMCNOT02), 2769412H1 (COLANOT02), SBDA04076F1
73	152	2842779	DRGLNOT01	1262711R1 (SYNORAT05), 1710449T6 (PROSNOT16), 2842779F6 (DRGLNOT01), 2842779H1 (DRGLNOT01), 2850941F6 (BRSTTUT13), 3123378H1 (LNOIDNOT05), 3457873H1 (293TFT1T01), SBGA04623F1, SAOA02667F1
74	153	2966260	SCORNOT04	530242H1 (BRAINOT03), 2113607H1 (BRAITUT03), 2125619F6 (BRSTNOT07), 2155349H1 and 2156022H1 (BRAINOT09), 2966260F6, 2966260H1, and 2966260T6 (SCORNOT04), 3270731H1 (BRAINOT20), 3272328F6 (PROSBPT06)
75	154	2993326	KIDNFET02	190217F1 (SYNORAB01), 815990R1 and 815990T1 (OVARUT01), 2993326H1 (KIDNFET02), 3629860H1 (COLNNOT38)
76	155	3001124	TYLMNOT06	2123347T6 (BRSTNOT07), 3001124H1 (TYLMNOT06), SBEA07088F3
77	156	3120070	LUNGTUT13	021565F1 (ADENINB01), 144798R1 (TYLMNOR01), 1216676H1 (BRSTTUT01), 2024357H1 (KERANOT02), 2616322H1 (GBLANOT01), 2742604H1 (BRSTTUT14), 2746025H1 (LUNGTUT11), 2924884H1 (SININOT04), 3120070H1 (LUNGTUT13)
78	157	3133035	SMCCNOT01	1478001F1 and 1482667H1 (CORPNOT02), 2812193F6 and 2812193T6 (OVARNOT10), 3133035H1 and 3133035T6 (SMCCNOT01), 5025075F6 (OVARNON03)
79	158	3436879	PENCNOT05	3323031F6 (PTHYNOT03), 3436879F6 and 3436879H1 (PENCNOT05), 4247733H1 (BRABDIT01)

Table 2

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
1	240	S233 S159 T194 T43 T77 T129 T134 S171	N73 N101 N167	S33-G36 L198-L219	Somatostatin receptor tyrosine kinase	BLAST, BLOCKS, HMM
2	100	S6 S64			Meningioma-expressed antigen 11	BLAST, PRINTS, HMM
3	416	S14 S62 T109 T177 T340 S365 S380 S6 T7 T205 S327 T331 Y56	N144 N277		PMP-22/EMP/MP20 family	BLOCKS, PRINTS, HMM
4	224	T31 T57 S86 S173 S214			B cell growth factor	BLAST
5	247	S103 T60 S113 S235			5-hydroxytryptamine receptor	PRINTS
6	72				Frizzled protein	PRINTS, HMM
7	106	S97 S9 S24 T31			Dopamine 2 receptor	BLAST, PRINTS, HMM
8	239	S233	N230		PB39 protein	BLAST, HMM
9	150	S53 S111 T127			CD44 antigen precursor	PRINTS, HMM
10	110	S12	N92		Anion exchanger	BLOCKS, PRINTS, HMM
11	58		N5 N9		Neurofibromatosis type 2	BLAST, PRINTS, HMM
12	221	S35 S178 S60 S183			mitsugumin 23	BLAST, HMM

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
13	262	T33 S94 S150 T225 T245 T114 S22 T30 T57 S137 T201 S207 T230	N104		C5a-anaphylatoxin receptor	PRINTS, HMM
14	90	S67 T52			Frizzled protein	PRINTS, HMM
15	208	T119 T123 T132 S56 S142	N121		Rieske iron-sulphur protein	BLOCKS, PRINTS, HMM
16	97	S61 T2			Endothelin B receptor	PRINTS, HMM
17	243	S82 T104 S168 T181 S6 S99 T195 Y24			Thromboxane receptor	PRINTS, HMM
18	162	S26	N6		G protein-couple receptor	BLOCKS, PRINTS, HMM
19	470	S285 S29 T136 S145 T167 T168 S199 S236 S249 T401 S172 S209 S254 T264 S335 T385	N118 N298 N466	R306-D308	Molluscan rhodopsin C-terminus	PRINTS, HMM
20	144	S42 S21 T72	N30 N36		Lysosome-associated membrane protein	PRINTS, HMM
21	221	S75 T82		S151-G154	Glycoprotein hormone receptor	BLAST, PRINTS, HMM
22	688	T60 T186 T103 T298 S405 S484 S488 S492 S494 S498 S499 S503 S584 S601 S611 S647 T663 T109 T188 T284 T315 S324 S347 T402 T573 S643 T658 T681 Y118	N198 N576 N577 N582	S5-G8 A80-N140	Ring3	BLAST, PRINTS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
23	439	T175 T257 S397 S424 S210 S435	N227	S365-G368	Prostanoid EP3 receptor	BLOCKS, PRINTS
24	192	S20 S44	N68		PMP-22/EMP/MP20 family	BLOCKS, PRINTS, HMM
25	175	T171 T43 S136 T7			Progesterone receptor	PRINTS
26	91	S34 S19 S29			Similar to mouse dishevelled-3(Dvl-3).	BLAST, BLOCKS, PRINTS, HMM
27	214	T34 S83 T118 T152 S17			Somatostatin receptor tyrosine kinase	BLOCKS, PRINTS, HMM
28	250	S64 S132 T154			Sec22 homolog	BLAST, HMM
29	84	T80 T3 S76			DPM2 protein	BLAST, HMM
30	277	T140 S217 S19 S85 T129			Somatomedin B domain protein	BLOCKS, PRINTS, HMM
31	273	S64 S4 S114 S179 S256 S14 T167 T218	N187		Anion exchanger family	BLOCKS, PRINTS, HMM
32	524	T190 S5 T131 S148 S171 S262 S275 T302 S356 S404 S473 S177 S207 T492	N152 N471 N501 N513	I46-I67	G protein-coupled receptor	BLOCKS, PRINTS, HMM
33	257	S48 S52 S55 T64 S82 T90 S96 T97 S123 T129 T144 S192 S224 T227 S250	N98 N187		Nucleoporin p62 homolog	BLAST
34	274	S16 T84 S249 S56 S113	N234		Molluscan rhodopsin C-terminus	PRINTS

Table 2 (cont.)

SEQ ID NO.	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
35	281	S52 T150 S165 S263 T48 S116 T167 T226 T241		G125-S132 S185-G188	ABC-2 type transport protein	BLOCKS, PRINTS, HMM
36	335	S96 T113 T131 T308 T14 T146 T292 S302 S312 T317 Y258	N104 N111	E296 to A307 R127 to G129	pregnancy-specific beta 1-glycoprotein 4 precursor	Blast, BLOCKS, PRINTS, Motifs
37	280	T41 S102 T135 S148	N35 N53 N127	T56 to Y70	lysosomal membrane glycoprotein-type A precursor	Blast, BLOCKS, PRINTS, Motifs
38	210	S50 S143 S151 S63 S107 S153			Butyrophilin	Blast
39	279	T90	N66 N171		Plasma membrane glycoprotein C1G30	Blast
40	154	T75 S121 S48 S58 T112 Y84 Y90		G101 to G122 V115 to F130	Pathogenesis-related protein PR-1	Blast, BLOCKS, PRINTS
41	582	S160 S255 T256 S291 S292 S316 S351 S352 S411 S412 S471 S472 T485 S533 T559 S79 T93 S96 S151 S231		G520 to S527	semenogelin II	Blast, Motifs
42	71	S17 T45 T50		M1 to T50 P5 to C29	Integral membrane protein	BLOCKS, PRINTS
43	102	T44 S33 T75		S6 to L24 S33 to G36 I49 to I74 A2 to S29	TM4SF	BLOCKS, PRINTS, HMM
44	226	S60 T3 T4 S85 T169	N46 N82 N83	I184 to R205 G128 to Q152 Y179 to Y201	Cation-dependant mannose transporter protein	PRINTS, HMM

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
45	154	T145 T148 S33 T134 T141 S152		M1 to A22 P56 to M78 P58 to M82 L91 to S110 L109 to L125	Frizzled protein	PRINTS, HMM
46	167	S154 S3 T25 T29 T126 S140		E72 to F103	GPCR	BLOCKS, PRINTS, HMM
47	545	T257 S513 S10 T11 S47 S166 S408 S495	N8 N406	E376 to K410	Human secreted protein K640 variant	Blast, BLOCKS, PRINTS, HMM
48	570	T529 S128 S130 T184 T235 T161 S293 Y199	N27 N61 N75 N87 N264	V296 to C309 F321 to F332	GPCR	Blast, BLOCKS, PRINTS, HMM
49	127	S24 T118		N10 to G30	Antion exchanger	PRINTS, HMM
50	152	T49 S16		L78 to L99 L85 to L106 V47 to Y63 Y45 to V94	TM4SF GNS1/SUR4 family	BLOCKS, HMM, Motifs
51	777	T48 S66 S162 T268 S272 T322 T355 S393 S471 S559 S574 S624 S660 S700 T742 S750 S11 T12 S196 S346 T400 S423 T493 T579 T582 S599 S723	N64 N205 N470 N706	T20 to D34 R122 to L132 L598 to L619 D331 to L349 R565 to T582	pecanex protein	Blast, PRINTS, Motifs
52	108	S52 T31 T105		L76 to Y92	GNS1/SUR4 family	BLOCKS, PRINTS, PROFILESCAN
53	66	S4 S35	N2	F22 to G58	NF2 protein	Blast, BLOCKS, PRINTS, HMM

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
54	540	S135 S149 T527 T82 T94 T177 S441	N50 N92 N160 N334 N395	S115 to G118 L295 to L308 L490 to L518	I.V.-I protein	Blast, PRINTS, HMM, Motifs
55	87	T4 S13 S37 S68 S69		I46 to I82	calvicolin	BLOCKS, HMM
56	100	S94		I7 to N34 G8 to F21 K65 to N91 T78 to C97	ammonium ion transporters	BLOCKS, PRINTS, HMM
57	58	T43			shox protein	BLAST, HMM
58	61	S51 S58 S42		R2 to L23	carboxyl ester lipase	Blast, PRINTS, HMM
59	50	S9		C33 to W45 C11 to L40	Lipoxygenase; growth factor and cytokines receptor family	BLOCKS, PRINTS, HMM, Motifs
60	310	T46 T156 S301 T81 S108 S166 S305		A153 to S166	C4 methyl-sterol oxidase	Blast, PRINTS, HMM
61	160	S114		L71 to W84 Y143 to T154	C5A-anaphylatoxin receptor	Blast, BLOCKS, PRINTS, HMM
62	35			K11 to M34	steroid hormone receptor	PRINTS
63	323	T92 S105 S182 T263 S301 S271	N90	M1-G31 Signal Peptide M1-A27 Signal Peptide L234-I.254 TM Protein	Signal Peptide Containing Transmembrane Protein	Motifs SPScan HMM

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
64	129	T112 T117 S5 S54		M1-G27 Signal Peptide M1-G27 Signal Peptide I81-V100 TM Prot.	Signal Peptide Containing Transmembrane Protein	Motifs SPScan HMM
65	461	T56 T41 S47 T56 T127 S146 S147 S197 S198 T407 S8 S47 T51 T284 T341 T407	N193 N236		Signal Peptide Containing Transmembrane Protein	Motifs
66	264	S243 T264 S33 T211 S260 S22 S243 S260	N172 N250	M1-A17 Signal Peptide M1-S22 Signal Peptide L173-Y195 TM Prot. M1-L21 TM Prot. L25-R30 Prot. Splicing	Protein Splicing Protein	Motifs SPScan HMM BLOCKS
67	339	T99 S119 S157 S166 S321 T54 S55 T77 S149 S211 S279 T336 Y105	N172	M1-G30 Signal Peptide M1-G26 Signal Peptide L176-L194 TM. Prot.	Signal Peptide Containing Transmembrane Protein	Motifs SPScan HMM
68	397	S104 T148 T166 T259 S303 S317 T127 T191 S302		G202-S209 ATP/GTP binding L10-L31 Leucine zipper D106-L108 Ca binding S367-L384 Signal Peptide M1-G29 Transmembr. Prot.	Gene Regulatory Protein	Motifs SPScan BLAST HMM
69	301	T7 S52 S100 S133 S239 T155 T206	N162 N211	V12-A32 TM. Prot. V282-G300 TMr. Prot. L59-V64 aaRNA ligase	Aminoacyl tRNA ligase	Motifs HMM BLOCKS
70	217	S8 S142 T112 T197		W73-I99 TM. Prot.	Cell Proliferation Protein	Motifs HMM

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
71	143	S81 T120 S139 S116		M1-C26 Signal Peptide M1-R25 Signal Peptide M1-V22 TM Prot.	Signal Peptide Containing Transmembrane Protein	Motifs SPScan HMM
72	186	T50 S132 T151 S116 Y43	N29 N104	M1-S25 Signal Peptide M1-S31 Signal Peptide F9-F28 TM Prot. A27-G89 T-cell receptor interacting molecule	T-cell Receptor Interacting Molecule	Motifs SPScan HMM BLAST
73	364	S172 S213 S243 S302	N229	L234-L255 Leucine zipper M1-G28 Signal Peptide L151-L170 TM. Prot. L72-E92 TM Prot.	Gene Regulatory Protein	Motifs SPScan HMM
74	605	S46 T54 S108 S129 S195 S220 S231 T254 T261 S316 S440 S472 S536 S560 T124	N106 N193 N395 N480	M1-A32 Signal Peptide V494-I515 TM. Prot. L17-E36 TM Prot.	2-Membrane Spanning Signal Peptide Containing Transmembrane Protein	Motifs SPScan HMM
75	97	T2 S87		M1-G26 Signal Peptide M1-G23 Signal Peptide V35-M54 TM. Prot. I11-I34 TM Prot.	2-Membrane Spanning Signal Peptide Containing Transmembrane Protein	Motifs SPScan HMM
76	247	S160 T204 S165		F72-L90 Transmembr. Prot. L45-T64 Transmembr. Prot.	2-Membrane Spanning Signal Peptide Containing Transmembrane Protein	Motifs HMM

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
77	193	S60 S67		M1-D26 Signal Peptide M1-A31 Signal Peptide M80-M104 TM Prot. R109-Y129 TM Prot. S67-I108 PMP-22 Y149-Y176 PMP-22 N150-A159 Trehalase	Peripheral Myelin Protein 22	Motifs SPScan HMM BLOCKS
78	128	S30 S30 S50	N71 N84 N91	N126-L128 microbodies targeting motif	Microbody Protein	Motifs
79	115	S109		M1-S16 Signal Peptide M1-T24 Signal Peptide M1-W19 TM Prot. V27-Y46 TM Prot. V5-V15 G Prot. Receptor	G Protein Receptor	Motifs SPScan HMM PRINTS

Table 3

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease Class (Fraction of Total)	Vector
80	Reproductive (0.321) Cardiovascular (0.143) Gastrointestinal (0.134)	Cancer (0.527) Inflammation (0.232) Fetal (0.170)	pBLUESCRIPT
81	Cardiovascular (0.500) Gastrointestinal (0.250) Other (0.250)	Cancer (0.500) Fetal (0.250) Other (0.250)	pBLUESCRIPT
82	Reproductive (0.260) Cardiovascular (0.220) Gastrointestinal (0.120)	Cancer (0.500) Inflammation (0.180) Fetal (0.160)	pSPORT 1
83	Nervous (0.400) Gastrointestinal (0.300) Developmental (0.100)	Cancer (0.500) Inflammation (0.300) Fetal (0.200)	pINCY 1
84	Reproductive (0.266) Gastrointestinal (0.141) Cardiovascular (0.125)	Cancer (0.469) Inflammation (0.250) Fetal (0.195)	pINCY 1
85	Reproductive (0.750) Developmental (0.250)	Cancer (0.750) Fetal (0.250)	pINCY 1
86	Reproductive (0.250) Cardiovascular (0.143) Nervous (0.143)	Inflammation (0.321) Trauma (0.286) Cancer (0.250)	pINCY 1
87	Reproductive (0.368) Developmental (0.158) Cardiovascular (0.105)	Cancer (0.421) Fetal (0.368) Inflammation (0.211)	pINCY 1
88	Hematopoietic/Immune (0.417) Cardiovascular (0.250) Reproductive (0.167)	Inflammation (0.417) Cancer (0.333) Fetal (0.167)	pINCY 1
89	Cardiovascular (0.220) Nervous (0.171) Reproductive (0.122)	Cancer (0.463) Inflammation (0.195) Trauma (0.171)	pINCY 1
90	Gastrointestinal (0.200) Reproductive (0.200) Urologic (0.200)	Cancer (0.500) Inflammation (0.300) Other (0.100)	pINCY 1

Table 3 (cont.)

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease Class (Fraction of Total)	Vector
91	Reproductive (0.306) Cardiovascular (0.204) Nervous (0.122)	Cancer (0.510) Inflammation (0.204) Fetal (0.143)	pINCY I
92	Reproductive (0.227) Hematopoietic/Immune (0.182) Cardiovascular (0.136)	Cancer (0.432) Fetal (0.273) Inflammation (0.273)	pINCY I
93	Gastrointestinal (0.375) Reproductive (0.188) Cardiovascular (0.125)	Cancer (0.500) Inflammation (0.250) Trauma (0.125)	pINCY I
94	Reproductive (0.333) Cardiovascular (0.214) Gastrointestinal (0.143)	Cancer (0.548) Inflammation (0.167) Fetal (0.143)	pINCY I
95	Cardiovascular (0.231) Gastrointestinal (0.231) Reproductive (0.192)	Cancer (0.500) Inflammation (0.231) Fetal (0.154)	pINCY I
96	Gastrointestinal (0.208) Cardiovascular (0.167) Reproductive (0.167)	Cancer (0.542) Inflammation (0.292) Other (0.083)	pINCY I
97	Hematopoietic/Immune (0.341) Reproductive (0.268) Cardiovascular (0.122)	Cancer (0.415) Inflammation (0.415) Fetal (0.195)	pINCY I
98	Gastrointestinal (0.346) Reproductive (0.231) Hematopoietic/Immune (0.154)	Inflammation (0.462) Cancer (0.385) Fetal (0.115)	pSPORT I
99	Gastrointestinal (0.400) Developmental (0.200) Nervous (0.200)	Cancer (0.400) Fetal (0.200) Neurological (0.200)	pSPORT I
100	Reproductive (0.231) Nervous (0.168) Cardiovascular (0.140)	Cancer (0.441) Inflammation (0.231) Fetal (0.133)	pSPORT I
101	Hematopoietic/Immune (0.225) Reproductive (0.225) Gastrointestinal (0.125)	Cancer (0.475) Inflammation (0.325) Fetal (0.175)	pINCY I
102	Reproductive (0.333) Gastrointestinal (0.185) Nervous (0.148)	Cancer (0.630) Fetal (0.185) Inflammation (0.111)	pINCY I

Table 3 (cont.)

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease Class (Fraction of Total)	Vector
103	Gastrointestinal (0.242) Reproductive (0.182) Developmental (0.121)	Cancer (0.455) Inflammation (0.364) Fetal (0.182)	pINCY 1
104	Gastrointestinal (0.188) Hematopoietic/Immune (0.188) Urologic (0.188)	Inflammation (0.438) Cancer (0.281) Fetal (0.250)	pINCY 1
105	Urologic (0.250) Cardiovascular (0.167) Gastrointestinal (0.167)	Fetal (0.500) Cancer (0.417) Inflammation (0.333)	pINCY 1
106	Hematopoietic/Immune (0.333) Urologic (0.333)	Cancer (0.333) Fetal (0.333) Inflammation (0.333)	pINCY 1
107	Reproductive (0.286) Cardiovascular (0.204) Nervous (0.184)	Cancer (0.592) Fetal (0.143) Inflammation (0.143)	pINCY 1
108	Reproductive (0.231) Gastrointestinal (0.215) Hematopoietic/Immune (0.154)	Cancer (0.462) Inflammation (0.292) Fetal (0.185)	pINCY 1
109	Reproductive (0.304) Cardiovascular (0.261) Gastrointestinal (0.130)	Cancer (0.609) Inflammation (0.174) Trauma (0.087)	pINCY 1
110	Reproductive (0.256) Gastrointestinal (0.186) Hematopoietic/Immune (0.186)	Cancer (0.558) Inflammation (0.349) Trauma (0.070)	pINCY 1
111	Nervous (0.200) Reproductive (0.200) Gastrointestinal (0.175)	Cancer (0.550) Fetal (0.175) Inflammation (0.150)	pINCY 1
112	Developmental (0.222) Endocrine (0.222) Hematopoietic/Immune (0.222)	Cancer (0.222) Inflammation (0.222) Fetal (0.222)	pINCY 1
113	Hematopoietic/Immune (0.267) Nervous (0.200) Gastrointestinal (0.133)	Cancer (0.467) Trauma (0.267) Inflammation (0.200)	pINCY 1
114	Hematopoietic/Immune (0.304) Gastrointestinal (0.130) Nervous (0.130)	Inflammation (0.391) Cancer (0.304) Fetal (0.130)	pINCY 1

Table 3 (cont.)

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease Class (Fraction of Total)	Vector
115	Developmental (0.333) Cardiovascular (0.167) Dermatologic (0.167)	Fetal (0.667) Inflammation (0.500)	pBLUESCRIPT
116	Nervous (0.478) Gastrointestinal (0.130) Hematopoietic/Immune (0.130)	Cancer (0.565) Fetal (0.217) Inflammation (0.217)	pBLUESCRIPT
117	Reproductive (0.222) Hematopoietic/Immune (0.200) Nervous (0.156)	Cancer (0.422) Inflammation (0.311) Fetal (0.178)	pINCY
118	Reproductive (0.256) Gastrointestinal (0.148) Nervous (0.125)	Cancer (0.430) Inflammation (0.259) Fetal (0.196)	pSPORT1
119	Reproductive (0.190) Nervous (0.167) Developmental (0.143)	Cancer (0.381) Inflammation (0.333) Fetal (0.262)	pINCY
120	Reproductive (0.800) Urologic (0.100)	Cancer (0.900) Trauma (0.100)	pINCY
121	Reproductive (0.295) Nervous (0.182) Cardiovascular (0.159)	Cancer (0.455) Inflammation (0.182) Cell Proliferation (0.159)	pBLUESCRIPT
122	Developmental (0.250) Musculoskeletal (0.250) Nervous (0.250)	Cancer (0.500) Cell Proliferation (0.250) Inflammation (0.250)	pINCY
123	Gastrointestinal (0.786) Developmental (0.071) Nervous (0.071)	Cancer (0.500) Inflammation (0.429) Cell Proliferation (0.071)	pINCY
124	Reproductive (0.348) Cardiovascular (0.159) Hematopoietic/Immune (0.130)	Cancer (0.493) Inflammation (0.246) Cell Proliferation (0.145)	pINCY
125	Nervous (0.405) Reproductive (0.324) Cardiovascular (0.108)	Cancer (0.459) Proliferation (0.189) Inflammation (0.108)	pINCY
126	Reproductive (0.275) Nervous (0.231) Gastrointestinal (0.154)	Cancer (0.549) Inflammation (0.220) Cell Proliferation (0.154)	pINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease Class (Fraction of Total)	Vector
127	Reproductive (0.250) Nervous (0.150) Cardiovascular (0.133)	Cancer (0.517) Cell Proliferation (0.350) Inflammation (0.233)	pINCY
128	Nervous (0.333) Reproductive (0.333) Hematopoietic/Immune (0.111)	Cancer (0.593) Inflammation (0.259) Neurological (0.111)	pINCY
129	Hematopoietic/Immune (0.304) Gastrointestinal (0.214) Reproductive (0.196)	Cancer (0.446) Inflammation (0.446) Cell Proliferation (0.161)	pINCY
130	Nervous (0.400) Reproductive (0.300) Endocrine (0.100)	Cancer (0.300) Inflammation (0.300) Cell Proliferation (0.200)	pBLUESCRIPT
131	Reproductive (0.364) Cardiovascular (0.227) Nervous (0.227)	Cancer (0.545) Inflammation (0.318) Cell Proliferation (0.091)	pSPORT1
132	Cardiovascular (0.667) Nervous (0.333)	Cell Proliferation (1.000) Cancer (0.333)	pINCY
133	Gastrointestinal (0.750) Developmental (0.125) Reproductive (0.083)	Cancer (0.375) Cell Proliferation (0.292) Inflammation (0.250)	pINCY
134	Cardiovascular (0.250) Developmental (0.250) Gastrointestinal (0.250)	Cancer (0.500) Cell Proliferation (0.500) Inflammation (0.250)	pINCY
135	Reproductive (0.250) Nervous (0.208) Endocrine (0.167)	Inflammation (0.417) Cancer (0.208) Trauma (0.167)	pINCY
136	Developmental (0.500) Reproductive (0.500)	Cancer (0.500) Cell Proliferation (0.500)	pINCY
137	Developmental (1.000)	Cell Proliferation (1.000)	pINCY
138	Developmental (0.333) Endocrine (0.333) Gastrointestinal (0.333)	Cancer (0.666) Fetal (0.333)	pINCY
139	Reproductive (0.538) Developmental (0.154) Gastrointestinal (0.154)	Cancer (0.462) Inflammation (0.231) Cell Proliferation (0.154)	pINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease Class (Fraction of Total)	Vector
140	Gastrointestinal (0.385) Endocrine (0.231) Reproductive (0.231)	Cancer (0.308) Inflammation (0.308) Cell Proliferation (0.077)	pINCY
141	Nervous (0.500) Cardiovascular (0.167) Gastrointestinal (0.167)	Cancer (0.333) Trauma (0.333) Neurological (0.167)	pINCY
142	Reproductive (0.220) Gastrointestinal (0.155) Nervous (0.152)	Cell Proliferation (0.637) Inflammation (0.312)	pBLUESCRIPT
143	Cardiovascular (0.202) Reproductive (0.190) Gastrointestinal (0.179)	Cell Proliferation (0.583) Inflammation (0.322)	pBLUESCRIPT
144	Reproductive (0.242) Nervous (0.158) Gastrointestinal (0.116)	Cell Proliferation (0.632) Inflammation (0.379)	pINCY
145	Cardiovascular (0.238) Reproductive (0.238) Nervous (0.143)	Cell Proliferation (0.619) Inflammation (0.476)	pINCY
146	Reproductive (0.235) Nervous (0.189) Hematopoietic/Immune (0.131)	Cell Proliferation (0.625) Inflammation (0.348)	pINCY
147	Reproductive (0.191) Hematopoietic/Immune (0.173) Nervous (0.145)	Cell Proliferation (0.582) Inflammation (0.455)	pINCY
148	Reproductive (0.279) Hematopoietic/Immune (0.140) Nervous (0.128)	Cell Proliferation (0.674) Inflammation (0.232)	pINCY
149	Reproductive (0.286) Nervous (0.214) Cardiovascular (0.095)	Cell Proliferation (0.834) Inflammation (0.215)	pINCY
150	Hematopoietic/Immune (0.400) Endocrine (0.200) Gastrointestinal (0.200)	Cell Proliferation (0.200) Inflammation (0.800)	pINCY
151	Hematopoietic/Immune (0.667) Gastrointestinal (0.167) Musculoskeletal (0.167)	Cell Proliferation (0.167) Inflammation (0.667)	pINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease Class (Fraction of Total)	Vector
152	Reproductive (0.240) Nervous (0.173) Hematopoietic/Immune (0.133)	Cell Proliferation (0.546) Inflammation (0.360)	pINCY
153	Reproductive (0.308) Nervous (0.231) Gastrointestinal (0.115)	Cell Proliferation (0.885) Inflammation (0.154)	pINCY
154	Nervous (0.455) Reproductive (0.182) Developmental (0.136)	Cell Proliferation (0.682) Inflammation (0.181)	pINCY
155	Reproductive (0.286) Urologic (0.286) Cardiovascular (0.143)	Cell Proliferation (0.857) Inflammation (0.429)	pINCY
156	Reproductive (0.299) Gastrointestinal (0.216) Cardiovascular (0.120)	Cell Proliferation (0.767) Inflammation (0.246)	pINCY
157	Nervous (0.222) Reproductive (0.222)	Cell Proliferation (0.333) Inflammation (0.222)	pINCY
158	Reproductive (0.429) Nervous (0.357)	Cell Proliferation (0.286) Inflammation (0.357)	pINCY

Table 4

Nucleotide SEQ ID NO:	Clone ID	Library	Library Comment
80	153831	THP1PLB02	The THP1PLB02 library was constructed by reamplification of THP1PLB01, which was made using RNA isolated from THP-1 cells cultured for 48 hours with 100 ng/ml phorbol ester (PMA), followed by a 4-hour culture in media containing 1 g/ml LPS. THP-1 (ATCC TIB 202) is a human promonocyte line derived from the peripheral blood of a 1-year-old male with acute monocytic leukemia (ref: Int. J. Cancer (1980) 26:171).
81	350629	LVENNOT01	The LVENNOT01 library was constructed using RNA isolated from the left ventricle of a 51-year-old Caucasian female, who died from an intracranial bleed.
82	729171	LUNGNOT03	The LUNGNOT03 library was constructed using polyA RNA isolated from nontumorous lung tissue of a 79-year-old Caucasian male. Tissue had been removed from the upper and lower left lobes of the lung, superior (left paratracheal) and inferior (subclavian) mediastinal lymph nodes, and the right paratracheal region. Pathology for the associated tumor tissue indicated grade 4 carcinoma. Patient history included a benign prostate neoplasm, atherosclerosis, benign hypertension, and tobacco use.
83	1273641	TESTTUT02	The TESTTUT02 library was constructed using polyA RNA isolated from a testicular tumor removed from a 31-year-old Caucasian male during unilateral orchiectomy. Pathology indicated embryonal carcinoma forming a largely necrotic mass involving the entire testicle. Rare foci of residual testicle showed intralobular germ cell neoplasia and tumor was identified at the spermatic cord margin.
84	1427389	SINTBST01	The SINTBST01 library was constructed using polyA RNA isolated from the ileum tissue of an 18-year-old Caucasian female with irritable bowel syndrome (IBS). Pathology indicated Crohn's disease of the ileum, involving 15 cm of the small bowel. Patient history included osteoporosis of the vertebra and abnormal blood chemistry. Family history included cerebrovascular disease and atherosclerotic coronary artery disease.
85	1458357	COLNFET02	The COLNFET02 library was constructed using RNA isolated from the colon tissue of a Caucasian female fetus, who died at 20 weeks' gestation from fetal demise. Serology was negative.
86	1482837	CORPNOT02	The CORPNOT02 library was constructed using polyA RNA isolated from diseased corpus callosum tissue removed from the brain of a 74-year-old Caucasian male, who died from Alzheimer's disease. Serologies were negative.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
87	1517434	PANCTUT01	The PANCTUT01 library was constructed using polyA RNA isolated from pancreatic tumor tissue removed from a 65-year-old Caucasian female during radical subtotal pancreatectomy. Pathology indicated an invasive grade 2 adenocarcinoma. Patient history included osteoarthritis, benign hypertension, atherosclerotic coronary artery disease, an acute myocardial infarction, benign neoplasm in the large bowel, and a cataract disorder. Family history included benign hypertension and atherosclerotic coronary artery disease, Type II diabetes, impaired renal function, and stomach cancer.
88	1536052	SPLNNOT04	The SPLNNOT04 library was constructed using polyA RNA isolated from the spleen tissue of a 2-year-old Hispanic male, who died from cerebral anoxia. Past medical history and serologies were negative.
89	1666118	BRSTNOT09	The BRSTNOT09 library was constructed using polyA RNA isolated from nontumor breast tissue removed from a 45-year-old Caucasian female during unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated invasive nuclear grade 2-3 adenocarcinoma in the same breast, with 3 of 23 lymph nodes positive for metastatic disease. There were also positive estrogen/progesterone receptors and uninvolved tissue showing proliferative changes. Patient history included valvuloplasty of mitral valve without replacement, rheumatic mitral insufficiency, rheumatic heart disease, and tobacco use. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, and Type II diabetes.
90	1675560	BLADNOT05	The BLADNOT05 library was constructed using polyA RNA isolated from nontumorous bladder tissue removed from a 60-year-old Caucasian male during a radical cystectomy, prostatectomy, and vasectomy. Pathology for the associated tumor tissue indicated grade 3 transitional cell carcinoma. The patient presented with dysuria. Family history included Type I diabetes, a malignant neoplasm of the stomach, atherosclerotic coronary artery disease, and an acute myocardial infarction.
91	1687323	PROSTUT10	The PROSTUT10 library was constructed using polyA RNA isolated from prostatic tumor tissue removed from a 66-year-old Caucasian male during radical prostatectomy and regional lymph node excision. Pathology indicated an adenocarcinoma (Gleason grade 2+3). Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Family history included prostate cancer, secondary bone cancer, and benign hypertension.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
92	1692236	PROSTUT10	The PROSTUT10 library was constructed using polyA RNA isolated from prostatic tumor tissue removed from a 66-year-old Caucasian male during radical prostatectomy and regional lymph node excision. Pathology indicated an adenocarcinoma (Gleason grade 2+3). Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Family history included prostate cancer, secondary bone cancer, and benign hypertension.
93	1720847	BLADNOT06	The BLADNOT06 library was constructed using polyA RNA isolated from the posterior wall bladder tissue removed from a 66-year-old Caucasian male during a radical prostatectomy, radical cystectomy, and urinary diversion. Pathology for the associated tumor tissue indicated grade 3 transitional cell carcinoma. The patient presented with prostatic inflammatory disease. Family history included a malignant breast neoplasm, benign hypertension, cerebrovascular disease, atherosclerotic coronary artery disease, and lung cancer.
94	1752821	LIVRTUT01	The LIVRTUT01 library was constructed using polyA RNA isolated from liver tumor tissue removed from a 51-year-old Caucasian female during a hepatic lobectomy. Pathology indicated metastatic grade 3 adenocarcinoma consistent with colon cancer. Patient history included thrombophlebitis and pure hypercholesterolemia. Patient medications included Premarin and Provera. The patient had also received 8 cycles of fluorouracil and leucovorin in the two years prior to surgery. Family history included a malignant neoplasm of the liver.
95	1810923	PROSTUT12	The PROSTUT12 library was constructed using polyA RNA isolated from prostate tumor tissue removed from a 65-year-old Caucasian male during a radical prostatectomy. Pathology indicated an adenocarcinoma (Gleason grade 2+2). Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA).
96	1822315	GBLATUT01	The GBLATUT01 library was constructed using polyA RNA isolated from gallbladder tumor tissue removed from a 78-year-old Caucasian female during a cholecystectomy. Pathology indicated invasive grade 3 transitional cell carcinoma. The patient was taking Indural (propranolol hydrochloride) for hypertension. Family history included a cholecystectomy, atherosclerosis, hyperlipidemia, and benign hypertension.
97	1877777	LEUKNOT03	The LEUKNOT03 library was constructed using polyA RNA isolated from white blood cells of a 27-year-old female with blood type A+. The donor tested negative for cytomegalovirus (CMV).
98	1879819	LEUKNOT03	The LEUKNOT03 library was constructed using polyA RNA isolated from white blood cells of a 27-year-old female with blood type A+. The donor tested negative for cytomegalovirus (CMV).

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
99	1932945	COLNNOT16	The COLNNOT16 library was constructed using polyA RNA isolated from nontumorous sigmoid colon tissue removed from a 62-year-old Caucasian male during a sigmoidectomy and permanent colostomy. Pathology for the associated tumor tissue indicated invasive grade 2 adenocarcinoma. Family history included benign hypertension, atherosclerotic coronary artery disease, hyperlipidemia, breast cancer, and prostate cancer.
100	2061026	OVARNOT03	The OVARNOT03 library was constructed using polyA RNA isolated from nontumorous ovarian tissue removed from a 43-year-old Caucasian female during a bilateral salpingo-oophorectomy. Pathology for the associated tumor tissue indicated grade 2 mucinous cystadenocarcinoma. Family history included atherosclerotic coronary artery disease, pancreatic cancer, stress reaction, cerebrovascular disease, breast cancer, and uterine cancer.
101	2096687	BRAITUT02	The BRAITUT02 library was constructed using polyA RNA isolated from brain tumor tissue removed from the frontal lobe of a 58-year-old Caucasian male during excision of a cerebral meningeal lesion. Pathology indicated a grade 2 metastatic hypernephroma. Patient history included a grade 2 renal cell carcinoma, insomnia, and chronic airway obstruction. Previous surgeries included a nephroureterectomy. Patient medications included Decadron (dexamethasone) and Dilantin (phenytoin). Family history included a malignant neoplasm of the kidney.
102	2100530	BRAITUT02	The BRAITUT02 library was constructed using polyA RNA isolated from brain tumor tissue removed from the frontal lobe of a 58-year-old Caucasian male during excision of a cerebral meningeal lesion. Pathology indicated a grade 2 metastatic hypernephroma. Patient history included a grade 2 renal cell carcinoma, insomnia, and chronic airway obstruction. Previous surgeries included a nephroureterectomy. Patient medications included Decadron (dexamethasone) and Dilantin (phenytoin). Family history included a malignant neoplasm of the kidney.
103	2357636	LUNGNOT20	The LUNGNOT20 library was constructed using polyA RNA isolated from lung tissue removed from the right upper lobe of a 61-year-old Caucasian male during a segmental lung resection. Pathology indicated panacinar emphysema. Family history included a subdural hemorrhage, cancer at an unidentified site, benign hypertension, atherosclerotic coronary artery disease, pneumonia, and an unspecified muscle disorder.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
104	2365230	ADRENOT07	The ADRENOT07 library was constructed using polyA RNA isolated from adrenal tissue removed from a 61-year-old female during a bilateral adrenalectomy. Patient history included an unspecified disorder of the adrenal glands, depressive disorder, benign hypertension, vocal cord paralysis, hemiplegia, subarachnoid hemorrhage, communicating hydrocephalus, neoplasm of uncertain behavior of pituitary gland, hyperlipidemia, Type II diabetes, a benign neoplasm of the colon, osteoarthritis, Meckel's diverticulum, and tobacco use. Previous surgeries included total excision of the pituitary gland and a unilateral thyroid lobectomy. Patient medications included Calderol and Premarin (conjugated estrogen). Family history included prostate cancer, benign hypertension, myocardial infarction, atherosclerotic coronary artery disease, congestive heart failure, hyperlipidemia, depression, anxiety disorder, colon cancer, and gas gangrene.
105	2455121	ENDANOT01	The ENDANOT01 library was constructed using polyA RNA isolated from aortic endothelial cell tissue from an explanted heart removed from a male during a heart transplant.
106	2472514	THPINOT03	The THPINOT03 library was constructed using polyA RNA isolated from untreated THP-1 cells. THP-1 (ATCC TIB 202) is a human promonocyte line derived from the peripheral blood of a 1-year-old Caucasian male with acute monocytic leukemia (ref: Int. J. Cancer (1980) 26:171).
107	2543486	UTRSNOT11	The UTRSNOT11 library was constructed using polyA RNA isolated from uterine myometrial tissue removed from a 43-year-old female during a vaginal hysterectomy and salpingo-oophorectomy. The endometrium was in proliferative phase. Family history included benign hypertension, hyperlipidemia, colon cancer, Type II diabetes, and atherosclerotic coronary artery disease.
108	2778171	OVARTUT03	The OVARTUT03 library was constructed using polyA RNA isolated from ovarian tumor tissue removed from the left ovary of a 52-year-old mixed ethnicity female during a total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal and lymphatic structure biopsy, regional lymph node excision, and peritoneal tissue destruction. Pathology indicated an invasive grade 3 (of 4) seroanaplastic carcinoma. Pathology also indicated a metastatic grade 3 seroanaplastic carcinoma. Patient history included breast cancer, chronic peptic ulcer, joint pain, and a normal delivery. Family history included colon cancer, cerebrovascular disease, breast cancer, Type II diabetes, esophagus cancer, and depressive disorder.
109	2799575	PENCNOT01	The PENCNOT01 library was constructed using polyA RNA isolated from penis corpus cavernosum tissue removed from a 53-year-old male. Patient history included an untreated penile carcinoma.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
110	2804955	BLADTUT08	The BLADTUT08 library was constructed using polyA RNA isolated from bladder tumor tissue removed from a 72-year-old Caucasian male during a radical cystectomy and prostatectomy. Pathology indicated an invasive grade 3 (of 3) transitional cell carcinoma. Family history included myocardial infarction, cerebrovascular disease, and brain cancer.
111	2806395	BLADTUT08	The BLADTUT08 library was constructed using polyA RNA isolated from bladder tumor tissue removed from a 72-year-old Caucasian male during a radical cystectomy and prostatectomy. Pathology indicated an invasive grade 3 (of 3) transitional cell carcinoma. Family history included myocardial infarction, cerebrovascular disease, and brain cancer.
112	2836858	TYMNOT03	The TYMNOT03 library was constructed using polyA RNA isolated from nonactivated Th1 cells. These cells were differentiated from umbilical cord CD4 T cells with IL-12 and B7-transfected COS cells.
113	2844513	DRGLNOT01	The DRGLNOT01 library was constructed using polyA RNA isolated from dorsal root ganglion tissue removed from the low thoracic/high lumbar region of a 32-year-old Caucasian male, who died from acute pulmonary edema, acute bronchopneumonia, bilateral pleural effusions, pericardial effusion, and malignant lymphoma (natural killer cell type). Patient medications included Diflucan (fluconazole), Deltasone (prednisone), hydrocodone, Lortab, Alprazolam, Reazodone, Cytabom, Etoposide, Cisplatin, Cytarabine, and dexamethasone. The patient received radiation therapy and multiple blood transfusions.
114	3000380	TYMNOT06	The TYMNOT06 library was constructed using polyA RNA isolated from activated Th2 cells. These cells were differentiated from umbilical cord CD4 T cells with IL-4 in the presence of anti-IL-12 antibodies and B7-transfected COS cells, and then activated for six hours with anti-CD3 and anti-CD28 antibodies.
115	182532	PLACNOB01	The PLACNOB01 library was constructed using RNA isolated from placenta.
116	239589	HIPONOT01	The HIPONOT01 library was constructed using RNA isolated from the hippocampus tissue of a 72-year-old Caucasian female who died from an intracranial bleed. Patient history included nose cancer, hypertension, and arthritis.
117	1671302	BMARNOT03	The BMARNOT03 library was constructed using RNA isolated from the left tibial bone marrow tissue of a 16-year-old Caucasian male during a partial left tibial osteotomy with free skin graft. Patient history included an abnormality of the red blood cells. Family history included osteoarthritis.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
118	2041858	HIPONON02	This normalized hippocampus library was constructed from 1.13M independent clones from HIPONOT01 library. RNA was isolated from the hippocampus tissue of a 72-year-old Caucasian female who died from an intracranial bleed. Patient history included nose cancer, hypertension, and arthritis. The normalization and hybridization conditions were adapted from Soares et al. (PNAS (1994) 91:9928).
119	2198863	SPLNFET02	The SPLNFET02 library was constructed using RNA isolated from spleen tissue removed from a Caucasian male fetus, who died at 23 weeks gestation.
120	3250703	SEMVNOT03	The SEMVNOT03 library was constructed using RNA isolated from seminal vesicle tissue removed from a 56-year-old male during a radical prostatectomy. Pathology for the associated tumor tissue indicated adenocarcinoma (Gleason grade 3+3).
121	350287	LVENNOT01	The LVENNOT01 library was constructed using RNA isolated from the left ventricle of a 51-year-old Caucasian female who died from intracranial bleeding.
122	1618171	BRAITUT12	The BRAITUT12 library was constructed using RNA isolated from brain tumor tissue removed from the left frontal lobe of a 40-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated grade 4 gemistocytic astrocytoma. Medications included dexamethasone and phenytoin sodium.
123	1625863	COLNPOT01	The COLNPOT01 library was constructed using RNA isolated from colon polyp tissue removed from a 40-year-old Caucasian female during a total colectomy. Pathology indicated an inflammatory pseudopolyp; this tissue was associated with a focally invasive grade 2 adenocarcinoma and multiple tubovillous adenomas. Patient history included a benign neoplasm of the bowel. Medications included Zantac, betamethasone, furosemide, and amiodarone.
124	1638353	UTRSNOT06	The UTRSNOT06 library was constructed using RNA isolated from myometrial tissue removed from a 50-year-old Caucasian female during a vaginal hysterectomy. Pathology indicated residual atypical complex endometrial hyperplasia. Pathology for the associated tissue removed during dilation and curettage indicated fragments of atypical complex hyperplasia and a single microscopic focus suspicious for grade 1 adenocarcinoma. Patient history included benign breast neoplasm, hypothyroid disease, polypectomy, and arthralgia.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
125	1726843	PROSNOT14	The PROSNOT14 library was constructed using RNA isolated from diseased prostate tissue removed from a 60-year-old Caucasian male during radical prostatectomy and regional lymph node excision. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated an adenocarcinoma (Gleason grade 3+4). The patient presented with elevated prostate specific antigen (PSA). Patient history included a kidney cyst and hematuria. Family history included benign hypertension, cerebrovascular disease, and arteriosclerotic coronary artery disease.
126	1754506	LIVRTUT01	The LIVRTUT01 library was constructed using RNA isolated from liver tumor tissue removed from a 51-year-old Caucasian female during a hepatic lobectomy. Pathology indicated metastatic grade 3 adenocarcinoma consistent with colon cancer. Medications included Premarin, Provera, and earlier, fluorouracil, and leucovorin. Family history included a malignant neoplasm of the liver.
127	1831378	THPIAZT01	The THPIAZT01 library was constructed using RNA isolated from THP-1 promonocyte cells treated for 3 days with 0.8 micromolar 5-aza-2'-deoxycytidine. THP-1 (ATCC TIB 202) is a human promonocyte line derived from peripheral blood of a one-year-old Caucasian male with acute monocytic leukemia (Int. J. Cancer (1980) 26:171).
128	1864943	PROSNOT19	The PROSNOT19 library was constructed using RNA isolated from diseased prostate tissue removed from a 59-year-old Caucasian male during a radical prostatectomy with regional lymph node excision. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated an adenocarcinoma (Gleason grade 3+3). The patient presented with elevated prostate-specific antigen (PSA). Family history included benign hypertension, multiple myeloma, hyperlipidemia, and rheumatoid arthritis.
129	1911316	CONNTUT01	The CONNTUT01 library was constructed using RNA isolated from a soft tissue tumor removed from the clival area of the skull of a 30-year-old Caucasian female. Pathology indicated chondroid chordoma with neoplastic cells reactive for keratin. Medications included medroxyprogesterone acetate.
130	1943120	HIPONOT01	The HIPONOT01 library was constructed using RNA isolated from the hippocampus tissue of a 72-year-old Caucasian female who died from intracranial bleeding. Patient history included nose cancer, hypertension, and arthritis.
131	2314236	NGANNT01	The NGANNT01 library was constructed using RNA isolated from tumorous neuroganglion tissue removed from a 9-year-old Caucasian male during a soft tissue excision of the chest wall. Pathology indicated a ganglioneuroma forming an encapsulated lobulated mass. The tissue from the medial aspect pleura surrounding the tumor showed fibrotic tissue with chronic inflammation. Family history included asthma.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
132	2479409	SMC'ANO'101	The SMC'ANO'101 library was constructed using RNA isolated from an aortic smooth muscle cell line derived from the explanted heart of a male during a heart transplant.
133	2683149	SINIUCT01	The SINIUCT01 library was constructed using RNA isolated from ileum tissue obtained from a 42-year-old Caucasian male during a total intra-abdominal colectomy and endoscopic jejunostomy. Previous surgeries included polypectomy, colonoscopy, and spinal canal exploration. Medications included Prednisone, mesalamine, and Deltasone. Family history included cerebrovascular disease, benign hypertension, atherosclerotic coronary artery disease, and type II diabetes.
134	2774051	PANCNOT15	The PANCNOT15 library was constructed using RNA isolated from diseased pancreatic tissue removed from a 15-year-old Caucasian male during an exploratory laparotomy with distal pancreatectomy and total splenectomy. Pathology indicated islet cell hyperplasia. A single pancreatic lymph node was negative. Family history included prostate cancer and cardiovascular disease.
135	2869038	THYRNOT10	The THYRNOT10 library was constructed using RNA isolated from the diseased left thyroid tissue removed from a 30-year-old Caucasian female during a unilateral thyroid lobectomy and parathyroid reimplantation. Pathology indicated lymphocytic thyroiditis. Pathology for the associated tumor indicated grade 1 (of 4) papillary carcinoma of the right thyroid gland, follicular variant. Multiple perithyroidal and other lymph nodes were negative. Patient history included hyperlipidemia and benign ovary neoplasm. Medications included Premarin, Provera, and Anaprox.
136	2918334	THYMFET03	The THYMFET03 library was constructed using RNA isolated from thymus tissue removed from a Caucasian male fetus who died at premature birth. Serology was negative.
137	2949916	KIDNFET01	The KIDNFET01 library was constructed using RNA isolated from kidney tissue removed from a Caucasian female fetus, who died at 17 weeks gestation from anencephalus. Serology was negative.
138	2989375	KIDNFET02	The KIDNFET02 library was constructed using RNA isolated from kidney tissue removed from a Caucasian male fetus who was stillborn with a hypoplastic left heart at 23 weeks gestation. Serology was negative.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
139	3316764	PROSBP103	The PROSBP103 library was constructed using RNA isolated from diseased prostate tissue removed from a 59-year-old Caucasian male during a radical prostatectomy and regional lymph node excision. Pathology indicated benign prostatic hyperplasia. Pathology for the associated tumor indicated adenocarcinoma, Gleason grade 3+3. The patient presented with elevated prostate specific antigen (PSA), benign hypertension, and hyperlipidemia. Medications included Lotensin and Pravachol. Family history included cerebrovascular disease, benign hypertension, and prostate cancer.
140	3359559	PROSTUT16	The PROSTUT16 library was constructed using RNA isolated from prostate tumor tissue removed from a 55-year-old Caucasian male. Pathology indicated adenocarcinoma, Gleason grade 5+4. Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Patient history included calculus of the kidney. Family history included lung cancer and breast cancer.
141	4289208	BRABDIR01	The BRABDIR01 library was constructed using RNA isolated from diseased cerebellum tissue removed from the brain of a 57-year-old Caucasian male who died from a cerebrovascular accident. Patient history included Huntington's disease, emphysema, and long-term tobacco use.
142	2454013	ENDANOT01	The ENDANOT01 library was constructed using RNA isolated from aortic endothelial cell tissue from an explanted heart removed from a male during a heart transplant.
143	2454048	ENDANOT01	The ENDANOT01 library was constructed using RNA isolated from aortic endothelial cell tissue from an explanted heart removed from a male during a heart transplant.
144	2479282	SMCANOT01	The SMCANOT01 library was constructed using RNA isolated from an aortic smooth muscle cell line derived from the explanted heart of a male during a heart transplant.
145	2483432	SMCANOT01	The SMCANOT01 library was constructed using RNA isolated from an aortic smooth muscle cell line derived from the explanted heart of a male during a heart transplant.
146	2493824	ADRETUT05	The ADRETUT05 library was constructed using RNA isolated from adrenal tumor tissue removed from a 52-year-old Caucasian female during a unilateral adrenalectomy. Pathology indicated a pheochromocytoma.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
147	2555823	TI1YMNOT03	The TI1YMNOT03 library was constructed using 0.5 micrograms of polyA ⁺ RNA isolated from thymus tissue removed from a 21-year-old Caucasian male during a thymectomy. Pathology indicated an unremarkable thymus and a benign parathyroid adenoma in the right inferior parathyroid. Patient history included atopic dermatitis, a benign neoplasm of the parathyroid, and tobacco use. Patient medications included multivitamins. Family history included atherosclerotic coronary artery disease and benign hypertension.
148	2598242	OVARTUT02	The OVARTUT02 library was constructed using RNA isolated from ovarian tumor tissue removed from a 51-year-old Caucasian female during an exploratory laparotomy, total abdominal hysterectomy, salpingo-oophorectomy, and an incidental appendectomy. Pathology indicated mucinous cystadenoma presenting as a multiloculated neoplasm involving the entire left ovary. The right ovary contained a follicular cyst and a hemorrhagic corpus luteum. The uterus showed proliferative endometrium and a single intramural leiomyoma. The peritoneal biopsy indicated benign glandular inclusions consistent with endosalpingiosis. Family history included atherosclerotic coronary artery disease, benign hypertension, breast cancer, and uterine cancer.
149	2634120	COLNTUT15	The COLNTUT15 library was constructed using RNA isolated from colon tumor tissue obtained from a 64-year-old Caucasian female during a right hemicolectomy with ileostomy and bilateral salpingo-oophorectomy (removal of the fallopian tubes and ovaries). Pathology indicated an invasive grade 3 adenocarcinoma. Patient history included hypothyroidism, depression, and anemia. Family history included colon cancer and uterine cancer.
150	2765411	BRSTNOT12	The BRSTNOT12 library was constructed using RNA isolated from diseased breast tissue removed from a 32-year-old Caucasian female during a bilateral reduction mammoplasty. Pathology indicated nonproliferative fibrocystic disease. Family history included benign hypertension and atherosclerotic coronary artery disease.
151	2769412	COLANOT02	The COLANOT02 library was constructed using RNA isolated from diseased ascending colon tissue removed from a 25-year-old Caucasian female during a multiple segmental resection of the large bowel. Pathology indicated moderately to severely active chronic ulcerative colitis, involving the entire colectomy specimen and sparing 2 cm of the attached ileum. Grossly, the specimen showed continuous involvement from the rectum proximally; marked mucosal atrophy and no skip areas were identified. Microscopically, the specimen showed dense, predominantly mucosal inflammation and crypt abscesses. Patient history included benign large bowel neoplasm.

Table 4 (cont.)

Protein SEQ ID NO:	Clone ID	Library	Library Comment
152	2842779	DRGLNOT01	The DRGLNOT01 library was constructed using RNA isolated from dorsal root ganglion tissue removed from the low thoracic/high lumbar region of a 32-year-old Caucasian male who died from acute pulmonary edema and bronchopneumonia, bilateral pleural and pericardial effusions, and malignant lymphoma (natural killer cell type). Patient history included probable cytomegalovirus, infection, hepatic congestion and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, and Bell's palsy.
153	2966260	SCORNOT04	The SCORNOT04 library was constructed using RNA isolated from cervical spinal cord tissue removed from a 32-year-old Caucasian male who died from acute pulmonary edema and bronchopneumonia, bilateral pleural and pericardial effusions, and malignant lymphoma (natural killer cell type). Patient history included probable cytomegalovirus, infection, hepatic congestion and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, and Bell's palsy.
154	2993326	KIDNFET02	The KIDNFET02 library was constructed using RNA isolated from kidney tissue removed from a Caucasian male fetus, who was stillborn with a hypoplastic left heart and died at 23 weeks' gestation.
155	3001124	TYMNOT06	The TYMNOT06 library was constructed using 0.5 micrograms of polyA RNA isolated from activated Th2 cells. These cells were differentiated from umbilical cord CD4 T cells with IL-4 in the presence of anti-IL-12 antibodies and B7-transfected COS cells, and then activated for six hours with anti-CD3 and anti-CD28 antibodies.
156	3120070	LUNGTUT13	The LUNGTUT13 library was constructed using RNA isolated from tumorous lung tissue removed from the right upper lobe of a 47-year-old Caucasian male during a segmental lung resection. Pathology indicated invasive grade 3 (of 4) adenocarcinoma. Family history included atherosclerotic coronary artery disease, and type II diabetes.
157	3133035	SMCCNOT01	The SMCCNOT01 library was constructed using RNA isolated from smooth muscle cells removed from the coronary artery of a 3-year-old Caucasian male.
158	3436879	PENCNOT05	The PENCNOT05 library was constructed using RNA isolated from penis left corpus cavernosum tissue.

Table 5

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25: 3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLOCKS IMPROVED Searcher that matches a sequence against those in BLOCKS and PRINTS databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S and J.G. Henikoff, Nucl. Acid Res., 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424.	Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and Probability value= 1.0E-3 or less
PFAM	A Hidden Markov Models-based application useful for protein family search.	Krogh, A. et al. (1994) J. Mol. Biol., 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322.	Score=10-50 bits, depending on individual protein families

Table 5 cont.

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221.	Score= 4.0 or greater
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439.	Score=5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch et al. <u>supra</u> ; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, and SEQ ID NO:79 and fragments thereof.
2. A substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of claim 1.
3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
4. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 3.
5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.
7. A method for detecting a polynucleotide, the method comprising the steps of:
 - (a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid

in a sample, thereby forming a hybridization complex; and

(b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.

5 8. The method of claim 7 further comprising amplifying the polynucleotide prior to hybridization.

9. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87,
10 SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID
15 NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID
20 NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, and SEQ ID NO:158 and fragments thereof.

25 10. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 9.

11. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 9.

12. An expression vector comprising at least a fragment of the polynucleotide
30 of claim 3.

13. A host cell comprising the expression vector of claim 12.

14. A method for producing a polypeptide, the method comprising the steps of:

- a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and
 - b) recovering the polypeptide from the host cell culture.
15. A pharmaceutical composition comprising the polypeptide of claim 1 in
5 conjunction with a suitable pharmaceutical carrier.
16. A purified antibody which specifically binds to the polypeptide of claim 1.
17. A purified agonist of the polypeptide of claim 1.
18. A purified antagonist of the polypeptide of claim 1.
19. A method for treating or preventing a disorder associated with decreased
10 expression or activity of HTMPN, the method comprising administering to a subject in
need of such treatment an effective amount of the pharmaceutical composition of claim 15.
20. A method for treating or preventing a disorder associated with increased
expression or activity of HTMPN, the method comprising administering to a subject in
need of such treatment an effective amount of the antagonist of claim 18.

15

<110> INCYTE PHARMACEUTICALS, INC.

TANG, Y. Tom
LAL, Preeti
HILLMAN, Jennifer L.
YUE, Henry
GUEGLER, Karl J.
CORLEY, Neil C.
BANDMAN, Olga
PATTERSON, Chandra
GORGONE, Gina A.
KASER, Matthew R.
BAUGHN, Mariah R.
AU-YOUNG, Janice

<120> HUMAN TRANSMEMBRANE PROTEINS

<130> PF-0526 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/087,260; 60/091,674; 60/102,954; 60/109,869

<151> 1998-05-29; 1998-07-02; 1998-10-02; 1998-11-24

<160> 158

<170> PERL Program

<210> 1

<211> 240

<212> PRT

<213> Homo sapiens

<220>

<221> misc feature

<223> Incyte Clone No: 153831

<400> 1

Met	Gly	Asn	Cys	Gln	Ala	Gly	His	Asn	Leu	His	Leu	Cys	Leu	Ala
1				5					10					15
His	His	Pro	Pro	Leu	Val	Cys	Ala	Thr	Leu	Ile	Leu	Leu	Leu	Leu
				20					25					30
Gly	Leu	Ser	Gly	Leu	Gly	Leu	Gly	Ser	Phe	Leu	Leu	Thr	His	Arg
				35					40					45
Thr	Gly	Leu	Arg	Ser	Pro	Asp	Ile	Pro	Gln	Asp	Trp	Val	Ser	Phe
				50					55					60
Leu	Arg	Ser	Phe	Gly	Gln	Leu	Thr	Leu	Cys	Pro	Arg	Asn	Gly	Thr
				65					70					75
Val	Thr	Gly	Lys	Trp	Arg	Gly	Ser	His	Val	Val	Gly	Leu	Leu	Thr
				80					85					90
Thr	Leu	Asn	Phe	Gly	Asp	Gly	Pro	Asp	Arg	Asn	Lys	Thr	Arg	Thr
				95					100					105
Phe	Gln	Ala	Thr	Val	Leu	Gly	Ser	Gln	Met	Gly	Leu	Lys	Gly	Ser
				110					115					120

Ser	Ala	Gly	Gln	Leu	Val	Leu	Ile	Thr	Ala	Arg	Val	Thr	Thr	Glu
				125						130				135
Arg	Thr	Ala	Gly	Thr	Cys	Leu	Tyr	Phe	Ser	Ala	Val	Pro	Gly	Ile
				140						145				150
Leu	Pro	Ser	Ser	Gln	Pro	Pro	Ile	Ser	Cys	Ser	Glu	Glu	Gly	Ala
				155						160				165
Gly	Asn	Ala	Thr	Leu	Ser	Pro	Arg	Met	Gly	Glu	Glu	Cys	Val	Ser
				170						175				180
Val	Trp	Ser	His	Glu	Gly	Leu	Val	Leu	Thr	Lys	Leu	Leu	Thr	Ser
				185						190				195
Glu	Glu	Leu	Ala	Leu	Cys	Gly	Ser	Arg	Leu	Leu	Val	Leu	Gly	Ser
				200						205				210
Phe	Leu	Leu	Leu	Phe	Cys	Gly	Leu	Leu	Cys	Cys	Val	Thr	Ala	Met
				215						220				225
Cys	Phe	His	Pro	Arg	Arg	Glu	Ser	His	Trp	Ser	Arg	Thr	Arg	Leu
				230						235				240

<210> 2
 <211> 100
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 350629

<400> 2
 Met Glu Gly Leu Arg Ser Ser Val Glu Leu Asp Pro Glu Leu Thr
 1 5 10 15
 Pro Gly Lys Leu Asp Glu Glu Met Val Gly Leu Pro Pro His Asp
 20 25 30
 Ala Ser Pro Gln Val Thr Phe His Ser Leu Asp Gly Lys Thr Val
 35 40 45
 Val Cys Pro His Phe Met Gly Leu Leu Leu Gly Leu Leu Leu Leu
 50 55 60
 Leu Thr Leu Ser Val Arg Asn Gln Leu Cys Val Arg Gly Glu Arg
 65 70 75
 Gln Leu Ala Glu Thr Leu His Ser Gln Val Lys Glu Lys Ser Gln
 80 85 90
 Leu Ile Gly Lys Lys Thr Asp Cys Arg Asp
 95 100

<210> 3
 <211> 416
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 729171

<400> 3

```

Met Ser Gly His Arg Ser Thr Arg Lys Arg Cys Gly Asp Ser His
  1          5          10          15
Pro Glu Ser Pro Val Gly Phe Gly His Met Ser Thr Thr Gly Cys
  20          25          30
Val Leu Asn Lys Leu Phe Gln Leu Pro Thr Pro Pro Leu Ser Arg
  35          40          45
His Gln Leu Lys Arg Leu Glu Glu His Arg Tyr Gln Ser Ala Gly
  50          55          60
Arg Ser Leu Leu Glu Pro Leu Val Gln Gly Tyr Trp Glu Trp Leu
  65          70          75
Val Arg Arg Val Pro Ser Trp Ile Ala Pro Asn Leu Ile Thr Ile
  80          85          90
Ile Gly Leu Ser Ile Asn Ile Cys Thr Thr Ile Leu Leu Val Phe
  95          100         105
Tyr Cys Pro Thr Ala Thr Glu Gln Ala Pro Leu Trp Ala Tyr Ile
  110         115         120
Ala Cys Ala Cys Gly Leu Phe Ile Tyr Gln Ser Leu Asp Ala Ile
  125         130         135
Gly Gly Lys Gln Ala Arg Arg Thr Asn Ser Ser Ser Pro Leu Gly
  140         145         150
Glu Leu Phe Asp His Gly Cys Asp Ser Leu Ser Thr Val Phe Val
  155         160         165
Val Leu Gly Thr Cys Ile Ala Val Gln Leu Gly Thr Asn Pro Asp
  170         175         180
Trp Met Phe Phe Cys Cys Phe Ala Gly Thr Phe Met Phe Tyr Cys
  185         190         195
Ala His Trp Gln Thr Tyr Val Ser Gly Thr Leu Arg Phe Gly Ile
  200         205         210
Ile Asp Val Thr Glu Val Gln Ile Phe Ile Ile Ile Met His Leu
  215         220         225
Leu Ala Val Met Gly Gly Pro Pro Phe Trp Gln Ser Met Ile Pro
  230         235         240
Val Leu Asn Ile Gln Met Lys Ile Phe Pro Ala Leu Cys Thr Val
  245         250         255
Ala Gly Thr Ile Phe Pro Val Thr Asn Tyr Phe Arg Val Ile Phe
  260         265         270
Thr Gly Gly Val Gly Lys Asn Gly Ser Thr Ile Ala Gly Thr Ser
  275         280         285
Val Leu Ser Pro Phe Leu His Ile Gly Ser Val Ile Thr Leu Ala
  290         295         300
Ala Met Ile Tyr Lys Lys Ser Ala Val Gln Leu Phe Glu Lys His
  305         310         315
Pro Cys Leu Tyr Ile Leu Thr Phe Gly Phe Val Ser Ala Lys Ile
  320         325         330
Thr Asn Lys Leu Val Val Ala His Met Thr Lys Ser Glu Met His
  335         340         345
Leu His Asp Thr Ala Phe Ile Gly Pro Ala Leu Leu Phe Leu Asp
  350         355         360
Gln Tyr Phe Asn Ser Phe Ile Asp Glu Tyr Ile Val Leu Trp Ile
  365         370         375
Ala Leu Val Phe Ser Phe Phe Asp Leu Ile Arg Tyr Cys Val Ser
  380         385         390
Val Cys Asn Gln Ile Ala Ser His Leu His Ile His Val Phe Arg
  395         400         405
Ile Lys Val Ser Thr Ala His Ser Asn His His

```

410

415

<210> 4
 <211> 224
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1273641

<400> 4
 Met Thr Ile Thr Ser Phe Tyr Ala Val Cys Phe Tyr Leu Leu Met
 5 10 15
 Leu Val Met Val Glu Gly Phe Gly Gly Lys Glu Ala Val Leu Arg
 20 25 30
 Thr Leu Arg Asp Thr Pro Met Met Val His Thr Gly Pro Cys Cys
 35 40 45
 Cys Cys Cys Pro Cys Cys Gln Arg Leu Leu Leu Thr Arg Lys Lys
 50 55 60
 Leu Gln Leu Leu Met Leu Gly Pro Phe Gln Tyr Ala Phe Leu Lys
 65 70 75
 Ile Thr Leu Thr Trp Trp Ala Leu Phe Ser Ser Pro Thr Glu Ser
 80 85 90
 Tyr Asp Pro Ala Asp Ile Ser Glu Gly Ser Thr Ala Leu Trp Ile
 95 100 105
 Asn Thr Phe Leu Gly Val Ser Thr Leu Leu Ala Leu Trp Thr Leu
 110 115 120
 Gly Ile Ile Ser Arg Gln Ala Arg Leu His Leu Gly Glu Gln Asn
 125 130 135
 Met Gly Ala Lys Phe Ala Leu Phe Gln Val Leu Leu Ile Leu Thr
 140 145 150
 Ala Leu Gln Pro Ser Ile Phe Ser Val Leu Ala Asn Gly Gly Gln
 155 160 165
 Ile Ala Cys Ser Pro Pro Tyr Ser Ser Lys Thr Arg Ser Gln Val
 170 175 180
 Met Asn Cys His Leu Leu Ile Leu Glu Thr Phe Leu Met Thr Val
 185 190 195
 Leu Thr Arg Met Tyr Tyr Arg Arg Lys Asp His Lys Val Gly Tyr
 200 205 210
 Glu Thr Phe Ser Ser Pro Asp Leu Asp Leu Asn Leu Lys Ala
 215 220

<210> 5
 <211> 247
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1427389

<400> 5


```

Met Gly Ala Ala Val Phe Phe Gly Cys Thr Phe Val Ala Phe Gly
 1           5           10           15
Pro Ala Phe Ala Leu Phe Leu Ile Thr Val Ala Gly Asp Pro Leu
          20           25           30
Arg Val Ile Ile Leu Val Ala Gly Ala Phe Phe Trp Leu Val Ser
          35           40           45
Leu Leu Leu Ala Ser Val Val Trp Phe Ile Leu Val His Val Thr
          50           55           60
Asp Arg Ser Asp Ala Arg Leu Gln Tyr Gly Leu Leu Ile Phe Gly
          65           70           75
Ala Ala Val Ser Val Leu Leu Gln Glu Val Phe Arg Phe Ala Tyr
          80           85           90
Tyr Lys Leu Leu Lys Lys Ala Asp Glu Gly Leu Ala Ser Leu Ser
          95          100          105
Glu Asp Gly Arg Ser Pro Ile Ser Ile Arg Gln Met Ala Tyr Val
          110          115          120
Ser Gly Leu Ser Phe Gly Ile Ile Ser Gly Val Phe Ser Val Ile
          125          130          135
Asn Ile Leu Ala Asp Ala Leu Gly Pro Gly Val Val Gly Ile His
          140          145          150
Gly Asp Ser Pro Tyr Tyr Phe Leu Thr Ser Ala Phe Leu Thr Ala
          155          160          165
Ala Ile Ile Leu Leu His Thr Phe Trp Gly Val Val Phe Phe Asp
          170          175          180
Ala Cys Glu Arg Arg Arg Tyr Trp Ala Leu Gly Leu Val Val Gly
          185          190          195
Ser His Leu Leu Thr Ser Gly Leu Thr Phe Leu Asn Pro Trp Tyr
          200          205          210
Glu Ala Ser Leu Leu Pro Ile Tyr Ala Val Thr Val Ser Met Gly
          215          220          225
Leu Trp Ala Phe Ile Thr Ala Gly Gly Ser Leu Arg Ser Ile Gln
          230          235          240
Arg Ser Leu Leu Cys Lys Asp
          245

```

<210> 6

<211> 72

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1458357

<400> 6

```

Met Tyr Trp Leu His Gln Asp Met Phe Trp Leu Leu Val Leu Ile
 1           5           10           15
Leu Ile Cys Leu Val Thr His Leu Ile Thr Arg Glu Thr Ile Tyr
          20           25           30
Val Lys Ser Leu Phe Tyr Phe Lys Ile Leu Phe Val Tyr Leu Glu
          35           40           45
Ser Lys Pro Ala His Cys Asn Leu Cys Leu Tyr Ala Lys Glu Leu
          50           55           60

```

Asp Phe Phe Val Phe Val Leu Phe Phe Lys Leu Leu
 65 70

<210> 7
 <211> 106
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1482837

<400> 7
 Met His Tyr Gly Phe Leu Leu Trp Ser Gly Lys Lys Arg Gly Leu
 1 5 10 15
 Ala Gly Pro Gln Gly Ile Cys Lys Ser Gln Lys Thr Val Phe Leu
 20 25 30
 Thr Ala Arg Cys His Ser Thr Leu Val Gly Lys Glu Glu Lys Lys
 35 40 45
 Ile Lys Leu Phe His Arg Thr Ser Trp Pro Pro His Ser His Ala
 50 55 60
 Leu Pro Thr Gln Pro Gly Pro Leu Pro Ala Pro Phe Ile Lys Ala
 65 70 75
 Glu Arg Val Glu Leu Ile Phe Thr Asn Cys Asn Ile Phe Val Val
 80 85 90
 Ser Val Ser Ser Phe Val Ser Ser Ala Glu Pro Cys Pro Phe Leu
 95 100 105
 Leu

<210> 8
 <211> 239
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1517434

<400> 8
 Met Cys Val Thr Gln Leu Arg Leu Ile Phe Tyr Met Gly Ala Met
 1 5 10 15
 Asn Asn Ile Leu Lys Phe Leu Val Ser Gly Asp Gln Lys Thr Val
 20 25 30
 Gly Leu Tyr Thr Ser Ile Phe Gly Val Leu Gln Leu Leu Cys Leu
 35 40 45
 Leu Thr Ala Pro Val Ile Gly Tyr Ile Met Asp Trp Arg Leu Lys
 50 55 60
 Glu Cys Glu Asp Ala Ser Glu Glu Pro Glu Glu Lys Asp Ala Asn
 65 70 75
 Gln Gly Glu Lys Lys Lys Lys Lys Arg Asp Arg Gln Ile Gln Lys
 80 85 90
 Ile Thr Asn Ala Met Arg Ala Phe Ala Phe Thr Asn Leu Leu Leu
 95 100 105

Val Gly Phe Gly	Val Thr Cys Leu Ile	Pro Asn Leu Pro Leu Gln
110	115	120
Ile Leu Ser Phe	Ile Leu His Thr Ile	Val Arg Gly Phe Ile His
125	130	135
Ser Ala Val Gly	Gly Leu Tyr Ala Ala	Val Tyr Pro Ser Thr Gln
140	145	150
Phe Gly Ser Leu	Thr Gly Leu Gln Ser	Leu Ile Ser Ala Leu Phe
155	160	165
Ala Leu Leu Gln	Gln Pro Leu Phe Leu	Ala Met Met Gly Pro Leu
170	175	180
Gln Gly Asp Pro	Leu Trp Val Asn Val	Gly Leu Leu Leu Leu Ser
185	190	195
Leu Leu Gly Phe	Cys Leu Pro Leu Tyr	Leu Ile Cys Tyr Arg Arg
200	205	210
Gln Leu Glu Arg	Gln Leu Gln Gln Arg	Gln Glu Asp Asp Lys Leu
215	220	225
Phe Leu Lys Ile	Asn Gly Ser Ser Asn	Gln Glu Ala Phe Val
230	235	

<210> 9

<211> 150

<212> PRT

<213> Homo sapiens

<220>

<221> misc feature

<223> Incyte Clone No: 1536052

<400> 9

Met Trp Leu Pro	Trp Ala Leu Leu Leu	Leu Trp Val Pro Ala Ser
1	5	10 15
Thr Ser Met Thr	Pro Ala Ser Ile Thr	Ala Ala Lys Thr Ser Thr
20	25	30
Ile Thr Thr Ala	Phe Pro Pro Val Ser	Ser Thr Thr Leu Phe Ala
35	40	45
Val Gly Ala Thr	His Ser Ala Ser Ile	Gln Glu Glu Thr Glu Glu
50	55	60
Val Val Asn Ser	Gln Leu Pro Leu Leu	Leu Ser Leu Leu Ala Leu
65	70	75
Leu Leu Leu Leu	Leu Val Gly Ala Ser	Leu Leu Ala Trp Arg Met
80	85	90
Phe Gln Lys Trp	Ile Lys Ala Gly Asp	His Ser Glu Leu Ser Gln
95	100	105
Asn Pro Lys Gln	Ala Ser Pro Arg Glu	Glu Leu His Tyr Ala Ser
110	115	120
Val Val Phe Asp	Ser Asn Thr Asn Arg	Ile Ala Ala Gln Arg Pro
125	130	135
Arg Glu Glu Glu	Pro Asp Ser Asp Tyr	Ser Val Ile Arg Lys Thr
140	145	150

<210> 10

<211> 110

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1666118

<400> 10

```

Met Pro Ala Cys Ile Leu Glu Asp Val Glu Ile Ser Phe Arg Gln
 1           5           10           15
Lys Trp Ser Ile Asn Ser Asp Thr Leu Leu Gly Cys Leu Thr Leu
           20           25           30
Phe Ile Ser Ala Phe Phe Ala Ser Glu Thr Trp Gln Lys Leu Val
           35           40           45
Ser Gln Ser Thr Ala Phe Leu Thr Met Cys Gly Val Thr Tyr Ala
           50           55           60
Trp Tyr Met Pro Leu Leu Leu Lys Phe Tyr Ser Leu Leu Leu
           65           70           75
Ala Gln Val Leu Leu Asn Pro Phe Leu Met Cys Thr Gly Trp Arg
           80           85           90
Lys Asn Tyr Ser Gln His Phe Glu Arg Lys Val Phe Arg Asn Asn
           95          100          105
Ile Asn Trp His Tyr
           110

```

<210> 11

<211> 58

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1675560

<400> 11

```

Met Leu Val Thr Asn Ile Thr Val Asn Arg Ser Leu Leu His Ala
 1           5           10           15
Lys Asp Gln Cys Asp Leu Trp Met Glu Met Ile Val Met Lys Phe
           20           25           30
Leu Phe His Gly Ala Val Phe Leu Phe Ile Ser Leu Gly Ser Arg
           35           40           45
Phe Ser Glu Ala Val Arg Cys Cys Cys Cys Gly Phe Leu
           50           55

```

<210> 12

<211> 221

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1687323

<400> 12

```

Met Ala Ala Ser Ser Ile Ser Ser Pro Trp Gly Lys His Val Phe
  1           5           10           15
Lys Ala Ile Leu Met Val Leu Val Ala Leu Ile Leu Leu His Ser
           20           25           30
Ala Leu Ala Gln Ser Arg Arg Asp Phe Ala Pro Pro Gly Gln Gln
           35           40           45
Lys Arg Glu Ala Pro Val Asp Val Leu Thr Gln Ile Gly Arg Ser
           50           55           60
Val Arg Gly Thr Leu Asp Ala Trp Ile Gly Pro Glu Thr Met His
           65           70           75
Leu Val Ser Glu Ser Ser Ser Gln Val Leu Trp Ala Ile Ser Ser
           80           85           90
Ala Ile Ser Val Ala Phe Phe Ala Leu Ser Gly Ile Ala Ala Gln
           95          100          105
Leu Leu Asn Ala Leu Gly Leu Ala Gly Asp Tyr Leu Ala Gln Gly
          110          115          120
Leu Lys Leu Ser Pro Gly Gln Val Gln Thr Phe Leu Leu Trp Gly
          125          130          135
Ala Gly Ala Leu Val Val Tyr Trp Leu Leu Ser Leu Leu Leu Gly
          140          145          150
Leu Val Leu Ala Leu Leu Gly Arg Ile Leu Trp Gly Leu Lys Leu
          155          160          165
Val Ile Phe Leu Ala Gly Phe Val Ala Leu Met Arg Ser Val Pro
          170          175          180
Asp Pro Ser Thr Arg Ala Leu Leu Leu Leu Ala Leu Leu Ile Leu
          185          190          195
Tyr Ala Leu Leu Ser Arg Leu Thr Gly Ser Arg Ala Ser Gly Ala
          200          205          210
Gln Leu Glu Ala Lys Val Arg Gly Leu Glu Arg
          215          220

```

<210> 13

<211> 262

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1692236

<400> 13

```

Met Ala Leu Gly Leu Lys Cys Phe Arg Met Val His Pro Thr Phe
  1           5           10           15
Arg Asn Tyr Leu Ala Ala Ser Ile Arg Pro Val Ser Glu Val Thr
           20           25           30
Leu Lys Thr Val His Glu Arg Gln His Gly His Arg Gln Tyr Met
           35           40           45
Ala Tyr Ser Ala Val Pro Val Arg His Phe Ala Thr Lys Lys Ala
           50           55           60
Lys Ala Lys Gly Lys Gly Gln Ser Gln Thr Arg Val Asn Ile Asn
           65           70           75
Ala Ala Leu Val Glu Asp Ile Ile Asn Leu Glu Glu Val Asn Glu
           80           85           90

```

Glu Met Lys Ser Val Ile Glu Ala Leu Lys Asp Asn Phe Asn Leu
 95 100 105
 Thr Leu Asn Ile Arg Ala Ser Pro Gly Ser Leu Asp Lys Ile Ala
 110 115 120
 Val Val Thr Ala Asp Gly Lys Leu Ala Leu Asn Gln Ile Ser Gln
 125 130 135
 Ile Ser Met Lys Ser Pro Gln Leu Ile Leu Val Asn Met Ala Ser
 140 145 150
 Phe Pro Glu Cys Thr Ala Ala Ala Ile Lys Ala Ile Arg Glu Ser
 155 160 165
 Gly Met Asn Leu Asn Pro Glu Val Glu Gly Thr Leu Ile Arg Val
 170 175 180
 Pro Ile Pro Gln Val Thr Arg Glu His Arg Glu Met Leu Val Lys
 185 190 195
 Leu Ala Lys Gln Asn Thr Asn Lys Ala Lys Asp Ser Leu Arg Lys
 200 205 210
 Val Arg Thr Asn Ser Met Asn Lys Leu Lys Lys Ser Lys Asp Thr
 215 220 225
 Val Ser Glu Asp Thr Ile Arg Leu Ile Glu Lys Gln Ile Ser Gln
 230 235 240
 Met Ala Asp Asp Thr Val Ala Glu Leu Asp Arg His Leu Ala Val
 245 250 255
 Lys Thr Lys Glu Leu Gly
 260

<210> 14

<211> 90

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1720847

<400> 14

Met Glu Ala Ala Met Glu Trp Glu Gly Gly Ala Ile Arg His Pro
 1 5 10 15
 Ser Thr Glu Leu Gly Ile Met Gly Ser Trp Phe Tyr Leu Phe Leu
 20 25 30
 Ala Pro Leu Phe Lys Gly Leu Ala Gly Ser Leu Pro Phe Gly Cys
 35 40 45
 Leu Ser Leu Leu Gln Pro Thr Glu Lys Thr Ala Leu Gln Arg Trp
 50 55 60
 Arg Val Phe Met Lys His Ser Cys Gln Glu Pro Arg His Arg Ala
 65 70 75
 Gly Gly Leu Glu Lys Gly Gly His Thr Gly Gly Gly Arg Ser Trp
 80 85 90

<210> 15

<211> 208

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1752821

<400> 15

```

Met Ala Ser Ser Leu Leu Ala Gly Glu Arg Leu Val Arg Ala Leu
  1             5             10             15
Gly Pro Gly Gly Glu Leu Glu Pro Glu Arg Leu Pro Arg Lys Leu
  20             25             30
Arg Ala Glu Leu Glu Ala Ala Leu Gly Lys Lys His Lys Gly Gly
  35             40             45
Asp Ser Ser Ser Gly Pro Gln Arg Leu Val Ser Phe Arg Leu Ile
  50             55             60
Arg Asp Leu His Gln His Leu Arg Glu Arg Asp Ser Lys Leu Tyr
  65             70             75
Leu His Glu Leu Leu Glu Gly Ser Glu Ile Tyr Leu Pro Glu Val
  80             85             90
Val Lys Pro Pro Arg Asn Pro Glu Leu Val Ala Arg Leu Glu Lys
  95             100            105
Ile Lys Ile Gln Leu Ala Asn Glu Glu Tyr Lys Arg Ile Thr Arg
  110            115            120
Asn Val Thr Cys Gln Asp Thr Arg His Gly Gly Thr Leu Ser Asp
  125            130            135
Leu Gly Lys Gln Val Arg Ser Leu Lys Ala Leu Val Ile Thr Ile
  140            145            150
Phe Asn Phe Ile Val Thr Val Val Ala Ala Phe Val Cys Thr Tyr
  155            160            165
Leu Gly Ser Gln Tyr Ile Phe Thr Glu Met Ala Ser Arg Val Leu
  170            175            180
Ala Ala Leu Ile Val Ala Ser Val Val Gly Leu Ala Glu Leu Tyr
  185            190            195
Val Met Val Arg Ala Met Glu Gly Glu Leu Gly Glu Leu
  200            205

```

<210> 16

<211> 97

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1810923

<400> 16

```

Met Thr Lys Lys Lys Arg Glu Asn Leu Gly Val Ala Leu Glu Ile
  1             5             10             15
Asp Gly Leu Glu Glu Lys Leu Ser Gln Cys Arg Arg Asp Leu Glu
  20             25             30
Ala Val Asn Ser Arg Leu His Ser Arg Glu Leu Ser Pro Glu Ala
  35             40             45
Arg Arg Ser Leu Glu Lys Glu Lys Asn Ser Leu Met Asn Lys Ala
  50             55             60

```

```

Ser Asn Tyr Glu Lys Glu Leu Lys Phe Leu Arg Gln Glu Asn Arg
      65                      70                      75
Lys Asn Met Leu Leu Ser Val Ala Ile Phe Ile Leu Leu Thr Leu
      80                      85                      90
Val Tyr Ala Tyr Trp Thr Met
      95

```

```

<210> 17
<211> 243
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 1822315

```

```

<400> 17
Met Phe Phe Leu Ser Ser Ser Lys Leu Thr Lys Trp Lys Gly Glu
  1          5          10          15
Val Lys Lys Arg Leu Asp Ser Glu Tyr Lys Glu Gly Gly Gln Arg
      20          25          30
Asn Trp Val Gln Val Phe Cys Asn Gly Ala Val Pro Thr Glu Leu
      35          40          45
Ala Leu Leu Tyr Met Ile Glu Asn Gly Pro Gly Glu Ile Pro Val
      50          55          60
Asp Phe Ser Lys Gln Tyr Ser Ala Ser Trp Met Cys Leu Ser Leu
      65          70          75
Leu Ala Ala Leu Ala Cys Ser Ala Gly Asp Thr Trp Ala Ser Glu
      80          85          90
Val Gly Pro Val Leu Ser Lys Ser Ser Pro Arg Leu Ile Thr Thr
      95          100          105
Trp Glu Lys Val Pro Val Gly Thr Asn Gly Gly Val Thr Val Val
      110          115          120
Gly Leu Val Ser Ser Leu Leu Gly Gly Thr Phe Val Gly Ile Ala
      125          130          135
Tyr Phe Leu Thr Gln Leu Ile Phe Val Asn Asp Leu Asp Ile Ser
      140          145          150
Ala Pro Gln Trp Pro Ile Ile Ala Phe Gly Gly Leu Ala Gly Leu
      155          160          165
Leu Gly Ser Ile Val Asp Ser Tyr Leu Gly Ala Thr Met Gln Tyr
      170          175          180
Thr Gly Leu Asp Glu Ser Thr Gly Met Val Val Asn Ser Pro Thr
      185          190          195
Asn Lys Ala Arg His Ile Ala Gly Lys Pro Ile Leu Asp Asn Asn
      200          205          210
Ala Trp Ile Cys Phe Leu Leu Phe Leu Leu Pro Ser Cys Ser Gln
      215          220          225
Leu Leu Leu Gly Val Phe Gly Pro Gly Gly Glu Leu Tyr Phe Ile
      230          235          240
Ser Thr Gly

```

```

<210> 18
<211> 162

```


<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1877777

<400> 18

```

Met Leu Gln Thr Ser Asn Tyr Ser Leu Val Leu Ser Leu Gln Phe
 1              5              10              15
Leu Leu Leu Ser Tyr Asp Leu Phe Val Asn Ser Phe Ser Glu Leu
              20              25              30
Leu Gln Lys Thr Pro Val Ile Gln Leu Val Leu Phe Ile Ile Gln
              35              40              45
Asp Ile Ala Val Leu Phe Asn Ile Ile Ile Ile Phe Leu Met Phe
              50              55              60
Phe Asn Thr Phe Val Phe Gln Ala Gly Leu Val Asn Leu Leu Phe
              65              70              75
His Lys Phe Lys Gly Thr Ile Ile Leu Thr Ala Val Tyr Phe Ala
              80              85              90
Leu Ser Ile Ser Leu His Val Trp Val Met Asn Leu Arg Trp Lys
              95              100             105
Asn Ser Asn Ser Phe Ile Trp Thr Asp Gly Leu Gln Met Leu Phe
              110             115             120
Val Phe Gln Arg Leu Ala Ala Val Leu Tyr Cys Tyr Phe Tyr Lys
              125             130             135
Arg Thr Ala Val Arg Leu Gly Asp Pro His Phe Tyr Gln Asp Ser
              140             145             150
Leu Trp Leu Arg Lys Glu Phe Met Gln Val Arg Arg
              155             160

```

<210> 19

<211> 470

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1879819

<400> 19

```

Met Leu Ser Pro Ser Pro Gly Lys Gly Pro Pro Pro Ala Val Ala
 1              5              10              15
Pro Arg Pro Lys Ala Pro Leu Gln Leu Gly Pro Ser Ser Ser Ile
              20              25              30
Lys Glu Lys Gln Gly Pro Leu Leu Asp Leu Phe Gly Gln Lys Leu
              35              40              45
Pro Ile Ala His Thr Pro Pro Pro Pro Ala Pro Pro Leu Pro
              50              55              60
Leu Pro Glu Asp Pro Gly Thr Leu Ser Ala Glu Arg Arg Cys Leu
              65              70              75
Thr Gln Pro Val Glu Asp Gln Gly Val Ser Thr Gln Leu Leu Ala

```

	80		85		90
Pro Ser Gly Ser	Val Cys Phe Ser Tyr	Thr Gly Thr Pro Trp	Lys		
	95		100		105
Leu Phe Leu Arg	Lys Glu Val Phe Tyr	Pro Arg Glu Asn Phe	Ser		
	110		115		120
His Pro Tyr Tyr	Leu Arg Leu Leu Cys	Glu Gln Ile Leu Arg	Asp		
	125		130		135
Thr Phe Ser Glu	Ser Cys Ile Arg Ile	Ser Gln Asn Glu Arg	Arg		
	140		145		150
Lys Met Lys Asp	Leu Leu Gly Gly Leu	Glu Val Asp Leu Asp	Ser		
	155		160		165
Leu Thr Thr Thr	Glu Asp Ser Val Lys	Lys Arg Ile Val Val	Ala		
	170		175		180
Ala Arg Asp Asn	Trp Ala Asn Tyr Phe	Ser Arg Phe Phe Pro	Val		
	185		190		195
Ser Gly Glu Ser	Gly Ser Asp Val Gln	Leu Leu Ala Val Ser	His		
	200		205		210
Arg Gly Leu Arg	Leu Leu Lys Val Thr	Gln Gly Pro Gly Leu	Arg		
	215		220		225
Pro Asp Gln Leu	Lys Ile Leu Cys Ser	Tyr Ser Phe Ala Glu	Val		
	230		235		240
Leu Gly Val Glu	Cys Arg Gly Gly Ser	Thr Leu Glu Leu Ser	Leu		
	245		250		255
Lys Ser Glu Gln	Leu Val Leu His Thr	Ala Arg Ala Arg Ala	Ile		
	260		265		270
Glu Ala Leu Val	Glu Leu Phe Leu Asn	Glu Leu Lys Lys Asp	Ser		
	275		280		285
Gly Tyr Val Ile	Ala Leu Arg Ser Tyr	Ile Thr Asp Asn Cys	Ser		
	290		295		300
Leu Leu Ser Phe	His Arg Gly Asp Leu	Ile Lys Leu Leu Pro	Val		
	305		310		315
Cys His Pro Gly	Ala Arg Leu Ala Val	Trp Leu Cys Arg Gly	Pro		
	320		325		330
Phe Arg Thr Leu	Ser Cys Arg His Ser	Ala Ala Gly Cys Arg	Ser		
	335		340		345
Arg Leu Phe Leu	Leu Gln Gly Ala Glu	Glu Trp Leu Ala Gln	Gly		
	350		355		360
Ser Ala Val Gln	Arg Gly Thr Arg Ala	Gly Ser Val Gly Gln	Gly		
	365		370		375
Leu Arg Gly Glu	Glu Asp Gly Arg Gly	Thr Ser Arg Gly Lys	Ala		
	380		385		390
Cys Leu Arg Leu	Arg Lys Glu Arg Gly	Leu Thr Thr Pro Glu	Ala		
	395		400		405
Ala Met Arg Trp	Asp His Pro Ala Val	Arg Leu Leu Trp Leu	Pro		
	410		415		420
Leu Cys Pro Leu	Leu Met Ala Arg Leu	Val Ser Pro Ala Arg	Leu		
	425		430		435
Cys Thr Pro Cys	Arg Gln Gly Leu Gly	Trp Met Leu Leu Leu	Cys		
	440		445		450
Pro Thr Trp Tyr	Leu Val Gln Gly Cys	Pro Ser Arg Cys Leu	Ile		
	455		460		465
Asn Ser Ser Ser	Leu				
	470				

<210> 20

<211> 144

<212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1932945

<400> 20
 Met Glu Arg Glu Gly Ser Gly Gly Ser Gly Gly Ser Ala Gly Leu
 1 5 10 15
 Leu Gln Gln Ile Leu Ser Leu Lys Val Val Pro Arg Val Gly Asn
 20 25 30
 Gly Thr Leu Cys Pro Asn Ser Thr Ser Leu Cys Ser Phe Pro Glu
 35 40 45
 Met Trp Tyr Gly Val Phe Leu Trp Ala Leu Val Ser Ser Leu Phe
 50 55 60
 Phe His Val Pro Ala Gly Leu Leu Ala Leu Phe Thr Leu Arg His
 65 70 75
 His Lys Tyr Gly Arg Phe Met Ser Val Ser Ile Leu Leu Met Gly
 80 85 90
 Ile Val Gly Pro Ile Thr Ala Gly Ile Leu Thr Ser Ala Ala Ile
 95 100 105
 Ala Gly Val Tyr Arg Ala Ala Gly Lys Glu Met Ile Pro Phe Glu
 110 115 120
 Ala Leu Thr Leu Gly Thr Gly Gln Thr Phe Cys Val Leu Val Val
 125 130 135
 Ser Phe Leu Arg Ile Leu Ala Thr Leu
 140

<210> 21
 <211> 221
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2061026

<400> 21
 Met Ala Leu Ala Leu Ala Ala Leu Ala Ala Val Glu Pro Ala Cys
 1 5 10 15
 Gly Ser Arg Tyr Gln Gln Leu Gln Asn Glu Glu Glu Ser Gly Glu
 20 25 30
 Pro Glu Gln Ala Ala Gly Asp Ala Pro Pro Pro Tyr Ser Ser Ile
 35 40 45
 Ser Ala Glu Ser Ala Ala Tyr Phe Asp Tyr Lys Asp Glu Ser Gly
 50 55 60
 Phe Pro Lys Pro Pro Ser Tyr Asn Val Ala Thr Thr Leu Pro Ser
 65 70 75
 Tyr Asp Glu Ala Glu Arg Thr Lys Ala Glu Ala Thr Ile Pro Leu
 80 85 90
 Val Pro Gly Arg Asp Glu Asp Phe Val Gly Arg Asp Asp Phe Asp
 95 100 105
 Asp Ala Asp Gln Leu Arg Ile Gly Asn Asp Gly Ile Phe Met Leu

	110		115		120
Thr Phe Phe Met	Ala Phe Leu Phe Asn Trp	Ile Gly Phe Phe Leu			
	125		130		135
Ser Phe Cys Leu Thr	Ser Ala Ala Gly Arg Tyr Gly Ala Ile				
	140		145		150
Ser Gly Phe Gly Leu	Ser Leu Ile Lys Trp	Ile Leu Ile Val Arg			
	155		160		165
Phe Ser Thr Tyr Phe	Pro Gly Tyr Phe Asp Gly Gln Tyr Trp	Leu			
	170		175		180
Trp Trp Val Phe Leu	Val Leu Gly Phe Leu Leu Phe Leu Arg Gly				
	185		190		195
Phe Ile Asn Tyr Ala	Lys Val Arg Lys Met Pro Glu Thr Phe Ser				
	200		205		210
Asn Leu Pro Arg Thr	Arg Val Leu Phe Ile Tyr				
	215		220		

<210> 22

<211> 688

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2096687

<400> 22

Met Ser Ala Glu Ser	Gly Pro Gly Thr	Arg Leu Arg Asn Leu Pro			
1	5	10	15		
Val Met Gly Asp Gly	Leu Glu Thr Ser	Gln Met Ser Thr Thr Gln			
	20	25	30		
Ala Gln Ala Gln Pro	Gln Pro Ala Asn Ala	Ala Ser Thr Asn Pro			
	35	40	45		
Pro Pro Pro Glu Thr	Ser Asn Pro Asn Lys	Pro Lys Arg Gln Thr			
	50	55	60		
Asn Gln Leu Gln Tyr	Leu Leu Arg Val	Val Leu Lys Thr Leu Trp			
	65	70	75		
Lys His Gln Phe Ala	Trp Pro Phe Gln Gln	Pro Val Asp Ala Val			
	80	85	90		
Lys Leu Asn Leu Pro	Asp Tyr Tyr Lys	Ile Ile Lys Thr Pro Met			
	95	100	105		
Asp Met Gly Thr Ile	Lys Lys Arg Leu	Glu Asn Asn Tyr Tyr Trp			
	110	115	120		
Asn Ala Gln Glu Cys	Ile Gln Asp Phe	Asn Thr Met Phe Thr Asn			
	125	130	135		
Cys Tyr Ile Tyr Asn	Lys Pro Gly Asp	Asp Ile Val Leu Met Ala			
	140	145	150		
Glu Ala Leu Glu Lys	Leu Phe Leu Gln	Lys Ile Asn Glu Leu Pro			
	155	160	165		
Thr Glu Glu Thr Glu	Ile Met Ile Val	Gln Ala Lys Gly Arg Gly			
	170	175	180		
Arg Gly Arg Lys Glu	Thr Gly Thr Ala	Lys Pro Gly Val Ser Thr			
	185	190	195		
Val Pro Asn Thr Thr	Gln Ala Ser Thr	Pro Pro Gln Thr Gln Thr			

Pro Gln Pro Asn	200	205	210
Pro Pro Pro Val Gln	215	220	225
Pro Ala Val Thr	230	235	240
Val Val Pro Pro	245	250	255
Gln Pro Gln Pro	260	265	270
His Pro Pro Ile	275	280	285
Lys Gly Val Lys	290	295	300
Asp Pro Ile His	305	310	315
Thr Lys Leu Gly	320	325	330
Pro Lys Lys Asp	335	340	345
Lys Ser Ser Lys	350	355	360
Leu Lys Glu Met	365	370	375
Phe Tyr Lys Pro	380	385	390
Cys Asp Ile Ile	395	400	405
Lys Leu Glu Ala	410	415	420
Asp Val Arg Leu	425	430	435
Asp His Glu Val	440	445	450
Glu Met Arg Phe	455	460	465
Val Ala Val Ser	470	475	480
Ala Pro Pro Ser	485	490	495
Ser Asp Ser Ser	500	505	510
Leu Ala Glu Leu	515	520	525
Ala Ala Leu Ser	530	535	540
Lys Asp Lys Lys	545	550	555
Glu Val Glu Glu	560	565	570
Lys Lys Thr Lys	575	580	585
Lys Glu Pro Ala	590	595	600
Ser Glu Glu Glu	605	610	615
Arg Gln Leu Ser	620	625	630

Gly	Arg	Val	Val	His	Ile	Ile	Gln	Ser	Arg	Glu	Pro	Ser	Leu	Lys
				635					640					645
Asn	Ser	Asn	Pro	Asp	Glu	Ile	Glu	Ile	Asp	Phe	Glu	Thr	Leu	Lys
				650					655					660
Pro	Ser	Thr	Leu	Arg	Glu	Leu	Gly	Ala	Leu	Cys	His	Leu	Leu	Phe
				665					670					675
Ala	Glu	Glu	Lys	Glu	Thr	Phe	Lys	Leu	Arg	Lys	Leu	Met		
				680					685					

<210> 23

<211> 439

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2100530

<400> 23

Met	Gly	Ser	Gln	Glu	Val	Leu	Gly	His	Ala	Ala	Arg	Leu	Ala	Ser
1				5					10					15
Ser	Gly	Leu	Leu	Leu	Gln	Val	Leu	Phe	Arg	Leu	Ile	Thr	Phe	Val
				20					25					30
Leu	Asn	Ala	Phe	Ile	Leu	Arg	Phe	Leu	Ser	Lys	Glu	Ile	Val	Gly
				35					40					45
Val	Val	Asn	Val	Arg	Leu	Thr	Leu	Leu	Tyr	Ser	Thr	Thr	Leu	Phe
				50					55					60
Leu	Ala	Arg	Glu	Ala	Phe	Arg	Arg	Ala	Cys	Leu	Ser	Gly	Gly	Thr
				65					70					75
Gln	Arg	Asp	Trp	Ser	Gln	Thr	Leu	Asn	Leu	Leu	Trp	Leu	Thr	Val
				80					85					90
Pro	Leu	Gly	Val	Phe	Trp	Ser	Leu	Phe	Leu	Gly	Trp	Ile	Trp	Leu
				95					100					105
Gln	Leu	Leu	Glu	Val	Pro	Asp	Pro	Asn	Val	Val	Pro	His	Tyr	Ala
				110					115					120
Thr	Gly	Val	Val	Leu	Phe	Gly	Leu	Ser	Ala	Val	Val	Glu	Leu	Leu
				125					130					135
Gly	Glu	Pro	Phe	Trp	Val	Leu	Ala	Gln	Ala	His	Met	Phe	Val	Lys
				140					145					150
Leu	Lys	Val	Ile	Ala	Glu	Ser	Leu	Ser	Val	Ile	Leu	Lys	Ser	Val
				155					160					165
Leu	Thr	Ala	Phe	Leu	Val	Leu	Trp	Leu	Pro	His	Trp	Gly	Leu	Tyr
				170					175					180
Ile	Phe	Ser	Leu	Ala	Gln	Leu	Phe	Tyr	Thr	Thr	Val	Leu	Val	Leu
				185					190					195
Cys	Tyr	Val	Ile	Tyr	Phe	Thr	Lys	Leu	Leu	Gly	Ser	Pro	Glu	Ser
				200					205					210
Thr	Lys	Leu	Gln	Thr	Leu	Pro	Val	Ser	Arg	Ile	Thr	Asp	Leu	Leu
				215					220					225
Pro	Asn	Ile	Thr	Arg	Asn	Gly	Ala	Phe	Ile	Asn	Trp	Lys	Glu	Ala

	230		235		240
Lys Leu Thr Trp	Ser Phe Phe Lys Gln	Ser Phe Leu Lys Gln	Ile		
	245		250		255
Leu Thr Glu Gly	Glu Arg Tyr Val Met	Thr Phe Leu Asn Val	Leu		
	260		265		270
Asn Phe Gly Asp	Gln Gly Val Tyr Asp	Ile Val Asn Asn Leu	Gly		
	275		280		285
Ser Leu Val Ala	Arg Leu Ile Phe Gln	Pro Ile Glu Glu Ser	Phe		
	290		295		300
Tyr Ile Phe Phe	Ala Lys Val Leu Glu	Arg Gly Lys Asp Ala	Thr		
	305		310		315
Leu Gln Lys Gln	Glu Asp Val Ala Val	Ala Ala Ala Val	Leu Glu		
	320		325		330
Ser Leu Leu Lys	Leu Ala Leu Leu Ala	Gly Leu Thr Ile Thr	Val		
	335		340		345
Phe Gly Phe Ala	Tyr Ser Gln Leu Ala	Leu Asp Ile Tyr Gly	Gly		
	350		355		360
Thr Met Leu Ser	Ser Gly Ser Gly Pro	Val Leu Leu Arg Ser	Tyr		
	365		370		375
Cys Leu Tyr Val	Leu Leu Leu Ala Ile	Asn Gly Val Thr Glu	Cys		
	380		385		390
Phe Thr Phe Ala	Ala Met Ser Lys Glu	Glu Val Asp Arg Tyr	Ser		
	395		400		405
Ser Ala Val Ser	Arg Ala Gly Gln Pro	Asp Trp His Thr Leu	Leu		
	410		415		420
Trp Gly Pro Ser	Val Trp Glu Gln Leu	Ser Gly Gln His Xaa	Ser		
	425		430		435
Gln Arg Pro Ser					

<210> 24

<211> 192

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2357636

<400> 24

Met Thr Ala Val	Gly Val Gln Ala Gln	Arg Pro Leu Gly Gln	Arg
1	5	10	15
Gln Pro Arg Arg	Ser Phe Phe Glu Ser	Phe Ile Arg Thr Leu	Ile
	20	25	30
Ile Thr Cys Val	Ala Leu Ala Val Val	Leu Ser Ser Val Ser	Ile
	35	40	45
Cys Asp Gly His	Trp Leu Leu Ala Glu	Asp Arg Leu Phe Gly	Leu
	50	55	60
Trp His Phe Cys	Thr Thr Thr Asn Gln	Ser Val Pro Ile Cys	Phe
	65	70	75
Arg Asp Leu Gly	Gln Ala His Val Pro	Gly Leu Ala Val Gly	Met
	80	85	90
Gly Leu Val Arg	Ser Val Gly Ala Leu	Ala Val Val Ala Ala	Ile
	95	100	105
Phe Gly Leu Glu	Phe Leu Met Val Ser	Gln Leu Cys Glu Asp	Lys

	110		115		120
His Ser Gln Cys	Lys Trp Val Met Gly Ser Ile Leu Leu Leu Val				
	125		130		135
Ser Phe Val Leu	Ser Ser Gly Gly Leu Leu Gly Phe Val Ile Leu				
	140		145		150
Leu Arg Asn Gln	Val Thr Leu Ile Gly Phe Thr Leu Met Phe Trp				
	155		160		165
Cys Glu Phe Thr	Ala Ser Phe Leu Leu Phe Leu Asn Ala Ile Ser				
	170		175		180
Gly Leu His Ile	Asn Ser Ile Thr His Pro Trp Glu				
	185		190		

<210> 25

<211> 175

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2365230

<400> 25

Met Lys Glu Val	Thr Arg Thr Trp Lys Ile Val Gly Gly Val Thr				
1	5		10		15
His Ala Asn Ser	Tyr Tyr Lys Asn Gly Trp Ile Val Met Ile Ala				
	20		25		30
Ile Gly Trp Ala	Arg Gly Ala Gly Gly Thr Ile Ile Thr Asn Phe				
	35		40		45
Glu Arg Leu Val	Lys Gly Asp Trp Lys Pro Glu Gly Asp Glu Trp				
	50		55		60
Leu Lys Met Ser	Tyr Pro Ala Lys Val Thr Leu Leu Gly Ser Val				
	65		70		75
Ile Phe Thr Phe	Gln His Thr Gln His Leu Ala Ile Ser Lys His				
	80		85		90
Asn Leu Met Phe	Leu Tyr Thr Ile Phe Ile Val Ala Thr Lys Ile				
	95		100		105
Thr Met Met Thr	Thr Gln Thr Ser Thr Met Thr Phe Ala Pro Phe				
	110		115		120
Glu Asp Thr Leu	Ser Trp Met Leu Phe Gly Trp Gln Gln Pro Phe				
	125		130		135
Ser Ser Cys Glu	Lys Lys Ser Glu Ala Lys Ser Pro Ser Asn Gly				
	140		145		150
Val Gly Ser Leu	Ala Ser Lys Pro Val Asp Val Ala Ser Asp Asn				
	155		160		165
Val Lys Lys Lys	His Thr Lys Lys Asn Glu				
	170		175		

<210> 26

<211> 91

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2455121

<400> 26

```

Met Tyr Pro Pro Pro Pro Pro Pro Pro His Arg Asp Phe Ile Ser
 1           5           10           15
Val Thr Leu Ser Phe Gly Glu Ser Tyr Asp Asn Ser Lys Ser Trp
           20           25           30
Arg Arg Arg Ser Cys Trp Arg Lys Trp Lys Gln Leu Ser Arg Leu
           35           40           45
Gln Arg Asn Met Ile Leu Phe Leu Leu Ala Phe Leu Leu Phe Cys
           50           55           60
Gly Leu Leu Phe Tyr Ile Asn Leu Ala Asp His Trp Lys Ala Leu
           65           70           75
Ala Phe Arg Leu Gly Glu Glu Gln Lys Met Arg Pro Glu Ile Ala
           80           85           90
Gly

```

<210> 27

<211> 214

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2472514

<400> 27

```

Met Gln Pro Thr Ser Trp Ala Val Ser Cys Gly Leu Arg Pro Leu
 1           5           10           15
Pro Ser Trp Lys Pro Gln Gly Gly Glu Gly Arg Gly Gly Glu Glu
           20           25           30
Arg Arg Gly Thr Val Met Gly Pro Trp Ser Arg Val Arg Val Ala
           35           40           45
Lys Cys Gln Met Leu Val Thr Cys Phe Phe Ile Leu Leu Leu Gly
           50           55           60
Leu Ser Val Ala Thr Met Val Thr Leu Thr Tyr Phe Gly Ala His
           65           70           75
Phe Ala Val Ile Arg Arg Ala Ser Leu Glu Lys Asn Pro Tyr Gln
           80           85           90
Ala Val His Gln Trp Ala Phe Ser Ala Gly Leu Ser Leu Val Gly
           95          100          105
Leu Leu Thr Leu Gly Ala Val Leu Ser Ala Ala Ala Thr Val Arg
          110          115          120
Glu Ala Gln Gly Leu Met Ala Gly Gly Phe Leu Cys Phe Ser Leu
          125          130          135
Ala Phe Cys Ala Gln Val Gln Val Val Phe Trp Arg Leu His Ser
          140          145          150
Pro Thr Gln Val Glu Asp Ala Met Leu Asp Thr Tyr Asp Leu Val
          155          160          165
Tyr Glu Gln Ala Met Lys Gly Thr Ser His Val Arg Arg Gln Glu
          170          175          180
Leu Ala Ala Ile Gln Asp Val Val Ser Val Gly Thr Ala Gly Trp
          185          190          195
Gln Gly Gly Gln Leu Leu Leu Gly Leu Gln Phe Arg Glu Gln Ala

```

```
<210> 29
<211> 84
<212> PRT
<213> Homo sapiens
<220>
```

<221> misc_feature

<223> Incyte Clone No: 2778171

<400> 29

```

Met Ala Thr Gly Thr Asp Gln Val Val Gly Leu Gly Leu Val Ala
 1           5           10           15
Val Ser Leu Ile Ile Phe Thr Tyr Tyr Thr Ala Trp Val Ile Leu
          20           25           30
Leu Pro Phe Ile Asp Ser Gln His Val Ile His Lys Tyr Phe Leu
          35           40           45
Pro Arg Ala Tyr Ala Val Ala Ile Pro Leu Ala Ala Gly Leu Leu
          50           55           60
Leu Leu Leu Phe Val Gly Leu Phe Ile Ser Tyr Val Met Leu Lys
          65           70           75
Ser Lys Arg Val Thr Lys Lys Ala Gln
          80

```

<210> 30

<211> 277

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2799575

<400> 30

```

Met Ala Ser Ala Glu Leu Asp Tyr Thr Ile Glu Ile Pro Asp Gln
 1           5           10           15
Pro Cys Trp Ser Gln Lys Asn Ser Pro Ser Pro Gly Gly Lys Glu
          20           25           30
Ala Glu Thr Arg Gln Pro Val Val Ile Leu Leu Gly Trp Gly Gly
          35           40           45
Cys Lys Asp Lys Asn Leu Ala Lys Tyr Ser Ala Ile Tyr His Lys
          50           55           60
Arg Gly Cys Ile Val Ile Arg Tyr Thr Ala Pro Trp His Met Val
          65           70           75
Phe Phe Ser Glu Ser Leu Gly Ile Pro Ser Leu Arg Val Leu Ala
          80           85           90
Gln Lys Leu Leu Glu Leu Leu Phe Asp Tyr Glu Ile Glu Lys Glu
          95          100          105
Pro Leu Leu Phe His Val Phe Ser Asn Gly Gly Val Met Leu Tyr
          110          115          120
Arg Tyr Val Leu Glu Leu Leu Gln Thr Arg Arg Phe Cys Arg Leu
          125          130          135
Arg Val Val Gly Thr Ile Phe Asp Ser Ala Pro Gly Asp Ser Asn
          140          145          150
Leu Val Gly Ala Leu Arg Ala Leu Ala Ala Ile Leu Glu Arg Arg
          155          160          165
Ala Ala Met Leu Arg Leu Leu Leu Leu Val Ala Phe Ala Leu Val
          170          175          180
Val Val Leu Phe His Val Leu Leu Ala Pro Ile Thr Ala Leu Phe
          185          190          195
His Thr His Phe Tyr Asp Arg Leu Gln Asp Ala Gly Ser Arg Trp

```

	200		205		210
Pro Glu Leu Tyr	Leu Tyr Ser Arg Ala Asp	Glu Val Val Leu Ala			
	215		220		225
Arg Asp Ile Glu	Arg Met Val Glu Ala Arg	Leu Ala Arg Arg Val			
	230		235		240
Leu Ala Arg Ser	Val Asp Phe Val Ser	Ser Ala His Val Ser His			
	245		250		255
Leu Arg Asp Tyr	Pro Thr Tyr Tyr Thr	Ser Leu Cys Val Asp Phe			
	260		265		270
Met Arg Asn Cys	Val Arg Cys				
	275				

<210> 31
 <211> 273
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2804955

<400> 31

Met Ser Gly Ser Gln Ser Glu Val Ala Pro Ser Pro Gln Ser Pro		
1	5	10 15
Arg Ser Pro Glu Met Gly Arg Asp Leu Arg Pro Gly Ser Arg Val		
	20	25 30
Leu Leu Leu Leu Leu Leu Leu Leu Val Tyr Leu Thr Gln Pro		
	35	40 45
Gly Asn Gly Asn Glu Gly Ser Val Thr Gly Ser Cys Tyr Cys Gly		
	50	55 60
Lys Arg Ile Ser Ser Asp Ser Pro Pro Ser Val Gln Phe Met Asn		
	65	70 75
Arg Leu Arg Lys His Leu Arg Ala Tyr His Arg Cys Leu Tyr Tyr		
	80	85 90
Thr Arg Phe Gln Leu Leu Ser Trp Ser Val Cys Gly Gly Asn Lys		
	95	100 105
Asp Pro Trp Val Gln Glu Leu Met Ser Cys Leu Asp Leu Lys Glu		
	110	115 120
Cys Gly His Ala Tyr Ser Gly Ile Val Ala His Gln Lys His Leu		
	125	130 135
Leu Pro Thr Ser Pro Pro Ile Ser Gln Ala Ser Glu Gly Ala Ser		
	140	145 150
Ser Asp Ile His Thr Pro Ala Gln Met Leu Leu Ser Thr Leu Gln		
	155	160 165
Ser Thr Gln Arg Pro Thr Leu Pro Val Gly Ser Leu Ser Ser Asp		
	170	175 180
Lys Glu Leu Thr Arg Pro Asn Glu Thr Thr Ile His Thr Ala Gly		
	185	190 195
His Ser Leu Ala Ala Gly Pro Glu Ala Gly Glu Asn Gln Lys Gln		
	200	205 210
Pro Glu Lys Asn Ala Gly Pro Thr Ala Arg Thr Ser Ala Thr Val		
	215	220 225
Pro Val Leu Cys Leu Leu Ala Ile Ile Phe Ile Leu Thr Ala Ala		

	230		235		240
Leu Ser Tyr Val	Leu Cys Lys Arg Arg	Arg Gly Gln Ser Pro	Gln		
	245		250		255
Ser Ser Pro Asp	Leu Pro Val His Tyr	Ile Pro Val Ala Pro	Asp		
	260		265		270
Ser Asn Thr					

<210> 32

<211> 524

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2806395

<400> 32

Met Ser Gln Gly Ser	Pro Gly Asp Trp	Ala Pro Leu Asp	Pro Thr
1	5	10	15
Pro Gly Pro Pro	Ala Ser Pro Asn Pro	Phe Val His Glu	Leu His
	20	25	30
Leu Ser Arg Leu	Gln Arg Val Lys Phe	Cys Leu Leu Gly	Ala Leu
	35	40	45
Leu Ala Pro Ile	Arg Val Leu Leu	Ala Phe Ile	Val Leu Phe Leu
	50	55	60
Leu Trp Pro Phe	Ala Trp Leu Gln	Val Ala Gly	Leu Ser Glu Glu
	65	70	75
Gln Leu Gln Glu	Pro Ile Thr Gly	Trp Arg Lys	Thr Val Cys His
	80	85	90
Asn Gly Val Leu	Gly Leu Ser Arg	Leu Leu Phe	Phe Leu Leu Gly
	95	100	105
Phe Leu Arg Ile	Arg Val Arg Gly	Gln Arg Ala	Ser Arg Leu Gln
	110	115	120
Ala Pro Val Leu	Val Ala Ala Pro	His Ser Thr	Phe Phe Asp Pro
	125	130	135
Ile Val Leu Leu	Pro Cys Asp Leu	Pro Lys Val	Val Ser Arg Ala
	140	145	150
Glu Asn Leu Ser	Val Pro Val Ile	Gly Ala Leu	Leu Arg Phe Asn
	155	160	165
Gln Ala Ile Leu	Val Ser Arg His	Asp Pro Ala	Ser Arg Arg Arg
	170	175	180
Val Val Glu Glu	Val Arg Arg Arg	Ala Thr Ser	Gly Gly Lys Trp
	185	190	195
Pro Gln Val Leu	Phe Phe Pro	Glu Gly Thr	Cys Ser Asn Lys Lys
	200	205	210
Ala Leu Leu Lys	Phe Lys Pro	Gly Ala Phe	Ile Ala Gly Val Pro
	215	220	225
Val Gln Pro Val	Leu Ile Arg Tyr	Pro Asn Ser	Leu Asp Thr Thr
	230	235	240
Ser Trp Ala Trp	Arg Gly Pro	Gly Val Leu	Lys Val Leu Trp Leu
	245	250	255
Thr Ala Ser Gln	Pro Cys Ser	Ile Val Asp	Val Glu Phe Leu Pro
	260	265	270
Val Tyr His Pro	Ser Pro Glu	Glu Ser Arg	Asp Pro Thr Leu Tyr
	275	280	285

Ala Asn Asn Val	Gln Arg Val Met Ala	Gln Ala Leu Gly Ile Pro	
290		295	300
Ala Thr Glu Cys	Glu Phe Val Gly Ser	Leu Pro Val Ile Val Val	
305		310	315
Gly Arg Leu Lys	Val Ala Leu Glu Pro	Gln Leu Trp Glu Leu Gly	
320		325	330
Lys Val Leu Arg	Lys Ala Gly Leu Ser	Ala Gly Tyr Val Asp Ala	
335		340	345
Gly Ala Glu Pro	Gly Arg Ser Arg Met	Ile Ser Gln Glu Glu Phe	
350		355	360
Ala Arg Gln Leu	Gln Leu Ser Asp Pro	Gln Thr Val Ala Gly Ala	
365		370	375
Phe Gly Tyr Phe	Gln Gln Asp Thr Lys	Gly Leu Val Asp Phe Arg	
380		385	390
Asp Val Ala Leu	Ala Leu Ala Ala Leu	Asp Gly Gly Arg Ser Leu	
395		400	405
Glu Glu Leu Thr	Arg Leu Ala Phe Glu	Leu Phe Ala Glu Glu Gln	
410		415	420
Ala Glu Gly Pro	Asn Arg Leu Leu Tyr	Lys Asp Gly Phe Ser Thr	
425		430	435
Ile Leu His Leu	Leu Leu Gly Ser Pro	His Pro Ala Ala Thr Ala	
440		445	450
Leu His Ala Glu	Leu Cys Gln Ala Gly	Ser Ser Gln Gly Leu Ser	
455		460	465
Leu Cys Gln Phe	Gln Asn Phe Ser Leu	His Asp Pro Leu Tyr Gly	
470		475	480
Lys Leu Phe Ser	Thr Tyr Leu Arg Pro	Pro His Thr Ser Arg Gly	
485		490	495
Thr Ser Gln Thr	Pro Asn Ala Ser Ser	Pro Gly Asn Pro Thr Ala	
500		505	510
Leu Ala Asn Gly	Thr Val Gln Ala Pro	Lys Gln Lys Gly Asp	
515		520	

<210> 33

<211> 257

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2836858

<400> 33

Met Asp Phe Ser Arg	Leu His Met Tyr Ser	Pro Pro Gln Cys Val	
1	5	10	15
Pro Glu Asn Thr Gly	Tyr Thr Tyr Ala Leu	Ser Ser Ser Tyr Ser	
20		25	30
Ser Asp Ala Leu Asp	Phe Glu Thr Glu His	Lys Leu Asp Pro Val	
35		40	45
Phe Asp Ser Pro Arg	Met Ser Arg Arg Ser	Leu Arg Leu Ala Thr	
50		55	60
Thr Ala Cys Thr Leu	Gly Asp Gly Glu Ala	Val Gly Ala Asp Ser	
65		70	75
Gly Thr Ser Ser Ala	Val Ser Leu Lys Asn	Arg Ala Ala Arg Thr	
80		85	90

<400> 34														
Met	Arg	Ala	Ala	Gly	Val	Gly	Leu	Val	Asp	Cys	His	Cys	His	Leu
1				5					10					15
Ser	Ala	Pro	Asp	Phe	Asp	Arg	Asp	Leu	Asp	Asp	Val	Leu	Glu	Lys
				20					25					30
Ala	Lys	Lys	Ala	Asn	Val	Val	Ala	Leu	Val	Ala	Val	Ala	Glu	His
				35					40					45
Ser	Gly	Glu	Phe	Glu	Lys	Ile	Met	Gln	Leu	Ser	Glu	Arg	Tyr	Asn
				50					55					60
Gly	Phe	Val	Leu	Pro	Cys	Leu	Gly	Val	His	Pro	Val	Gln	Gly	Leu
				65					70					75
Pro	Pro	Glu	Asp	Gln	Arg	Ser	Val	Thr	Leu	Lys	Asp	Leu	Asp	Val
				80					85					90
Ala	Leu	Pro	Ile	Ile	Glu	Asn	Tyr	Lys	Asp	Arg	Leu	Leu	Ala	Ile
				95					100					105
Gly	Glu	Val	Gly	Leu	Asp	Phe	Ser	Pro	Arg	Phe	Ala	Gly	Thr	Gly
				110					115					120
Glu	Gln	Lys	Glu	Glu	Gln	Arg	Gln	Val	Leu	Ile	Arg	Gln	Ile	Gln
				125					130					135
Leu	Ala	Lys	Arg	Leu	Asn	Leu	Pro	Val	Asn	Val	His	Ser	Arg	Ser
				140					145					150
Ala	Gly	Arg	Pro	Thr	Ile	Asn	Leu	Leu	Gln	Glu	Gln	Gly	Ala	Glu

	155		160		165
Lys Val Leu Leu	His Ala Phe Asp Gly	Arg Pro Ser Val Ala	Met		
	170		175		180
Glu Gly Val Arg	Ala Gly Tyr Phe Phe	Ser Ile Pro Pro Ser	Ile		
	185		190		195
Ile Arg Ser Gly	Gln Lys Gln Lys Leu	Val Lys Gln Leu Pro	Leu		
	200		205		210
Thr Ser Ile Cys	Leu Glu Thr Asp Ser	Pro Ala Leu Gly Pro	Glu		
	215		220		225
Lys Gln Val Arg	Asn Glu Pro Trp Asn	Ile Ser Ile Ser Ala	Glu		
	230		235		240
Tyr Ile Ala Gln	Val Lys Gly Ile Ser	Val Glu Glu Val Ile	Glu		
	245		250		255
Val Thr Thr Gln	Asn Ala Leu Lys Leu	Phe Pro Lys Leu Arg	His		
	260		265		270
Leu Leu Gln Lys					

<210> 35

<211> 281

<212> PRT

<213> Homo sapiens

<220>

<221> misc feature

<223> Incyte Clone No: 3000380

<400> 35

Met Ser Glu Pro	Gln Pro Asp Leu Glu	Pro Pro Gln His Gly	Leu
1	5	10	15
Tyr Met Leu Phe	Leu Leu Val Leu Val	Phe Phe Leu Met Gly	Leu
	20	25	30
Val Gly Phe Met	Ile Cys His Val Leu	Lys Lys Lys Gly Tyr	Arg
	35	40	45
Cys Arg Thr Ser	Arg Gly Ser Glu Pro	Asp Asp Ala Gln Leu	Gln
	50	55	60
Pro Pro Glu Asp	Asp Asp Met Asn Glu	Asp Thr Val Glu Arg	Ile
	65	70	75
Val Arg Cys Ile	Ile Gln Asn Glu Val	Trp Met Pro Pro Pro	Ala
	80	85	90
Cys Arg Thr Glu	Pro Pro Pro Ile Ile	Thr Gln Cys Thr Trp	Ala
	95	100	105
Leu Gln Pro Leu	Ala Val His Cys Ser	Arg Ser Lys Arg Pro	Pro
	110	115	120
Leu Val Arg Gln	Gly Arg Ser Lys Glu	Gly Lys Ser Arg Pro	Arg
	125	130	135
Thr Gly Glu Thr	Thr Val Phe Ser Val	Gly Arg Phe Arg Val	Thr
	140	145	150
His Ile Glu Lys	Arg Tyr Gly Leu His	Glu His Arg Asp Gly	Ser
	155	160	165
Pro Thr Asp Arg	Ser Trp Gly Ser Arg	Gly Gly Gln Asp Pro	Gly
	170	175	180
Gly Gly Gln Gly	Ser Gly Gly Gly His	Pro Lys Ala Gly Met	Leu
	185	190	195


```

Pro Trp Arg Gly Cys Pro Pro Glu Arg Pro Gln Pro Gln Val Leu
200 205 210
Ala Ser Pro Pro Val Gln Asn Gly Gly Leu Arg Asp Ser Ser Leu
215 220 225
Thr Pro Arg Ala Leu Glu Gly Asn Pro Arg Ala Ser Ala Glu Pro
230 235 240
Thr Leu Arg Ala Gly Gly Arg Gly Pro Ser Pro Gly Leu Pro Thr
245 250 255
Gln Glu Ala Asn Gly Gln Pro Ser Lys Pro Asp Thr Ser Asp His
260 265 270
Gln Val Ser Leu Pro Gln Gly Ala Gly Ser Met
275 280

```

```

<210> 36
<211> 335
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 182532

```

```

<400> 36
Met Gly Pro Leu Ser Ala Pro Pro Cys Thr His Leu Ile Thr Trp
1 5 10 15
Lys Gly Val Leu Leu Thr Ala Ser Leu Leu Asn Phe Trp Asn Pro
20 25 30
Pro Thr Thr Ala Gln Val Thr Ile Glu Ala Gln Pro Pro Lys Val
35 40 45
Ser Glu Gly Lys Asp Val Leu Leu Leu Val His Asn Leu Pro Gln
50 55 60
Asn Leu Ala Gly Tyr Ile Trp Tyr Lys Gly Gln Met Thr Tyr Val
65 70 75
Tyr His Tyr Ile Ile Ser Tyr Ile Val Asp Gly Lys Ile Ile Ile
80 85 90
Tyr Gly Pro Ala Tyr Ser Gly Arg Glu Arg Val Tyr Ser Asn Ala
95 100 105
Ser Leu Leu Ile Gln Asn Val Thr Gln Glu Asp Ala Gly Ser Tyr
110 115 120
Thr Leu His Ile Ile Lys Arg Gly Asp Gly Thr Arg Gly Glu Thr
125 130 135
Gly His Phe Thr Phe Thr Leu Tyr Leu Glu Thr Pro Lys Pro Ser
140 145 150
Ile Ser Ser Ser Asn Leu Tyr Pro Arg Glu Asp Met Glu Ala Val
155 160 165
Ser Leu Thr Cys Asp Pro Glu Thr Pro Asp Ala Ser Tyr Leu Trp
170 175 180
Trp Met Asn Gly Gln Ser Leu Pro Met Thr His Ser Leu Gln Leu
185 190 195
Ser Lys Asn Lys Arg Thr Leu Phe Leu Phe Gly Val Thr Lys Tyr
200 205 210
Thr Ala Gly Pro Tyr Glu Cys Glu Ile Arg Asn Pro Val Ser Gly
215 220 225
Ile Arg Ser Asp Pro Val Thr Leu Asn Val Leu Tyr Gly Pro Asp
230 235 240

```

```

Leu Pro Ser Ile Tyr Pro Ser Phe Thr Tyr Tyr Arg Ser Gly Glu
      245      250
Asn Leu Tyr Leu Ser Cys Phe Ala Glu Ser Asn Pro Arg Ala Gln
      260      265      270
Tyr Ser Trp Thr Ile Asn Gly Lys Phe Gln Leu Ser Gly Gln Lys
      275      280      285
Leu Phe Ile Pro Gln Ile Thr Thr Lys His Ser Gly Leu Tyr Ala
      290      295      300
Cys Ser Val Arg Asn Ser Ala Thr Gly Met Glu Ser Ser Lys Ser
      305      310      315
Met Thr Val Lys Val Ser Ala Pro Ser Gly Thr Gly His Leu Pro
      320      325      330
Gly Leu Asn Pro Leu
      335

```

<210> 37

<211> 280

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 239589

<400> 37

```

Met Asp Leu Gln Gly Arg Gly Val Pro Ser Ile Asp Arg Leu Arg
  1      5      10      15
Val Leu Leu Met Leu Phe His Thr Met Ala Gln Ile Met Ala Glu
      20      25      30
Gln Glu Val Glu Asn Leu Ser Gly Leu Ser Thr Asn Pro Glu Lys
      35      40      45
Asp Ile Phe Val Val Arg Glu Asn Gly Thr Thr Cys Leu Met Ala
      50      55      60
Glu Phe Ala Ala Lys Phe Ile Val Pro Tyr Asp Val Trp Ala Ser
      65      70      75
Asn Tyr Val Asp Leu Ile Thr Glu Gln Ala Asp Ile Ala Leu Thr
      80      85      90
Arg Gly Ala Glu Val Lys Gly Arg Cys Gly His Ser Gln Ser Glu
      95      100      105
Leu Gln Val Phe Trp Val Asp Arg Ala Tyr Ala Leu Lys Met Leu
      110      115      120
Phe Val Lys Glu Ser His Asn Met Ser Lys Gly Pro Glu Ala Thr
      125      130      135
Trp Arg Leu Ser Lys Val Gln Phe Val Tyr Asp Ser Ser Glu Lys
      140      145      150
Thr His Phe Lys Asp Ala Val Ser Ala Gly Lys His Thr Ala Asn
      155      160      165
Ser His His Leu Ser Ala Leu Val Thr Pro Ala Gly Lys Ser Tyr
      170      175      180
Glu Cys Gln Ala Gln Gln Thr Ile Ser Leu Ala Ser Ser Asp Pro
      185      190      195
Gln Lys Thr Val Thr Met Ile Leu Ser Ala Val His Ile Gln Pro
      200      205      210
Phe Asp Ile Ile Ser Asp Phe Val Phe Ser Glu Glu His Lys Cys
      215      220      225

```

```

Pro Val Asp Glu Arg Glu Gln Leu Glu Glu Thr Leu Pro Leu Ile
                230                235                240
Leu Gly Leu Ile Leu Gly Leu Val Ile Met Val Thr Leu Ala Ile
                245                250                255
Tyr His Val His His Lys Met Thr Ala Asn Gln Val Gln Ile Pro
                260                265                270
Arg Asp Arg Ser Gln Tyr Lys His Met Gly
                275                280

```

<210> 38
 <211> 210
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1671302

```

<400> 38
Met Ser Arg Met Phe Cys Gln Ala Ala Arg Val Asp Leu Thr Leu
  1                5                10                15
Asp Pro Asp Thr Ala His Pro Ala Leu Met Leu Ser Pro Asp Arg
                20                25                30
Arg Gly Val Arg Leu Ala Glu Arg Arg Gln Glu Val Ala Asp His
                35                40                45
Pro Lys Arg Phe Ser Ala Asp Cys Cys Val Leu Gly Ala Gln Gly
                50                55                60
Phe Arg Ser Gly Arg His Tyr Trp Glu Val Glu Val Gly Gly Arg
                65                70                75
Arg Gly Trp Ala Val Gly Ala Ala Arg Glu Ser Thr His His Lys
                80                85                90
Glu Lys Val Gly Pro Gly Gly Ser Ser Val Gly Ser Gly Asp Ala
                95                100               105
Ser Ser Ser Arg His His His Arg Arg Arg Arg Leu His Leu Pro
                110               115               120
Gln Gln Pro Leu Leu Gln Arg Glu Val Trp Cys Val Gly Thr Asn
                125               130               135
Gly Lys Arg Tyr Gln Ala Gln Ser Ser Thr Glu Gln Thr Leu Leu
                140               145               150
Ser Pro Ser Glu Lys Pro Arg Arg Phe Gly Val Tyr Leu Asp Tyr
                155               160               165
Glu Ala Gly Arg Leu Gly Phe Tyr Asn Ala Glu Thr Leu Ala His
                170               175               180
Val His Thr Phe Ser Ala Ala Phe Leu Gly Glu Arg Val Phe Pro
                185               190               195
Phe Phe Arg Val Leu Ser Lys Gly Thr Arg Ile Lys Leu Cys Pro
                200               205               210

```

<210> 39
 <211> 279
 <212> PRT
 <213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2041858

<400> 39

```

Met Glu Ala Val Val Asn Leu Tyr Gln Glu Val Met Lys His Ala
  1              5              10              15
Asp Pro Arg Ile Gln Gly Tyr Pro Leu Met Gly Ser Pro Leu Leu
              20              25              30
Met Thr Ser Ile Leu Leu Thr Tyr Val Tyr Phe Val Leu Ser Leu
              35              40              45
Gly Pro Arg Ile Met Ala Asn Arg Lys Pro Phe Gln Leu Arg Gly
              50              55              60
Phe Met Ile Val Tyr Asn Phe Ser Leu Val Ala Leu Ser Leu Tyr
              65              70              75
Ile Val Tyr Glu Phe Leu Met Ser Gly Trp Leu Ser Thr Tyr Thr
              80              85              90
Trp Arg Cys Asp Pro Val Asp Tyr Ser Asn Ser Pro Glu Ala Leu
              95              100             105
Arg Met Val Arg Val Ala Trp Leu Phe Leu Phe Ser Lys Phe Ile
              110             115             120
Glu Leu Met Asp Thr Val Ile Phe Ile Leu Arg Lys Lys Asp Gly
              125             130             135
Gln Val Thr Phe Leu His Val Phe His His Ser Val Leu Pro Trp
              140             145             150
Ser Trp Trp Trp Gly Val Lys Ile Ala Pro Gly Gly Met Gly Ser
              155             160             165
Phe His Ala Met Ile Asn Ser Ser Val His Val Ile Met Tyr Leu
              170             175             180
Tyr Tyr Gly Leu Ser Ala Phe Gly Pro Val Ala Gln Pro Tyr Leu
              185             190             195
Trp Trp Lys Lys His Met Thr Ala Ile Gln Leu Ile Gln Phe Val
              200             205             210
Leu Val Ser Leu His Ile Ser Gln Tyr Tyr Phe Met Ser Ser Cys
              215             220             225
Asn Tyr Gln Tyr Pro Val Ile Ile His Leu Ile Trp Met Tyr Gly
              230             235             240
Thr Ile Phe Phe Met Leu Phe Ser Asn Phe Trp Tyr His Ser Tyr
              245             250             255
Thr Lys Gly Lys Arg Leu Pro Arg Ala Leu Gln Gln Asn Gly Ala
              260             265             270
Pro Gly Ile Ala Lys Val Lys Ala Asn
              275

```

<210> 40

<211> 154

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2198863

<400> 40

```

Met Gly Lys Ser Ala Ser Lys Gln Phe His Asn Glu Val Leu Lys

```

1	5	10	15
Ala His Asn Glu Tyr Arg Gln Lys His Gly Val Pro Pro Leu Lys			
20	25	30	
Leu Cys Lys Asn Leu Asn Arg Glu Ala Gln Gln Tyr Ser Glu Ala			
35	40	45	
Leu Ala Ser Thr Arg Ile Leu Lys His Ser Pro Glu Ser Ser Arg			
50	55	60	
Gly Gln Cys Gly Glu Asn Leu Ala Trp Ala Ser Tyr Asp Gln Thr			
65	70	75	
Gly Lys Glu Val Ala Asp Arg Trp Tyr Ser Glu Ile Lys Asn Tyr			
80	85	90	
Asn Phe Gln Gln Pro Gly Phe Thr Ser Gly Thr Gly His Phe Thr			
95	100	105	
Ala Met Val Trp Lys Asn Thr Lys Lys Met Gly Val Gly Lys Ala			
110	115	120	
Ser Ala Ser Asp Gly Ser Ser Phe Val Val Ala Arg Tyr Phe Pro			
125	130	135	
Ala Gly Asn Val Val Asn Glu Gly Phe Phe Glu Glu Asn Val Leu			
140	145	150	
Pro Pro Lys Lys			

<210> 41

<211> 582

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3250703

<400> 41

Met Lys Pro Asn Ile Ile Phe Val Leu Ser Leu Leu Leu Ile Leu		
1	5	10
15		
Glu Lys Gln Ala Ala Val Met Gly Gln Lys Gly Gly Ser Lys Gly		
20	25	30
Arg Leu Pro Ser Glu Phe Ser Gln Phe Pro His Gly Gln Lys Gly		
35	40	45
Gln His Tyr Ser Gly Gln Lys Gly Lys Gln Gln Thr Glu Ser Lys		
50	55	60
Gly Ser Phe Ser Ile Gln Tyr Thr Tyr His Val Asp Ala Asn Asp		
65	70	75
His Asp Gln Ser Arg Lys Ser Gln Gln Tyr Asp Leu Asn Ala Leu		
80	85	90
His Lys Thr Thr Lys Ser Gln Arg His Leu Gly Gly Ser Gln Gln		
95	100	105
Leu Leu His Asn Lys Gln Glu Gly Arg Asp His Asp Lys Ser Lys		
110	115	120
Gly His Phe His Arg Val Val Ile His His Lys Gly Gly Lys Ala		
125	130	135
His Arg Gly Thr Gln Asn Pro Ser Gln Asp Gln Gly Asn Ser Pro		
140	145	150
Ser Gly Lys Gly Ile Ser Ser Gln Tyr Ser Asn Thr Glu Glu Arg		
155	160	165

Leu Trp Val His Gly Leu Ser Lys Glu Gln Thr Ser Val Ser Gly	170	175	180
Ala Gln Lys Gly Arg Lys Gln Gly Gly Ser Gln Ser Ser Tyr Val	185	190	195
Leu Gln Thr Glu Glu Leu Val Ala Asn Lys Gln Gln Arg Glu Thr	200	205	210
Lys Asn Ser His Gln Asn Lys Gly His Tyr Gln Asn Val Val Glu	215	220	225
Val Arg Glu Glu His Ser Ser Lys Val Gln Thr Ser Leu Cys Pro	230	235	240
Ala His Gln Asp Lys Leu Gln His Gly Ser Lys Asp Ile Phe Ser	245	250	255
Thr Gln Asp Glu Leu Leu Val Tyr Asn Lys Asn Gln His Gln Thr	260	265	270
Lys Asn Leu Asn Gln Asp Gln Gln His Gly Arg Lys Ala Asn Lys	275	280	285
Ile Ser Tyr Gln Ser Ser Ser Thr Glu Glu Arg Arg Leu His Tyr	290	295	300
Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gln Ser Ser Ile Tyr	305	310	315
Ser Gln Thr Glu Glu Lys Ile His Gly Lys Ser Gln Asn Gln Val	320	325	330
Thr Ile His Ser Gln Asp Gln Glu His Gly His Lys Glu Asn Lys	335	340	345
Ile Ser Tyr Gln Ser Ser Ser Thr Glu Glu Arg His Leu Asn Cys	350	355	360
Gly Glu Lys Gly Ile Gln Lys Gly Val Ser Lys Gly Ser Ile Ser	365	370	375
Ile Gln Thr Glu Glu Gln Ile His Gly Lys Ser Gln Asn Gln Val	380	385	390
Arg Ile Pro Ser Gln Ala Gln Glu Tyr Gly His Lys Glu Asn Lys	395	400	405
Ile Ser Tyr Gln Ser Ser Ser Thr Glu Glu Arg Arg Leu Asn Ser	410	415	420
Gly Glu Lys Asp Val Gln Lys Gly Val Ser Lys Gly Ser Ile Ser	425	430	435
Ile Gln Thr Glu Glu Lys Ile His Gly Lys Ser Gln Asn Gln Val	440	445	450
Thr Ile Pro Ser Gln Asp Gln Glu His Gly His Lys Glu Asn Lys	455	460	465
Met Ser Tyr Gln Ser Ser Ser Thr Glu Glu Arg Arg Leu Asn Tyr	470	475	480
Gly Gly Lys Ser Thr Gln Lys Asp Val Ser Gln Ser Ser Ile Ser	485	490	495
Phe Gln Ile Glu Lys Leu Val Glu Gly Lys Ser Gln Ile Gln Thr	500	505	510
Pro Asn Pro Asn Gln Asp Gln Trp Ser Gly Gln Asn Ala Lys Gly	515	520	525
Lys Ser Gly Gln Ser Ala Asp Ser Lys Gln Asp Leu Leu Ser His	530	535	540
Glu Gln Lys Gly Arg Tyr Lys Gln Glu Ser Ser Glu Ser His Asn	545	550	555
Ile Val Ile Thr Glu His Glu Val Ala Gln Asp Asp His Leu Thr	560	565	570
Gln Gln Tyr Asn Glu Asp Arg Asn Pro Ile Ser Thr	575	580	

<210> 42
 <211> 71
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 350287

<400> 42
 Met Phe Thr Ala Pro Leu Phe Phe Phe Phe Phe Phe Glu Ile Ile
 5 10 15
 Asn Ser Met Arg Asn Leu Gly Leu Asn Ile Cys Leu Leu Cys Leu
 20 25 30
 Leu Ile Glu His His Ser Arg Pro Ser Val Cys Leu Pro Phe Thr
 35 40 45
 Pro Lys Ile Phe Thr Lys Lys Ile Leu Arg Gln Gln Val Thr Ile
 50 55 60
 Tyr Arg Cys Leu Asn Asp Phe Leu Ile Phe Ile
 65 70

<210> 43
 <211> 102
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1618171

<400> 43
 Met Ala Val Leu Pro Ser Val Leu Leu Val Tyr Ser Leu Phe Phe
 5 10 15
 Cys Leu Arg Phe Cys Met Leu Leu Leu Pro Ser Tyr Ser His
 20 25 30
 Ser Arg Ser Gly Arg Gly Pro Gly Arg Tyr Gly His Ile Thr Leu
 35 40 45
 Ile Asp Val Ile His Val Ser Val Tyr Trp Phe Phe Glu Ala Leu
 50 55 60
 Ser Thr Phe Gln Ile Phe Tyr Tyr Cys Ile Thr Arg Thr Ile Thr
 65 70 75
 Val Arg Lys Gly Ile Val Val Ser Arg His Val Asn Glu Ala Gly
 80 85 90
 Val Ser Phe Val Ser Tyr Leu Cys Ile Asn Phe Lys
 95 100

<210> 44
 <211> 226
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1625863

<400> 44

```

Met Pro Thr Thr Lys Lys Thr Leu Met Phe Leu Ser Ser Phe Phe
 1           5           10           15
Thr Ser Leu Gly Ser Phe Ile Val Ile Cys Ser Ile Leu Gly Thr
           20           25           30
Gln Ala Trp Ile Thr Ser Thr Ile Ala Val Arg Asp Ser Ala Ser
           35           40           45
Asn Gly Ser Ile Phe Ile Thr Tyr Gly Leu Phe Arg Gly Glu Ser
           50           55           60
Ser Glu Glu Leu Ser His Gly Leu Ala Glu Pro Lys Lys Lys Phe
           65           70           75
Ala Val Leu Glu Ile Leu Asn Asn Ser Ser Gln Lys Thr Leu His
           80           85           90
Ser Val Thr Ile Leu Phe Leu Val Leu Ser Leu Ile Thr Ser Leu
           95          100          105
Leu Ser Ser Gly Phe Thr Phe Tyr Asn Ser Ile Ser Asn Pro Tyr
          110          115          120
Gln Thr Phe Leu Gly Pro Thr Gly Val Tyr Thr Trp Asn Gly Leu
          125          130          135
Gly Ala Ser Phe Val Phe Val Thr Met Ile Leu Phe Val Ala Asn
          140          145          150
Thr Gln Ser Asn Gln Leu Ser Glu Glu Leu Phe Gln Met Leu Tyr
          155          160          165
Pro Ala Thr Thr Ser Lys Gly Thr Thr His Ser Tyr Gly Tyr Ser
          170          175          180
Phe Trp Leu Ile Leu Leu Val Ile Leu Leu Asn Ile Val Thr Val
          185          190          195
Thr Ile Ile Ile Phe Tyr Gln Lys Ala Arg Tyr Gln Arg Lys Gln
          200          205          210
Glu Gln Arg Lys Pro Met Glu Tyr Ala Pro Arg Asp Gly Ile Leu
          215          220          225
Phe

```

<210> 45

<211> 154

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1638353

<400> 45

```

Met Ala Leu Leu Leu Ser Val Leu Arg Val Leu Leu Gly Gly Phe
 1           5           10           15
Phe Ala Leu Val Gly Leu Ala Lys Leu Ser Glu Glu Ile Ser Ala
           20           25           30
Pro Val Ser Glu Arg Met Asn Ala Leu Phe Val Gln Phe Ala Glu
           35           40           45
Val Phe Pro Leu Lys Val Phe Gly Tyr Gln Pro Asp Pro Leu Asn
           50           55           60
Tyr Gln Ile Ala Val Gly Phe Leu Glu Leu Leu Ala Gly Leu Leu
           65           70           75

```



```

Leu Val Met Gly Pro Pro Met Leu Gln Glu Ile Ser Asn Leu Phe
      80                      85                      90
Leu Ile Leu Leu Met Met Gly Ala Ile Phe Thr Leu Ala Ala Leu
      95                      100                     105
Lys Glu Ser Leu Ser Thr Cys Ile Pro Ala Ile Val Cys Leu Gly
      110                     115                     120
Phe Leu Leu Leu Leu Asn Val Gly Gln Leu Leu Ala Gln Thr Lys
      125                     130                     135
Lys Val Val Arg Pro Thr Arg Lys Lys Thr Leu Ser Thr Phe Lys
      140                     145                     150
Glu Ser Trp Lys

```

```

<210> 46
<211> 167
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 1726843

```

```

<400> 46
Met Ala Ser Pro Arg Thr Val Thr Ile Val Ala Leu Ser Val Ala
  1              5              10              15
Leu Gly Leu Phe Phe Val Phe Met Gly Thr Ile Lys Leu Thr Pro
      20              25              30
Arg Leu Ser Lys Asp Ala Tyr Ser Glu Met Lys Arg Ala Tyr Lys
      35              40              45
Ser Tyr Val Arg Ala Leu Pro Leu Leu Lys Lys Met Gly Ile Asn
      50              55              60
Ser Ile Leu Leu Arg Lys Ser Ile Gly Ala Leu Glu Val Ala Cys
      65              70              75
Gly Ile Val Met Thr Leu Val Pro Gly Arg Pro Lys Asp Val Ala
      80              85              90
Asn Phe Phe Leu Leu Leu Val Leu Ala Val Leu Phe Phe His
      95              100             105
Gln Leu Val Gly Asp Pro Leu Lys Arg Tyr Ala His Ala Leu Val
      110             115             120
Phe Gly Ile Leu Leu Thr Cys Arg Leu Leu Ile Ala Arg Lys Pro
      125             130             135
Glu Asp Arg Ser Ser Glu Lys Lys Pro Leu Pro Gly Asn Ala Glu
      140             145             150
Glu Gln Pro Ser Leu Tyr Glu Lys Ala Pro Gln Gly Lys Val Lys
      155             160             165
Val Ser

```

```

<210> 47
<211> 545
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 1754506

```

<400> 47

Met	Ala	Gly	Ala	Ile	Ile	Glu	Asn	Met	Ser	Thr	Lys	Lys	Leu	Cys
1				5					10					15
Ile	Val	Gly	Gly	Ile	Leu	Leu	Val	Phe	Gln	Ile	Ile	Ala	Phe	Leu
				20					25					30
Val	Gly	Gly	Leu	Ile	Ala	Pro	Gly	Pro	Thr	Thr	Ala	Val	Ser	Tyr
				35					40					45
Met	Ser	Val	Lys	Cys	Val	Asp	Ala	Arg	Lys	Asn	His	His	Lys	Thr
				50					55					60
Lys	Trp	Phe	Val	Pro	Trp	Gly	Pro	Asn	His	Cys	Asp	Lys	Ile	Arg
				65					70					75
Asp	Ile	Glu	Glu	Ala	Ile	Pro	Arg	Glu	Ile	Glu	Ala	Asn	Asp	Ile
				80					85					90
Val	Phe	Ser	Val	His	Ile	Pro	Leu	Pro	His	Met	Glu	Met	Ser	Pro
				95					100					105
Trp	Phe	Gln	Phe	Met	Leu	Phe	Ile	Leu	Gln	Leu	Asp	Ile	Ala	Phe
				110					115					120
Lys	Leu	Asn	Asn	Gln	Ile	Arg	Glu	Asn	Ala	Glu	Val	Ser	Met	Asp
				125					130					135
Val	Ser	Leu	Ala	Tyr	Arg	Asp	Asp	Ala	Phe	Ala	Glu	Trp	Thr	Glu
				140					145					150
Met	Ala	His	Glu	Arg	Val	Pro	Arg	Lys	Leu	Lys	Cys	Thr	Phe	Thr
				155					160					165
Ser	Pro	Lys	Thr	Pro	Glu	His	Glu	Gly	Arg	Tyr	Tyr	Glu	Cys	Asp
				170					175					180
Val	Leu	Pro	Phe	Met	Glu	Ile	Gly	Ser	Val	Ala	His	Lys	Phe	Tyr
				185					190					195
Leu	Leu	Asn	Ile	Arg	Leu	Pro	Val	Asn	Glu	Lys	Lys	Lys	Ile	Asn
				200					205					210
Val	Gly	Ile	Gly	Glu	Ile	Lys	Asp	Ile	Arg	Leu	Val	Gly	Ile	His
				215					220					225
Gln	Asn	Gly	Gly	Phe	Thr	Lys	Val	Trp	Phe	Ala	Met	Lys	Thr	Phe
				230					235					240
Leu	Thr	Pro	Ser	Ile	Phe	Ile	Ile	Met	Val	Trp	Tyr	Trp	Arg	Arg
				245					250					255
Ile	Thr	Met	Met	Ser	Arg	Pro	Pro	Val	Leu	Leu	Glu	Lys	Val	Ile
				260					265					270
Phe	Ala	Leu	Gly	Ile	Ser	Met	Thr	Phe	Ile	Asn	Ile	Pro	Val	Glu
				275					280					285
Trp	Phe	Ser	Ile	Gly	Phe	Asp	Trp	Thr	Trp	Met	Leu	Leu	Phe	Gly
				290					295					300
Asp	Ile	Arg	Gln	Gly	Ile	Phe	Tyr	Ala	Met	Leu	Leu	Ser	Phe	Trp
				305					310					315
Ile	Ile	Phe	Cys	Gly	Glu	His	Met	Met	Asp	Gln	His	Glu	Arg	Asn
				320					325					330
His	Ile	Ala	Gly	Tyr	Trp	Lys	Gln	Val	Gly	Pro	Ile	Ala	Val	Gly
				335					340					345
Ser	Phe	Cys	Leu	Phe	Ile	Phe	Asp	Met	Cys	Glu	Arg	Gly	Val	Gln
				350					355					360
Leu	Thr	Asn	Pro	Phe	Tyr	Ser	Ile	Trp	Thr	Thr	Asp	Ile	Gly	Thr
				365					370					375
Glu	Leu	Ala	Met	Ala	Phe	Ile	Ile	Val	Ala	Gly	Ile	Cys	Leu	Cys
				380					385					390
Leu	Tyr	Phe	Leu	Phe	Leu	Cys	Phe	Met	Val	Phe	Gln	Val	Phe	Arg
				395					400					405
Asn	Ile	Ser	Gly	Lys	Gln	Ser	Ser	Leu	Pro	Ala	Met	Ser	Lys	Val

	410		415		420
Arg Arg Leu His Tyr Glu Gly Leu Ile Phe Arg Phe Lys Phe Leu					
	425		430		435
Met Leu Ile Thr Leu Ala Cys Ala Ala Met Thr Val Ile Phe Phe					
	440		445		450
Ile Val Ser Gln Val Thr Glu Gly His Trp Lys Trp Gly Gly Val					
	455		460		465
Thr Val Gln Val Asn Ser Ala Phe Phe Thr Gly Ile Tyr Gly Met					
	470		475		480
Trp Asn Leu Tyr Val Phe Ala Leu Met Phe Leu Tyr Ala Pro Ser					
	485		490		495
His Lys Asn Tyr Gly Glu Asp Gln Ser Asn Gly Met Gln Leu Pro					
	500		505		510
Cys Lys Ser Arg Glu Asp Cys Ala Leu Phe Val Ser Glu Leu Tyr					
	515		520		525
Gln Glu Leu Phe Ser Ala Ser Lys Tyr Ser Phe Ile Asn Asp Asn					
	530		535		540
Ala Ala Ser Gly Ile					
	545				

<210> 48

<211> 570

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1831378

<400> 48

Met Gly Phe Leu Gln Leu Leu Val Val Ala Val Leu Ala Ser Glu					
1	5		10		15
His Arg Val Ala Gly Ala Ala Glu Val Phe Gly Asn Ser Ser Glu					
	20		25		30
Gly Leu Ile Glu Phe Ser Val Gly Lys Phe Arg Tyr Phe Glu Leu					
	35		40		45
Asn Arg Pro Phe Pro Glu Glu Ala Ile Leu His Asp Ile Ser Ser					
	50		55		60
Asn Val Thr Phe Leu Ile Phe Gln Ile His Ser Gln Tyr Gln Asn					
	65		70		75
Thr Thr Val Ser Phe Ser Pro Thr Leu Leu Ser Asn Ser Ser Glu					
	80		85		90
Thr Gly Thr Ala Ser Gly Leu Val Phe Ile Leu Arg Pro Glu Gln					
	95		100		105
Ser Thr Cys Thr Trp Tyr Leu Gly Thr Ser Gly Ile Gln Pro Val					
	110		115		120
Gln Asn Met Ala Ile Leu Leu Ser Tyr Ser Glu Arg Asp Pro Val					
	125		130		135
Pro Gly Gly Cys Asn Leu Glu Phe Asp Leu Asp Ile Asp Pro Asn					
	140		145		150
Ile Tyr Leu Glu Tyr Asn Phe Phe Glu Thr Thr Ile Lys Phe Ala					
	155		160		165
Pro Ala Asn Leu Gly Tyr Ala Arg Gly Val Asp Pro Pro Pro Cys					
	170		175		180
Asp Ala Gly Thr Asp Gln Asp Ser Arg Trp Arg Leu Gln Tyr Asp					

	185	190	195
Val Tyr Gln Tyr Phe Leu Pro Glu Asn Asp Leu Thr Glu Glu Met			
	200	205	210
Leu Leu Lys His Leu Gln Arg Met Val Ser Val Pro Gln Val Lys			
	215	220	225
Ala Ser Ala Leu Lys Val Val Thr Leu Thr Ala Asn Asp Lys Thr			
	230	235	240
Ser Val Ser Phe Ser Ser Leu Pro Gly Gln Gly Val Ile Tyr Asn			
	245	250	255
Val Ile Val Trp Asp Pro Phe Leu Asn Thr Ser Ala Ala Tyr Ile			
	260	265	270
Pro Ala His Thr Tyr Ala Cys Ser Phe Glu Ala Gly Glu Gly Ser			
	275	280	285
Cys Ala Ser Leu Gly Arg Val Ser Ser Lys Val Phe Phe Thr Leu			
	290	295	300
Phe Ala Leu Leu Gly Phe Phe Ile Cys Phe Phe Gly His Arg Phe			
	305	310	315
Trp Lys Thr Glu Leu Phe Phe Ile Gly Phe Ile Ile Met Gly Phe			
	320	325	330
Phe Phe Tyr Ile Leu Ile Thr Arg Leu Thr Pro Ile Lys Tyr Asp			
	335	340	345
Val Asn Leu Ile Leu Thr Ala Val Thr Gly Ser Val Gly Gly Met			
	350	355	360
Phe Leu Val Ala Val Trp Trp Arg Phe Gly Ile Leu Ser Ile Cys			
	365	370	375
Met Leu Cys Val Gly Leu Val Leu Gly Phe Leu Ile Ser Ser Val			
	380	385	390
Thr Phe Phe Thr Pro Leu Gly Asn Leu Lys Ile Phe His Asp Asp			
	395	400	405
Gly Val Phe Trp Val Thr Phe Ser Cys Ile Ala Ile Leu Ile Pro			
	410	415	420
Val Val Phe Met Gly Cys Leu Arg Ile Leu Asn Ile Leu Thr Cys			
	425	430	435
Gly Val Ile Gly Ser Tyr Ser Val Val Leu Ala Ile Asp Ser Tyr			
	440	445	450
Trp Ser Thr Ser Leu Ser Tyr Ile Thr Leu Asn Val Leu Lys Arg			
	455	460	465
Ala Leu Asn Lys Asp Phe His Arg Ala Phe Thr Asn Val Pro Phe			
	470	475	480
Gln Thr Asn Asp Phe Ile Ile Leu Ala Val Trp Gly Met Leu Ala			
	485	490	495
Val Ser Gly Ile Thr Leu Gln Ile Arg Arg Glu Arg Gly Arg Pro			
	500	505	510
Phe Phe Pro Pro His Pro Tyr Lys Leu Trp Lys Gln Glu Arg Glu			
	515	520	525
Arg Arg Val Thr Asn Ile Leu Asp Pro Ser Tyr His Ile Pro Pro			
	530	535	540
Leu Arg Glu Arg Leu Tyr Gly Arg Leu Thr Gln Ile Lys Gly Leu			
	545	550	555
Phe Gln Lys Glu Gln Pro Ala Gly Glu Arg Thr Pro Leu Leu Leu			
	560	565	570

<210> 49

<211> 127

<212> PRT

<213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1864943

<400> 49
 Met Arg Arg Arg Phe Trp Gly Val Phe Asn Cys Leu Cys Ala Gly
 1 5 10 15
 Ala Phe Gly Ala Leu Ala Ala Ala Ser Ala Lys Leu Ala Phe Gly
 20 25 30
 Ser Glu Val Ser Met Gly Leu Cys Val Leu Gly Ile Ile Val Met
 35 40 45
 Ala Ser Thr Asn Ser Leu Met Trp Thr Phe Phe Ser Arg Gly Leu
 50 55 60
 Ser Phe Ser Met Ser Ser Ala Ile Ala Ser Val Thr Val Thr Phe
 65 70 75
 Ser Asn Ile Leu Ser Ser Ala Phe Leu Gly Tyr Val Leu Tyr Gly
 80 85 90
 Glu Cys Gln Glu Val Leu Trp Trp Gly Gly Val Phe Leu Ile Leu
 95 100 105
 Cys Gly Leu Thr Leu Ile His Arg Lys Leu Pro Pro Thr Trp Lys
 110 115 120
 Pro Leu Pro His Lys Gln Gln
 125

<210> 50
 <211> 152
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1911316

<400> 50
 Met Asp Asn Val Gln Pro Lys Ile Lys His Arg Pro Phe Cys Phe
 1 5 10 15
 Ser Val Lys Gly His Val Lys Met Leu Arg Leu Ala Leu Thr Val
 20 25 30
 Thr Ser Met Thr Phe Phe Ile Ile Ala Gln Ala Pro Glu Pro Tyr
 35 40 45
 Ile Val Ile Thr Gly Phe Glu Val Thr Val Ile Leu Phe Phe Ile
 50 55 60
 Leu Leu Tyr Val Leu Arg Leu Asp Arg Leu Met Lys Trp Leu Phe
 65 70 75
 Trp Pro Leu Leu Asp Ile Ile Asn Ser Leu Val Thr Thr Val Phe
 80 85 90
 Met Leu Ile Val Ser Val Leu Ala Leu Ile Pro Glu Thr Thr Thr
 95 100 105
 Leu Thr Val Gly Gly Gly Val Phe Ala Leu Val Thr Ala Val Cys
 110 115 120
 Cys Leu Ala Asp Gly Ala Leu Ile Tyr Arg Lys Leu Leu Phe Asn
 125 130 135
 Pro Ser Gly Pro Tyr Gln Lys Lys Pro Val His Glu Lys Lys Glu
 140 145 150
 Val Leu

<210> 51
 <211> 777
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1943120

<400> 51
 Met Thr Phe Tyr Pro Phe Val Ala Ser Ser Ser Thr Arg Arg Val
 5 10 15
 Asp Asn Ser Asn Thr Arg Leu Ala Val Gln Ile Glu Arg Asp Pro
 20 25 30
 Gly Asn Asp Asp Asn Asn Leu Asn Ser Ile Phe Tyr Glu His Leu
 35 40 45
 Thr Arg Thr Leu Leu Glu Ser Leu Cys Gly Asp Leu Val Leu Gly
 50 55 60
 Arg Trp Gly Asn Tyr Ser Ser Gly Asp Cys Phe Ile Leu Ala Ser
 65 70 75
 Asp Asp Leu Asn Ala Phe Val His Leu Ile Glu Ile Gly Asn Gly
 80 85 90
 Leu Val Thr Phe Gln Leu Arg Gly Leu Glu Phe Arg Gly Thr Tyr
 95 100 105
 Cys Gln Gln Arg Glu Val Glu Ala Ile Met Glu Gly Asp Glu Glu
 110 115 120
 Asp Arg Gly Cys Cys Cys Cys Lys Pro Gly His Leu Pro His Leu
 125 130 135
 Leu Ser Arg Asn Ala Ala Phe His Leu Arg Trp Leu Thr Trp Glu
 140 145 150
 Ile Thr Gln Thr Gln Tyr Ile Leu Glu Gly Tyr Ser Ile Leu Asp
 155 160 165
 Asn Asn Ala Ala Thr Met Leu Gln Val Phe Asp Leu Arg Arg Ile
 170 175 180
 Leu Ile Arg Tyr Tyr Ile Lys Ser Ile Ile Tyr Tyr Met Val Thr
 185 190 195
 Ser Pro Lys Leu Leu Ser Trp Ile Lys Asn Glu Ser Leu Leu Lys
 200 205 210
 Ser Leu Gln Pro Phe Ala Lys Trp His Tyr Ile Glu Arg Asp Leu
 215 220 225
 Ala Met Phe Asn Ile Asn Ile Asp Asp Tyr Val Pro Cys Leu
 230 235 240
 Gln Gly Ile Thr Arg Ala Ser Phe Cys Asn Val Tyr Leu Glu Trp
 245 250 255
 Ile Gln His Cys Ala Arg Lys Arg Gln Glu Pro Ser Thr Thr Leu
 260 265 270
 Asp Ser Asp Glu Asp Ser Pro Leu Val Thr Leu Ser Phe Ala Leu
 275 280 285
 Cys Thr Leu Gly Arg Arg Ala Leu Gly Thr Ala Ala His Asn Met
 290 295 300
 Ala Ile Ser Leu Asp Ser Phe Leu Tyr Gly Leu His Val Leu Phe
 305 310 315
 Lys Gly Asp Phe Arg Ile Thr Ala Arg Asp Glu Trp Val Phe Ala
 320 325 330
 Asp Met Asp Leu Leu His Lys Val Val Ala Pro Ala Ile Arg Met

	335		340		345
Ser Leu Lys Leu	His Gln Asp Gln Phe	Thr Cys Pro Asp Glu Tyr			
	350		355		360
Glu Asp Pro Ala	Val Leu Tyr Glu Ala	Ile Gln Ser Phe Glu Lys			
	365		370		375
Lys Val Val Ile	Cys His Glu Gly Asp	Pro Ala Trp Arg Gly Ala			
	380		385		390
Val Leu Ser Asn	Lys Glu Glu Leu Leu	Thr Leu Arg His Val Val			
	395		400		405
Asp Glu Gly Ala	Asp Glu Tyr Lys Val	Ile Met Leu His Arg Ser			
	410		415		420
Phe Leu Ser Phe	Lys Val Ile Lys Val	Asn Lys Glu Cys Val Arg			
	425		430		435
Gly Leu Trp Ala	Gly Gln Gln Gln Glu	Leu Ile Phe Leu Arg Asn			
	440		445		450
Arg Asn Pro Glu	Arg Gly Ser Ile Gln	Asn Asn Lys Gln Val Leu			
	455		460		465
Arg Asn Leu Ile	Asn Ser Ser Cys Asp	Gln Pro Leu Gly Tyr Pro			
	470		475		480
Met Tyr Val Ser	Pro Leu Thr Thr Ser	Tyr Leu Gly Thr His Arg			
	485		490		495
Gln Leu Lys Asn	Ile Trp Gly Gly Pro	Ile Thr Leu Asp Arg Ile			
	500		505		510
Arg Thr Trp Phe	Thr Lys Trp Val Arg	Met Arg Lys Asp Cys			
	515		520		525
Asn Ala Arg Gln	His Ser Gly Gly Asn	Ile Glu Asp Val Asp Gly			
	530		535		540
Gly Gly Ala Pro	Thr Thr Gly Gly Asn	Asn Ala Pro Asn Gly Gly			
	545		550		555
Ser Gln Glu Ser	Ser Ala Glu Gln Pro	Arg Lys Gly Gly Ala Gln			
	560		565		570
His Gly Val Ser	Ser Cys Glu Gly Thr	Gln Arg Thr Gly Arg Arg			
	575		580		585
Lys Gly Arg Ser	Gln Ser Val Gln Ala	His Ser Ala Leu Ser Gln			
	590		595		600
Arg Pro Pro Met	Leu Ser Ser Ser Gly	Pro Ile Leu Glu Ser Arg			
	605		610		615
Gln Thr Phe Leu	Gln Thr Ser Thr Ser	Val His Glu Leu Ala Gln			
	620		625		630
Arg Leu Ser Gly	Ser Arg Leu Ser Leu	His Ala Ser Ala Thr Ser			
	635		640		645
Leu His Ser Gln	Pro Pro Pro Val Thr	Thr Thr Gly His Leu Ser			
	650		655		660
Val Arg Glu Arg	Ala Glu Ala Leu Ile	Arg Ser Ser Leu Gly Ser			
	665		670		675
Ser Thr Ser Ser	Thr Leu Ser Phe Leu	Phe Gly Lys Arg Ser Phe			
	680		685		690
Ser Ser Ala Leu	Val Ile Ser Gly Leu	Ser Ala Ala Glu Gly Gly			
	695		700		705
Asn Thr Ser Asp	Thr Gln Ser Ser Ser	Ser Val Asn Ile Val Met			
	710		715		720
Gly Pro Ser Ala	Arg Ala Ala Ser Gln	Ala Thr Arg Val Arg Gly			
	725		730		735
Trp Ala Gly Leu	Thr Arg Thr Gly Trp	Asp Gly Gly Thr Gly Ser			
	740		745		750
Trp Pro Glu Arg	Gly Thr Cys Leu Ala	Phe Pro Pro Phe Cys Leu			
	755		760		765

Gln Asn Pro Ile Pro Phe Ser Met Gly Leu Pro Glu
 770 775

<210> 52
 <211> 108
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2314236

<400> 52
 Met Phe Lys His Glu Leu Glu Glu Leu Arg Thr Thr Ile Met Tyr
 1 5 10 15
 Arg Asp Ser His Ser Val Leu Ala Leu Asn Trp Lys Val Val Ala
 20 25 30
 Thr Leu Lys Tyr Phe Leu Leu Tyr Val Ile Ile Leu Tyr Asn Leu
 35 40 45
 Glu Arg Asp Asn Gly His Ser Asn Tyr Glu Asn Tyr Glu Leu Gly
 50 55 60
 Asp Lys Ser Leu Asn Leu Leu Leu Phe Tyr Asn Ser Met Tyr Lys
 65 70 75
 Leu Val Phe Pro Tyr Ile Phe Thr Phe Ser Ser Phe Leu Ile Ser
 80 85 90
 Ser Tyr Thr Ser Ile Leu Tyr Lys Met Phe Tyr Ile Gln Arg Thr
 95 100 105
 Val Lys Ser

<210> 53
 <211> 66
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2479409

<400> 53
 Met Asn Leu Ser Lys Lys Ser Ile Leu Leu Thr Gln Val Ile Lys
 1 5 10 15
 Phe Val Asp Ile Arg Leu Phe Ile Met Val Pro Ser Tyr Pro Phe
 20 25 30
 Asn Val Phe Arg Ser Cys Val Asp Asn Phe Leu Phe Ile Met Ile
 35 40 45
 Leu Val Ile Ser Val Leu Thr Phe Leu Ile Arg Leu Gly Arg Gly
 50 55 60
 Leu Ser Val Leu Leu Ile
 65

<210> 54

<211> 540
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2683149

<400> 54
 Met Met Gly Ser Pro Val Ser His Leu Leu Ala Gly Phe Cys Val
 5 10 15
 Trp Val Val Leu Gly Trp Val Gly Gly Ser Val Pro Asn Leu Gly
 20 25 30
 Pro Ala Glu Gln Glu Gln Asn His Tyr Leu Ala Gln Leu Phe Gly
 35 40 45
 Leu Tyr Gly Glu Asn Gly Thr Leu Thr Ala Gly Gly Leu Ala Arg
 50 55 60
 Leu Leu His Ser Leu Gly Leu Gly Arg Val Gln Gly Leu Arg Leu
 65 70 75
 Gly Gln His Gly Pro Leu Thr Gly Arg Ala Ala Ser Pro Ala Ala
 80 85 90
 Asp Asn Ser Thr His Arg Pro Gln Asn Pro Glu Leu Ser Val Asp
 95 100 105
 Val Trp Ala Gly Met Pro Leu Gly Pro Ser Gly Trp Gly Asp Leu
 110 115 120
 Glu Glu Ser Lys Ala Pro His Leu Pro Arg Gly Pro Ala Pro Ser
 125 130 135
 Gly Leu Asp Leu Leu His Arg Leu Leu Leu Leu Asp His Ser Leu
 140 145 150
 Ala Asp His Leu Asn Glu Asp Cys Leu Asn Gly Ser Gln Leu Leu
 155 160 165
 Val Asn Phe Gly Leu Ser Pro Ala Ala Pro Leu Thr Pro Arg Gln
 170 175 180
 Phe Ala Leu Leu Cys Pro Ala Leu Leu Tyr Gln Ile Asp Ser Arg
 185 190 195
 Val Cys Ile Gly Ala Pro Ala Pro Ala Pro Pro Gly Asp Leu Leu
 200 205 210
 Ser Ala Leu Leu Gln Ser Ala Leu Ala Val Leu Leu Leu Ser Leu
 215 220 225
 Pro Ser Pro Leu Ser Leu Leu Leu Leu Arg Leu Leu Gly Pro Arg
 230 235 240
 Leu Leu Arg Pro Leu Leu Gly Phe Leu Gly Ala Leu Ala Val Gly
 245 250 255
 Thr Leu Cys Gly Asp Ala Leu Leu His Leu Leu Pro His Ala Gln
 260 265 270
 Glu Gly Arg His Ala Gly Pro Gly Gly Leu Pro Glu Lys Asp Leu
 275 280 285
 Gly Pro Gly Leu Ser Val Leu Gly Gly Leu Phe Leu Leu Phe Val
 290 295 300
 Leu Glu Asn Met Leu Gly Leu Leu Arg His Arg Gly Leu Arg Pro
 305 310 315
 Arg Cys Cys Arg Arg Lys Arg Arg Asn Leu Glu Thr Arg Asn Leu
 320 325 330
 Asp Pro Glu Asn Gly Ser Gly Met Ala Leu Gln Pro Leu Gln Ala
 335 340 345
 Ala Pro Glu Pro Gly Ala Gln Gly Gln Arg Glu Lys Asn Ser Gln

	350		355		360
His Pro Pro Ala	Leu Ala Pro Pro Gly	His Gln Gly His Ser His			
	365		370		375
Gly His Gln Gly	Gly Thr Asp Ile Thr	Trp Met Val Leu Leu Gly			
	380		385		390
Asp Gly Leu His	Asn Leu Thr Asp Gly	Leu Ala Ile Gly Ala Ala			
	395		400		405
Phe Ser Asp Gly	Phe Ser Ser Gly Leu Ser	Thr Thr Leu Ala Val			
	410		415		420
Phe Cys His Glu	Leu Pro His Glu Leu	Gly Asp Phe Ala Met Leu			
	425		430		435
Leu Gln Ser Gly	Leu Ser Phe Arg Arg	Leu Leu Leu Leu Ser Leu			
	440		445		450
Val Ser Gly Ala	Leu Gly Leu Gly Gly	Ala Val Leu Gly Val Gly			
	455		460		465
Leu Ser Leu Gly	Pro Val Pro Leu Thr	Pro Trp Val Phe Gly Val			
	470		475		480
Thr Ala Gly Val	Phe Leu Tyr Val Ala	Leu Val Asp Met Leu Pro			
	485		490		495
Ala Leu Leu Arg	Pro Pro Glu Pro Leu	Pro Thr Pro His Val Leu			
	500		505		510
Leu Gln Gly Leu	Gly Leu Leu Leu Gly	Gly Gly Leu Met Leu Ala			
	515		520		525
Ile Thr Leu Leu	Glu Glu Arg Leu Leu	Pro Val Thr Thr Glu Gly			
	530		535		540

<210> 55

<211> 87

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2774051

<400> 55

Met Pro Phe Thr	Leu Asp Asp Tyr Gly	Ala Tyr Ser Ser Gln Lys			
1	5	10			15
Gln Tyr Thr Cys	Gln Phe Pro Ser Thr	Ile Ala Ile His Ala Glu			
	20	25			30
Asp Lys Arg Pro	Pro Gln Ser Arg Arg	Gly Ile Val Leu Gly Pro			
	35	40			45
Ile Phe Leu Ile	Val Leu Lys Ile Ile	Ile Arg Trp Thr Val Phe			
	50	55			60
Cys Glu Asp Phe	Leu Phe Pro Ser Ser	Lys Lys Pro Cys Gly Lys			
	65	70			75
Asn Ser Leu Ile	Thr Val Leu Ile Phe	Phe Phe Phe			
	80	85			

<210> 56

<211> 100

<212> PRT

<213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2869038

<400> 56
 Met Ile Met Ala Gln Lys Ile Gly Gly Leu Thr Trp Trp Ala Ile
 5 10 15
 Met Phe Ile Ile Leu Phe Glu Ile Thr Gly Thr Ser Ser Ser Phe
 20 25 30
 Leu Arg Ile Asn Ala Leu Pro His Phe Ser Met Asn Arg Cys Gly
 35 40 45
 Glu Ala Tyr Phe Pro Phe Ser Tyr Leu Tyr Thr Ser Leu Gln Lys
 50 55 60
 Gln Phe Leu Met Lys Val Ser Gly Ile Val Lys Asn Leu Arg Gly
 65 70 75
 Met Met Thr Gly Gly Val Trp Gly Phe Phe Leu Tyr Ser Phe Phe
 80 85 90
 Asn Glu Lys Ser Phe Lys Cys Ser Thr Gly
 95 100

<210> 57
 <211> 58
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2918334

<400> 57
 Met Asp Leu Leu Tyr Glu Ile Leu Leu Ala Leu Tyr Tyr Asn Ile
 5 10 15
 Cys Tyr Asp Ile Pro Phe Ile Phe Phe Asn Leu Asn Met Met Phe
 20 25 30
 Tyr Ile Val Leu Asp Leu Arg Ile Val Phe Phe Arg Thr Ile Arg
 35 40 45
 Glu Tyr Leu Ser Pro Pro Ser Leu Ser Phe Tyr Ile Tyr
 50 55

<210> 58
 <211> 61
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2949916

<400> 58
 Met Arg Arg Ile Ile Arg Leu Arg Leu Arg Phe Ser Asp Thr Phe

```

      1           5           10           15
Met Ala Ala Phe Leu Leu Cys Leu Gly Phe Val Leu Met Leu Phe
      20           25           30
Pro Ser Leu Leu Arg Asp Gly Gly Ser Ile Ser Ser Cys Arg Asn
      35           40           45
Ser Cys Ser Ser Pro Ser Ser Glu Glu Arg His Phe Ser Asn Leu
      50           55           60
Glu

```

<210> 59
 <211> 50
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2989375

```

<400> 59
Met Cys Leu Thr Pro His Arg Asp Ser Met Cys Glu Asp Ser Pro
      1           5           10           15
Phe Thr His Gln Ile Ile Ser Met Ala Thr Ala Cys Ser Leu Leu
      20           25           30
Leu Glu Cys Phe Val Leu Ala Ala Ser Leu Leu Val Cys Val Trp
      35           40           45
Ser Glu Trp Arg Arg
      50

```

<210> 60
 <211> 310
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 3316764

```

<400> 60
Met Arg Arg Thr Ala Phe Ile Leu Gly Ser Gly Leu Leu Ser Phe
      1           5           10           15
Val Ala Phe Trp Asn Ser Val Thr Trp His Leu Gln Arg Phe Trp
      20           25           30
Gly Ala Ser Gly Tyr Phe Trp Gln Ala Gln Trp Glu Arg Leu Leu
      35           40           45
Thr Thr Phe Glu Gly Lys Glu Trp Ile Leu Phe Phe Ile Gly Ala
      50           55           60
Ile Gln Val Pro Cys Leu Phe Phe Trp Ser Phe Asn Gly Leu Leu
      65           70           75
Leu Val Val Asp Thr Thr Gly Lys Pro Asn Phe Ile Ser Arg Tyr
      80           85           90
Arg Ile Gln Val Gly Lys Asn Glu Pro Val Asp Pro Val Lys Leu
      95           100          105

```

```

Arg Gln Ser Ile Arg Thr Val Leu Phe Asn Gln Cys Met Ile Ser
110 115 120
Phe Pro Met Val Val Phe Leu Tyr Pro Phe Leu Lys Trp Trp Arg
125 130 135
Asp Pro Cys Arg Arg Glu Leu Pro Thr Phe His Trp Phe Leu Leu
140 145 150
Glu Leu Ala Ile Phe Thr Leu Ile Glu Glu Val Leu Phe Tyr Tyr
155 160 165
Ser His Arg Leu Leu His His Pro Thr Phe Tyr Lys Lys Ile His
170 175 180
Lys Lys His His Glu Trp Thr Ala Pro Ile Gly Val Ile Ser Leu
185 190 195
Tyr Ala His Pro Ile Glu His Ala Val Ser Asn Met Leu Pro Val
200 205 210
Ile Val Gly Pro Leu Val Met Gly Ser His Leu Ser Ser Ile Thr
215 220 225
Met Trp Phe Ser Leu Ala Leu Ile Ile Thr Thr Ile Ser His Cys
230 235 240
Gly Tyr His Leu Pro Phe Leu Pro Ser Pro Glu Phe His Asp Tyr
245 250 255
His His Leu Lys Phe Asn Gln Cys Tyr Gly Val Leu Gly Val Leu
260 265 270
Asp His Leu His Gly Thr Asp Thr Met Phe Lys Gln Thr Lys Ala
275 280 285
Tyr Glu Arg His Val Leu Leu Leu Gly Phe Thr Pro Leu Ser Glu
290 295 300
Ser Ile Pro Asp Ser Pro Lys Arg Met Glu
305 310

```

<210> 61

<211> 160

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3359559

<400> 61

```

Met Ala Pro Ala Leu Trp Arg Ala Cys Asn Gly Leu Met Ala Ala
1 5 10 15
Phe Phe Ala Leu Ala Ala Leu Val Gln Val Asn Asp Pro Asp Ala
20 25 30
Glu Val Trp Val Val Val Tyr Thr Ile Pro Ala Val Leu Thr Leu
35 40 45
Leu Val Gly Leu Asn Pro Glu Val Thr Gly Asn Val Ile Trp Lys
50 55 60
Ser Ile Ser Ala Ile His Ile Leu Phe Cys Thr Val Trp Ala Val
65 70 75
Gly Leu Ala Ser Tyr Leu Leu His Arg Thr Gln Gln Asn Ile Leu
80 85 90
His Glu Glu Glu Gly Arg Glu Leu Ser Gly Leu Val Ile Ile Thr
95 100 105
Ala Trp Ile Ile Leu Cys His Ser Ser Ser Lys Asn Pro Val Gly
110 115 120

```

Gly	Arg	Ile	Gln	Leu	Ala	Ile	Ala	Ile	Val	Ile	Thr	Leu	Phe	Pro
				125						130				135
Phe	Ile	Ser	Trp	Val	Tyr	Ile	Tyr	Ile	Asn	Lys	Glu	Met	Arg	Ser
				140						145				150
Ser	Trp	Pro	Thr	His	Cys	Lys	Thr	Val	Ile					
				155					160					

<210> 62

<211> 35

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 4289208

<400> 62

Met	Ala	Val	Val	Asp	Ala	Gly	Asn	Asn	Gly	Lys	Val	Leu	Asp	Arg
1				5					10					15
Val	Cys	Val	Arg	Ser	Val	Pro	Ala	Leu	Phe	Leu	Ser	Lys	Cys	Ile
				20					25					30
Ser	Leu	Asp	Met	Glu										
				35										

<210> 63

<211> 323

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2454013

<400> 63

Met	Ala	Ala	Pro	Lys	Gly	Ser	Leu	Trp	Val	Arg	Thr	Gln	Leu	Gly
1				5					10					15
Leu	Pro	Pro	Leu	Leu	Leu	Leu	Thr	Met	Ala	Leu	Ala	Gly	Gly	Ser
				20					25					30
Gly	Thr	Ala	Ser	Ala	Glu	Ala	Phe	Asp	Ser	Val	Leu	Gly	Asp	Thr
				35					40					45
Ala	Ser	Cys	His	Arg	Ala	Cys	Gln	Leu	Thr	Tyr	Pro	Leu	His	Thr
				50					55					60
Tyr	Pro	Lys	Glu	Glu	Glu	Leu	Tyr	Ala	Cys	Gln	Arg	Gly	Cys	Arg
				65					70					75
Leu	Phe	Ser	Ile	Cys	Gln	Phe	Val	Asp	Asp	Gly	Ile	Asp	Leu	Asn
				80					85					90
Arg	Thr	Lys	Leu	Glu	Cys	Glu	Ser	Ala	Cys	Thr	Glu	Ala	Tyr	Ser
				95					100					105
Gln	Ser	Asp	Glu	Gln	Tyr	Ala	Cys	His	Leu	Gly	Cys	Gln	Asn	Gln
				110					115					120
Leu	Pro	Phe	Ala	Glu	Leu	Arg	Gln	Glu	Gln	Leu	Met	Ser	Leu	Met
				125					130					135
Pro	Lys	Met	His	Leu	Leu	Phe	Pro	Leu	Thr	Leu	Val	Arg	Ser	Phe

	140		145		150
Trp Ser Asp Met	Met Asp Ser Ala Gln Ser Phe Ile Thr Ser	Ser			
	155		160		165
Trp Thr Phe Tyr	Leu Gln Ala Asp Asp Gly Lys Ile Val Ile	Phe			
	170		175		180
Gln Ser Lys Pro	Glu Ile Gln Tyr Ala Pro His Leu Glu Gln	Glu			
	185		190		195
Pro Thr Asn Leu	Arg Glu Ser Ser Leu Ser Lys Met Ser Tyr	Leu			
	200		205		210
Gln Met Arg Asn	Ser Gln Ala His Arg Asn Phe Leu Glu Asp	Gly			
	215		220		225
Glu Ser Asp Gly	Phe Leu Arg Cys Leu Ser Leu Asn Ser Gly	Trp			
	230		235		240
Ile Leu Thr Thr	Thr Leu Val Leu Ser Val Met Val Leu Leu	Trp			
	245		250		255
Ile Cys Cys Ala	Thr Val Ala Thr Ala Val Glu Gln Tyr Val	Pro			
	260		265		270
Ser Glu Lys Leu	Ser Ile Tyr Gly Asp Leu Glu Phe Met Asn	Glu			
	275		280		285
Gln Lys Leu Asn	Arg Tyr Pro Ala Ser Ser Leu Val Val Val	Arg			
	290		295		300
Ser Lys Thr Glu	Asp His Glu Glu Ala Gly Pro Leu Pro Thr	Lys			
	305		310		315
Val Asn Leu Ala	His Ser Glu Ile				
	320				

<210> 64

<211> 129

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2454048

<400> 64

Met Ala Arg Gly	Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu	
1	5	10 15
Gly Leu Trp Leu	Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala	
	20	25 30
Pro Gly Thr Ala	Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp	
	35	40 45
Leu Asp Lys Cys	Met Asp Cys Ala Ser Cys Arg Ala Arg Pro His	
	50	55 60
Ser Asp Phe Cys	Leu Gly Cys Ala Ala Ala Pro Pro Ala Pro Phe	
	65	70 75
Arg Leu Leu Trp	Pro Ile Leu Gly Gly Ala Leu Ser Leu Thr Phe	
	80	85 90
Val Leu Gly Leu	Leu Ser Gly Phe Leu Val Trp Arg Arg Cys Arg	
	95	100 105
Arg Arg Glu Lys	Phe Thr Thr Pro Ile Glu Glu Thr Gly Gly Glu	
	110	115 120
Gly Cys Pro Ala	Val Ala Leu Ile Gln	
	125	

<210> 65
 <211> 461
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2479282

<400> 65
 Met Ala Pro Gln Ser Leu Pro Ser Ser Arg Met Ala Pro Leu Gly
 1 5 10 15
 Met Leu Leu Gly Leu Leu Met Ala Ala Cys Phe Thr Phe Cys Leu
 20 25 30
 Ser His Gln Asn Leu Lys Glu Phe Ala Leu Thr Asn Pro Glu Lys
 35 40 45
 Ser Ser Thr Lys Glu Thr Glu Arg Lys Glu Thr Lys Ala Glu Glu
 50 55 60
 Glu Leu Asp Ala Glu Val Leu Glu Val Phe His Pro Thr His Glu
 65 70 75
 Trp Gln Ala Leu Gln Pro Gly Gln Ala Val Pro Ala Gly Ser His
 80 85 90
 Val Arg Leu Asn Leu Gln Thr Gly Glu Arg Glu Ala Lys Leu Gln
 95 100 105
 Tyr Glu Asp Lys Phe Arg Asn Asn Leu Lys Gly Lys Arg Leu Asp
 110 115 120
 Ile Asn Thr Asn Thr Tyr Thr Ser Gln Asp Leu Lys Ser Ala Leu
 125 130 135
 Ala Lys Phe Lys Glu Gly Ala Glu Met Glu Ser Ser Lys Glu Asp
 140 145 150
 Lys Ala Arg Gln Ala Glu Val Lys Arg Leu Phe Arg Pro Ile Glu
 155 160 165
 Glu Leu Lys Lys Asp Phe Asp Glu Leu Asn Val Val Ile Glu Thr
 170 175 180
 Asp Met Gln Ile Met Val Arg Leu Ile Asn Lys Phe Asn Ser Ser
 185 190 195
 Ser Ser Ser Leu Glu Glu Lys Ile Ala Ala Leu Phe Asp Leu Glu
 200 205 210
 Tyr Tyr Val His Gln Met Asp Asn Ala Gln Asp Leu Leu Ser Phe
 215 220 225
 Gly Gly Leu Gln Val Val Ile Asn Gly Leu Asn Ser Thr Glu Pro
 230 235 240
 Leu Val Lys Glu Tyr Ala Ala Phe Val Leu Gly Ala Ala Phe Ser
 245 250 255
 Ser Asn Pro Lys Val Gln Val Glu Ala Ile Glu Gly Gly Ala Leu
 260 265 270
 Gln Lys Leu Leu Val Ile Leu Ala Thr Glu Gln Pro Leu Thr Ala
 275 280 285
 Lys Lys Lys Val Leu Phe Ala Leu Cys Ser Leu Leu Arg His Phe
 290 295 300
 Pro Tyr Ala Gln Arg Gln Phe Leu Lys Leu Gly Gly Leu Gln Val
 305 310 315
 Leu Arg Thr Leu Val Gln Glu Lys Gly Thr Glu Val Leu Ala Val
 320 325 330
 Arg Val Val Thr Leu Leu Tyr Asp Leu Val Thr Glu Lys Met Phe
 335 340 345

Ala	Glu	Glu	Glu	Ala	Glu	Leu	Thr	Gln	Glu	Met	Ser	Pro	Glu	Lys
				350					355					360
Leu	Gln	Gln	Tyr	Arg	Gln	Val	His	Leu	Leu	Pro	Gly	Leu	Trp	Glu
				365					370					375
Gln	Gly	Trp	Cys	Glu	Ile	Thr	Ala	His	Leu	Leu	Ala	Leu	Pro	Glu
				380					385					390
His	Asp	Ala	Arg	Glu	Lys	Val	Leu	Gln	Thr	Leu	Gly	Val	Leu	Leu
				395					400					405
Thr	Thr	Cys	Arg	Asp	Arg	Tyr	Arg	Gln	Asp	Pro	Gln	Leu	Gly	Arg
				410					415					420
Thr	Leu	Ala	Ser	Leu	Gln	Ala	Glu	Tyr	Gln	Val	Leu	Ala	Ser	Leu
				425					430					435
Glu	Leu	Gln	Asp	Gly	Glu	Asp	Glu	Gly	Tyr	Phe	Gln	Glu	Leu	Leu
				440					445					450
Gly	Ser	Val	Asn	Ser	Leu	Leu	Lys	Glu	Leu	Arg				
				455					460					

<210> 66

<211> 264

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2483432

<400> 66

Met	Arg	Pro	Leu	Leu	Gly	Leu	Leu	Leu	Val	Phe	Ala	Gly	Cys	Thr
1				5					10					15
Phe	Ala	Leu	Tyr	Leu	Leu	Ser	Thr	Arg	Leu	Pro	Arg	Gly	Arg	Arg
				20					25					30
Leu	Gly	Ser	Thr	Glu	Glu	Ala	Gly	Gly	Arg	Ser	Leu	Trp	Phe	Pro
				35					40					45
Ser	Asp	Leu	Ala	Glu	Leu	Arg	Glu	Leu	Ser	Glu	Val	Leu	Arg	Glu
				50					55					60
Tyr	Arg	Lys	Glu	His	Gln	Ala	Tyr	Val	Phe	Leu	Leu	Phe	Cys	Gly
				65					70					75
Ala	Tyr	Leu	Tyr	Lys	Gln	Gly	Phe	Ala	Ile	Pro	Gly	Ser	Ser	Phe
				80					85					90
Leu	Asn	Val	Leu	Ala	Gly	Ala	Leu	Phe	Gly	Pro	Trp	Leu	Gly	Leu
				95					100					105
Leu	Leu	Cys	Cys	Val	Leu	Thr	Ser	Val	Gly	Ala	Thr	Cys	Cys	Tyr
				110					115					120
Leu	Leu	Ser	Ser	Ile	Phe	Gly	Lys	Gln	Leu	Val	Val	Ser	Tyr	Phe
				125					130					135
Pro	Asp	Lys	Val	Ala	Leu	Leu	Gln	Arg	Lys	Val	Glu	Glu	Asn	Arg
				140					145					150
Asn	Ser	Leu	Phe	Phe	Phe	Leu	Leu	Phe	Leu	Arg	Leu	Phe	Pro	Met
				155					160					165
Thr	Pro	Asn	Trp	Phe	Leu	Asn	Leu	Ser	Ala	Pro	Ile	Leu	Asn	Ile
				170					175					180
Pro	Ile	Val	Gln	Phe	Phe	Phe	Ser	Val	Leu	Ile	Gly	Leu	Ile	Pro
				185					190					195
Tyr	Asn	Phe	Ile	Cys	Val	Gln	Thr	Gly	Ser	Ile	Leu	Ser	Thr	Leu
				200					205					210

```

Thr Ser Leu Asp Ala Leu Phe Ser Trp Asp Thr Val Phe Lys Leu
      215      220      225
Leu Ala Ile Ala Met Val Ala Leu Ile Pro Gly Thr Leu Ile Lys
      230      235      240
Lys Phe Ser Gln Lys His Leu Gln Leu Asn Glu Thr Ser Thr Ala
      245      250      255
Asn His Ile His Ser Arg Lys Asp Thr
      260

```

<210> 67

<211> 339

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2493824

<400> 67

```

Met Ala Ala Ala Cys Gly Pro Gly Ala Ala Gly Tyr Cys Leu Leu
  1      5      10      15
Leu Gly Leu His Leu Phe Leu Leu Thr Ala Gly Pro Ala Leu Gly
  20      25      30
Trp Asn Asp Pro Asp Arg Met Leu Leu Arg Asp Val Lys Ala Leu
  35      40      45
Thr Leu His Tyr Asp Arg Tyr Thr Thr Ser Arg Arg Leu Asp Pro
  50      55      60
Ile Pro Gln Leu Lys Cys Val Gly Gly Thr Ala Gly Cys Asp Ser
  65      70      75
Tyr Thr Pro Lys Val Ile Gln Cys Gln Asn Lys Gly Trp Asp Gly
  80      85      90
Tyr Asp Val Gln Trp Glu Cys Lys Thr Asp Leu Asp Ile Ala Tyr
  95     100     105
Lys Phe Gly Lys Thr Val Val Ser Cys Glu Gly Tyr Glu Ser Ser
 110     115     120
Glu Asp Gln Tyr Val Leu Arg Gly Ser Cys Gly Leu Glu Tyr Asn
 125     130     135
Leu Asp Tyr Thr Glu Leu Gly Leu Gln Lys Leu Lys Glu Ser Gly
 140     145     150
Lys Gln His Gly Phe Ala Ser Phe Ser Asp Tyr Tyr Tyr Lys Trp
 155     160     165
Ser Ser Ala Asp Ser Cys Asn Met Ser Gly Leu Ile Thr Ile Val
 170     175     180
Val Leu Leu Gly Ile Ala Phe Val Val Tyr Lys Leu Phe Leu Ser
 185     190     195
Asp Gly Gln Tyr Ser Pro Pro Pro Tyr Ser Glu Tyr Pro Pro Phe
 200     205     210
Ser His Arg Tyr Gln Arg Phe Thr Asn Ser Ala Gly Pro Pro Pro
 215     220     225
Pro Gly Phe Lys Ser Glu Phe Thr Gly Pro Gln Asn Thr Gly His
 230     235     240
Gly Ala Thr Ser Gly Phe Gly Ser Ala Phe Thr Gly Gln Gln Gly
 245     250     255

```

```

Tyr Glu Asn Ser Gly Pro Gly Phe Trp Thr Gly Leu Gly Thr Gly
      260      265      270
Gly Ile Leu Gly Tyr Leu Phe Gly Ser Asn Arg Ala Ala Thr Pro
      275      280      285
Phe Ser Asp Ser Trp Tyr Tyr Pro Ser Tyr Pro Pro Ser Tyr Pro
      290      295      300
Gly Thr Trp Asn Arg Ala Tyr Ser Pro Leu His Gly Gly Ser Gly
      305      310      315
Ser Tyr Ser Val Cys Ser Asn Ser Asp Thr Lys Thr Arg Thr Ala
      320      325      330
Ser Gly Tyr Gly Gly Thr Arg Arg Arg
      335

```

<210> 68

<211> 397

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2555823

<400> 68

```

Met Val Arg Pro Gly Ala Arg Leu Cys Leu Gly Ser Val Gly Arg
  1      5      10      15
Gly Leu Cys Leu Val Leu Pro Leu Leu Cys Leu Gly Ala Gly Phe
      20      25      30
Leu Phe Leu Asn Thr Leu Phe Ile Gln Arg Gly Arg His Glu Thr
      35      40      45
Thr Trp Thr Ile Leu Arg Arg Phe Gly Tyr Ser Asp Ala Leu Glu
      50      55      60
Leu Thr Ala Asp Tyr Leu Ser Pro Leu Ile His Val Pro Pro Gly
      65      70      75
Cys Ser Thr Glu Leu Asn His Leu Gly Tyr Gln Phe Val Gln Arg
      80      85      90
Val Phe Glu Lys His Asp Gln Asp Arg Asp Gly Ala Leu Ser Pro
      95     100     105
Val Glu Leu Gln Ser Leu Phe Ser Val Phe Pro Ala Ala Pro Trp
     110     115     120
Gly Pro Glu Leu Pro Arg Thr Val Arg Thr Glu Ala Gly Arg Leu
     125     130     135
Pro Leu His Gly Tyr Leu Cys Gln Trp Thr Leu Val Thr Tyr Leu
     140     145     150
Asp Val Arg Ser Cys Leu Gly His Leu Gly Tyr Leu Gly Tyr Pro
     155     160     165
Thr Leu Cys Glu Gln Asp Gln Ala His Ala Ile Thr Val Thr Arg
     170     175     180
Glu Lys Arg Leu Asp Gln Glu Lys Gly Gln Thr Gln Arg Ser Val
     185     190     195
Leu Leu Cys Lys Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala
     200     205     210
Phe Leu Gln Ala Phe Leu Gly Arg Gly Leu Gly His Gln Asp Thr
     215     220     225
Arg Glu Gln Pro Pro Gly Tyr Ala Ile Asp Thr Val Gln Val Asn
     230     235     240

```

```

Gly Gln Glu Lys Tyr Leu Ile Leu Cys Glu Val Gly Thr Asp Gly
      245                250                255
Leu Leu Ala Thr Ser Leu Asp Ala Thr Cys Asp Val Ala Cys Leu
      260                265                270
Met Phe Asp Gly Ser Asp Pro Lys Ser Phe Ala His Cys Ala Ser
      275                280                285
Val Tyr Lys His His Tyr Met Asp Gly Gln Thr Pro Cys Leu Phe
      290                295                300
Val Ser Ser Lys Ala Asp Leu Pro Glu Gly Val Ala Val Ser Gly
      305                310                315
Pro Ser Pro Ala Glu Phe Cys Arg Lys His Arg Leu Pro Ala Pro
      320                325                330
Val Pro Phe Ser Cys Ala Gly Pro Ala Glu Pro Ser Thr Thr Ile
      335                340                345
Phe Thr Gln Leu Ala Thr Met Ala Ala Phe Pro His Leu Val His
      350                355                360
Ala Glu Leu His Pro Ser Ser Phe Trp Leu Arg Gly Leu Leu Gly
      365                370                375
Val Val Gly Ala Ala Val Ala Ala Val Leu Ser Phe Ser Leu Tyr
      380                385                390
Arg Val Leu Val Lys Ser Gln
      395

```

<210> 69

<211> 301

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2598242

<400> 69

```

Met Glu Leu Ser Asp Val Thr Leu Ile Glu Gly Val Gly Asn Glu
  1          5          10          15
Val Met Val Val Ala Gly Val Val Val Leu Ile Leu Ala Leu Val
      20          25          30
Leu Ala Trp Leu Ser Thr Tyr Val Ala Asp Ser Gly Ser Asn Gln
      35          40          45
Leu Leu Gly Ala Ile Val Ser Ala Gly Asp Thr Ser Val Leu His
      50          55          60
Leu Gly His Val Asp His Leu Val Ala Gly Gln Gly Asn Pro Glu
      65          70          75
Pro Thr Glu Leu Pro His Pro Ser Glu Gly Asn Asp Glu Lys Ala
      80          85          90
Glu Glu Ala Gly Glu Gly Arg Gly Asp Ser Thr Gly Glu Ala Gly
      95          100         105
Ala Gly Gly Gly Val Glu Pro Ser Leu Glu His Leu Leu Asp Ile
      110         115         120
Gln Gly Leu Pro Lys Arg Gln Ala Gly Ala Gly Ser Ser Ser Pro
      125         130         135
Glu Ala Pro Leu Arg Ser Glu Asp Ser Thr Cys Leu Pro Pro Ser
      140         145         150
Pro Gly Leu Ile Thr Val Arg Leu Lys Phe Leu Asn Asp Thr Glu
      155         160         165

```

Glu	Leu	Ala	Val	Ala	Arg	Pro	Glu	Asp	Thr	Val	Gly	Ala	Leu	Lys
				170						175				180
Ser	Lys	Tyr	Phe	Pro	Gly	Gln	Glu	Ser	Gln	Met	Lys	Leu	Ile	Tyr
				185						190				195
Gln	Gly	Arg	Leu	Leu	Gln	Asp	Pro	Ala	Arg	Thr	Leu	Arg	Ser	Leu
				200						205				210
Asn	Ile	Thr	Asp	Asn	Cys	Val	Ile	His	Cys	His	Arg	Ser	Pro	Pro
				215						220				225
Gly	Ser	Ala	Val	Pro	Gly	Pro	Ser	Ala	Ser	Leu	Ala	Pro	Ser	Ala
				230						235				240
Thr	Glu	Pro	Pro	Ser	Leu	Gly	Val	Asn	Val	Gly	Ser	Leu	Met	Val
				245						250				255
Pro	Val	Phe	Val	Val	Leu	Leu	Gly	Val	Val	Trp	Tyr	Phe	Arg	Ile
				260						265				270
Asn	Tyr	Arg	Gln	Phe	Phe	Thr	Ala	Pro	Ala	Thr	Val	Ser	Leu	Val
				275						280				285
Gly	Val	Thr	Val	Phe	Phe	Ser	Phe	Leu	Val	Phe	Gly	Met	Tyr	Gly
				290						295				300

Arg

<210> 70

<211> 217

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2634120

<400> 70

Met	Val	Glu	Val	Gln	Leu	Glu	Ser	Asp	His	Glu	Tyr	Pro	Pro	Gly
				5					10					15
Leu	Leu	Val	Ala	Phe	Ser	Ala	Cys	Thr	Thr	Val	Leu	Val	Ala	Val
				20					25					30
His	Leu	Phe	Ala	Leu	Met	Val	Ser	Thr	Cys	Leu	Leu	Pro	His	Ile
				35					40					45
Glu	Ala	Val	Ser	Asn	Ile	His	Asn	Leu	Asn	Ser	Val	His	Gln	Ser
				50					55					60
Pro	His	Gln	Arg	Leu	His	Arg	Tyr	Val	Glu	Leu	Ala	Trp	Gly	Phe
				65					70					75
Ser	Thr	Ala	Leu	Gly	Thr	Phe	Leu	Phe	Leu	Ala	Glu	Val	Val	Leu
				80					85					90
Val	Gly	Trp	Val	Lys	Phe	Val	Pro	Ile	Gly	Ala	Pro	Leu	Asp	Thr
				95					100					105
Pro	Thr	Pro	Met	Val	Pro	Thr	Ser	Arg	Val	Pro	Gly	Thr	Leu	Ala
				110					115					120
Pro	Val	Ala	Thr	Ser	Leu	Ser	Pro	Ala	Ser	Asn	Leu	Pro	Arg	Ser
				125					130					135
Ser	Ala	Ser	Ala	Ala	Pro	Ser	Gln	Ala	Glu	Pro	Ala	Cys	Pro	Pro
				140					145					150
Arg	Gln	Ala	Cys	Gly	Gly	Gly	Gly	Ala	His	Gly	Pro	Gly	Trp	Gln
				155					160					165
Ala	Ala	Met	Ala	Ser	Thr	Ala	Ile	Met	Val	Pro	Val	Gly	Leu	Val
				170					175					180
Phe	Val	Ala	Phe	Ala	Leu	His	Phe	Tyr	Arg	Ser	Leu	Val	Ala	His

	185		190		195
Lys Thr Asp Arg Tyr Lys Gln Glu Leu Glu Glu Leu Asn Arg Leu					
	200		205		210
Gln Gly Glu Leu Gln Ala Val					
	215				

<210> 71
 <211> 143
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> misc_feature
 <223> Incyte Clone No: 2765411

<400> 71	
Met Phe Pro Val Leu Gly Trp Ile Leu Ile Ala Val Val Ile Ile	
1 5 10 15	
Ile Leu Leu Ile Phe Thr Ser Val Thr Arg Cys Leu Ser Pro Val	
20 25 30	
Ser Phe Leu Gln Leu Lys Phe Trp Lys Ile Tyr Leu Glu Gln Glu	
35 40 45	
Gln Gln Ile Leu Lys Ser Lys Ala Thr Glu His Ala Thr Glu Leu	
50 55 60	
Ala Lys Glu Asn Ile Lys Cys Phe Phe Glu Gly Ser His Pro Lys	
65 70 75	
Glu Tyr Asn Thr Pro Ser Met Lys Glu Trp Gln Gln Ile Ser Ser	
80 85 90	
Leu Tyr Thr Phe Asn Pro Lys Gly Gln Tyr Tyr Ser Met Leu His	
95 100 105	
Lys Tyr Val Asn Arg Lys Glu Lys Thr His Ser Ile Arg Ser Thr	
110 115 120	
Glu Gly Asp Thr Val Ile Pro Val Leu Gly Phe Val Asp Ser Ser	
125 130 135	
Gly Ile Asn Ser Thr Pro Glu Leu	
140	

<210> 72
 <211> 186
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> misc_feature
 <223> Incyte Clone No: 2769412

<400> 72	
Met Ser Gly Ile Ser Gly Cys Pro Phe Phe Leu Trp Gly Leu Leu	
1 5 10 15	
Ala Leu Leu Gly Leu Ala Leu Val Ile Ser Leu Ile Phe Asn Ile	
20 25 30	

```

Ser His Tyr Val Glu Lys Gln Arg Gln Asp Lys Met Tyr Ser Tyr
      35                      40                      45
Ser Ser Asp His Thr Arg Val Asp Glu Tyr Tyr Ile Glu Asp Thr
      50                      55                      60
Pro Ile Tyr Gly Asn Leu Asp Asp Met Ile Ser Glu Pro Met Asp
      65                      70                      75
Glu Asn Cys Tyr Glu Gln Met Lys Ala Arg Pro Glu Lys Ser Val
      80                      85                      90
Asn Lys Met Gln Glu Ala Thr Pro Ser Ala Gln Ala Thr Asn Glu
      95                      100                     105
Thr Gln Met Cys Tyr Ala Ser Leu Asp His Ser Val Lys Gly Lys
     110                      115                     120
Arg Arg Lys Pro Arg Lys Gln Asn Thr His Phe Ser Asp Lys Asp
     125                      130                     135
Gly Asp Glu Gln Leu His Ala Ile Asp Ala Ser Val Ser Lys Thr
     140                      145                     150
Thr Leu Val Asp Ser Phe Ser Pro Glu Ser Gln Ala Val Glu Glu
     155                      160                     165
Asn Ile His Asp Asp Pro Ile Arg Leu Phe Gly Leu Ile Arg Ala
     170                      175                     180
Lys Arg Glu Pro Ile Asn
      185

```

<210> 73

<211> 364

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2842779

<400> 73

```

Met Pro Gly Cys Pro Cys Pro Gly Cys Gly Met Ala Gly Pro Arg
  1                      5                      10                      15
Leu Leu Phe Leu Thr Ala Leu Ala Leu Glu Leu Leu Gly Arg Ala
      20                      25                      30
Gly Gly Ser Gln Pro Ala Leu Arg Ser Arg Gly Thr Ala Thr Ala
      35                      40                      45
Cys Arg Leu Asp Asn Lys Glu Ser Glu Ser Trp Gly Ala Leu Leu
      50                      55                      60
Ser Gly Glu Arg Leu Asp Thr Trp Ile Cys Ser Leu Leu Gly Ser
      65                      70                      75
Leu Met Val Gly Leu Ser Gly Val Phe Pro Leu Leu Val Ile Pro
      80                      85                      90
Leu Glu Met Gly Thr Met Leu Arg Ser Glu Ala Gly Ala Trp Arg
      95                      100                     105
Leu Lys Gln Leu Leu Ser Phe Ala Leu Gly Gly Leu Leu Gly Asn
     110                      115                     120
Val Phe Leu His Leu Leu Pro Glu Ala Trp Ala Tyr Thr Cys Ser
     125                      130                     135
Ala Ser Pro Gly Gly Glu Gly Gln Ser Leu Gln Gln Gln Gln Gln
     140                      145                     150
Leu Gly Leu Trp Val Ile Ala Gly Ile Leu Thr Phe Leu Ala Leu
     155                      160                     165

```

Glu Lys Met Phe	Leu Asp Ser Lys Glu	Glu Gly Thr Ser Gln	Ala
170		175	180
Pro Asn Lys Asp	Pro Thr Ala Ala Ala	Ala Leu Asn Gly	Gly
185		190	195
His Cys Leu Ala	Gln Pro Ala Ala Glu	Pro Gly Leu Gly	Ala Val
200		205	210
Val Arg Ser Ile	Lys Val Ser Gly Tyr	Leu Asn Leu Leu	Ala Asn
215		220	225
Thr Ile Asp Asn	Phe Thr His Gly Leu	Ala Val Ala Ala	Ser Phe
230		235	240
Leu Val Ser Lys	Lys Ile Gly Leu Leu	Thr Thr Met Ala	Ile Leu
245		250	255
Leu His Glu Ile	Pro His Glu Val Gly	Asp Phe Ala Ile	Leu Leu
260		265	270
Arg Ala Gly Phe	Asp Arg Trp Ser Ala	Ala Lys Leu Gln	Leu Ser
275		280	285
Thr Ala Leu Gly	Gly Leu Leu Gly Ala	Gly Phe Ala Ile	Cys Thr
290		295	300
Gln Ser Pro Lys	Gly Val Glu Glu Thr	Ala Ala Trp Val	Leu Pro
305		310	315
Phe Thr Ser Gly	Gly Phe Leu Tyr Ile	Ala Leu Val Asn	Val Leu
320		325	330
Pro Asp Leu Leu	Glu Glu Asp Pro Trp	Arg Ser Leu Gln	Gln
335		340	345
Leu Leu Leu Leu	Cys Ala Gly Ile Val	Val Met Val Leu	Phe Ser
350		355	360
Leu Phe Val Asp			

<210> 74

<211> 605

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2966260

<400> 74

Met Gly Arg Leu	Leu Arg Ala Ala Arg	Leu Pro Pro Leu	Leu Ser
1	5	10	15
Pro Leu Leu Leu	Leu Val Gly Gly	Ala Phe Leu Gly	Ala Cys
20		25	30
Val Ala Gly Ser	Asp Glu Pro Gly	Pro Glu Gly Leu	Thr Ser Thr
35		40	45
Ser Leu Leu Asp	Leu Leu Leu Pro	Thr Gly Leu Glu	Pro Leu Asp
50		55	60
Ser Glu Glu Pro	Ser Glu Thr Met	Gly Leu Gly Ala	Gly Leu Gly
65		70	75
Ala Pro Gly Ser	Gly Phe Pro Ser	Glu Glu Asn Glu	Glu Ser Arg
80		85	90
Ile Leu Gln Pro	Pro Gln Tyr Phe	Trp Glu Glu Glu	Glu Leu
95		100	105
Asn Asp Ser Ser	Leu Asp Leu Gly	Pro Thr Ala Asp	Tyr Val Phe
110		115	120

Pro	Asp	Leu	Thr	Glu	Lys	Ala	Gly	Ser	Ile	Glu	Asp	Thr	Ser	Gln
				125					130					135
Ala	Gln	Glu	Leu	Pro	Asn	Leu	Pro	Ser	Pro	Leu	Pro	Lys	Met	Asn
				140					145					150
Leu	Val	Glu	Pro	Pro	Trp	His	Met	Pro	Pro	Arg	Glu	Glu	Glu	Glu
				155					160					165
Glu	Glu	Glu	Glu	Glu	Glu	Glu	Met	Glu	Lys	Glu	Glu	Val	Glu	Lys
				170					175					180
Gln	Asp	Val	Glu	Glu	Glu	Glu	Leu	Leu	Pro	Val	Asn	Gly	Ser	
				185					190					195
Gln	Glu	Glu	Ala	Lys	Pro	Gln	Val	Arg	Asp	Phe	Ser	Leu	Thr	Ser
				200					205					210
Ser	Ser	Gln	Thr	Pro	Gly	Ala	Thr	Lys	Ser	Arg	His	Glu	Asp	Ser
				215					220					225
Gly	Asp	Gln	Ala	Ser	Ser	Gly	Val	Glu	Val	Glu	Ser	Ser	Met	Gly
				230					235					240
Pro	Ser	Leu	Leu	Leu	Pro	Ser	Val	Thr	Pro	Thr	Ile	Val	Thr	Pro
				245					250					255
Gly	Asp	Gln	Asp	Ser	Thr	Ser	Gln	Glu	Ala	Glu	Ala	Thr	Val	Leu
				260					265					270
Pro	Ala	Ala	Gly	Leu	Gly	Val	Glu	Phe	Glu	Ala	Pro	Gln	Glu	Ala
				275					280					285
Ser	Glu	Glu	Ala	Thr	Ala	Gly	Ala	Ala	Gly	Leu	Ser	Gly	Gln	His
				290					295					300
Glu	Glu	Val	Pro	Ala	Leu	Pro	Ser	Phe	Pro	Gln	Thr	Thr	Ala	Pro
				305					310					315
Ser	Gly	Ala	Glu	His	Pro	Asp	Glu	Asp	Pro	Leu	Gly	Ser	Arg	Thr
				320					325					330
Ser	Ala	Ser	Ser	Pro	Leu	Ala	Pro	Gly	Asp	Met	Glu	Leu	Thr	Pro
				335					340					345
Ser	Ser	Ala	Thr	Leu	Gly	Gln	Glu	Asp	Leu	Asn	Gln	Gln	Leu	Leu
				350					355					360
Glu	Gly	Gln	Ala	Ala	Glu	Ala	Gln	Ser	Arg	Ile	Pro	Trp	Asp	Ser
				365					370					375
Thr	Gln	Val	Ile	Cys	Lys	Asp	Trp	Ser	Asn	Leu	Ala	Gly	Lys	Asn
				380					385					390
Tyr	Ile	Ile	Leu	Asn	Met	Thr	Glu	Asn	Ile	Asp	Cys	Glu	Val	Phe
				395					400					405
Arg	Gln	His	Arg	Gly	Pro	Gln	Leu	Leu	Ala	Leu	Val	Glu	Glu	Val
				410					415					420
Leu	Pro	Arg	His	Gly	Ser	Gly	His	His	Gly	Ala	Trp	His	Ile	Ser
				425					430					435
Leu	Ser	Lys	Pro	Ser	Glu	Lys	Glu	Gln	His	Leu	Leu	Met	Thr	Leu
				440					445					450
Val	Gly	Glu	Gln	Gly	Val	Val	Pro	Thr	Gln	Asp	Val	Leu	Ser	Met
				455					460					465
Leu	Gly	Asp	Ile	Arg	Arg	Ser	Leu	Glu	Glu	Ile	Gly	Ile	Gln	Asn
				470					475					480
Tyr	Ser	Thr	Thr	Ser	Ser	Cys	Gln	Ala	Arg	Ala	Ser	Gln	Val	Arg
				485					490					495
Ser	Asp	Tyr	Gly	Thr	Leu	Phe	Val	Val	Leu	Val	Val	Ile	Gly	Ala
				500					505					510
Ile	Cys	Ile	Ile	Ile	Ile	Ala	Leu	Gly	Leu	Leu	Tyr	Asn	Cys	Trp
				515					520					525
Gln	Arg	Arg	Leu	Pro	Lys	Leu	Lys	His	Val	Ser	His	Gly	Glu	Glu
				530					535					540
Leu	Arg	Phe	Val	Glu	Asn	Gly	Cys	His	Asp	Asn	Pro	Thr	Leu	Asp

	545		550		555
Val Ala Ser Asp	Ser Gln Ser Glu Met	Gln Glu Lys His Pro Ser			
	560		565		570
Leu Asn Gly Gly	Gly Ala Leu Asn Gly	Pro Gly Ser Trp Gly Ala			
	575		580		585
Leu Met Gly Gly	Lys Arg Asp Pro Glu	Asp Ser Asp Val Phe Glu			
	590		595		600
Glu Asp Thr His	Leu				
	605				

<210> 75
 <211> 97
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2993326

<400> 75	
Met Thr Gly Arg Phe Lys Ala Cys Gln Val Ile Leu Gly Leu Leu	
1 5 10 15	
Val Ala Ile Ser Leu Ala Ala Gly Thr Gly Gly Ala Ala Gly Ala	
20 25 30	
Ala Leu Val Ile Val Phe Ile Gly Ala Phe Leu Val Leu Leu Phe	
35 40 45	
Leu Gly Arg Leu Thr Thr Gly Gly Ser Met Ala Arg Glu Ser Leu	
50 55 60	
Val Ala Ala Asn Arg Val Cys Ile Ser Arg Thr Leu Ser Ser Ser	
65 70 75	
Val Val Ser Val Cys Ile Ser Gly Gly Lys Gly Ser Pro Arg Leu	
80 85 90	
Pro Gly Gly Gly Arg Gly Pro	
95	

<210> 76
 <211> 247
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 3001124

<400> 76	
Met Val Thr Leu Val Ser Asp Thr Ala Met Thr Pro Ile Ala Ser	
1 5 10 15	
Val Asp Thr Ile Ala Val Cys Leu Phe Ala Gly Ala Trp Gly Gly	
20 25 30	
Ala Met Val Pro Met His Leu Leu Gly Arg Leu Glu Lys Pro Leu	
35 40 45	
Leu Leu Leu Cys Cys Ala Ser Phe Leu Leu Gly Leu Ala Leu Leu	

	50		55		60
Gly Ile Lys Thr	Asp Ile Thr Pro Val	Ala Tyr Phe Phe Leu Thr			
	65		70		75
Leu Gly Gly Phe	Phe Leu Phe Ala Tyr	Leu Leu Val Arg Phe Leu			
	80		85		90
Glu Trp Gly Leu	Arg Ser Gln Leu Gln	Ser Met Gln Thr Glu Ser			
	95		100		105
Pro Gly Pro Ser	Gly Asn Ala Arg Asp	Asn Glu Ala Phe Glu Val			
	110		115		120
Pro Val Tyr Glu	Glu Ala Val Val Gly	Leu Glu Ser Gln Cys Arg			
	125		130		135
Pro Gln Glu Leu	Asp Gln Pro Pro Pro	Tyr Ser Thr Val Val Ile			
	140		145		150
Pro Pro Ala Pro	Glu Glu Glu Gln Pro	Ser His Pro Glu Gly Ser			
	155		160		165
Arg Arg Ala Lys	Leu Glu Gln Arg Arg	Met Ala Ser Glu Gly Ser			
	170		175		180
Met Ala Gln Glu	Gly Ser Pro Gly Arg	Ala Pro Ile Asn Leu Arg			
	185		190		195
Leu Arg Gly Pro	Arg Ala Val Ser Thr	Ala Pro Asp Leu Gln Ser			
	200		205		210
Leu Ala Ala Val	Pro Thr Leu Glu Pro	Leu Thr Pro Pro Pro Ala			
	215		220		225
Tyr Asp Val Cys	Phe Gly His Pro Asp	Asp Asp Ser Val Phe Tyr			
	230		235		240
Glu Asp Asn Trp	Ala Pro Pro				
	245				

<210> 77

<211> 193

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3120070

<400> 77

Met Ile Arg Cys	Gly Leu Ala Cys	Glu Arg Cys Arg	Trp Ile Leu	
1	5	10	15	
Pro Leu Leu Leu	Leu Ser Ala Ile	Ala Phe Asp Ile	Ile Ala Leu	
	20	25	30	
Ala Gly Arg Gly	Trp Leu Gln Ser	Ser Asp His Gly	Gln Thr Ser	
	35	40	45	
Ser Leu Trp Trp	Lys Cys Ser Gln	Glu Gly Gly Gly	Ser Gly Ser	
	50	55	60	
Tyr Glu Glu Gly	Cys Gln Ser Leu	Met Glu Tyr Ala	Trp Gly Arg	
	65	70	75	
Ala Ala Ala Ala	Met Leu Phe Cys	Gly Phe Ile Ile	Leu Val Ile	
	80	85	90	
Cys Phe Ile Leu	Ser Phe Phe Ala	Leu Cys Gly Pro	Gln Met Leu	
	95	100	105	
Val Phe Leu Arg	Val Ile Gly Gly	Leu Leu Ala Leu	Ala Ala Val	
	110	115	120	
Phe Gln Ile Ile	Ser Leu Val Ile	Tyr Pro Val Lys	Tyr Thr Gln	

	125		130		135
Thr Phe Thr Leu	His Ala Asn Pro Ala	Val Thr Tyr Ile Tyr Asn			
	140		145		150
Trp Ala Tyr Gly	Phe Gly Trp Ala Ala	Thr Ile Ile Leu Ile Gly			
	155		160		165
Cys Ala Phe Phe	Phe Cys Cys Leu Pro	Asn Tyr Glu Asp Asp Leu			
	170		175		180
Leu Gly Asn Ala	Lys Pro Arg Tyr Phe	Tyr Thr Ser Ala			
	185		190		

<210> 78
 <211> 128
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 3133035

<400> 78

Met Asn Met Lys Gln Lys Ser Val Tyr Gln Gln Thr Lys Ala Leu	
1 5 10 15	
Leu Cys Lys Asn Phe Leu Lys Lys Trp Arg Met Lys Arg Glu Ser	
20 25 30	
Leu Leu Glu Trp Gly Leu Ser Ile Leu Leu Gly Leu Cys Ile Ala	
35 40 45	
Leu Phe Ser Ser Ser Met Arg Asn Val Gln Phe Pro Gly Met Ala	
50 55 60	
Pro Gln Asn Leu Gly Arg Val Asp Lys Phe Asn Ser Ser Ser Leu	
65 70 75	
Met Val Val Tyr Thr Pro Ile Ser Asn Leu Thr Gln Gln Ile Met	
80 85 90	
Asn Lys Thr Ala Leu Ala Pro Leu Leu Lys Gly Thr Ser Val Ile	
95 100 105	
Gly Ala Gln Ile Ile His Thr Trp Thr Lys Tyr Phe Trp Lys Ile	
110 115 120	
Tyr Ile Cys Tyr Gly Asn His Leu	
125	

<210> 79
 <211> 115
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 3436879

<400> 79

Met Ala Val Ala Val Leu Leu Cys Gly Cys Ile Val Ala Thr Val	
1 5 10 15	
Ser Phe Phe Trp Glu Glu Ser Leu Thr Gln His Val Ala Gly Leu	
20 25 30	
Leu Phe Leu Met Thr Gly Ile Phe Cys Thr Ile Ser Leu Cys Thr	

	35		40		45									
Tyr	Ala	Ala	Ser	Ile	Ser	Tyr	Asp	Leu	Asn	Arg	Leu	Pro	Lys	Leu
	50		55		60									
Ile	Tyr	Ser	Leu	Pro	Ala	Asp	Val	Glu	His	Gly	Tyr	Ser	Trp	Ser
	65		70		75									
Ile	Phe	Cys	Ala	Trp	Cys	Ser	Leu	Gly	Phe	Ile	Val	Ala	Ala	Gly
	80		85		90									
Gly	Leu	Cys	Ile	Ala	Tyr	Pro	Phe	Ile	Ser	Arg	Thr	Lys	Ile	Ala
	95		100		105									
Gln	Leu	Lys	Ser	Gly	Arg	Asp	Ser	Thr	Val					
	110		115											

<210> 80

<211> 1869

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 153831

<400> 80

```

gcgagcggtt ggcggtatccg acgcgcgaga ccgggagggg acgagggcgt tgcaatcggt 60
cggggagggg gctttccggg gaggggggtgc tcaggtgcac cagcggcggc ggaccctcag 120
actctgcctt cccctccctt taacccctt ccagccggac gggagggcgg gcagggttga 180
gcatttgtga cacctacatt tccgtggctc ccttcttttc ccccgacccc tgtttatctc 240
ttcgcttcc agaagttctt ttccatcagg ccgtcgacac ttgcgtggga aggagcacc 300
cacttgggaag caggagggcg gggttcagatc ttggccctac cctcctgtg ttaaagtccg 360
cgagcctcag ttccctcac agtatttttt gcctcgctt acccggtttt gaggatctgt 420
acgagaaaaga gaaaggaagt ggacatttgt tgaattcctg catggccaaa taccacgcag 480
actgcttcat ccgccacgtt taatccttat tacttgggtg tctcagaact cccatttcat 540
ggattcttaa gtcacagag tcagtgaata acagaaaggg attcagatct agccgttttag 600
ctgcacagtg gatttcttct ccagagtctt cccttgtctg ggctctggct ggaactattc 660
ctcagccaaa tcctcgcccc agaacagtgc ttctgttttc tccagctgag aagtctccct 720
ttcagtttcc ttcttccagc acggagtaca ctgctctgcc tccacttaga ttacttcaga 780
aatgaaatgc agcaaatatt tatccagcag tgcaggaggt tgaacttttg gagtccggaa 840
ccttggattc ttgttctggc tctgccactt actgtgtggc cttgggaagt ctttctctt 900
ctctgagctt tcttttctct ttgcgtaaaa gcggtgctct tgtcccatc tccctccctg 960
tcttccagca ggctctcccc ggaggtctcag cccctctgc tcccatagg caactgccag 1020
gcagggcaca acctgcacct gtgtctggcc caccaccac ctctggctct tgccactttg 1080
atcctgctgc tccttggcct ctctggcctg ggccttggca gcttctcct caccacagg 1140
actggcctgc gcagccctga catccccag gactgggtct cttttttgag atcttttggc 1200
cagctgacct tgtgtcccag gaatgggaca gtcacaggga agtggcgagg gtctcacgtc 1260
gtgggcttgc tgaccacctt gaacttcgga gacggtccag acaggaacaa gaccgggaca 1320
ttccaggcca cagtccctgg aagtcagatg ggattgaaag gatcttctgc aggacaactg 1380
gtccttatca cagccagggt gaccacagaa aggactgcag gaacctgcct atattttagt 1440
gctgttccag gaatcctacc ctccagccag ccacccatat cctgctcaga ggagggggct 1500
ggaaatgcc aacctgagccc tagaatgggt gaggaatgtg ttagtgtctg gagccatgaa 1560
ggccttgtgc tgaccaagct gctcacctcg gaggagctgg ctctgtgtgg ctccaggctg 1620
ctgggtcttg gctccttctt gcttctcttc tgtggccttc tctgtgtgt cactgctatg 1680
tgcttccacc cgcgcgggga gtcccaactg tctagaaccc ggctctgagg gcactggcct 1740
agttcccgac ttgtttctca ggtgtgaatc aacttcttgg gccttggctc tgagtggaa 1800
aaggttttag aaaaagtga gagctggaat gtgggggaaa ataaaaagct tttttgcccc 1860
aaaaaaaaa

```

<210> 81
 <211> 1044
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> misc_feature
 <223> Incyte Clone No: 350629

<400> 81
 tgcagttaac atctgcacac ttactatat ttttaagtttt tgtaaatata aaagaataag 60
 aaaacagaaa agtattactg ttaaacaata atagagaaat gtatacttta tttacaaatt 120
 tctccctcta gctgatcata cagttgacca gttcaggggtg cccgctgctg gttggatgcc 180
 aggcggaatg tcagggtgtt ctctggtgtc tgttgtggct gtgggatcca cggttactgg 240
 gcggagcctg tgggtggctgt ggtgccatgg aggggctgcg atcttctgtg gagctggacc 300
 ctgagctgac tccagggaaag ctggatgagg agatgggtggg gctgccaccc catgacgcga 360
 gtccctcaagt cactttccac agcctcgatg ggaagacagt ggtgtgtcca cacttcatgg 420
 gcttactgct ggggtctctta cttttattga ctttgtctgt taggaaccaa ctctgtgtta 480
 gaggtgaaa gacagcttgc gaaacactgc attcacaggt gaaggagaaa tccagctca 540
 ttggcaagaa aacagattgt agagactgag gcatctttaa aagatgtcag ggtacagaaa 600
 aagtctttca acacccccgg ctttgtatag gcctacaaga aggtgaatag caccaacgag 660
 atgctgatgg agaaatttac caccctcgtt caagaactga aagaagagac atcctccaga 720
 ctctcctcaa tgggcgggtgc ctccaaatct aaagaatatg gaggtcctgg agcacaccaa 780
 gaaatgaggg actttttctt tgcagaaagt ttgaattctg tcttaatgag acagaatgcc 840
 ataactgagc acctcatctt ttgctcaaat tgaaatgtca tgcgaactgta tttctcaagt 900
 caatggctctg taaatatgat ttatgtatta atctcctaag tgaacaattt atattttatc 960
 ctctacataa ttatcgtatt atgctttaa tatatattta gtttatcaat aaagacattc 1020
 agtactcaat agcaaaaaaa aaaa 1044

<210> 82
 <211> 3079
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> misc_feature
 <223> Incyte Clone No: 729171

<400> 82
 cggctcgagg tcggctggag tcggaggcga ttttctagg ggtgtacttg ttggggtcag 60
 ggtaagcacc agccacaaaa acctacaaaa gaagggaat tactgtcttt aaatattaaa 120
 aaaaaacaag atccatgagt gggcatcgat caacaaggaa aagatgtgga gattcccacc 180
 cggagtcccc agtgggcttc gggcatatga gtactacagg atgtgtatta aataaattgt 240
 ttcagttacc aacaccacca ttgtcaagac accaactaaa gcggctagaa gaacacagat 300
 atcaaagtgc tggacgggtcc ctgcttgagc ccttagtgca agggatttgg gaatggctcg 360
 ttagaagagt tcctcctcgg attgccccaa atctcatcac catcattgga ctgtcaataa 420
 acatctgtac aactatttta ttagtcttct actgccctac agctacagag caggcacctc 480
 tgtgggcata tattgcttgt gctgtggcc ttttcattta ccagtctttg gatgctattg 540
 gtgggaaaca ggcaagaaga accaatagta gttctcctct gggagaactt tttgatcatg 600
 gctgtgattc actatcaaca gtttttgtgg ttcttggaac ttgtatagca gtgcagctgg 660
 ggacaaaccc tgattggatg tttttttgtt gttttgcggg gacatttatg ttctattgtg 720
 cgcactggca aacgtatgtt tctggaacat tgcgatttgg aataattgat gtgactgaag 780
 tgcaaatctt cataataatc atgcatttgc tggcagtgat gggaggacca cctttttggc 840

```

aatctatgat tccagtgtcg aatattcaaa tgaaaatttt tcctgcactt tgtactgtag 900
caggggacat atttcctgta acaaattact tccgtgtaat cttcacaggt ggtgttggca 960
aaaatggatc aacaatagca ggaacaagtg tcctttctcc ttttctccat attggatcag 1020
tgattacatt agctgcaatg atctacaaga aatctgcagt tcagcttttt gaaaagcatc 1080
cctgtcttta tatactgaca tttggttttg tgtctgctaa aatcactaat aagcttggg 1140
ttgcacacat gacgaaaagt gaaatgcatt tgcacacac agcattcata ggtccggcac 1200
ttttgtttct ggaccagtat tttaacagct ttattgatga atattattgta ctttggattg 1260
ccctggtttt ctctttcttt gatttgatcc gctactgtgt cagtgtttgc aatcagattg 1320
cgtctcacct gcacatacat gtcttcagaa tcaaggcttc tacagctcat tctaatacat 1380
attaatgatg taattgggtat ataggaacat catgttttct gcaggaaaaga aagtaacata 1440
ttaaggagaa tgggggtgga taagaacaaa tataatttat aataatcaat gttgtataac 1500
ttttattctt tattattggg aacacgccct aactatcctg tgtgagaatg ggaatttcaa 1560
gtcccatctt gtaaatgtga tatgttgta tgcaggggtt gggccaagaa agcatgcaga 1620
aaaaaatgcc atgtgattgt aattatcctg gattcagaat aatactgtga tggggagcca 1680
gatccgcagt ggtggagagt tctaattgtg actgtttgca ggccaaaaga tgattgcttt 1740
ataattttaa caaatcattg tcttttagta acatcctgtg ttagtgtctt ctcaagcttt 1800
ctttactgag gaattcagct tgtgacacag atacatccca ctactgtgtg aggtggaact 1860
agtaataaag acctgaatt tggattgaaa agtttcttat ctttacttg ttgaggaagt 1920
cctttttttt tttttttttt tttttaattg ctcaagaaat gattctctca caggcttggg 1980
aaatcctgtt agcatgcaga ataattgtgt aactttgtca atttccatt ttattttttt 2040
aaataaatat atgatctaaa agccaacttt ttctcagttt tactcagtg aaagataaac 2100
taagttttaa tgttattttt ttaaatttaa gcaaaattta tttctgttct ttaataaata 2160
agaaaatgtg gtccactgca ttgttgtgat gtgtctgtg acatttctat tttgtagaaa 2220
ctttaaaaag gagaactatg ttcatttttc ctgtcaatgg tttttttgtg ttgtagtgt 2280
cacctgtgtg attatcaatc atttagaaat ctcatacct tcccctaaat tttcagcaag 2340
tgctggggcc tctctaagag gtcactttgt actctcttt tctggcagtc tctcttttg 2400
tatctgtact atcgtttgaa atgggaacca gatattgttc cattttatac agataattca 2460
gttgcttgaa gaagagggac acaggagaaa agatttaaac tattggctaa aatgaggtg 2520
cttattattg attttcatct atactctgtc ccataatcag gaataaacag tagctacact 2580
gccttgatg gcagccagag cgtgctgtg ttgcactttt aatgattcca tcaatccat 2640
gtagattgaa ttagcaagga gaagtaaac tttcatttct ttgccagact atattgggaa 2700
atgaaaatcc gtcattactt ttccttgcta gcaattgttc gaatatctgg gataaagaaa 2760
tacatacagg aaaatgttag ggcagaccaa gtattaaaag ctaggacaga gcaggacaaa 2820
ggaggaagga taattctact tgtttggcaa agttacatca gttgtcttac tgacacatca 2880
ggtactatct atagtggaaa ttgaggcccg gagagggtta atggcatgcc agtgtcact 2940
gctatttttc agaacaaaaa ttagaatcca gatctgaatc ctggtgcagt gttctctct 3000
atgccctact gggctttagt gggctaaaag tctgaagcaa gatgttaagg gctaattgaa 3060
atgcgtttat tctcctaga 3079

```

<210> 83

<211> 1298

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1273641

<400> 83

```

cccgggtgct gcgggattgc tggagagaac gcggcgatgg agccgggcag gaccagata 60
aagcttgacc ccaggtacac agcagatctt ctggagggtg tgaagaccaa ttacggcatc 120
ccctccgctt gcttctctca gcctcccaca gcagccact cctgagagcc ctgggccctg 180
tggaacttgc cctcactagc atcctgacct tgcctggcgt gggctccatt gccatcttcc 240
tggaggatgc cgtctacctg tacaagaaca ccctttgcc catcaagagg cggactctgc 300
tctggaagag ctcggcacc acggtggtgt ctgtgctgtg ctgctttggt ctctggatcc 360

```

```

ctcgcttccct ggtgctggtg gaaatgacca tcacctcggt ttatgccgtg tgcttttacc 420
tgctgatgct ggtcatggtg gaaggctttg gggggaagga ggcagtgtg aggacgtga 480
gggacacccc gatgatggtc cacacaggcc cctgctgctg ctgctgcccc tgctgtcaac 540
ggctgctgct caccaggaag aagcttcagc tgctgatgtt gggccctttc caatacgct 600
tcttgaagat aacgctgacc tgggtggcct tgttctcgtc cccgacggaa tcttatgacc 660
cagcagacat ttctgagggg agcacagctc tatggatcaa cactttcctt ggcgtgtcca 720
cactgctggc tctctggacc ctgggcatca ttcccgctca agccaggcta cacctgggtg 780
agcagaacat gggagccaaa tttgctctgt tccaggttct cctcatcctg actgccctac 840
agccctccat cttctcagtc ttggccaacg gtgggcagat tgcttggtcg cctccctatt 900
cctctaaaac caggtctcaa gtgatgaatt gccacctcct catactggag acttttctaa 960
tgactgtgct gacacgaatg tactaccgaa ggaaagacca caaggttggg tatgaaactt 1020
tctcttctcc agacctggac ttgaacctca aagcctaagg tggatggctt ggacaatgaa 1080
aggatgctgt actcattaga atacaagatt cctttactgt ccctcaacct tgaccaaagt 1140
ggaagcattc ccccttgtca acacaagctg gcagatacat ttgactctac agatgaaggt 1200
gaacaatgtt aggataaaat tgctttggat ctgacctgga aggtgtttta agttttgtaa 1260
taaacaagat gatgtctgaa aatgtgaaaa aaaaaaaa 1298

```

<210> 84

<211> 2106

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1427389

<400> 84

```

gtggggctgc ggcggggatt tgtccctctc tcggcttccg tagaggaaat ggcgcggacc 60
ttcatttggg gtttcggttc ccccccttcc ccttccccgg ggtctggggg tgacattgca 120
ccgcgccccct cgtggggtcg cgttgccacc ccacgcggac tccccagctg gcgcgccccct 180
cccatttgcc tgtcctggtc agggcccccac cccccctccc acctgaccag ccatgggggc 240
tgcggtgttt ttcggtgca ctttcgtcgc gttcggcccc gccttcgcgc ttttcttgat 300
cactgtggct ggggacccgc ttcgcgttat catcctggtc gcaggggcat ttttctggct 360
ggtctccctg ctccctggct ctgtggtctg gttcatcttg gtccatgtga ccgaccggtc 420
agatgccccg ctccagtaac gcctcctgat ttttgggtgct gctgtctctg tcttctaca 480
ggaggtgttc cgctttgcct actacaagct gcttaagaag gcagatgagg ggttagcatc 540
gctgagtgag gacggaagat caccatctc catccggcag atggcctatg tttctggctc 600
ctccttcggg atcatcagtg gtgtcttctc tggtatcaat attttggctg atgcacttgg 660
gccaggtgtg gttgggatcc atggagactc accctattac ttcctgactt cagcctttct 720
gacagcagcc attatcctgc tccatacctt ttggggagtt gtgttctttg atgcctgtga 780
gaggagacgg tactgggctt tgggcctggt ggttgggagt cacctactga catcgggact 840
gacattcctg aaccctggt atgaggccag cctgctgccc atctatgcag tcaactgttc 900
catggggctc tgggccttca tcacagctgg aggttccctc cgaagtattc agcgcagcct 960
cttgtgtaag gactgactac ctggactgat cgcctgacag atcccacctg cctgtccact 1020
gcccctgact gagccagacc ccagcccggg tccattgccc acattctctg tctccttctc 1080
gtcgtgtctac cccactacct ccagggtttt gctttgtcct tttgtgaccg ttagtctcta 1140
agctttacca ggagcagcct gggttcagcc agtcagtga tggtgggttt gaactctgac 1200
ttatccccac cacctgggga ccccttgtt gtgtccagga ctccccctgt gtcagtgtc 1260
tgctctcacc ctgcccaga ctcacctccc ttccctctg caggccgacg gcaggaggac 1320
agtcgggtga tgggtgtatt tgccctgcgc atcccacccg aggactgagg gaacctaggg 1380
gggacccctg ggcctggggt gccctcctga tgtcctgcgc ctgtatttct ccatctccag 1440
ttctggacag tgcaggttgc caagaaaagg gacctagttt agccattgcc ctggagatga 1500
aattaatgga ggctcaagga tagatgagct ctgagtttct cagtactccc tcaagactgg 1560
acatcttggg ctttttctca ggctgaggg ggaaccattt ttggtgtgat aaatacccta 1620
aactgccttt ttttcttttt tgagggtggg ggaggaggga ggtatattgg aactcttcta 1680

```



```

acctccttgg gctatatattt ctctcctcga gttgctcctc atggctgggc tcatttcggt 1740
ccctttctcc ttggtcccag accttggggg aaaggaagga agtgcattgt tgggaactgg 1800
cattactgga actaatggtt ttaacctcct taaccaccag catccctcct ctccccaagg 1860
tgaagtggag ggtgctgtgg tgagctggcc actccagagc tgcagtgcc a ctggaggagt 1920
cagactacca tgacatcgta ggggaaggagg ggagattttt ttgtagtgtt taattggggg 1980
gtgggagggg cggggagggtt ttctataaac tgtatcattt tctgctgagg gtggagtgtc 2040
ccatcctttt aatcaagggtg attgtgattt tgactaataa aaaagaattt gtaaaaaaaaa 2100
aaaaaa                                     2106

```

<210> 85
 <211> 899
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1458357

```

<400> 85
gctgtattca ggccccgat gggcatatac atcttagccg gtgatacact acctcttacg 60
tggtgcctct ttgtgttgct tgggtgctctt tcgaaaacaa ggtgcttatg gctttcatag 120
actatttcct ttttcattctt tgtcattcct taaaagtgtg tgtagtggtt acatcaagat 180
atgttttggg ttgttagtact tattttaatt tgtttggtca cacacttaat aacacgtgaa 240
actatttatg tgaagtcctt gttttatttt aaaattctct ttgtgtattt ggaatcaaag 300
ccagcacatt gtaacctgtg cttgtacgca aaagaattag atttctttgt ttttgtttta 360
ttttttaaat tgttgtaaaa attattatag gccagctaca tctagtagta ggtttggggg 420
acagattggg ggttggtgcca tactgttttt aaagttcatg atcatctgga atgatactta 480
gtgtatata attttgtaaa gttttaattc agcaaatttt ttgaaattgc tgctgtttta 540
aattataaaa cctttatatt tctgctttgt agaaattata tgtttttagt tattcattga 600
ttttctttca ctgtacttaa atttagtgtt agtactttaa aatttttaat ttaccagtct 660
ttaagcaac atccagaaaa aaaaaagtct ttcccatctt aaaataggct cagccagttc 720
aatgtcgctt tgttatcaga gaaatattag ttcaatactg aaagaaaaat attataacct 780
ttggtatcta gaaaaacttg ttcattccatt ataaatatat cttaggccac agcaaaccac 840
acttaacctt tctataataa aaatgtgctt taaataaaac caaaaaaaga aaaaaaaaaa 899

```

<210> 86
 <211> 2000
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1482837

```

<400> 86
tttgtccagt tgttcttttg ttcttttccc gcctccatt ctgctgctct tctcctctct 60
tttccccaac ctcccccgac cctcctgaat ttggaaaagc acatttgcaa tattcgtgtt 120
tgctttggga cggacctctc gtttcattct atgctttatg tgtaagagtt ttttattatt 180
attttttctt tctttctctt ctctgagaaa gttgtggctg cgttttgatc ttaggtttta 240
caaagtgggt tagggaagcg gttttgggga gaaggatcac gaggaatgta ggggaagccg 300
agggatgggt gctgctgcca cgaccccccc gtccctcggc cccagccctc ctgccctccc 360
cgtcaatctc atccacaaa tctgaaggcc ttaaaattgt gtgttgggag gatgtgaatt 420
gggaggacgg tgctactaga ctgtggatta gggatggtaa agtagggagg atgctatttt 480

```

```

gcaactatag taacgactta gtgttttggg aaggaaaaga agttaaactt gaaatacgtg 540
actagaacag ttgtcatgtt tataatgtga aaaggggtgaa atcatttaga ggagggggccg 600
tctgtaagaa atcattatgc actatggctt cctcctctgg tctgggaaga agcggggact 660
ggctggccct caggggatct gtaaattcca gaaaacagta tttttaacag caagatgtca 720
ttcaacattg gtggggaagg aagagaaaaa aatcaaaacta ttccatagaa ctactgtggc 780
ccctcactcc catgcccttc ccactcagcc tggggccctc cccgctccat tcataaaagc 840
tgagaggggt gagctaactc tcacaaattg taatattttt gtagtatctg ttagttcctt 900
cgtcagttct gcagaacctt gccctttcct tttgtaatgt gaataggaag acaaaagaca 960
aaaaaaaaat ccaccaccac caaaatatcc ctttgtacat gtatgtgcgt gtgcgcgtgt 1020
gctttgtgtg tgtggttgtg tgttaaatca tgcagtattg tctaatctg gtgttgacgc 1080
aatggatggt actaaatcag cacctggatg ccccaaccaa ccccggtggc cctgcagacc 1140
ccagtaggga ggtatgggga gagctcaggg gagtgtggtt tctgagggct actgtctggg 1200
gacacctctg aacttactgt accttcctct ccccatgaag acacctgaat agagtctaac 1260
atgcctcttc tccaacttcc tacctacaac aacagaacag ttctaagtgt gcacggccta 1320
gtggccaggg ggcaagctaa gaggtgtctt ggaggcttta tatgtgtctg gagttaaggg 1380
gagaggagga gggtagacag gggctctctc ccaggtggga tctgaatata tgcctctccc 1440
tcttcttcac gccacctgac tcttcggcc ccttggtgct ctttagctgt ggtactgctg 1500
acaacctgc ttgctactgc cttatccagc acagtgaaaa acttctccag cctggcaagg 1560
ccacgttggt taatagtccc tttcccatgt ccagctccta caaatatgtc ccttaatgca 1620
tttggtgaca ttacacctc actcatgtgc tcttcccta ttcactcctt cactcattca 1680
aagcattaaa atcctatgta tatataggat agacaaatat atagatatat agatatatat 1740
atatatagca agagattgat ataaaatagt aaatatcatt gctgctttgg gctgctttgg 1800
aggaggaggg catgaatatg ggggaaggcag atctgggggt caggggtagg tagggaggct 1860
gggggaccca gtgattcagt acaatccaag ggatgcaacg cgggcttggt taatccttgt 1920
gcctgaacag tttttccatg ttgagaaaac tgttcaggca cagagattaa acagttttct 1980
caacatggga aaaaaaaaaa
2000

```

<210> 87

<211> 1359

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1517434

<400> 87

```

tgcccatcct gctgctcagc ctggtcacca tgtgcgtcac gcagctgagg ctcatcttct 60
acatgggggc tatgaacaac atcctcaagt tcctggtcag cggcgaccag aagacagttg 120
gcctctacac ctccatcttc gccgtgctcc agctgctgtg cctgctgacg gccccgtca 180
ttggctacat catggactgg aggtggaagg agtggaaga cgcctccgag gagcccgagg 240
agaaaagacg caaccaaggc gagaagaaaa agaagaagcg ggaccggcag atccagaaga 300
tactaatgc catgcgggccc ttcgccttca ccaacctgct gctcgtgggc tttgggggtga 360
cctgcctcat tcccaacctg cctctccaga tccctcctt catcctgcac acaatcgtgc 420
gaggttcat ccactccgct gtcggggggc tgtacgtgc cgtgtacccc tccaccagc 480
tcggcagcct caggggactg cagtctctga tcagcgcgt cttcgcctt ctgcagcagc 540
cgctgtttct ggccatgatg ggtcctctcc agggagaccc tctgtgggtg aacgtggggc 600
tgctccttct cagcctgctg ggcttctgcc tcccgtctc cctgatctgc taccggcgcc 660
agctggagcg gcagctgcag cagaggcagg aggatgacaa actcttcctc aaaatcaacg 720
gctcgtccaa ccaggaggcc ttcgtgtagt ggctgcccgc tcggaaactgc ggtctcctgc 780
ctgtgcttca gtgactgacc cctgtcctgc cctccagag taccacacgc acccccagga 840
ccttcgcccgt ctccgtgcca gcgttcacgc tccctcccg ggccctgcct cggagctctg 900
tggtggaagg acgggagagg gcccgggaca cgcgcgtttt ctctgcccga acgcaggggc 960
tgccctgact ttgctctgcc gcccccggg gacccggggc ctgggggtctc tgtggtgcct 1020
gcagcaggag ccaggaaacg ccggcaggca ggcgctctcc cgcagtgctc tggattctgc 1080
ctcttgccaa agcagagggg gctgccatcc cctgcctgcc acctgcccct cggctgcatg 1140

```

```

ccccacagccg tacctgcctg aggacaaagg cttgcactgt ctgcgccgcg cctggccccc 1200
acccctctccc cgaccagcct gatcaacatg gtgaagcccc gtctctacta aagatacaaa 1260
aattaggggg gcatggtggt ggatgcctgt aatcccggct gctcgggagg ctgaggcgga 1320
tgaatcgctt gaaccaggag gtggagggtt cagtgaggg 1359

```

<210> 88

<211> 1397

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1536052

<400> 88

```

gctggggaag ggaccatgtg gctgccttgg gctctgttgc ttctctgggt cccagcatca 60
acgtcaatga cacctgcaag tatcactgcg gccaaagacct caacaatcac aactgcattt 120
ccacctgtat catccactac cctgtttgca gtgggtgccca cccacagtgc cagcatccag 180
gaggaaactg aggaggtggt gaactcacag ctcccgtgc tctctccct gctggcattg 240
ttgctgcttc tgttgggtggg ggccctccctg ctagcctgga ggatgtttca gaaatggatc 300
aaagctggtg accattcaga gctgtcccag aacccaagc aggcctccc cagggaagaa 360
cttcactatg cctcggtggt gtttgattct aacaccaaca ggatagctgc tcagaggcct 420
cgggaggagg aaccagattc agattacagt gtgataagga agacataggc tttgtcctg 480
cctcgccatc ggagctctca tgggcccag gaagtccagg gacagctccc ttatacctgg 540
cccagctcct tctcagcctg cctcgcacaa cagtgaccaa cagacaggca gctgggtttc 600
ccaggccatc cctctgttgc catcagcttg attggcttcc ccgagggccca gcagggctgg 660
gggctccgga gagcagcagg aagcactccc agccaccagt gcctgtcacc tcttccct 720
ttgcccctgc ttcattcccag ctctgtgtgt ggaggacaaa gcttcttctt gctggctcc 780
aggaaaagat gtggctcacg taggtggcac ctgccaatag ctttgtcaat cacagcccca 840
taggaacgtc tgggaattgct tgggagttgg ggagaactgt caagaagagt gaagagagt 900
ccaaagcgga gatctgttca cctggggggc atggaggggg gacccactaa agatcaagat 960
caaagattct ccccatctca cagacaagga aactgaggcc agaggaggga gagaattgct 1020
catggctcca gaactggtgg caagtttctc tggactctta ggtttatttt taatatgaaa 1080
tataaaaaa gtttcaaata tcttattgag ggagaagtaa aaacttattt aaacaataaa 1140
aaaataaaaa aaaggggcg ggttcccag cccgaatccg aaatcaggta aaagctgttc 1200
cctgtgtaaa attgttacc gcccaaaatt ccacaaaata taggaccggg agccttaaa 1260
tttaaaccct tgggggccc aattgggtgg gccatcccc atttaattgg cttggcccc 1320
aatggccggt ttccacattg ggggaaacct ttttggccca acggctttta atgaaatcgg 1380
cccaaaccgc gggggaa 1397

```

<210> 89

<211> 1570

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1666118

<400> 89

```

atgtccatca tgtcagcagg tgcaaatcac ttttcccctt tgcattgatct gaggcacctc 60
ctcagttggt tcaactgccaa ctcttatttc agaacctgtt tacaacaag ccttccagtt 120
ggtgaatggt tagccattgg agctcctacc ctgtacatca gcacatcttc tggtttacia 180

```

```

gttgggtaac aatgaaagct ggagatacta aatggaaatc cagcattgca tacccttaga 240
cctgatcaca taccagtaaa agccttaatt tagatgttag ttgtatgtgt tggacagatc 300
cttgcaaaag tgtgtctgtc tattagtgtt aaatttgaaa attataaaatc tctgaatctg 360
ctactatcca agtttcatcc cttttgaaga tgaggcatga gcctattaaa atatttataa 420
tcatttttctg tccctactcg caagactttt agattcctac aaatgattac tacaggaata 480
gtggccactt aatgtcagtt actccggttg aagaatttat ctagtttttt ttcttttctt 540
ttttggaagg atggtgtgaa aaatagcaag attagagaat gagttgtata gttttttcta 600
tcacatttca tctaaaatga tttgaaggac ttttgaagat ttttaccaac atccttaaat 660
caactccagg ttggatgaac aactgattta aaacaaacta agagaacatt aactagatgt 720
gggcttttta aaatatatag gtattgcatt tcctaccttg ttatttattc cactttgaat 780
acttttagagg gcttaacttt caactcttta aggtagtaat ggatagtttt atacttgttc 840
tcacaaaatt gttatgttca gtttatatca ttgctccatg cattgattat aaaaattcag 900
tattaatttt ttctgatctt ataagcttta taggagtttt cttttctctt ataaagtgtt 960
tcaccttatg taaaacaaat gcctgcttgc atattggaag atgttgaaat tagttttaga 1020
caaaagtggg ccatcaattc agacactctg cttggatgcc ttaccctttt cattagtga 1080
ttctttgctt ctgaaacttg gcagaaactg gttagccagt ccactgcctt tctgacaatg 1140
tgtggagtca cgtatgcttg gtatatgcct ttactacttt taaagtctta cagtttatta 1200
cttgcccaag tgttactaaa tccttttctt atgtgtactg gatggagaaa aaattatagc 1260
cagcactttg agaggaaagt tttcagaaac aatattaact ggcactacta actgaaggcc 1320
acaggagatg ctatcaatgt tttttgtaat ctgaagattg aacaaggctg tgaggctcat 1380
ttcaaaactat tttgaggtgt taaaatatat atatgctgtt tctcagctgt tccactcaa 1440
ccgtgttagg actctcaaag gtaaaatgtc acaggggctt ttcagttgtt acagagctca 1500
gcagctgttg ttgccctgt tctacaccaa tttcagttca ataaaaatgt taactttgaa 1560
aaaaaaaaa 1570

```

<210> 90
 <211> 718
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1675560

```

<400> 90
gggtgtgcgt gcctgtaatc ccaactactt gggaggctga ggcaggagaa tcgcttgaac 60
ctgggaggca gcggttgag taagccaaga ctatgccact gcactccgc ctgggtgaca 120
aagcaatatt ctgtgtcaaa taaataaatt cattcttctg ctctcctgac ttagagaaat 180
ggtttgccta aaatgctagt aacaaacatc acagtcaaca ggagcttgct tcatgcgaag 240
gatcaatgtg atttgtggat ggagatgata gtgatgaaat tcctgtttca tggggctgtt 300
tttcttttca tctcactggg cagcaggttt agtgaggcag tgagatgctg ctgctgtgga 360
ttctgtagc tatgcctcgg cttcttgga tatcaggtag gaacctgtta caagtgaat 420
acttgaaacc tctctgacca agagcctctg atggagtggg aggtgagcta attctctgac 480
cagcttaggg cactgtttca gccactggtc acattccttg cttcaaactg aaattcagtt 540
tggctttgag tatagggata catggtggat tcatgtactt cagtgtttgt tttgacaaa 600
gtttattttt ctagtgcatt ttctaagtca aagtgggtgaa aatatgtaat aattttagta 660
tgcagtactc agtctgaaac aataaaaatc tctgaaaaat gaaaaaaaaa aaaaaagg 718

```

<210> 91
 <211> 904
 <212> DNA
 <213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1687323

<400> 91

```

gcttgtgggg ggaaaaagaa acgcaataga taaagcgggg cgcattgcgt cccggcacag 60
gcttcgattg tgaggaaggg cggctagtct ccgagctcat cccgccttgc gcatgcggag 120
aaggtaaacc agcgccccga gttgaggcgc gggtttggtg gcgcgtttca gcgaagtcgc 180
acgtgaagga tagcagtggc ctgagaaaga cccagtcatt gcagcctcca gcatcagttc 240
accatgggga aagcatgtgt tcaaagccat tctgatggtc ctagtggccc ttatcctcct 300
ccactcagca ttggcccagt cccgtcgaga ctttgacca ccaggccaac agaagagaga 360
agccccagtt gatgtcttga cccagatagg tcgatctgtg cgaggggacac tggatgcctg 420
gattggggcca gagaccatgc acctggtgtc agagtcttcg tcccagtggt tgtggggccat 480
ctcatcagcc atttctgtgg ccttctttgc tctgtctggg atcgccgcac agctgctgaa 540
tgccttggga ctagtgggtg attacctcgc ccaggggcctg aagctcagcc ctggccagggt 600
ccagaccctt ctgctgtggg gagcaggggc cctgggtcgt tactggctgc tgtctctgct 660
cctcggtctg gtcttggcct tgctggggcg gatcctgtgg ggcctgaagc ttgtcatctt 720
cctggccggc ttctgtggcc tgatgaggtc ggtgcccgc ccttccaccc gggccctgct 780
actcctggcc ttgtgatcc tctacgcctt gctgagccgg ctactgggt cccgagcctc 840
tgggggccaa ctcgaggcca aggtgcgagg gctggaacgc taggtggagg agctgcgctg 900
gcgc 904

```

<210> 92

<211> 1948

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1692236

<400> 92

```

gaagacctct tagcggggcc atcgctgagg tgaggggaca tgtcgcggcc gaactcacct 60
cgtggcctcg gcgtgggtgt ctcagctcat gcccggaac cagggtcccga cgccgcggtc 120
agacggacct ctacgcggt ccgcctcaat gccgccagct gccaggccgc ccgtgacgcg 180
ttacgcctgc gccgcctcct ggcttcgtga cgtcacgacg tccgcgcagt gcggtcgccc 240
ccgtcgacag agtctttcct tagtaacctg ggcgatactg tggatgtttc caaggattgt 300
cttcagtcatt ggccttggga ttaaagtgtt tccgcatggt ccacctacc ttctgcaatt 360
atcttgacgc ctctatcaga cccgtttcag aagttacact gaagacagtg catgaaagac 420
aacatggcca taggcaatac atggcctatt cagctgtacc agtccgccat ttgctacca 480
agaaagccaa agccaaaggg aaaggacagt cccaaaccag agtgaatatt aatgctgcct 540
tggttgagga tataatcaac ttggaagagg tgaatgaaga aatgaagtct gtgatagaag 600
ctctcaagga taatttcaat ctgactctca atataagggc ctcaccagga tcccttgaca 660
agattgctgt ggtaactgct gacgggaagc ttgctttaaa ccagattagc cagatctcca 720
tgaagtgcgc acagctgatt ttggtgaata tggccagctt cccagagtgt acagctgcag 780
ctatcaaggc tataagagaa agtggaaatg atctgaaccc agaagtggaa gggacgctaa 840
ttcgggtacc cattcccaa gtaaccagag agcacagaga aatgctgggt aaactggcca 900
aacagaacac caacaaggcc aaagactctt tacggaaggt tcgcaccaac tcaatgaaca 960
agctgaagaa atccaaggat acagtctcag aggacacat taggctaata gagaaacaga 1020
tcagccaaat ggccgatgac acagtggcag aactggacag gcatctggca gtgaagacca 1080
aagaactcct tggatgaaag tccactgggg ccagcaatac tccagagccc agtttctgct 1140
ggatcccatg ggtggcacat tgggacttct ctccctcccc catctacaca gaagactgtc 1200
accatgctga cagaagcctg tccttgtaag gccagcctt ccagggggaac actcagacat 1260

```

```

gttcattctc ttccctgcttc tgctctgggc cggtaggggtg ctctcagaaa atacttgctg 1320
ctggcaaaag gctgtactc aggcatttgc tttgacttga tgttgccaag ggactgaggc 1380
cattggcagg cttagtacca cctgctcctc atcttaggag tctccttttc aaataattag 1440
gctctgttcc cattttaaaa ctctgatatt ggccttcacc tgtgactgga cactttacta 1500
gaggccccatt ttactaaac aataaaatct aaataaattg gaaggaataa caaccacaaa 1560
ggaagaata gagttggtct ggattgatga tcaactgagga tctgtatgtg aggcacccat 1620
aacagtagtt ttgcctgtga gtcgtcttca cacatgctgt tttctctgcc tggctctctc 1680
ttccctcct tacctggcca gtccctgttta tcatcaggcc ttgtcttgga tatcacgtcc 1740
tctgggaagt cttcttttcc cctctaacct aggacctca ttaccggctc tcatagcaca 1800
gtctactgct ttgtacgaat tctaagtatt cttgttgac ttaattagcc tgtatatcct 1860
cagaactttg tgtaatgcct ggagcatagt aggcagtcac atgttgatc gtgaataaat 1920
tgcacatagt agctacccaa aaaaaaaaa 1948

```

<210> 93

<211> 990

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1720847

<400> 93

```

acagagactg gcacaggacc tcttcattgc aggaagatgg tagtgtaggc aggtaacatt 60
gagctctttt caaaaaagga gagctcttct tcaagataag gaagtggtag ttatggtggt 120
aacccecggc tatcagtcct gatggttgcc acccctcctg ctgtaggatg gaagcagcca 180
tggagtggga gggaggcgca ataagacacc cctccacaga gcttggcatc atgggaagct 240
ggttctacct cttcctggct cctttgttta aaggcctggc tgggagcctt ccttttgggt 300
gtctttctct tctccaacca acagaaaaga ctgctcttca aaggtaggag gtcttcatga 360
aacacagctg ccaggagccc aggcacaggc ctgggggcct ggaaaaagga gggcacacag 420
gaggaggtag gagctggttag ggagatgctg gctttaccta aggtctcgaa acaaggaggg 480
cagaataggc agaggcctct ccgttccagg cccatttttg acagatggcg ggacggaaat 540
gcaatagacc agcctgcaag aaagacatgt gttttgatga caggcagtgt ggccgggtgg 600
aacaagcaca ggccttgga tccaatggac tgaatcagaa ccctaggcct gccatctgtc 660
agccgggtga cctgggtcaa ttttagcctc taaaagcctc agtctcctta tctgcaaaat 720
gaggcttgatg atacctgttt tgaagggttg ctgagaaaat taaagataag ggtatccaaa 780
atagtctacg gccataccac cctgaacgtg cctaattctg taagctaagc agggctcaggc 840
ctggttagta cctggatggg gagagtatgg aaaacatacc tgcccgagc tggagtggga 900
ctctgtctta acagtagcgt ggcacacaga aggcactcag taaatacttg ttgaataaat 960
gaagtagcga tttggtgtga aaaaaaaaa 990

```

<210> 94

<211> 1638

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1752821

<400> 94

```

tagatatggc gtccctctttg cttgcggggc agcgattggt gcgtgctttg ggccccggcg 60
gggagctgga gccagagcgg ctaccccgaa agctgcgggc cgagcttgag gccgcgctgg 120

```

```

ggaagaagca caagggcggt gatagctcca gtggccccc acgcttggtt tctttccgtc 180
tcatccggga tctgcaccag catctgagag aaagggattc caaactatac ctccatgagc 240
tcctagaagg cagtgaatc tatctcccag aggttggtgaa gcctccacgg aaccagaac 300
tagttgcccg gctggagaag attaagatac agctggccaa tgaggaatat aaacggatca 360
cccgcaacgt cacttgctcag gatacaagac atgggtgggac tctcagcgac ctgggaaagc 420
aagtgagatc attgaaggct ctgggtcatca ccactctcaa tttcattgtc acggtgggtg 480
ctgccttcgt ctgcacttac cttggaagcc aatatatctt cacagaaatg gcctcgcggtg 540
tgctagctgc attgatcgtc gcctctgtgg tgggtctggc cgagctgtat gtcattggtgc 600
gggcaatgga aggcgagctg ggagaactgt aactgggtgt tcatcatcaa gtctagagaa 660
gactttgggg gcttcaggct ccaattggca gtcaccgact cagtcaaccc atcagacttt 720
ttgtattcag ctccagttag tcagaagacc agcccaggcc agctgctgtt tctgtgggga 780
gccctaattc tctgtgaatt tccaaaggga gcattggagg agattgagat aacacatctt 840
taaaacagaa agaactggtc ttgggtctatc agtacctctt cctgaatctg gtacccatct 900
gccttctcca gttcattcta aacactgctg ggactagggt ttttccatca ggagcaaatg 960
gaatccaggc cttcccagaa gtagaccata ctgccttgaa cttgtccata tgtacaaact 1020
aatcaccagc ttttccata catttttaac gcagacctgt aattgagttc agaagcctcc 1080
aagaaaacag aaaggatccc ctttctccag tttgtgctgg aaggaggagct gatcagagac 1140
atcaaataag agaaagatgg gttgctagag gatggtagaa ctggaagcaa ggcagctacc 1200
tttttgcaaa aggaaatggg gttaggcccc ttttccagaa gataagacag actcatagag 1260
attaaatgat cactatggtc cttcttctgt taaatggagc caaagacgcc tatgttgttc 1320
tgaagtcttg taatgtttaa cttctgagaa cttagattag tgggtgtgatg atagagtctg 1380
tataacgcat tgaaaagggt atcaggctta gttattttat caataaatat ttattgtatg 1440
caggggtattc ctattttaac tctgtgaca acacaaagca tagcgatttc catagtctca 1500
actgttcagg gtctgctcct cctgggtacac tctttttggt tcaactgtatg tactcctgtt 1560
gtcttttttt ttttttccaa agcacttttc tgttttcata aattatatac tcattcactc 1620
agtggacaaa aaaaaaaa 1638

```

<210> 95

<211> 595

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1810923

<400> 95

```

gtgggcgcgt ccagtgatga ctgggggatc ccggcaagta acatgactaa aaagaagcgg 60
gagaatctgg gcgtcgctct agagatcgat gggctagagg agaagctgtc ccagtgtcgg 120
agagacctgg aggcctgtaa ctccagactc cacagccggg agctgagccc agaggccagg 180
aggtccctgg agaaggagaa aaacagccta atgaacaaag cctccaacta cgagaaggaa 240
ctgaagtttc ttcggcaaga gaaccggaag aacatgctgc tctctgtggc catctttatc 300
ctcctgacgc tcgtctatgc ctactggacc atgtgagcct ggcacttccc cacaaccagc 360
acaggcttcc acttggtccc ttgatcagga tcaagcaggc acttcaagcc tcaataggac 420
caagggtgctg ggggtgtccc ctcccaacct agtgttcaag catggcttcc tggcggtcca 480
ggccttgctc ccctggcctg ctgggggggt ccgggtctcc agaaggacat ggtgctgggt 540
cctcccttag cccaaggagg aggcataaaa gaacacaaag ctgtaaaaaa aaaaa 595

```

<210> 96

<211> 1858

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature
<223> Incyte Clone No: 1822315

<400> 96
aaaagtctag atcacagtgg ggctctagga gggctagtcg ttggatttat cctaaccatt 60
gcaaatttca gcttttttac ctctttgctg atgtttttct tgtcttcttc gaaactcact 120
aaatgggaagg gagaagtga gaaagcgtcta gattcagaat ataagggaagg tgggcaaagg 180
aattgggttc aggtgttctg taatggagct gtaccacag aactggccct gctgtacatg 240
atagaaaatg gccccgggga aatcccagtc gatttttcca agcagtactc cgcttctctg 300
atgtgtttgt ctctcttggc tgcactggcc tgctctgctg gagacacatg ggcttcagaa 360
gttggtccag ttctgagtaa aagttctcca agactgataa caacctggga gaaagttcca 420
gttggtacca atggaggagt tacagtgggt ggccttgtct ccagtctcct tgggtgtacc 480
tttgtgggca ttgcatactt cctcacacag ctgatttttg tgaatgattt agacatttct 540
gccccgcagt ggccaattat tgcatttggg ggttttagctg gattactagg atcaattgtg 600
gactcatact taggggctac aatgcagtat actgggttgg atgaaagcac tggcatgggtg 660
gtcaacagcc caacaaataa ggcaaggcac atagcaggga aacctattct tgataacaac 720
gcggtggtat gttttcttct gttcttattg ccctcttctc cccaactgct gcttgggggt 780
tttggccag ggggtgaact ttatttcatt tccacagggt gaaactgggt agtccagcta 840
aatttgcaat tccaactttc atcctaagaa taataactgt aatggcaaag cggaaatgcc 900
agttctcctt gtattccatt gagatgggat ttcacatttt cctctcatca actccccctg 960
aatagctagc gtctttctag tgaagagaa gaattcctag aacttatgca tttttttcct 1020
gctgaatgga agtcttgagc aatgaagcta tattgtccct acatattact atatattgaa 1080
ctgaaagtgc ttacataatc aatgtcaagt tttgtcttat tttgttttgt ttgtttaaac 1140
cagtgtagga aataaaagt atgatattta aaatagttct cagttgaagc agagaaatgc 1200
cactgtgcta gttgcccata tgtgtatctc attttaataa gtttaagctg atgtgtatgg 1260
gagcctaacc aagtgtagta tctgaactct cctccattaa ttgctattca caattgggaa 1320
aagtgtggag attggttctt agtgagtttt gtggcctact ccacatttgt tcttcttcc 1380
tcagggttag tgatgaaaaa aagtaaatat ctttttcata tgtccattag aatgtatgaa 1440
aaaaaatcatt ttaactaaaa gcaaaagaat tttatcttat atctaaaaaa tatataactt 1500
actatatgtt tcagttgtct tctgaacaaa aattatcttc aatttaatat gtggaatgtg 1560
ttttctagct ttctttgaat tatgtatggc aacctggttt agcactggca tctgaacag 1620
ttaagagtca ctgggaaatt attgtatttc tttataaatt tactgtcata tcaattgctg 1680
gaaaaatgcta tgatttttct attattacct tctaagttgt attctctctt acactgtagc 1740
ctcaactaag gcaattctgc tatgtttgtt cttcactatg atttactgtg tgccaaagga 1800
gttttgacag ggtacagagt attttactaa aagtattttt aaatgttaaa aaaaaaaa 1858

<210> 97
<211> 698
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone No: 1877777

<400> 97
tgggtgtccg catgacaacc gacgttgagg tttggaggtg cttgccttag agcaaggga 60
acagctctca ttcaaaggaa ctagaagcct ctccctcagt ggtagggaga cagccaggag 120
cggttttctg ggaactgtgg gatgtgccct tgggggcccc agaaaacaga aggaagatgc 180
tccagaccag taactacagc ctggtgctct ctctgcagtt cctgctgctg tcctatgacc 240
tctttgtcaa ttcttctca gaactgctcc aaaagactcc tgtcatccag cttgtgctct 300
tcatcatcca ggatattgca gtctcttca acatcatcat cattttctc atgttcttca 360
acaccttcgt cttccaggct ggctgggtca acctcctatt ccataagttc aaagggaacca 420
tcatcctgac agctgtgtac tttgccctca gcatctccct tcatgtctgg gtcataaact 480


```

tacgctggaa aaactccaac agcttcatat ggacagatgg acttcaaatg ctgtttgtat 540
tccagagact agcagcagtg ttgtactgct acttctataa acggacagcc gtaagactag 600
gcgatcctca cttctaccag gactctttgt ggctgcgcaa ggagttcatg caagttcgaa 660
ggtgacctct tgtcacactg atggatactt ttccttcc 698

```

<210> 98

<211> 1476

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1879819

<400> 98

```

caaggacgag gctctggcca agctgggtat caacggtgcc cactcgtccc cgccgatgct 60
gtcccccagc ccaggaaagg gcccccgcc agctgtggct cctcgacca aggccccgct 120
acagcttggg ccctctagct ccatcaagga aaagcagggg ccccttctgg acctgtttgg 180
ccagaagctg cctattgccc acacaccccc acctccacca gcgccaccac tgctctgccc 240
cgaggaccca gggacccttt cagcagagcg tcgttgcttg acacagcccg tggaggacca 300
gggggtctcc acccagctac tcgcgccctc tggcagcgtg tgcttctcct acaccggcac 360
gccctggaag ttgttcctac gcaaggaggt gttctaccca cgggagaact tcagccatcc 420
ctactacctg aggctcctct gtgagcagat cctacgggac accttctccg agtcctgtat 480
ccggaatttc cagaatgagc ggcggaataa gaaagacctg ctgggagggt tggagggtgga 540
cctggattct ctcaccacca ccgaagacag cgtcaagaag cgcctcgtgg tggccgctcg 600
ggacaactgg gcccaattact tctcccgtt ctttcctgtc tcgggcgaga gtggcagcga 660
cgtgcagctg tttagccgtgt cccaccgtgg gctgcgactg ctcaagggtga cccaaggccc 720
cggcctccgc cccgaccagc tgaagattct ctgctcatac agctttgcgg aggtgctggg 780
tgtggagtgc cggggcggct ccacctgga gctgtcactg aagagcgagc agctggtgct 840
gcacacagcc cgggcaaggc ccatcgaggc gctggttgag ctattcctga atgagcttaa 900
gaaggactcc ggctatgtca tcgccctgcg cagctacatc actgacaact gcagcctcct 960
cagcttccac cgtggggacc tcatcaagct gctgccggtg tgccaccctg gagccaggct 1020
ggcagtttgg ctctgcgggg ggccgttccg gactctttcc tgccgacata gtgcagccgg 1080
ctgccgctcc cgacttttcc ttctccaagg agcagaggag tggctggcac aagggtcagc 1140
tgtccaacgg ggaaccaggc ctggctcggg gggacagggc ctcagagggt aggaagatgg 1200
gagagggaca agcagaggca aggcctgcct gagactgagg aaggaaaggg gtttgaccac 1260
tcccagggct gccatgcggg gggaccaccc tgctgtccgt ctcctgtggc tgcccctctg 1320
cccgtcctct atggctcgcc ttgtctctcc agcaagactg tgcactcctt gcaggcaggg 1380
gctgggctgg atgctgctct tgtgtccac gtggtactta gttcaaggct gccccagcag 1440
atgcttaata aacagctctt cactttaaaa aaaaaa 1476

```

<210> 99

<211> 646

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1932945

<400> 99

```

ccggctggag gtgacgctga ggcggcgagg gtgagtcggc gccggccgct accgcacttc 60
gggcgctcgt ccctcatttc tctgtggtga atggcgacgg gatggagcgc gaggggagcg 120

```

```

gcggcagcgg cggtcgcc ggcctcctgc agcagatcct gagcctgaag gttgtgccgc 180
gggtgggcaa cgggaccctg tgccccaact ctacttcctt ctgctccttc ccagagatgt 240
ggtatggtgt attcctgtgg gacttggtgt cttctctctt ctttcatgtc cctgctggat 300
tactggccct cttcaccctc agacatcaca aatattggtg gttcatgtct gtaagcatcc 360
tggtgatggg catcgtggga ccaattactg ctggaatctt gacaagtgca gctattgctg 420
gagtttaccg agcagcaggg aaggaaatga taccatttga agccctcaca ctgggcactg 480
gacagacatt ttgctgtctg gtggtctcct ttttacggat tttagctact ctatagcata 540
catccttatg ctgagatgtt gaacttaaac tttatggaat cctccaaaag aatacattat 600
ggagtgtagt gttttcttag ttcttccaaa gggagccact tggatg 646

```

<210> 100

<211> 1735

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2061026

<400> 100

```

gcgggctgcg ccatggcggt ggctgtggcg gcgctggcgg cggtcgagcc ggctgcgggc 60
agccggtacc agcagttgca gaatgaagaa gagtctggag aacctgaaca ggctgcaggt 120
gatgctcttc cactttacag cagcatttct gcagagagcg cagcatattt tgactacaag 180
gatgagtctg ggtttccaaa gcccccatct tacaatgtag ctacaacact gcccagttat 240
gatgaagcgg agaggaccaa ggctgaagct actatccctt tggttcctgg gagagatgag 300
gattttgtgg gtcgggatga ttttgatgat gctgaccagc tgaggatagg aaatgatggg 360
attttcatgt taactttttt catggcatct ctctttaact ggattgggtt tttcctgtct 420
ttttgcctga ccacttcagc tgcaggaagg tatggggcca tttcaggatt tggctctctc 480
ctaattaaat ggatcctgat tgtcagggtt tccacctatt tccctggata ttttgatggt 540
cagtactggc tctggtgggt gttccttggt ttaggcttct tcctgtttct cagaggattt 600
atcaattatg caaaagtctg gaagatgcca gaaactttct caaatctccc caggaccaga 660
gttctcttta tttattaaag atgttttctg gcaaaggcct tctgcatatt atgaattctc 720
tctcaagaag caagagaaca cctgcaggaa gtgaatcaag atgcagaaca cagaggaata 780
atcacctgct ttaaaaaaat aaagtactgt tgaaaagatc atttctctct atttgttctc 840
aggtgtaaaa ttttaatagt taatgcagaa ttctgtaatc attgaatcat tagtggttaa 900
tgtttgaaaa agctcttgca atcaagtctg tgatgtatta ataatgcctt atatatgtt 960
tgtagtcatt ttaagtagca tgagccatgt ccctgtagtc ggtagggggc agtcttgctt 1020
tattcatcct ccatctcaaa atgaacttgg aattaaatat tgtaagatat gtataatgct 1080
ggccatttta aaggggtttt ctcaaaagtt aaacttttgt tatgactgtg tttttgcaca 1140
taatccatat ttgctgttca agttaatcta gaaatttatt caattctgta tgaacacctg 1200
gaagcaaaat catagtgcaa aaatacatat aagggtgtgt caaaaataag tctttaattg 1260
gtaataataa agcattaatt ttttatagcc tgtattcaca attctgcggt accttattgt 1320
acctaaagga ttctaaaggt gttgtcactg tataaaacag aaagcactag gatacaaatg 1380
aagcttaatt actaaaatgt aattcttgac actctttcta taattagcgt tcttcacccc 1440
caccceccac cccacccccc ttattttcct tttgtctcct ggtgattagg ccaaagtctg 1500
ggagtaagga gaggattagg tacttaggag caaagaaaga agtagcttgg aacttttgag 1560
atgatcccta acatactgta ctacttgctt ttacaatgtg ttagcagaaa ccagtgggtt 1620
ataatgtaga atgatgtgct ttctgcccac gtggtaattc atcttggttt gctatgttaa 1680
aactgtaaat acaacagaac attaataaat atctcttggt tagcaaaaaa aaaaa 1735

```

<210> 101

<211> 2329

<212> DNA

<213> Homo sapiens

<220>

<221>

<222> 2084, 2101, 2110, 2128, 2137, 2156, 2177, 2226, 2265, 2296, 2303, 2310, 2325

<223> a or g or c or t, unknown, or other

<220>

<221> misc_feature

<223> Incyte Clone No: 2096687

<400> 101

```
gcagggatca ctatcatgtc tgcggagagc ggccctggga cgagattgag aaatctgcca 60
gtaatggggg atggactaga aacttcccaa atgtctacaa cacaggccca ggcccaaccc 120
cagccagcca acgcagccag caccaacccc ccgccccag agacctccaa ccctaacaag 180
cccaagaggc agaccaacca actgcaatac ctgctcagag tgggtgctcaa gacactatgg 240
aaacaccagt ttgcatggcc ttccagcag cctgtggatg ccgtcaagct gaacctccct 300
gattactata agatcattaa aacgcctatg gatatgggaa caataaagaa gcgcttgga 360
aacaactatt actggaatgc tcaggaatgt atccaggact tcaacactat gtttaciaat 420
tgttacatct acaacaagcc tggagatgac atagtcttaa tggcagaagc tctggaaaag 480
ctcttcttgc aaaaaataaa tgagctaccc acagaagaaa ccgagatcat gatagtcag 540
gcaaaaggaa gaggacgtgg gaggaaagaa acagggacag caaacctgg cgtttccacg 600
gtaccaaaaca caactcaagc atcgactcct ccgcagaccc agaccctca gccgaatcct 660
cctcctgtgc aggccacgccc tcaccccttc cctgccgtca ccccgaccc catcgctccag 720
acccctgtca tgacagtggg gcctccccag ccactgcaga cgccccgcc agtgcccccc 780
cagccacaac cccacccgc tcagctccc cagcccgta agagccacc acccatcatc 840
gcgccacccc cacagcctgt gaagacaaa agggagtgga agaggaaagc agacaccacc 900
acccccacca ccattgaccc cattcacgag ccaccctcgc tgcccccgga gcccaagacc 960
accaagctgg gccagcggcg ggagagcagc cgccctgtga aacctccaaa gaaggacgtg 1020
cccgactctc agcagcacc agcaccagag aagagcagca aggtctcgga gcagctcaag 1080
tgctgcagcg gcacccctca ggagatgttt gccaaagaagc acgccccta cgctggccc 1140
ttctacaagc ctgtggacgt ggaggcactg ggcctacacg actactgtga catcatcaag 1200
caccccatgg acatgagcac aatcaagtct aaactggagg cccgtgagta ccgtgatgct 1260
caggagtttg gtgctgacgt ccgattgatg ttctccaact gctataagta caaccctcct 1320
gaccatgagg tgggtggccat ggcccgcaag ctccaggatg tggtcgaaat gcgctttgcc 1380
aagatgccgg acgagcctga ggagccagtg gtggccgtgt cctccccggc agtgccccct 1440
cccaccaagg ttgtggcccc gccctcatcc agcgacagca gcagcgatag ctccctcgac 1500
agtgacagtt cgactgatga ctctgaggag gagcgagccc agcggtctggc tgagctccag 1560
gagcagctca aagccgtgca cgagcagctt gcagccctct ctcagcccca gcagaacaaa 1620
ccaaagaaaa aggagaaa gaagaaggaa aagaaaaaag aaaagcaca aaggaaagag 1680
gaagtggag agataaaaa aagcaaagcc aaggaaacct ctctaaaaa gacgaagaaa 1740
aataatagca gcaacagcaa tgtgagcaag aaggagccag cgcccatgaa gagcaagccc 1800
cctcccacgt atgagtcgga ggaagaggac aagtgaagc ctatgtccta tgaggagaag 1860
cggcagctca gcttgacat caacaagctc cccggcgaga agctgggccc cgtggtgcac 1920
atcatccagt caggggagcc ctccctgaag aattccaacc ccgacgagat tgaaatcgac 1980
tttgagaccc tgaagccgtc cacactgcgt gagcttggag cgctatgtca cctcctgttt 2040
gcggaagaaa aggaaacctt caagctgaga aagttgatgt gatntgccgg gttcctccaa 2100
natgaaaggn ttctcgtctc tcaagagnct ggagagnctc ccagttgaat tccaanttct 2160
tttgacaagc ggaaganttc cggaaaacaa agggctcctt gccttaaaatt caatttggga 2220
aaaccnggga cttccttaaa tttaaaaaaa gggggctttt caagntttcc caaggaattt 2280
ccttttcccc caaggnaaag gcntaattan gcctttaaaa ggtnccca 2329
```

<210> 102

<211> 1451

<212> DNA
 <213> Homo sapiens
 <220>
 <221>
 <222> 1346, 1373, 1430
 <223> a or g or c or t, unknown, or other

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2100530

<400> 102
 ctcgagcggc ggcatttcct ggtgtctgag cctggcgcgg aggcctatggg cagccaggag 60
 gtgctgggcc acgcggcccg gctggcctcc tccggctccc tcctgcagggt gttgtttcgg 120
 ttgatcacct ttgtcttgaa tgcatttatt ctctgcctcc tgtcaaagga aatcgttggc 180
 gtagtaaatg taagactaac gctgctttac tcaaccaccc tcttcctggc cagagaggcc 240
 ttccgcagag catgtctcag tgggggcacc cagcgagact ggagccagac cctcaacctg 300
 ctgtggctaa cagtcacctt ggggtgtgtt tggctcctat tcctgggctg gatctgggtg 360
 cagctgcttg aagtgcctga tcctaagtgt gtccctcact atgcaactgg agtgggtgctg 420
 tttggctctc cggcagtggt ggagcttcta ggagagccct tttgggtctt ggcacaagca 480
 catatgtttg tgaagctcaa ggtgattgca gagagcctgt cggtaattct taagagcgtt 540
 ctgacagctt ttctcgtgct gtggttgccct cactggggat tgtacatttt ctctttggcc 600
 cagcttttct ataccacagt tctggtgctc tgctatgtta tttatttcac aaagtactg 660
 ggttccccag aatcaaccaa gcttcaaact ctctcgtct ccagaataac agatctgtta 720
 cccaatatta caagaaatgg agcgtttata aactggaaag aggcataaact gacttggagt 780
 tttttcaaac agtcttttctt gaaacagatt ttgacagaag gcgagcgata tgtgatgaca 840
 tttttgaatg tattgaactt tgggtgatcag ggtgtgtatg atatagtga taatcttggc 900
 tcccttgctg ccagattaat tttccagcca atagaggaaa gtttttatat attttttgc 960
 aagggtgctg agaggggaaa ggatgccaca cttcagaagc aggaggacgt tgctgtggct 1020
 gctgcagctc tggagtcctt gctcaagctg gccctgctgg ccggcctgac catcactgtt 1080
 tttggctttg cctattctca gctggctctg gatattctac gagggaccat gcttagctca 1140
 ggatccggtc ctgttttgct gcgttcctac tgtctctatg ttctcctgct tgccatcaat 1200
 ggagtgcag agtgtttcac atttgctgcc atgagcaaag aggaggtcga caggtattcc 1260
 tctgctgtga gcagggtggt ccagccagac tggcacacat tgctgtgggg gccttctgtc 1320
 tgggagcaac tctcgggaca gcattnctca cagagaccaa gctgatccat ttntcagga 1380
 ctcagttagg tgtcccaga cggactgaca aaatgacgtg acttcagggg aggctgggac 1440
 aaacgaggca a 1451

<210> 103
 <211> 1685
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte Clone No: 2357636

<400> 103
 gcgatcgagg ctgcagcgcg gccgcccggc gcacatgact gccgtcggcg tgcaggccca 60
 gaggcctttg ggccaaaggc agccccgccg gtcccttctt gaatccttca tccggacctt 120
 catcatcacg tgtgtggccc tggctgtggc cctgtcctcg gtctccattt gtgatgggca 180
 ctggctcctg gctgaggacc gcctcttcgg gctctggcac ttctgcacca ccaccaacca 240

```

gagtgtgccg atctgcttca gagacctggg ccaggcccat gtgccccggc tggccgtggg 300
catgggcctg gtacgcagcg tgggcgcctt ggccgtggtg gccgccattt ttggcctgga 360
ttcctcatg gtgtcccagt tgtgcgagga caaacactca cagtgcaggt gggcatggg 420
ttccatcctc ctctcgtgtg cttctgtcct ctccctccggc gggctcctgg gttttgtgat 480
cctcctcagg aaccaagtca cactcatcgg cttcacccta atgttttggg gcgaattcac 540
tgctccttc ctctccttcc tgaacgccat cagcggcctt cacatcaaca gcatcaccca 600
tccttgggaa tgaccgtgga aatttttagg ccctccagg gacatcagat tccacaagaa 660
aatatggtca aaatgggact tttccagcat gtggcctctg gtggggctgg gttggacaag 720
ggccttgaaa cggctgcctg tttgccgata acttgtgggt ggtcagccag aaatggccgg 780
ggggcctctg cacctgggtc gcagggccag aggccaggag ggtgcctcag tgccaccaac 840
tgacagggt tagccagatg ttgattttag aggaagaaaa aaacatttta aaactccttc 900
ttgaattttc ttccctggac ttgaatacag ttggaagcac aggggtaact ggtacctgag 960
ctagctgcac agccaaggat agttcatgcc tgtttcattg acacgtgctg ggataggggc 1020
tgcagaatcc ctggggctcc cagggttgtt aagaatggat cattcttcca gctaagggtc 1080
caatcagtc ctattcttcc accagctcaa aggcctctg tatgtatgtc cctggcttca 1140
gctttggtca tgccaaagag gcagagtcca ggattccctc agaatgcctt gcacacagta 1200
ggtttccaaa ccatttgact cggtttgcct ccctgccctg tgtttaaacc ttacaaaacc 1260
tgataaacc catcttctag cagctggctg tccctctgg gagctctgcc tatcagaacc 1320
ctaccttaag gtgggtttcc ttccgagaag agttcttgag caagctctcc caggaggggc 1380
cacctgactg ctaatacaca gccctcccca aggcccggt gtgcatgtgt ctgtcttttg 1440
tgagggttag acagcctcag ggcaccattt ttaatccag aacacatttc aaagagcacg 1500
tatctagacc tgctggactc tgcagggggt gagggggaac agcgagagct tgggtaatga 1560
ttaacaccca tgctgggat gcatggaggt gaagggggcc aggaaccagt ggagatttcc 1620
atccttgcca gcacgtctgt acttctgttc attaaagtgc tccctttcta gtcaaaaaaa 1680
aaaaa

```

<210> 104

<211> 2674

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2365230

<400> 104

```

ctactcctca ccgcgcgagc gcggggaacc agtagccgcg gctgcttcgg ttgccgcggg 60
cggtgggtcgt tatggattct ccatgggacg agttggctct ggcttcttcc cgcacgtcca 120
tgtttccctt ttttgacatc gcgcactatc tagtgtcagt gatggcggtg aaacgtcagc 180
cgggagcagc tgcattggca tggagaatc ctatttcaag ctggtttact gctatgctcc 240
actgttttgg tggaggaatt ttatcctgtc tactgcttgc agagcctcca ttgaagtttc 300
ttgcaaacca cactaacata ttactggcat cttcaatctg ggtatattac atttttttgc 360
ccgcatgacc tagtttccca gggctattca tatctacctg ttcaactact ggcttcggga 420
atgaagggaag tgaccagaac ttggaaaata gtaggtggag tcacacatgc taatagctat 480
tacaaaaaat gctggatagt catgatagct attggatggg cccgaggtgc aggtggtacc 540
attataacga attttgagag gttggtaaaa ggagattgga aaccagaagg tgatgaatgg 600
ctgaagatgt cataccctgc caaggtaacc ctgctggggg cagttatctt cacattccag 660
cacaccagc atctggcaat atcaaagcat aatcttatgt tcttttatac catctttatt 720
gtggccacaa agataacat gatgactaca cagacttcta ctatgacatt tgctcctttt 780
gaggatacat tgagttggat gctatttggc tggcagcagc cgttttcatc atgtgagaag 840
aaaagtgaag caaagtcacc ttccaatggc gttgggtcat tggcctcaa gccggtagat 900
gttgcctcag ataagttaa aaagaaacat actaagaaga atgaataaat ttacgtgatg 960
agctctagca agccaaaaat tttttttctt atctacctgt tatattgtgc taattttcta 1020
tgtatgtgat gtgaaatgaa gactatatat atggaatgga ggtgacagaa agaaagaaat 1080
tctttgtttg agggagactt cccctttctg gattgtattt gtagagtgtt acgagtgtat 1140

```

```

catgtgatta tgctttaccg gtataagaga ttctgtgtg attatttgaa tagttttata 1200
ttaataaaaag aagacaaaat tttttaaatg ttagaaaaag cagatctgtc attgcaaagt 1260
aacaaaaaatt ttaagctttt aaaaatgtag atttttcata tttttaaaat ttgaatctat 1320
ttgagcttta gttcagcaga attaaatttt tacttgacat tatcattaaa attgctagggt 1380
atggagaaca attcctattt tattttgaac actgagaaga gtaaaactttt cctaaaaacac 1440
tttatattat aaatgaaaat aaattgctag tttatatttt agatataaac atcatatttt 1500
ttattaatac ctacatcaaa tggaaaatat ctgaaatttt tttccatag cagggtatttt 1560
ctactagaag tagttttact acttttcatt tagaacagag tatgagtctt aatctgaagt 1620
ctttttcatg cccttgttt aaaaaaacta ctttttttgg cctcaaaaaa atcaaggggtg 1680
taattttttaa taaattgtta atcctatgtt ttgtaatttt catttttagga gcttgactta 1740
ttttttttct ctctcataaa aacacatttg ttttaattgt aggagaaatt ttctcagcat 1800
tttgcatgtt ttttctaate tttgttggtc tgaatatatt ggtagtaatt actgtaatta 1860
ttcaacaaaa agcatatccg ttcaaaaatt tttccactat gtcttttttc tagtgggtac 1920
tggttttagtt ttctagtga atatctctga caagcttttc tatgggtttg ttatattttc 1980
atctacatgt aatgtgttat taattttatt aaatgaaaac taatcacctt catgtggaaa 2040
tgctctgaga attgtcctta ggcatttggg agtaaccagc taaccaagaa gaaacagaga 2100
aaccagaact tcataaggca gtccatttag atgaagaatg atgatataaa atctgggtcc 2160
ttcttagcaa aataaaaaac aaacaagaaa agatactaaa tgatgttaat tttcttactt 2220
tatgatttag aagtcaggtt ataattataa aactctgtga catagtctt tttaccaaaa 2280
ccatgaacct actcccgtta tcagggtattt tcatgggtt agaagtactc aagtcacatc 2340
acattcaagt tagaagtttt ttttttgttg ttgttatatt aaatttttaa caaatataaa 2400
caccagcaga tactattact tgcttaaaaa attgggaggg ggcacttttc atagtcttgg 2460
aatgctaaga agttttattt ttaattattg gacagaaagc ttaagtatt taagagctct 2520
gtattatatt tgatactctt acagttaaaa acttttcaaa attaatatcat tgtaattat 2580
tgaccagttt tgaagtttgg gttaactgt agttgaaatg gaaggactct tgttttacac 2640
ttgtattaaa gataaattta ttaaaataag ttat 2674

```

<210> 105

<211> 488

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2455121

<400> 105

```

gactacgggg ctgttgacgg cgctgcatg gctgcctgag agggcaggag aagcggactc 60
tcggttcctc tcagtcggac ttctgacgc cgccagttgg cggggccctt tgggctgctg 120
ccaccactgt agtcatgtac ccaccgccc cgccgcccgc tcacggggac ttcatctcgg 180
tgacgctgag ctttggcgag agctatgaca acagcaagag ttggcgggcg cgctcgtgct 240
ggaggaaatg gaagcaactg tcgagattgc agcggaatat gattctcttc ctcttgctc 300
ttctgctttt ctgtggactc ctcttctaca tcaacttggc tgaccattgg aaagctctgg 360
ctttcaggct aggggaagag cagaagatga ggccagaaat tgctgggtaa aaccagcaaa 420
tccaccgctc ttaccagctc ctccagaaggc ggacaccggc cctgagaact tacctgagat 480
ttcgtcac

```

<210> 106

<211> 1028

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2472514

<400> 106

```

ccagcagctc ggtcctaggg cgatgttgac agacagacag aggggcggat gcagcctacc 60
tcctgggcag tgagctgcgg tctgaggccc ctgcccagct ggaaaccaca gggaggggaa 120
gggaggggag gagaggagag gagaggaacc gtcattggggc cttggagtcg agtcagggtt 180
gccaaatgcc agatgctggt cacctgcttc tttatcttgc tgctgggcct ctctgtggcc 240
accatggtga ctcttaccta ctctggggcc cactttgctg tcatccgcgc agcgtccctg 300
gagaagaacc cgtaccaggc tgtgcaccaa tgggccttct ctgcggggtt gagcctggtg 360
ggcctcctga ctctgggagc cgtgctgagc gctgcagcca ccgtgaggga ggcccagggc 420
ctcatggcag ggggcttctc gtgcttctcc ctggcgcttct gcgcacaggc gcagggtggtg 480
ttctggagac tccacagccc caccaggtg gaggacgcca tgctggacac ctacgacctg 540
gtatatgagc aggcgatgaa aggtacgtcc cactgcccgc ggcaggagct ggcggccatc 600
caggacgtgg tgagcgtggg gacggctggg tggcaggggc gtcagcttct gcttggactg 660
cagttcagag aacaggcgca ggggtggccag tgagaggctc ggccaggcac cgagggggtt 720
ccaggacaca ggccagagtt gccctcagc gctgggggca aaaagctccc accctctgtc 780
tgcccaggac aaggccgcct accagattct cgaggcccag tgcaaaacga gagggcaggg 840
ccctgtattc agaaacactg aaggatttca agagcattaa agcaaatagc gggccgaaca 900
tagtggctca cactgtaat cccagcactt tgggaggagg ttgaggcagg tgaattgctt 960
gagcccagga gttcgagacc agcctgagca acatagggag acctgtgtct tactttaaaa 1020
aaaaaaaaa                                     1028

```

<210> 107

<211> 1551

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2543486

<400> 107

```

ctgcgcctgg gctgccggtg acctggggcc agccctcccg gtcggctaag attgctgagg 60
aggcggcggg tagctggcag gcgcgcgactt ccgaaggccg ccgtccgggc gaggtgtcct 120
catgacttct cttgtggacc atgtccgtga tcttttttgc ctgcgtggta cgggtaaggg 180
atggactgcc cctctcagcc tctactgatt tttaccacac ccaagatttt ttggaatgga 240
ggagacggct caagagttta gccttgcgac tggcccagta tccaggtcga ggttctgcag 300
aaggttgtga ctttagtata catttttctt ctttcgggga cgtggcctgc atggctatct 360
gtcctgcca gtgtccagca gccatggcct tctgcttctt ggagaccctg tgggtgggaat 420
tcacagcttc ctatgacact acctgcattg gcctagcctc caggccatac gcttttcttg 480
agtttgacag catcattcag aaagtgaagt ggcattttta ctatgtaagt tcctctcaga 540
tggagtgcag cttggaaaaa attcaggagg agctcaagtt gcagcctcca gcggttctca 600
ctctggagga cacagatgtg gcaaatgggg tgatgaatgg tcacacaccg atgcacttgg 660
agcctgtctc taatttccga atggaaccag tgacagccct gggtatcctc tccctcattc 720
tcaacatcat gtgtgctgcc ctgaatctca ttcgaggagt tcaccttgca gaacattctt 780
tacaggttgc ccatgaggaa attggaaaca ttctggcttt tcttgcttct ttcgtagcct 840
gcattttcca ggatccaagg agctggttct gctgggttga ccaaaccctc tgagccagcc 900
accctgacc caaatgagga gagctctgat tctcccatcc gggagcagtg atgtcaaaact 960
ctgctgtctg gggaaatctc atcagcaggg agcctgtgga aaagggcatg tcagtgaat 1020
ctgggaatgg ctggattcgg aaacatctgc ccatgtgtat tgatggcaga gctgttgccc 1080
acaagcgctt tttatttagg gtaaaattaa caaatccatt ctattcctct gacctatgct 1140
tagtacatat gacctttaac ccttacattt atatgattct ggggttgctt cagaagtgtt 1200
atttcatgaa tcattcatat gatttgatcc ccaggattc tattttgttt aatgggcttt 1260
tctactaaaa gcataaaata ctgaggctga tttagtcagg gcaaaaccat ttactttaca 1320

```

```

tattcgtttt caatacttgc tgttcatggt acacaagctt cttacggttt tcttgttaaca 1380
ataaatatatt tgagtaaaata atgggtacat ttttaacaaac tcagtagtac aacctaact 1440
tgtataaaag tgtgtaaaaa tgtatagcca tttatatcct atgtataaat taaatgaggt 1500
ggcttcagaa atggcagaat aaatctaaag tggtttattaa caaaaaaaaaa a 1551

```

<210> 108

<211> 922

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2778171

<400> 108

```

gcttgcggct cgggtggctg agcgcgcggt gaaatggcca cggggacaga ccaggtggtg 60
ggactcggcc tcgtcgccgt tagcctgac atcttcacct actacaccgc ctgggtgatt 120
ctcttgccat tcacgacag tcagcatgtc atccacaagt atttcctgcc ccgagcctat 180
gctgtcgcca tcccactggc tgcaggcctc ctgctgctcc tgtttgggg actgttcac 240
tcctacgtga tgctgaagag caagagagt accaagaagg ctgagtgaag gtcccgcagg 300
atgaggctgc cagccccctt tctgcttccc ctccagcaca gggaccaagt gggggagcct 360
gcagaacctg tccaggcaca gtggctcctc aagcctgcct gtcctgcaga gtcccatgg 420
catggagctt acacctgact gactggagcc cctccccga ctcccacttc cagaagctag 480
gagggaggga tacctggaag actccggtca cctccttctt gtcagggcc taaaagatgc 540
tggtcctccc aacctcactc tcagactccc tgccaccttt tcccctgggt tctgcccgt 600
tgccctactt cccctcctgt cacatgctga cgttggactt agcaggttct aaggccacat 660
gtgtgacctc tctgacttct ctctctccac caaggcagct ttccttacc tgacacagcc 720
ccagacccca caaagccttc tggacctgga aagcctgggg aaggactgac agacccagg 780
accagccctg gggctcaggg cagccacccc gggcgcgtga ccgactgacc tctcctcacg 840
gagggcccag cccaaagccc cagggtgggc ccgtttggga cagctgacca ataaactg 900
atggtgtgtt aaaaaaaaaa aa 922

```

<210> 109

<211> 985

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2799575

<400> 109

```

gcccaggagg cgcccggtg aggcacgggt gcgcaagcga ggagttccgg ctggagaccc 60
gtgctctggg ccggcgccct caccatggcc tcggcagagc tggactacac catcgagatc 120
ccgatcagc cctgctggag ccagaagaac agcccagcc caggtgggaa ggaggcagaa 180
actcggcagc ctgtggtgat tctcttgggc tgggtgggt gcaaggacaa gaaccttgcc 240
aagtacagt ccactacca caaaaggggc tgcacgtaa tccgatacac agcccctgg 300
cacatggtct tcttctccga gtcactgggt atcccttcac ttcgtgtttt ggcccagaag 360
ctgctcagc tgcctttga ttatgagatt gagaaggagc ccctgctctt ccatgtcttc 420
agcaacgggt gcgtcatgct gtaccgctac gtgctggagc tcctgcagac ccgtcgcttc 480
tgccgcctgc gtgtggtggg caccatcttt gacagcgctc ctggtgacag caacctggt 540
ggggctctgc gggccctggc agccatcctg gagcgccggg ccgccatgct gcgcctgtt 600
ctgctggtgg cctttgccct ggtggctgct ctgttccacg tcctgcttgc tcccatcaca 660

```



```

gccctcttcc acaccactt ctatgacagg ctacaggacg cgggctctcg ctggcccag 720
ctctacctct actcgagggc tgacgaagta gtcctggcca gagacataga acgcatggtg 780
gaggcacgcc tggcacgccg ggtcctggcg cgttctgtgg atttcgtgtc atctgcacac 840
gtcagccacc tccgtgacta ccctacttac tacacaagcc tctgtgtcga cttcatgcgc 900
aactgcgtcc gctgctgagg ccattgctcc atctcacctc tgctccagaa ataaatgcct 960
gacacctccc cacaaaaaaa aaaaa

```

<210> 110

<211> 1562

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2804955

<400> 110

```

tgcgctccaga ggctggcatg gcgcgggccc agtactgagc gcacggtcgg ggcacagcag 60
ggccggtggg tgagctggc tcgcgcctcc tctccggccg ccgtctctc cggtccccgg 120
cgaaagcatt gagacaccag ctggacgtca gcgcgcggag catgtctggg agtcagagcg 180
aggtggctcc atccccgcag agtccgcgga gccccgagat gggacgggac ttgcggcccg 240
ggtcgccgt gtcctgtctc ctgcttctgc tctgctggt gtacctgact cagccaggca 300
atggcaacga gggcagcgtc actggaagtt gttattgtgg taaaagaatt tcttccgact 360
ccccgccatc gggtcagttc atgaatcgtc tccggaacaa cctgagagct taccatcggt 420
gtctatacta cacgaggttc cagctccttt cctggagcgt gtgtggaggc aacaaggacc 480
catgggttca ggaattgatg agctgtcttg atctcaaaga atgtggacat gcttactcgg 540
ggattgtggc ccaccagaag catttacttc ctaccagccc cccaatttct caggcctcag 600
agggggcatc ttcagatata cacaccctg ccagatgct cctgtccacc ttgcagtcca 660
ctcagcgccc caccctccca gtaggatcac tgtcctcgga caaagagctc actcgtccca 720
atgaaaccac cattcacact gcggggccaca gtctggcagc tgggcctgag gctggggaga 780
accagaagca gccggaaaaa aatgctggtc ccacagccag gacatcagcc acagtgccag 840
tctgtgcct cctggccatc atcttcatcc tcaccgcagc cctttcctat gtgctgtgca 900
agaggaggag ggggcagtca ccgcagtcct ctccagatct gccggttcat tatatacctg 960
tggcacctga ctctaatacc tgagccaaga atggaagttt gtgaggagac ggactctatg 1020
ttgcccaggc tggtatggaa ctctgagtc aagtgatcct cccaccttgg cctctgaagg 1080
tgcgaggatt ataggcgta cctaccat ccagcctaca cgtatttgtt aatatctaac 1140
ataggactaa ccagccactg cctctcttta ggcctctcat ttaaaaacgg ttatactata 1200
aaatctgctt ttcacactgg gtgataataa cttggacaaa ttctatgtgt attttgttt 1260
gttttgcttt gctttgtttt gagacggagt ctgcgtctgt catccaggct ggagtgcagt 1320
ggcatgatct cggctcactg caacccccat ctcccagggt caagcgattc tcctgcctcc 1380
tcctaagtag ctgggactac aggtgctcac caccacacc ggctaatttt ttgtattttt 1440
agtagagacg gggtttcacc atgttgacca ggctggtctc gaactcctga cctggtgatc 1500
tgcccaccag gcctcccaaa gtgctgggat taaagggtgt agccacatgg ctggcctatg 1560
tt

```

<210> 111

<211> 1851

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2806395

```

<400> 111
gctctgcaga gtggtggccg gggccagggc cggggtgccc tccctccac cttctccgc 60
catgagccag ggaagtccgg gggactgggc ccccttagat cccaccccg gacccccagc 120
atcccccaac cccttcgtgc atgagttaca tctctctcgc ctccagaggg ttaagttctg 180
cctcctgggg gcattgctgg ccccatccg agtgcttctg gcctttatcg tctctttct 240
cctctggccc ttgctctggc ttcaagtggc cggctcttagt gaggagcagc ttcaggagcc 300
aattacagga tggaggaaga ctgtgtgcca caacggggtg ctaggcctga gccgcctgct 360
gtttttcctg ctgggcttcc tccggattcg cgttcgtggc cagcgagcct ctgccttca 420
agccccctgc cttgttgctg ccccaactc cactttcttt gacccattg ttctgctgac 480
ctgtgacctg cccaaagtgt tgtcccgagc tgagaacctt tccgttcctg tcattggagc 540
ccttcttcga ttcaaccaag ccattcctgg atccccgcat gaccggcctt ctgcagcag 600
agtgtgtgag gaggtccgaa ggcgggccac ctcaggaggg aagtggccgc aggtgctatt 660
ctttcctgag ggcacctgtt ccaacaagaa ggctttgctt aagtcaaac caggagcctt 720
catcgagggg gtgcctgtgc agcctgtcct catccgctac cccaacagtc tggacaccac 780
cagctgggca tggaggggtc ctggagtact caaagtctc tggctcacag cctctcagcc 840
ctgcagcatt gtgatgtgg agttccctcc tgtgtatcac cccagccctg aggagagcag 900
ggacccccacc ctctatgcc acaatgttca gagggtcatg gcacaggctc tgggcattcc 960
agccaccgaa tgtgagtgtt tagggagctt acctgtgatt gtggtgggccc ggctgaagggt 1020
ggcggttgaa ccacagctct gggaaactgg aaaagtgtt cgggaaggctg ggctgtccgc 1080
tggctatgtg gacgtggggg cagagccagg ccggagtcga atgatcagcc aggaagagtt 1140
tgccaggcag ctacagctct ctgatcctca gacggtggct ggtgcctttg gctacttcca 1200
gcaggatacc aagggttttg tggacttccg agatgtggcc cttgcactag cagctctgga 1260
tgggggcagg agcctggaag agctaactcg tctggccttt gagctctttg ctgaagagca 1320
agcagagggt cccaaccgcc tgcgtgtaca agacggcttc agcaccatcc tgcacctgct 1380
gctgggttca cccacccctg ctgccacagc ttgtcatgct gagctgtgcc aggcaggatc 1440
cagccaaggc ctctccctct gtcagtcca gaacttctcc ctccatgacc cactctatgg 1500
gaaactcttc agcacctacc tgcgcccccc acacacctct cgaggcacct cccagacacc 1560
aaatgcctca tcccaggca acccactgc tctggccaat gggactgtgc aagcacccaa 1620
gcagaaggga gactgagtgc ctcagcctct caccctctcc tctcagggc agcgctaggg 1680
gctcccccta tgcctcagcc ccattctctg tctgtttga atttgttat tgtgttttg 1740
ttgtgtttt tttaagtga ttttaatttt ttgtttggtt gatttttttg taaaaaacta 1800
ttttatatat aaatataaat ctatatctat atctattaaa aaaaatgaat t 1851

```

<210> 112

<211> 992

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2836858

<400> 112

```

ggcgcgaggc agtatggttt gaagtgggtga acatggattt ttctcggtt cacatgtaca 60
gtcctcccca gtgtgtgccg gagaacacgg gctacacgta tgcgtcagt tccagctatt 120
cttcagatgc tctggatttt gagacggagc acaaatggga ccctgtattt gattctccac 180
ggatgtcccg ccgtagtgtt gcgctggcca cgacagcatg caccctgggg gatggtgagg 240
ctgtgggtgc cgacagcggc accagcagcg ctgtctccct gaagaaccga gcggccagaa 300
caacaaaaca gcgcagaagc acaaaacaat cagcttttag tatcaaccac gtgtcaaggc 360
aggtcacgtc ctctggcgtc agccacggcg gcactgtcag cctgcaggat gctgtgactc 420
gacggcctcc tgtattggac gagtcttggg ttcgtgaaca gaccacagtg gaccattct 480
ggggtcttga tgatgatggg gatctttaaag ttggaaataa agctgccatt cagggaaacg 540
gggatgtggg agcccgccgc gccaccgcgc acaacggctt ctctgcagc aactgcagca 600
tgctgtccga gcgcaaggac gtgctcacgg cgcaccccg ggccccggg cccgtgtcga 660
gagtttatcc tagggacagg aatcaaaaat gtaagtctca gtcctttaa actcagaaaa 720

```

```

aggtgtgttt tccaaattta atatttcctt tctgtaagtc tcagtgtctg cactatttgt 780
cttgggagact taaaattatc ccttgaaagc ataagaagta caccctaaac cagctttgtc 840
cttcctgtcc tcttctagtt tacattttat gtggttagta attttgtacc taaaagtatt 900

```

```

tgaaattcta taaatttgga cttgacgtga gcaaaagaaa atttctacgt aagcgaaact 960
aataaaacta cagtcacttt caaaaaaaaa aa 992

```

<210> 113

<211> 1251

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2844513

<400> 113

```

ctctgctggc cggctctaaag cggcagccgc cggggcgcaa tgcgagcggc tggcgtaggc 60
ttggtggact gtcactgcc a cctctccgcc cgggactttg accgcgattt ggatgatgtg 120
ttggagaaag ccaagaaggc caatgttgtg gcccttgttg cagttgccga acattcagg a 180
gaatttgaaa agattatgca actttcagaa aggtataatg ggtttgcctt gccatgcttg 240
ggtgttcac cagttcaagg acttccacca gaagaccaa gaagtgtcac actaaaggat 300
ttggatgtag ctttgcccat tattgagaat tataaggatc ggttgttggc aattggagag 360
gttggtactag atttctcccc cagatttgct ggcaactggg aacagaagga agagcaaaga 420
caagtcctaa tcagacagat ccagttagcc aaaagactaa atttgcctgt aaatgtgcac 480
tcacgctctg ctggaagacc taccatcaac cttttacaag agcaagggtg tgagaaggta 540
ctgctgcatg catttgatgg tcggccatct gtagccatgg aaggagtaag agctgggtac 600
ttcttctcaa tcccccttc tatcataaga agtggacaga agcagaaact tgtgaaacaa 660
ttgcctttaa cttctatatg cttagaaaca gattcacctg cactaggacc agaaaaacag 720
gtacggaatg agccctggaa catttctatt tcagcagaat atattgccc a ggtgaaaggg 780
atctcagtg aagaagttat agaagtgacg acacagaatg cattaaaact gtttcctaag 840
ctccgacact tgctccagaa atagcttcaa aaccatccat taaaaaatcg aatcaactgc 900
agggggcagc atttgaaaaa tagaaatgtt ctgatgaaga atctgaactg aagaagctgt 960
tttatagggt tatagaagat tgtaattgta gagaaatatt tctcttagaa ataaaactgg 1020
gcttggtacc tgaaaccctg ggttctgatt ctagccttgt gctgcttttc aattagccga 1080
gttctggcag gatattggga aaatactgct acttcttaca ttgccctttt atatagaacc 1140
accacctgaa ctgaaacat tgctactggg aagggtggct cccacaggaa gagtataagc 1200
actactgtga tgaggatgga gtaagctaaa gtatactttt tttttttttt g 1251

```

<210> 114

<211> 1397

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3000380

<400> 114

```

ctaggacgcc cctggagccg gaaccccgagc agaagccgga accagaacca aatcaccggt 60
accggctgca gccccctaaa cccaggaggc gccctggccc gcgctcgccc cccagggcct 120
catgtcgga ccacagcctg acctggaacc gccccaacat gggctatata tgctcttcc 180
gcttgtgtg gtcttcttcc tcatgggctt ggtaggcttc atgatctgcc acgtgctcaa 240

```

```

gaagaagggc taccgctgcc gcacgtcgag gggctctgag cctgacgatg cccagcttca 300
gccccctgag gacgatgaca tgaatgagga cacagtagag aggtattgttc gctgcatcat 360
ccagaatgaa gtgtggatgc cacctccagc ctgcaggacg gagccccctc ccatcatcac 420
acagtgcacc tgggctctgc agccccctgc cgtccattgc agccgcagca agaggcctcc 480
acttgctcgt cagggacgct ccaaggaagg aaaaagccgc ccccgagacag gggagaccac 540
tgtgttctct gtgggcagggt tccgggtgac acacattgag aagcgctatg gactgcacga 600
acaccgtgat ggctccccc cagacaggag ctggggctct cgtgggggac aggaccagg 660
gggtggtcag gggctctggg gagggcaccc caaggcagg atgctgccat ggagaggctg 720
ccccctgag agggcacagc cccaggctct agccagcccc ccagtacaga atggaggact 780
cagggacagc agcctaacc ctcgtgcact tgaagggaac cccagagctt ctgcagagcc 840
aacactgagg gccggaggga ggggcccag cccagggtct cccactcaag aggcaaatgg 900
gcagccaagc aaaccagaca cttctgatca ccagggtgtc ctaccacagg gagcaggagg 960
tatgtgagtc tccttcattg tgctgatgga ctaccagctg gcagggccag ggggtgggtg 1020
ggcgtgaaag cctccctc cactggacag cactgcccc cagctgaggg accagctcta 1080
cttcacctg gagttgcaca gtctcaggct gggggcctca ggagagggtc cagccccctc 1140
gtctcttctc cttccctgc ctgcaacagg ctgcctgccc cgccttcccc aacacctcgc 1200
tccatatgat agagcgtggc agctgggagc agggccctgc ccgtgggtggg cccctaaagc 1260
aatagcaccg taggccccct gccctcttag cacaagaggc ccaggccctg gcctggcctt 1320
cgtgcccttt attcattgtc aataaatccg ctcagaccat taaaaaatac aactcaaggg 1380
gtagccaaaa aaaaaaa 1397

```

<210> 115

<211> 1581

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 182532

<400> 115

```

acagcacagc tgacagccgt actcaggaag cttctggtat cctaggctta tctccacaga 60
ggagaacaca caagcagcag agaccatggg gccccctcct gccccctcct gcacacacct 120
catcacttgg aagggggtcc tgctcacagc atcactttta aacttctgga atccgcccac 180
aactgcccaa gtcacgattg aagcccagcc acccaaagt tctgagggga aggatgttct 240
tctacttgtc cacaatttgc cccagaatct tgctggctac atttggtaca aagggcaaat 300
gacatacgtc taccattaca ttatatcgta tatagtgtat ggtaaaataa ttatatatgg 360
gcctgcatac agtggaagag aaagagtata ttccaatgca tccctgctga tccagaatgt 420
cacgcaggag gatgcaggat cctacacctt acacatcata aagcgagggtg atgggactag 480
aggagaaact ggacatttca ccttcacctt atacctggag actcccaagc cctccatctc 540
cagcagcaac ttatacccca gggaggacat ggaggctgtg agcttaacct gtgatcctga 600
gactccggac gcaagctacc tgtgggtggat gaatgggtcag agcctcccta tgactcacag 660
cttgacgttg tccaaaaaca aaaggaccct ctttctattt ggtgtcacia agtacactgc 720
aggaccctat gaatgtgaaa tacggaaccc agtgagtggc atccgcagtg acccagtcac 780
cctgaatgtc ctctatggtc cagacctccc cagcatttac ccttcattca cctattaccg 840
ttcaggagaa aacctctact tgtcctgctt cgccgagtct aacccacggg cacaatatcc 900
ttggacaatt aatgggaagt ttcagctatc aggacaaaag ctctttatcc cccaaattac 960
tacaaagcat agtgggtctc atgcttgctc tgttcgtaac tcagccactg gcatggaaag 1020
ctccaaatcc atgacagtca aagtctctgc tccttcagga acaggacatc ttctggcct 1080
taatccatta tagcagccgt gatgtcattt ctgtatttca ggaagactgg cagacagttg 1140
ctttcattct tcctcaaagt atttaccatc agctacagtc caaaattgct ttttgttcaa 1200
ggagatttat gaaaagactc tgacaaggac tcttgaatac aagttcctga taacttcaag 1260
atcataccac tggactaaga actttcaaaa ttttaatgaa caggctgata cttcatgaaa 1320
ttcaagacaa agaaaaaac ccaattttat tggactaaat agtcaaaaac atgttttcat 1380
aattttctat ttgaaatgt gctgattctt tgaatgtttt attctccaga tttatgcact 1440

```

```

ttttttcttc agcaattggt aaagtatact tttgtaaaca aaaattgaaa catttgcttt 1500
tgctccctaa gtgccccaga attgggaaac tattcatgag tattcatatg tttatggtaa 1560
taaagttatc tgcacaagtt c                                     1581

```

```

<210> 116
<211> 1566
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 239589

```

```

<400> 116
cggctcgagt atggatctcc aaggaagagg ggtccccagc atcgacagac ttcgagttct 60
cctgatgttg ttccatacaa tggtcaaat catggcagaa caagaagtgg aaaatctctc 120
aggcctttcc actaaccctg aaaaagatat atttggtgtg cgggaaaatg ggacgacgtg 180
tctcatggca gagtttgag ccaaatttat tgtaccttat gatgtgtggg ccagcaacta 240
cgtagatctg atcacagaac aggcgatata cgcattgacc cggggagctg aggtgaaggg 300
ccgctgtggc cacagccagt cggagctgca agtgttctgg gtggatcgcg catatgcact 360
caaaatgctc tttgtaaagg aaagccacaa catgtccaag ggacctgagg cgacttggag 420
gctgagcaaa gtgcagtttg tctacgactc ctcgagaaaa acccacttca aagacgcagt 480
cagtgtctgg aagcacacag ccaactcgca ccacctctct gccttgggtc cccccgctgg 540
gaagtcttat gagtgtcaag ctcaacaaac catttcaact gcctctagt atccgcagaa 600
gacggtcacc atgatcctgt ctgcggtcca catccaacct ttgacatta tctcagattt 660
tgtcttcagt gaagagcata aatgcccagt ggatgagcgg gagcaactgg aagaaacctt 720
gcccttgatt ttggggctca tcttgggcct cgtcatcatg gtaacactcg cgatttacca 780
cgtccaccac aaaatgactg ccaaccaggt gcagatccct cgggacagat cccagtataa 840
gcacatgggc tagaggccgt taggcaggca cccctattc ctgctcccc aactggatca 900
ggtagaacaa caaaagcact tttccatctt gtacacgaga tacaccaaca tagctacaat 960
caaacaggcc tgggtatctg aggcttgctt ggcttgtgtc catgcttaaa cccacggaag 1020
ggggagactc tttcggattt gtagggtgaa atggcaatta ttctctccat gctggggagg 1080
aggggaggag ggtctcagac agctttcgtg ctcatggtgg cttggctttg actctccaaa 1140
gagcaataaa tgccacttgg agctgtatct ggcccccagg tttagggtt gaaaacatgc 1200
ttctttgagg aggaaacccc tttaggttca gaagaatat ggggtgcttg ctcccttggg 1260
cacagctggc ttatcctata cagtgtgcaa tgcacacaga atacaacctc atgctccctg 1320
cagcaagacc cctgaaagtg attcatgctt ctggctggca ttctgcatgt ttagtgattg 1380
tcttgggaat gtttactgct taccgcgcat cagcgactgc agcaccagaa aacgactaat 1440
gtaactatgc agagtgtgtt ggacttcttc ctgtgccagg tccaagtcgg gggacctgaa 1500
gaatcaatct gtgtgagtct gtttttcaaa atgaaataaa acacactatt ctctggcaaa 1560
aaaaaa

```

```

<210> 117
<211> 1815
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 1671302

```

```

<400> 117

```

```

tttgtttctc ttattcccag gacatcaagg agactttcaa taggtgtgaa gaggtacagc 60
tgacagcccc agaggtctgg tcccctgacc cgtgccaaacc ccatagccat gacttcctga 120
cagatgccat cgtgaggaaa atgagccgga tgttctgtca ggctgcgaga gtggacctga 180
cgctggaccc tgacacggct caccggccc tgatgctgtc ccctgaccgc cgggggggtcc 240
gcctggcaga gcggcggcag gaggttgctg accatcccaa gcgcttctcg gccgactgct 300
gcgtactggg ggcccagggc ttccgctccg gccggcacta ctgggaggta gaggtgggcg 360
ggcggcgggg ctggggcggtg ggtgctgccc gtgaatcaac ccatcataag gaaaagggtg 420
gccctggggg ttcttccgtg ggcagcgggg atgccagctc ctgcgccat caccatcgcc 480
gccgcgggt ccacctgccc cagcagcccc tgctccagcg ggaagtgtgg tgcgtgggca 540
ccaaacgcaa acgctatcag gccagagct ccacagaaca gacgctgctg agccccagt 600
agaaaccaag gcgctttggg gtgtacctgg actatgaagc tgggcgcctg ggcttctaca 660
acgcagagac tctagccac gtgcacacct tctcggtgc cttcctgggc gagcgtgtct 720
ttcttttctt cgggtgctc tccaaggga cccgcacaa gctctgccct tgattatcct 780
gccacccgca gggccctct gtcagcactt ggggggtggg tgggtggaggg tggcccgtaa 840
gtttgagggc tcaaaggctc ttcccactgc ttgttactgt gttgcttccc actccccctt 900
gaccccaggc ccctgcttct ccctctagga gcctaaagaa ccctcctggc ctccagctca 960
gccttctctc acctactatg tctgtccaac aggtctgcat ggggccctga taatgagaac 1020
agctgcctgg tcttctctcc cagtctgcct agcccagccc tgggactgga atttgagtag 1080
gggatgaggg gaaattgtaa tttcattcct taacttcctt tccccaccc ctgctcttca 1140
acctctttat cagtctgag gctggagggt ttgggcaagg caacatcccc attccaattc 1200
cattttctga tgcagatttt agctgaggga tttggaagcc atttggggag gcaggctggg 1260
ccaaagggtg gagctgggta ataaatgtct attctcctgg ggaggaggga ttctaaactt 1320
tccttccgtc ctcaatttct acctccatag accggccaga atttagcttc acttgagaga 1380
gatctggaat ggtcgccatg attgaaacca cgcaccatta catcatcatt acattaatta 1440
catcaacata aattatttct tcccccttcc cttttccagc actcaaccaa ggagcaaagc 1500
tcaccccacc ccacacccct cccagggtctg ctactgccca ggctcctctc ccctttgttc 1560
agtggagctg gcttttctcc cagccccttt ccattgcctt cactccattt ggcaagctct 1620
gagggggagc ctggggacgg gtttgggtcc ccaggaggag agccttgggt ataacttatt 1680
tttctaggag cctcttgcc tgtcacttgc agctttcgcc ctctgctttg atggctgagg 1740
tgaactcatg ttctttggga aaagggaagg cgtgctgtgg aaataaaatg tttatttgct 1800
tctctaaaaa aaaaa 1815

```

<210> 118

<211> 1566

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2041858

<400> 118

```

caaagagcca ggctccagga gaggaagggc tctgcgagag gagagaggag agcgctggag 60
aggagaggct ggaggtgaga gtcccaggaa aggcagagga gaatcgtagg gacataagt 120
tcccagcaca ggcaaggagg aatccgagga taaggttctg gagggacaga agggcccaga 180
gagagtcctt agccaggatg gaggtgtgtg tgaacttgta ccaagagggt atgaagcacg 240
cagatccccg gatccagggc taccctctga tggggtcccc cttgctaata acctccattc 300
tcctgacctc cgtgtacttc gttctctcac ttgggcctcg catcatggct aatcggaagc 360
ccttccagct ccgtggcttc atgattgtct acaacttctc actgggtggc ctctccctct 420
acattgtcta tgagttcctg atgtcgggct ggctgagcac ctatacctgg cgctgtgacc 480
ctgtggacta ttccaacagc cctgaggcac ttaggatggg tcgggtggcc tggctcttcc 540
tcttctccaa gttcattgag ctgatggaca cagtgatctt tattctccga aagaaagacg 600
ggcagggtgac cttcctacat gtcttccatc actctgtgct tccctggagc tgggtgggtg 660
gggtaaagat tgccccggga ggaatgggct ctttccatgc catgataaac tcttccgtgc 720
atgtcataat gtacctgtac tacggattat ctgcctttgg ccctgtggca caaccctacc 780

```

```

tttgggtggaa aaagcacatg acagccattc agctgatecca gtttgcctg gtctcactgc 840
acatctccca gtactacttt atgtccagct gtaactacca gtaccagtc attattcacc 900
tcattctggat gtatggcacc atcttcttca tgctgttctc caacttctgg tatcactctt 960
ataccaaggg caagcggtg ccccggtgcac ttcagcaaaa tggagctcca ggtattgcca 1020
aggtaaggc caactgagaa gcatggccta gataggcgcc cacctaagtg cctcaggact 1080
gcaccttagg gcagtgtccg tcagtgcctc ctccacctac acctgtgacc aaggcttatg 1140
tggtcaggac tgagcagggg actggccctc ccctccccc agctgtctta cagggaccac 1200
ggctttggtt cctcaccac ttccccggg cagctccagg gatgtggcct cattgctgtc 1260
tgccactcca gagctggggg ctaaaagggc tgtacagtta tttccccct cctgccttaa 1320
aacttgggag aggagcactc agggctggcc ccacaaaggg tctcgtggcc tttttcctca 1380
cacagaagag gtcagcaata atgtcactgt ggaccagtc tcaactctcc accccacaca 1440
ctgaagcagt agcttctggg ccaaaggta ggggtggcg gggcctggga atacagcctg 1500
tggaggctgc ttactcaact tgtgtcttaa ttaaaagtga cagaggaaac cacggaaaaa 1560
aaaaaa 1566

```

<210> 119

<211> 1055

<212> DNA

<213> Homo sapiens

<220>

<221>

<222> 1032, 1037, 1042

<223> a or g or c or t, unknown, or other

<220>

<221> misc_feature

<223> Incyte Clone No: 2198863

<400> 119

```

tcagcagcca gcaaggtctt tgagaaacac atggagctca ctgccctgct ccctttcagt 60
ggcttcccat tgccttgat aaagacccaa atgcctaaca gggcccataa ggcccacat 120
gatccacggg ctttagatgt gcagagatgt ggagcgcat gccaggtagg gtgagcagt 180
gcgtggagca gggccacttg gctggggtgc caggtgttgg aggggagcag cagcctgtcc 240
acatggccta aggtttgagc tgggtgttgc tgctgggccc ggcgagcgca gtgcagcgca 300
ccgcggggag cgaggagcgc gcggaccggc catgggcaag tcagcttcca aacagtttca 360
taatgaggtc ctgaaggccc acaatgagta ccggcagaag cacggcgctc cccactgaa 420
gctctgcaag aacctcaacc gggaggctca acagtattct gaggccctgg ccagcacgag 480
gatcctcaag cacagcccgg agtccagccg tggccagtgt ggggagaacc ttgcatgggc 540
atcctatgat cagacaggaa aggaggtggc tgatagatgg tacagtgaat tcaagaacta 600
taacttccag cagcctggct tcacctcggg gactggacac ttcacggcca tggatggaa 660
gaacaccaag aagatggcg tggggaaggc gtccgcaagt gacgggtcct cctttgtggt 720
ggccagatac tccccagcg ggaatgttgt caatgagggc ttcttcgaag aaaacgtcct 780
gccgcgaag aagtaacttg ttaaatgtaa tgggaagggt gcagacttaa gaacgtggat 840
atgaagtgcc tagaaccacc acaacctggc tgtgcgtctg tccctgtggg tgaatgtgct 900
tgtgtgtgtg atgcatgtga gcgtctctgg cacacacatt ggcatacagt tccgtgttctg 960
cccatcttat tacaggagtg agcaaaggaa gcattttacc cgatgggtac ctagaccacg 1020
attaattgga tnccccngaa anggggatcg gtttt 1055

```

<210> 120

<211> 1956

<212> DNA

<213> Homo sapiens

<220>

<221>

<222> 1893, 1896, 1899, 1906, 1911, 1921, 1926, 1927, 1928, 1929, 1932, 1935, 1940, 1948, 1950, 1951, 1953

<223> a or g or c or t, unknown, or other

<220>

<221> misc_feature

<223> Incyte Clone No: 3250703

<400> 120

```

cactcaagga agatataaat gacaaggctcg gctcagctct cagacaagggt tttccaagca 60
agatgaagcc caacatcatc tttgtacttt ccttgctcct catcttggag aagcaagcag 120
ctgtgatggg acaaaaagggt ggatcaaaaag gccgattacc aagtgaattt tccaatttc 180
cacacggaca aaagggccag cactattctg gacaaaaagg caagcaacaa actgaatcca 240
aaggcagttt ttctattcaa tacacatata atgtagatgc caatgatcat gaccagtccc 300
gaaaaagtca gcaatatgat ttgaatgccc tacataagac gacaaaatca caacgacatc 360
taggtggaag tcaacaactg ctccataata aacaagaagg cagagaccat gataaatcaa 420
aagggtcattt tcacagggtg gttatacacc ataaaggagg caaagctcat cgtgggacac 480
aaaatccttc tcaagatcag gggaatagcc catctggaaa gggaatatcc agtcaatatt 540
caaacacaga agaaggctg tgggttcctg gactaagtaa agaacaaact tccgtctctg 600
gtgcacaaaa aggtagaaaa caaggcggat cccaaagcag ttatgttctc caaactgaag 660
agctagttagc taacaaacaa caacgtgaga ctaaaaattc tcatcaaaat aaagggcatt 720
acaaaaatgt ggttgaagt agagaggaac attcaagtaa agtacaaacc tcactctgtc 780
ctgcgcacca agacaaactc caacatggat ccaaagacat tttttctacc caagatgagc 840
tcctagtata taacaagaat caacaccaga caaaaaatct caatcaagat caacagcatg 900
gccgaaaggc aaataaaaata tcataccaat cttcaagtac agaagaaaga cgactccact 960
atggagaaaa tgggtgtgcag aaagatgtat cccaaagcag tatttatagc caaactgaag 1020
agaaaaatata tggcaagtct caaaaccagg taacaattca tagtcaagat caagagcatg 1080
gccataagga aaataaaaata tcataccaat cttcaagtac agaagaaaga catctcaact 1140
gtggagaaaa gggcatccag aaaggtgtat ccaaaggcag tatttcgatc caaactgaag 1200
agcaaatata tggcaagtct caaaaccagg taagaattcc tagtcaagct caagagtatg 1260
gccataagga aaataaaaata tcataccaat cttcgagtac agaagaaaga cgtctcaaca 1320
gtggagaaaa ggtgttacag aaaggtgtat ccaaaggcag tatttctatc caaactgaag 1380
agaaaaatata tggcaagtct caaaaccagg taacaattcc tagtcaagat caagagcatg 1440
gccataagga aaataaaaatg tcataccaat cttcaagtac agaagaaaga cgactcaact 1500
atggaggaaa gagcacgcag aaagatgtat cccaaagcag tatttctttc caaattgaaa 1560
agctagttaga aggcaagtct caaatccaga caccaaatcc taatcaagat caatgggtctg 1620
gccaaaatgc aaaaggaaaag tctggtcaat ctgcagatag caaacaagac ctactcagtc 1680
atgaacaaaa aggagatac aaacaggaat ccagtgaagc acataatatt gtaattactg 1740
agcatgaggt tgcccaagat gatcatttga cacaacaata taatgaagac agaaatccaa 1800
tatctacata gccctgttgc ttagcaaccc attgaaaagc tggaccaata gcaagggtgc 1860
accccgacct cagtgaagta gggttcgttt gancngant aggaanggggt nccggaaggc 1920
naaaannnnt anttnagccn ctgttgtntn nanacc 1956

```

<210> 121

<211> 1737

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 350287

<400> 121

```

gaaatacagt ggctctttat taaaaataat agttggataa tataaactga actatttatg 60
cattttttata tacttataaa tccttccaaa tagttttaat tctatccttt tacatataaa 120
taacttaata agtgtgctgg aaaaacacag atgttcacag caccactgtt tttttttttt 180
ttttttgaga taataaattc catgagaaat ctgggtttga atatttggtt actttgtctc 240
ctaattgaac accactccag gccttctgtc tgtctcccct ttacccccaa aatattcaca 300
aaaaaaattt taagacaaca agtaaccata tataggtgtt tgaatgattt tctcattttt 360
atctaatttc atttcataag tcccagataa tttacctacc ataggctact atactgataa 420
tataaatgaa accgaacatt ttttgctact aactctcccc aatttaattgt gttttcgaaa 480
taaaaaattt aatttttttc cttttaatta aaaagtcac tttgaagtcc ttattggctg 540
tacattttac atgtttgctg gtactattat tttgtcagt agttaagct ggcatgtaca 600
gctcttggtt ttaatgaaaa gcacattgac ataatgttag taaattccaa accccggcac 660
agaatgtgag ttaaaattaa gtcttgctgg gttagtgtac aataaactat acctacagac 720
ttttttttta tagaagaag acaaagctgc tggatatagga tttgttcctt tgaagaaaaa 780
atgagggaaa caaacacaaa aacctcaatg cagtgtataa ataacatttt gttcaactac 840
ctcttaattg ggaattatct actttaatag tttcctgaca gtaatgttaa atagtaactg 900
ccaaatttgt tattttccca tctctcttaa aaaagtcttt atgattattt tatatagttt 960
tgagaacttt aaagccactt ttttttaacc ttacatttgc ataaaaatgt ttagctttta 1020
agtagagagc aaattatgat catatatttt gatattcatg acctgtttga ctataggatt 1080
ttttttaaaa aaatgcactt tggctataaa accatggatg atttgatcca taagatttaa 1140
atgtgccacc attatagtat tcctagacat gagcttgatg aatggatttc tgtaattata 1200
acgtgccaca cattattgtg tcttaattgc ccttagcctg aattttaatg atcaatttgt 1260
tattgttgca gatgtgaata ttgtgcataa acttactaaa tttatgtaaa attgtataaa 1320
atagaattag aagtcactaa gttctttctg tgtagaagta ataaatttat tgtaacacaa 1380
tgtagttgtg tatatgacat tctgtaatc cttgaactgg atcatatatt cataagttct 1440
gtagatactt atgcatgaac attttctcat ttagttcttg ggttcattat ttgtattgtg 1500
tttactactt gtgatcatgt agttgtgcct tactttgtga gaaagggttag ctgataaagt 1560
actgcaattt ctaaaactcag tgattggaag gttattaatt ataaatgtaa ctgataaagt 1620
acgtgacagc atttaaatct gtataaagaa caatggaagg atccttattg aattgttgct 1680
tttttttaat atgtttaaat attatattaa aaacatttct ttctaaaaaa aaaaaaa 1737

```

<210> 122

<211> 789

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<223> Incyte Clone No: 1618171

<400> 122

```

caagatataa agtagcagtt ggctacctaa aatgaaaaga gcaatgttcc atggcacctg 60
aaatgttaaa aatattagaa actctcccca ccccatattc ctcccacccc aattgagtct 120
ctcgcaataa tcttctcgct tctctaacta gttgactttc attatggatg gggataggct 180
aaaaaacggg cccctgggat ggctgtgctg ccatcagtgc tgttggttta ctactcttt 240
ttctgtcttc gtttttgcat gctactgtc ctgccctctt acagccacag tagaagcgg 300
agaggcccg gagggtatgg ccatattact ctgatagatg tgatccatgt gtctgtgtac 360
tggtttttcg aagctttatc aacatttcaa atattttatt attgcatcac cagaactata 420
acagtgaaga aaggatatgt tgtttctagg catgttaacg aagcagggtt ttcctttgtg 480
tcctatcttt gcattaattt taaataacct tcaccacagc tacagttttt tttctgggct 540
ctactagctt taatgcaacg gcagaagctt aagcaactgg tcatgagagg tcaagtgggt 600
tacttctgta tcccttccat gtacaagaga catccatttg attctcaaga gagccaaata 660
ggtcagcctc ttcagcgatt ctaaaagatt tcaagagcag aggcaggaag taggactggg 720
aatttagttc aattcattat ctgagggtgc cctaaggtag ggcaagttta aatttaactt 780
tgtttctat

```

<210> 123
 <211> 1116
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1625863

<400> 123
 tttatatttg acaataaagt gtttagactcc atttctaaat accagacttc aaaagataag 60
 gttcaaaagt gttataagaa gatattcctt tttttgtcct agagaactta ttttcctgtg 120
 aaaatgccta ccacaaagaa gacattgatg ttcttatcaa gctttttcac cagccttgagg 180
 tccttcattg taatttgctc tattcttgagg acacaagcat ggatcaccag tacaattgct 240
 gtttagagact ctgcttcaaa tgggagcatt ttcacactt acggactttt tcgtggggag 300
 agtagtgaag aattgagtca cggacttgca gaaccaaaga aaaagtttgc agtttttagag 360
 atactgaata attcttccca aaaaactctg cattcgggtga ctatcctgtt cctgggtcctg 420
 agtttgatca cgtcgtctgt gagctctggg tttaccttct acaacagcat cagcaaccct 480
 taccagacat tcctggggcc gacgggggtg tacacctgga acgggctcgg tgcaccttc 540
 gtttttgtga ccatgatact gtttgtggcg aacacgcagt ccaaccaact ctccgaagag 600
 ttgttccaaa tgctttacc ggcaaccacc agtaaaggaa cgacccacag ttacggatac 660
 tcgttctggc tcatactgct cgtcattctt ctaaataatag tcaactgtaac catcatcatt 720
 ttctaccaga aggccagata ccagcggaag caggagcaga gaaagccaat ggaatatgct 780
 ccaagggacg gaattttatt ctgaattctc tttcatctca ttttggcgtt gcatctattg 840
 tacatcagcc ctgagtagta actgggttagc ttctctggac aattcagcat ggtaacgtga 900
 ctgtcatctg tgacagcatt tgtgtttcat gacactgtgt tcttcattga tgctgtactc 960
 ctgaaaattt ttcccacaag gttggggaaa tgaatgggaa atgtcgtctg tctgtgtggt 1020
 attcaaagca gtagtatcat gatgagcgtg acgacccttc tgacctggtc tcacgatctg 1080
 aaataataaa aggctgtgtc atgtttcttt tcaaaa 1116

<210> 124
 <211> 914
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 1638353

<400> 124
 ggccaaccca cgggtgggggg agcgcggcca tggcgctcct gctttcgggtg ctgcgtgtac 60
 tgctggggcg cttcttcgctg ctctgtgggtg tggccaagct ctcgaggag atctcggctc 120
 cagtttcgga gcgatgaat gccctgttgc tgcagtttgc tgaggtgttc ccgctgaagg 180
 tatttggtca ccagccagat ccctgaact accaaatagc tgtgggcttt ctggaactgc 240
 tggctgggtt gctgctggtc atgggcccac cgatgctgca agagatcagt aactgtttct 300
 tgattctgct catgatgggg gctatcttca ccttggcagc tctgaaagag tactaagca 360
 cctgtatccc agccattgtc tgctgggggt tcctgctgct gctgaatgtc ggccagctct 420
 tagcccagac taagaagggtg gtcagaccca ctaggaaaga gactctaagt acattcaagg 480
 aatcctggaa gtagagcatc tctgtctctt tatgccatgc agctgtcaca gcaggaacat 540
 ggtagaacac agagtctatc atcttggtac cagtataata tccagggtca gccagtgttg 600
 aaagagacat tttgtctacc tggcactgct ttctcttttt agctttacta ctcttttgtg 660

```

aggagtacat gttatgcata ttaacattcc tcatgtcata tgaaaaataca aaataagcag 720
aaaagaaatt taaatcaacc aaaattctga tgccccaat aaccactttt aatgccttgg 780
tgtaagtata cctctgaact tttttctgtg cctttaaaca gatataatatt ttttttaaat 840
gaaaaataaaa ccataatatcc tattttattt cctcctttta aaaccttata aactataaca 900
ctgtaaaaaaa aaaa                                     914

```

<210> 125

<211> 2016

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1726843

<400> 125

```

gctgcctgct gcctccgcag cgtcccccca gctctccctg tgctaactgc ctgcaccttg 60
gacagagcgg gtgcgcaaatt cagaaggatt agttgggacc tgccttggcg accccatggc 120
atccccccaga accgtaacta ttgtggccct ctcaagtggc ctgggactct tctttgtttt 180
catggggact atcaagctga cccccaggct cagcaaggat gcctacagtg agatgaaacg 240
tgcttacaag agctatgttc gagccctccc tctgctgaag aaaaatgggga tcaattccat 300
tctcctccga aaaagcattg gtgcccttga agtggcctgt ggcatcgtca tgacccttgt 360
gcctggggcgt cccaaagatg tggccaaactt ctctctactg ttgctgggtg ttgctgtgct 420
cttcttccac cagctggctg gtgatcctct caaacgctac gccatgctc tgggtgttgg 480
aatcctgctc acttgccgcc tgctgattgc tcgcaagccc gaagaccggt cttctgagaa 540
gaagcctttg ccagggaatg ctgaggagca accctcctta tatgagaagg cccctcaggg 600
caaagtgaag gtgtcataga aaagtgaag tgcaaagagt ggaccttcca ggcagttgcg 660
tccatgacac caggaagatg tcagtgtgtg tttttcattt gatttattta tcttggggaa 720
agtgaaaaat gtaatctgca agttaatgac cctattggct tgtgtacatc tatatgctaa 780
aatgacttcc ccacattgac atttgtgcgc cacctttaat cactctgggg caactctcac 840
atcttgctgc atgtacatgt atacggctac tattgaagtg taattgtgag atggactcca 900
acaagcatgt gactgtgaga ttgtgtgtgg gaaaatgtat ttaactactc tgtgtgtgtg 960
tgtgtgtgtg tgtgtgcgcg cgcgcgcacg cgcacacact cagcgcaca caagcagaga 1020
aggcgtgat cttgaactaa tcctgcacag gcatccttcc ctttatagat tgattccagc 1080
aaaggcggaa taaaacaaat ttcctatgaa gagaatcctg atatgaaaca agtcattgtg 1140
tctcatggcc gggaatctct ccacagatac taacaactta aacttactac tttaggagaa 1200
aaaaaaaaac attcaatttc ggacactgag ttatatatga aattaattag gctctagtcc 1260
aacagttgtt tacattttta atagtccata ttgaatttaa ttaaaacaag ggatgcatgc 1320
agtcaaattg atagtttaat tcttcaagtg ataatatgga agtttcacct tgcctttgtc 1380
caagccccac ctattaaaac cctttactca cagtttgaaa ctgaagcagt aaacttgttt 1440
ccagacatct ttttcagatt gtcttaagcc caaagttgcc tcacttccac tattctcagc 1500
agccaaccag gatttggcag ctgctccact gttacggttg agggaaacag gatcagtcct 1560
gttagaagtc tgtgagcctc aaactctacc tgttctctgc aatcatccaa aatttgaaaa 1620
agaagctata tccagtgttt cactgccaaa cagattcact actcttactg attcttcaat 1680
gagctttgct agtataagca gagttccaag tctcccctag ggttgtctct acatttcttt 1740
atcattccag tgggtagggt ttagctgggg gaaggacatt tcataagggg tagttggact 1800
gagcagtatg gacatttgct tttttcatta cgtactgttg tttttccttg ttaggtgtgc 1860
tttggtggtt ttaatattat tgtgccaggg atggggaaat ggggggggtt gtgtgggaag 1920
agtacttatt attgtgtttt cttcagtgtg attgttcttg gtaattgata cctctctggt 1980
ttatttctct cattctttca aaataaaact ttttgt                                     2016

```

<210> 126

<211> 2067

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<223> Incyte Clone No: 1754506

<400> 126

```
tgctccttta agcgtccaca ggcggcggac ggccacaatc acagctccgg gcattggggg 60
aaccgcagcc ggctgcgcgc ggggaatccg tgcgggcgcc ttccgtcccg gtcccatcct 120
cgccgcgctc cagcacctct gaagttttgc agcgcccaga aaggaggcga ggaaggaggg 180
agtgtgtgag aggaggaggc aaaaagctca ccctaaaaaca tttatttcaa ggagaaaaga 240
aaaagggggg gcgcaaaaat ggctggggca attatagaaa acatgagcac caagaagctg 300
tgcatgttg gtgggattct gctcgtgttc caaatcatcg cttttctggt gggaggcttg 360
attgtccag ggcccacaac ggcagtgtcc tacatgtcgg tgaaatgtgt ggatgcccgt 420
aagaaccatc acaagacaaa atgggttcgt ccttggggac ccaatcattg tgacaagatc 480
cgagacattg aagaggcaat tccaaggga attgaagcca atgacatcgt gttttctgtt 540
cacattcccc tccccacat ggagatgagt ccttgggtcc aattcatgct gtttatcctg 600
cagctggaca ttgccttcaa gctaaacaac caaatcagag aaaatgcaga agtctccatg 660
gacgtttccc tggcttaccg tgatgacgcg tttgctgagt ggactgaaat ggcccatgaa 720
agagtaccac ggaaactcaa atgcaccttc acatctccca agactccaga gcatgaggcg 780
cgttactatc aatgtgatgt ccttcctttc atggaaattg ggtctgtggc ccataagttt 840
taccttttaa acatccggct gcctgtgaat gagaagaaga aaatcaatgt gggaattggg 900
gagataaagg atatccggtt ggtggggatc caccaaaatg gaggcttcac caaggtgtgg 960
tttgccatga agaccttctc tacgcccagc atcttcatca ttatggtgtg gtattggagg 1020
aggatcacca tgatgtcccg acccccagtg cttctggaaa aagtcatctt tgcccttggg 1080
atttccatga cttttatcaa tatcccagtg gaatggtttt ccatcgggtt tgactggacc 1140
tggatgctgc tgtttggtga catccgacag ggcaccttct atgcatgct tctgtccttc 1200
tggatcatct aatgtggcga gcacatgatg gatcagcagc agcggaacca catcgagggg 1260
tattggaagc aagtcggacc cattgccgtt ggctccttct gcctcttcat atttgacatg 1320
tgtgagagag gggtaacaact cacgaatccc ttctacagta tctggactac agacattgga 1380
acagagctgg ccattggcct catcatcgtg gctggaatct gcctctgcct ctacttctcg 1440
tttctatgct tcatggtatt tcaggtgttt cggaaacatca gtgggaagca gtccagcctg 1500
ccagctatga gcaaagtccg gcggctacac tatgaggggc taatttttag gttcaagttc 1560
ctcatgctta tcaccttggc ctgcgctgcc atgactgtca tcttcttcat cgttagtcag 1620
gtaacggaag gccattggaa atggggcggc gtcacagtcc aagtgaacag tgcccttttc 1680
acaggcatct atgggatgtg gaatctgtat gtctttgtct tgatgttctt gtatgcacca 1740
tcccataaaa actatggaga agaccagtcc aatggaatgc aactcccatg taaatcgagg 1800
gaagattgtg ctttgtttgt ttcggaactt tatcaagaat tgttcagcgc ttcgaaatat 1860
tccttcatca atgacaacgc agcttctggt atttgagtca acaaggcaac acatgtttat 1920
cagctttgca tttgcagttg tcacagtcac attgattgta cttgtatacg cacacaaata 1980
cactcattta gcctttatct caaaatgtta aatataagga aaaaagcgtc aacaataaat 2040
attctttgag tattgaaaaa aaaaaaa 2067
```

<210> 127

<211> 2180

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<223> Incyte Clone No: 1831378

<400> 127

```
gcgaacgtct gcacctggcg ggcgatgacg cccgatgcgg gcgccccggg atagcgtggg 60
```

```

cgaggctgcg gggccccggc ggcacgccc gcacctctcc ccagccctgg cgtgggcccc 120
gcccgggcca ggcagcaatg gggttcctgc agctgctggt cgtagcgggt ctggcatccg 180
aacaccgggt ggctggtgca gccgaggtct tcgggaattc cagcgaggggt cttattgaat 240
tttctgtggg gaaatttaga tacttcgagc tcaataggcc ctttccagag gaagctattt 300
tgcataatat ttcaagcaat gtgacttttc ttattttcca aatacactca cagtatcaga 360
atacaactgt ttccctttct cgcactctcc ttccaattc ctcggaaca ggactgcca 420
gtggactggt tttcatcctt agaccagagc agagtacatg cacttggtac ttggggactt 480
caggcataca gcctgtccag aatatggcta tcctactctc ctactcagaa agagatcctg 540
tccctggagg ctgtaatttg gagttcgatt tagatattga tcccaacatt tacttgaggt 600
ataatttctt tgaacgact atcaagtttg cccagcaaaa cctaggctat gcgagaggcg 660
tagatccccc accatgtgac gctgggacag accaggactc caggtggagg ttgcagtatg 720
atgtctatca gtattttctg cctgagaatg acctcactga ggagatgttg ctgaagcatc 780
tgcagaggat ggtcagtggt ccccagggtg agggcagtg tctcaagggt gttaccctaa 840
cagctaatag taagacaagt gtttccttct cctccctccc gggacaagggt gtcataata 900
atgtcattgt ttgggacccg tttctaaata catctgctgc ctacattcct gctcacacat 960
acgcttgtag ctttgaggca ggagagggtg gttgtgcttc cctaggaaga gtgtcttcca 1020
aagtgttctt cactcttttt gccctgcttg gtttcttcat ttgtttcttt ggacacagat 1080
tctggaaaac agaattattc ttcataggct ttatcatcat gggattcttc ttttatatac 1140
tgattacaag actgacacct atcaagtatg atgtgaatct gattctgaca gctgtcactg 1200
gaagcgctcg tggaaatgtt ttggtagctg tgtgggtggc atttgaatc ctctcgatct 1260
gcatgctctg tgttgagcta gtgctggggt tcctcatctc gtcagtgaact ttctttactc 1320
cactgggaaa cctaaagatt tttcatgatg atgggtgatt ctgggtcact ttctcttgca 1380
tagctatcct cattccagta gttttcatgg gctgcctaag aatactgaac atactgactt 1440
gtggagtcac tggctcctat tcgggtggtt tagccattga cagtactagg tccacaagcc 1500
tttctacat cactttgaac gtactcaaga gagcgctcaa caaggatttc cacagagctt 1560
tcacaaatgt gccttttcaa actaatgact tcattatcct ggcagtatgg ggcagtctgg 1620
ctgtaagtgg aattacgtta cagattcgaa gagagagagg acgaccgttc tccctcccc 1680
accatacaaa gttatggaag caagagagag agcgccgagt gacaaacatt ctggacccta 1740
gctaccacat tcctccattg agagagaggc tctatggccg attaaccag attaaagggc 1800
tcttcagaa ggagcagcca gctggagaga gaacgccttt gcttctgtag atgccagggt 1860
gcttggtcag tgtgcctcag ctttgaggtt catgcctgga gtggttcaac agtctctggt 1920
gcaagtctaa taagagatca ggcataatata tctgttcttt gcataatatt atgggtgccct 1980
tattgatata tggtaaaggt gtactagggg attaggatga ttgtaagaga atgagaagaa 2040
tgacaaaaag gttgggtgta gggaggtctt ttcttatttc caaatacttg agaaattacc 2100
ttttggttta caaatctatg atcaacttat tccattaaat agatacatca aaaaaattaa 2160
aaactgaaaa aaaaaaaaaa

```

<210> 128

<211> 991

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1864943

<400> 128

```

cacgggtgtca gcaggcaaca tggccgagag gcggggcctc cgggcggcgc cgtgtccgcg 60
accggtgacc ctgacacccc cgcggaattc cctccgcacc tccaggcggg tgcgatgagg 120
cgccgctttt gggcggtatt caactgtctg tgcgcggcgc cgttcggggc cctggccgcc 180
gcctccgcca agctggcctt cggcagcgag gtgagcatgg gtttatgctt cttaggcatt 240
attgtgatgg cgagcaccaa ttctctgatg tggaccttct ttagccgggg cctcagtttc 300
tccatgtctt cagccattgc atctgtcaca gtgacttttt caaatatcct cagctcggcc 360
ttcctgggct atgtgctgta tggagagtgc caggaggtct tgtgggtggg aggagtggtt 420
cttattctct gcggactcac cctaattcac aggaagctcc caccacactg gaagccctt 480

```

```

ccacacaagc agcagtagca ccacttggt agacggacca gctggaaaga tcatgatggt 540
ggccccagcct tgggatgtca tgtgggactg tgtcctaggg cgatccagtt gtgcagcctt 600
ctgaccatca gccaaaggaa gcaggcctct gatggagcag gctctggctc tgtaaggaga 660
ggtgcagctg cagcagtggt ctaccggaag tgttttgatc atctgtacag tgctttggat 720
tcttcctccc aggcctacc cagtgaagcct tcgcagatgc tggagatcct ggggttggtc 780
tgctttgtgt atggtacttg aaaccacgct gtaattattg tcctgttgcc aaacaaaagc 840
cagtcagtga actctagaag cagtgaactg tggggcttcc tgacagttcc atgctgatgt 900
atcaggccat ctgtgtcatg cttatgtatt atggcaagaa gaggaaaact ggattaataa 960
atacgttttt ttgtaagtta aaaaaaaaaa a 991

```

<210> 129

<211> 637

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1911316

<400> 129

```

ggagggcggt gctccgcgcg ggtggcggtt gctatcgctt cgcagaacct actcaggcag 60
ccagctgaga agagttgagg gaaagtgtcg ctgctgggtc tgcagacgcg atggataacg 120
tgcagccgaa aataaaacat cgcccttctt gcttcagtggt gaaaggccac gtgaagatgc 180
tgccgctggc actaactgtg acatctatga ccttttttat catcgacaaa gcccctgaac 240
catatattgt tatcactgga tttgaagtca ccgttatctt atttttcata cttttatatg 300
tactcagact tgatcgatta atgaagtggg tattttggcc tttgcttgat attatcaact 360
cactggtaac aacagtattc atgctcatcg tatctgtgtt ggcactgata ccagaaacca 420
caacattgac agttgggtga ggggtgtttg cacttggtac agcagtatgc tgtcttgccg 480
acggggccct tatttaccgg aagcttctgt tcaatcccag cggctccttac cagaaaaagc 540
ctgtgcatga aaaaaaagaa gttttgtaat tttatattac tttttagttt gataactaagt 600
attaacata tttctgtatt cttccaaaaa aaaaaaa 637

```

<210> 130

<211> 2631

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 1943120

<400> 130

```

ctctcttctt gcagtgtggt aaaactacag caatcgtctt aacctgtgag atctgtcacc 60
tttgcatttt ccactcatgc agctggttct ataaaccaac tcttctgctt ggggggatct 120
aatcatgacc ttttaccctt ttgtggcctc ttctagtaca aggcgagtggt ataattccaa 180
cacaagactg gcagtccaaa ttgaaagaga tccagggaat gatgacaaca atctcaattc 240
cattttttat gaacacttga caaggaccct cctggagtcc ctctgtggag acttagttct 300
tggacgtttg ggcaactaca gctctggcga ttgctttatt ttggcttcag atgacctcaa 360
tgcctttgtt cacctgattg aaattggaaa tggctctgtc acctttcaac ttcgaggact 420
ggaattccga ggaacctact gccagcagag ggaggtagaa gccatcatgg agggcgacga 480
ggaggacaga ggctgctgct gctgcaaacc aggccacttg cctcacctgc tgtcccgcga 540

```

```

cgctgccttt cacctccgct ggctcacctg ggaaatcacg cagacccagt acatcctgga 600
gggctacagc atcctggaca acaacgcggc caccatgctg cagggtgtttg acctccgaag 660
gatcctcatc cgctactaca tcaagagtat aatatactat atggtaacgt ctcccaaact 720
cctctccttg atcaaaaatg aatcacttct gaagtccttg cagccctttg ccaagtggca 780
ttacattgag cgtgaccttg caatgttcaa cattaacatt gatgatgact acgtcccgtg 840
tctccagggg atcacacgag ctagtctctg caatgtttat ctagaatgga ttcaacactg 900
tgcacggaaa agacaagagc cttcaacgac cctggacagt gacgaggact ctcccttgg 960
gactctgtcc ttgccctgt gcaccctggg gaggagagct ctgggaacag ccgtcacaa 1020
tatggccatc agcctggatt ctttctgtga tggcctccat gtcctcttca aaggtgactt 1080
cagaataaca gcacgtgacg agtgggtatt tgcctgacatg gacctactgc ataaagtgtt 1140
agctccagct atcaggatgt cctgaaact tcaccaggac cagttcactt gccctgacga 1200
gtatgaagac ccagcagtcc tctacgaggc catccagtcc ttcgagaaga aggtggtcat 1260
ctgccacgag ggcgacccgg cctggcgggg cgcagtgtctg tccaacaagg aagagctgct 1320
caccctgcgg cagtggttg acgaggtgac cgacgagtac aaggtcatca tgctccacag 1380
aagcttcctg agcttcaagg tgatcaaggt taacaaagaa tgcgtccgag gactttgggc 1440
ogggcagcag caggagctta tatttcttgc caaccgcaat ccggagcgcg gcagtatcca 1500
gaacaataag caggtcctgc ggaacttgat taactcctcc tgcgatcagc ccctggggt 1560
ccccatgtat gtctccccac taaccacatc ctacctaggg acacacaggc agctgaagaa 1620
catctggggt ggacccatca ctttgacagc aattaggacc tggttcttga ccaagtgggt 1680
aaggatgcgg aaggattgca atgcccgcga gcacagtggc ggcaacattg aagacgtgga 1740
cggaggaggg gccccgacga caggtggcaa caatgcccga aatggtggca gccaggagag 1800
cagcgcagaa cagcccagaa aaggcgggtgc tcagcacggg gtgtcatcct gtgaaggag 1860
acagagaaca ggcaggagga aaggcaggag ccagtccgtg caggcacact cagcgctaag 1920
ccaaaggccg cccatgctga gctcatctgg ccccatctta gagagccgcc aaacattcct 1980
ccagacgtcc acctcagtgc acgagctggc ccagaggctc tcgggcagcc ggctctcctt 2040
gcacgcctcg gccacgtccc tgcactctca gccccgcgcc gtaccacca ccggccacct 2100
gagtgtccgt gagcggggccg aggcgctcat caggtccagc ctgggctcct ccaccagctc 2160
caccctgagc ttctcttctg gcaagaggag cttttccagc gcgtcgtca tttccggact 2220
ctctgtgctg gaggggggca ataccagtga caccagtca tccagcagcg tcaacatcgt 2280
gatgggcccc tcagccaggg ctgccagcca ggccactcgg gtaaggggct gggcagggct 2340
caccaggaca ggctgggatg gtggcacggg ctcttgccct gagcgtggca cctgccttgc 2400
gttccacccc ttctgcctgc agaaccctat ccccttctct atggggctcc cagagtga 2460
aaggacagtg attagacacg aagtggctta gctgctcttg aaagcagaca agatacagag 2520
cagatatcct gtaaacgata atgcccagcg aggcactgaa aggagtcacc ggatacagag 2580
gttctgcaga actgtggcca tctgccctac accggggcat gacggagaat g 2631

```

<210> 131

<211> 646

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2314236

<400> 131

```

tacatttact aaaatgatgt aataaataac atgttaatag actcaagctt taccttatga 60
aattgatgta tttttaccag ttattttctaa tgtaacattg aatatataag atctgacaaa 120
tgtatgttta aacatgaatt agaagagtgt agaactacca ttatgtatag ggattctcat 180
agtgtcttgg ccttaattg gaaagtgtgt gcaactttaa agtacttttt actgtatggt 240
ataattcttt ataacttaga gagagacaat ggtcactcaa actatgagaa ctatgaatta 300
ggagataaaa gtttaaattt gttgttgttt tataacagta tgtacaagtt agttttccct 360
tatatattta cgttttcaag ttttttaatc tcatcatata catccatact ctataaaatg 420
ttttatattc aaagaactgt aaaatcctaa acattagttt tcactattga aattgttttt 480
taaagatagg cataaatagt tgccttaga cttattcata caaatatagt catttacttc 540

```

tatgtagttt gagattctga gagttattcc aactttatga agattgattt caatgtgcct 600
gctaagtcct aaaagattca gaaagaaaat ttatatatta ttgatt 646

<210> 132
<211> 541
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone No: 2479409

<400> 132
ttcacatttt ttggtttgat cttggtgtca tttaggtaat gaatctatcc aagaaatcta 60
tcctttttgac ccagggttacc aaatttttag acataagggtt atttataatg gtcccttctt 120
acccttttaa tgtcttttagg agctgtgttg ataatttcct tttcattatg atactggtaa 180
tttctgttct cactttccta atcagggttg gtaggggttt atcagtttta ctgatctgac 240
tttttatttt attttatttt ttttgagaca gtcttacct gtctcccagg ctggagtga 300
gtggcgcat ctggcttac tgcaagctct gcttccggg ttcattgcat tctctgcct 360
cagcctcccc agtagctggg actacaggct ccacacacac gcccggttaa ttttttaaat 420
tcttagtgga gactgggggt caccggggta accaagaatg gctcggtatct ctttaacccc 480
ggggtccacc cgctcagcc tcccaaaaagt gctggggatt acaggggtga gcaccgggccc 540
c 541

<210> 133
<211> 1922
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone No: 2683149

<400> 133
tggcctccga tccacctgga cacctggagg ctaagcctgg attccccctt ccctgactca 60
ggaactgctt aacgtctaca gcaaggccta ataggggacc tgagggcaca gtccctcagga 120
tgttttcgggg agaataaggag ccagaacctg agcccccctt ccattccccct caccaatgat 180
gggggtcccca gtgagtcac tgctggccgg cttctgtgtg tgggtcgtct tgggctgggt 240
aggggggtca gtccccaacc tgggcccctg tgagcaggag cagaaccatt acctggccca 300
gctgtttggc ctgtacggcg agaattggag gctgactgca gggggcttgg cgcggttct 360
ccacagcctg gggctaggcc gatttcaggg gcttcgcctg ggacagcatg ggctctgac 420
tggacgggct gcatccccag ctgcagacaa ttccacacac aggccacaga accctgagct 480
gagtgtggat gtctgggcag ggatgcctct ggggtccctca ggggtgggtg acctggaaga 540
gtcaaaggcc cctcacctac cccgtgggccc agcccccctg ggcctggacc tgcttcacag 600
gcttctgttg ctggaccact cattggctga ccacctgaat gaggattgtc tgaacggctc 660
ccagctgctg gtcaattttg gcttgagccc cgctgctcct ctgaccctc gtcagtgttc 720
tctgctgtgc ccagccctgc ttatcagat cgacagccgc gtctgcatcg gcgctccggc 780
ccctgcaccc ccaggggac tactatctgc cctgcttcag agtgccctgg cagtcctgtt 840
gctcagcctc ccttctcccc tatccctgct gctgctgcgg ctctggggac ctgctctact 900
acggcccttg ctgggcttcc tgggggccc ggcgggtggc actctttgtg gggatgcact 960
gctacatctg ctaccgcatg cacaagaagg gcggcacgca ggacctggcg gactaccaga 1020
gaaggacctg gggccggggc tgtcagtgct cggaggcctc ttctgctct ttgtgctgga 1080
gaacatgctg gggcttttgc ggcaccgagg gctcaggcca agatgctgca ggcgaaaacg 1140


```

aaggaatctc gaaacacgca acttgatcc ggagaatggc agtgggatgg cccttcagcc 1200
cctacaggca gctccagagc caggggctca gggccagagg gagaagaaca gccagcacc 1260
accagctctg gccctcctg ggcaccaagg ccacagtcag gggcaccagg gtggcactga 1320
tatcacgtgg atgggtcctc tgggagatgg tctacacaac ctccactgat ggctggccat 1380
aggtgctgcc ttctctgatg gcttctccag cggcctcagt accaccttag cggctcttctg 1440
ccatgagctg cccacgaac tgggtgactt tgccatgctg ctccagtcag ggctgtcctt 1500
tcggcggctg ctgctgctga gcctcgtgctc tggagccctg ggattggggg gtgcagtcct 1560
ggggggtggg ctccagcctg gccctgtccc cctcactccc tgggtgtttg gggcactgc 1620
tggggtcttc ctctatgtgg ccctgtgga catgctacca gccctgcttc gtctccgga 1680
gccctgcct acgccccatg tgctcctgca ggggctgggg ctgctgctgg gggcgggcct 1740
catgcttgcc ataaccctgc tggaggagcg gctactgccc gtgaccactg agggctgatg 1800
gggccagtgg aaaggggtcg ggttgccctt ccttcccccc aaccacagga atggaggcgg 1860
gacacagggc cagtaggagc aataggattt taataaacag aacctatccc aaaaaaaaaa 1920
aa

```

<210> 134

<211> 840

<212> DNA

<213> Homo sapiens

<220>

<221>

<222> 814

<223> a or g or c or t, unknown, or other

<220>

<221> misc_feature

<223> Incyte Clone No: 2774051

<400> 134

```

ggtaattcgt actggtcatc ttctctgggt gtgagtcaaa tataagttaa acaattagct 60
ctgaaaaacat tccattgagc tggggaatgc aacagtctta ttacctcatc atggaattct 120
ctagcttagt taatttaaat attgtttctt agtttctggg tcaattaaat ttaaatgatg 180
tagtttatgc ttcgtgacca attaaattac taggttatta caaaaaaat tatcatcttt 240
tttgattaaa gagctgtggg tacagtatat ttataagca attttcatta gttcaaaaat 300
gttcctttag gctagattaa gcagccattc attgttagag cctggagacc ttattcgaag 360
gtgttcacg tattcacagt gactattac ttagaactaa agccaattga acctacttag 420
caatagcgtt atgcctttca cccttgatga ttatggagct tatagctctc agaaacaata 480
cacctgtcag ttccatcaa ctatagcaat ccatgcagaa gacaagaggc cccctcaaag 540
caggaggggt attgttttag gtccaatttt tcttattgtt ctcaaaatca ttataagggtg 600
gacagtgttt tgtgaagatt ttcttttccc cagctctaag aaacctatgt gaaagaattc 660
attgataact gttttgattt tttctttttt ttaagtacag gttttgctaa gtaatcacc 720
ttagtgagcc tgtgtagtgc agctgcctgt gagatgtttg gtgaccagct cagtgggtatc 780
ttgtattcct gatagagaat atttcagggg acanagtgtc ctttcagaca gactcaaata 840

```

<210> 135

<211> 1344

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2869038

```

<400> 135
gcaaattgat ctaaaagcca ctaataaatt ctaggggttg agtctagaag ccaagcaaac 60
gtcaccaat gtcagttgta aattagaatg caacatgagg cttcagactc atgacaatga 120
tatacatgaa aacaaaaata taattgtgtc taccttccta ctttcccttt tgacatatgt 180
agttggaatt ttacatagtc ttaaaatcca tatttagaat cttacctgtt tctataataa 240
ttagtaaaat gccaaagtag tgatagaata ttgtggcatt gaagtagccg aaaaattgtt 300
agttttagca tcaaaaaagt aaatagatgt tgaaatgaat ttttgtatgt gccagggtga 360
agagagtgtg ccagtgcacg gaagtagtct aaaaaattaa cagttatggg tttaatagga 420
tctgaaagac aatcctttaa gaaatgggag aaattggggg tatcagtga cctataccaa 480
cctctctttg tacataaata tgggtgatgt gctagatata aaaatcagtg tcttactggc 540
accatttaca gtttagaaaa caatcttttt cttaaaaatg cccatctgat ttctattttt 600
aggagctact tggatttgta tgtatttttt ctacgtgaaa atatatgtac tcttcacttt 660
tgttcocagta ctataattgc tcatgcactc tttctcccct ttgagaacat tcagtgaat 720
acaacttcat caaagatttg ctcaaaggag aagaatcgca tgagtgtgaa aagtagatgc 780
tcgtagccag aacagaaaag gttacacatg atcatggcac agaagatagg aggtttgact 840
tgggtgggcca taatgtttat tatccttttt gaaataacag ggaccagcag cagttttctc 900
aggataaatg ctctacccca cttctctatg aacagggtgtg gggaggctta ctttccattt 960
tcatatattat acacctctct acaaaagcaa tttttaatga aggttagtgg aattgttaaa 1020
aatctgagag gaatgatgac tggagggtgt tgggggtttt ttctgtattc attttttaat 1080
gagaaaagtt ttaaatgtag tacagggttag acccaactac taccttacta ttataggacg 1140
attctatgtt tctgttaaag tattcaagta gctttctctg ggggaaaaag taccacttgg 1200
acacttaaag gaattgggat ttttgtctac tttggataag gcagttgact tcttaagtaa 1260
aagcaatagt gtaaaatgtc atttgttttg gaatgttaag tgagcaaata aaaaacatgt 1320
tgaaattggt gtaaaaaaaa aaaa 1344

```

```

<210> 136
<211> 443
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 2918334

```

```

<400> 136
ctcgagattt tttatattta tgcatgccat ttagtttgct cctaaaaata gtgatactgg 60
tttttagttt ttacttacta aatcagtata gccaaatgtc catcttccta gtggtaatat 120
gcatcagaa tttctgagat tatttatgtg actatttttg gaaaagtttc ttttgataaa 180
acatggattt atttatatgaa attcttcttg cactgtatta caatatatgc tatgatatcc 240
cttttatttt tttcaactta aatatgatgt tttatattgt tttagactta cgaatcgtgt 300
ttttcagaac cataaggga tctctatctc ctccctcact ttccttttac atatattgaa 360
aagtctatga aattcaagtc tagcatttga attctctatg ctatcattgc atttacctaa 420
ttatttactt ttaaatttta ggg 443

```

```

<210> 137
<211> 467
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 2949916

```

```

<400> 137
gccatttaag gagatctgtt ttgcttgaat attctgactg tcagtcgca gacatagga 60
gtgtgtgagt gtgagtgtgt accaagatga ggaggataat caggctccgg ctccgttttt 120
ctgacacttt tatggctgcc tttcttctgt gcctgggctt cgttctcatg ctctttccct 180
cgttgttgcg ggatgggtggc agcatcagca gctgcagaaa ctcttgttca tctcctagct 240
ccgaggagcg tcatttctcc aacttggaat aaaagcccat cctctacctg attggggcac 300
tcagatcaag ggcttaacac tagcaacagt tgctaaggca ctgctagata ccgattagct 360
gaagcctggg tgtctgaacc aatcattgcc aagggggcgg gacttgcccc atccctggaa 420
ctatgaatgt ctcagccctt tgagatcacc tgggcgtgga agaaagt 467

```

```

<210> 138
<211> 902
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 2989375

```

```

<400> 138
cactgcactc cagtctaggt gacagagaag gactcgtctc aaaaaataaa aataaataaa 60
aaggaagcaa ggctaatacat cagtatgtgc ttgttacaag agctatgatg aaggcactcc 120
ttcgagttta accaaatgag atcatctctg tcatgtgcct cacgcctcac agggactcca 180
tgtgtgaaga ttcccccttc actcaccaga tcatctccat ggcaacagct tgcagcctgc 240
tcttggagtg ctttgttttg gcagcttctc tgctagtttg tgtatggagt gaatggagga 300
ggtaaatacca cagattaaga atatgctgtc aggagtcagg cagccaaggt cagaagccag 360
ctctgcttct cagtgtcttc tctttacaac acaggacttt gcaaggaaca tataattctg 420
tgactagcgc catttggaaa atgttgaaac tgaagtagag atgagagatc ttacgtctgc 480
ctaccagtg agatacgagg aaggtcaagg gaaaaaaaat tccaagctct tctttatctg 540
ctataggaaa tgaacattca attttttgca tgcaacgaca agaggtcaag gaccccagaa 600
gccagcccg tacttccaag ttgagagccc ctgggtcatac cctccagttg agctcagatt 660
tgtcacaaat ttaccctctc cctttccttc cattcccat gacctgcaga gagagatgtc 720
agataccttc ctcttggcct ccatgggca tccataagaa acttacttga agcaagaagc 780
ccagtatagg tgtctgggca gttggacatt tcctctagcc agatctgtcc gaatagagcc 840
atctgggtac atgacgcaga gggcatttga taaataactg gaaaagtcaa taaatctttg 900
tc 902

```

```

<210> 139
<211> 1332
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte Clone No: 3316764

```

```

<400> 139
cgcagatgtg ccttctctgt tgggtgagat gctgaccta cagcactccc gctgtgcctc 60
agcagtgagc tgggtgtaaa ggcaggaggc ttgctggggt ctgacacttc cctgcctcc 120
tccaggaggg acacatctgg gcctctatga ggaggacagc tttcatctg ggctctggac 180
ttctctcatt tgtggccttc tggaaactcag tgacatggca tcttcagaga ttttggggtg 240
cttctggcta cttttggcaa gccagtgagg agaggctgct gactacattt gaagggaggg 300
agtggatcct cttctttata ggtgccatcc aagtgccttg tctctcttc tggagcttca 360

```

```

atgggcttct attggtggtt gacacaacag gaaaaccta cttcatctct cgctaccgaa 420
ttcaggtcgg caagaatgaa cctgtggatc ctgtgaaact gcgccagtct atccgcacag 480
ttcttttcaa ccagtgcatg atatctttcc ccatggtggt cttcctctat cccttcctca 540
aatggtggag agacccctgc cgccgtgagc taccacactt ccactggttc ctccctggagc 600
tggccatctt cacgctgac gaggaagtct tgttctacta ttcacaccgg ctccctcacc 660
acccaacatt ctacaagaaa atccacaaga aacaccatga gtggacagct ccatttggcg 720
tgatctctct ctatgccac cctatagagc atgcagtctc caacatgcta ccggtgatag 780
tgggcccatt agtaatgggc tcccacttgt cctccatcac catgtggttt tccttgccc 840
tccatcatcac caccatctcc cactgtggt accaccttcc cttcctgcct tcgctgaat 900
tccacgacta ccaccatctc aagttcaacc agtgctatgg ggtgctgggt gtgctggacc 960
acctccatgg gactgacacc atgttcaagc agaccaaggc ctacgagaga catgtcctcc 1020
tgctgggctt cccccgctc tctgagagca tcccagactc cccaaagagg atggagttag 1080
agacagccta agtgctcatc tgggtgtccc tcagccatgg gatgcagaca cggcttccg 1140
attgcaccta acaatttgc tcttcggcc acacgcccta atgatggcac caccagggt 1200
gaggaaggt cggttcccg gaaaagcagg gccaaaggat aggttttctt caaactactg 1260
cccttgatgt ccctcaatgg gatcaggagt tagcttaaaa aaaaaaaaaa acaactgcgg 1320
ccgcaagctt at 1332

```

<210> 140

<211> 1252

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3359559

<400> 140

```

gtgaggaagg tagctttagt gaaaacaggg tttggagttg aacctatacg ggttcaaatt 60
cgacttccgt ccaccaccga gacctgcgct ccttgaggga ctgccttcc catccgcgaa 120
accaggacgg cgccgcctac accccgcggc gttcggggcg ggctgaatgg gtcgctgagt 180
aggggctaca cccacgccct tcgctccccg cccccggcac ggagcgacgg ccacggcagt 240
gtccccaaagg caccgaaacc gaggcggggg tctcggtccc tccgcgcaag gagggaggcg 300
gaccgtacgt ggcaggactc accgccccgc acgtggcagg actcaccgcc ccgcgcgctg 360
ttctccgagc catggcgcca gcgctgtggc gggcctgcaa cggactcatg gccgcctct 420
tcgcgctggc ggccttggtg caggtaaata acccagatgc agaggtgtgg gtggtggtgt 480
acacaatccc tgcaagtact accctgcttg ttggacttaa cctgaagtc acaggtaatg 540
ttatttggaa aagtatctct gcaatacaca tactcttttg tacggtgtgg gctgttggct 600
tggcgctcta cctcttgcac cgtacacaac agaacatctt acatgaggaa gaaggcagg 660
agctgtctgg tctggtgatt attacagcat ggattatcct gtgccacagt tcctcaaaga 720
atccagttgg tggagaatt caattggcta ttgccattgt aatcacactt ttccattta 780
tctcatgggt ctacatatat attaacaagg aaatgcggtc ctcttggcca actcactgca 840
agacagtaat ttaataaat tcaagaactt cgtttttaa atgaatattt tcaatcaatt 900
ttttataaac attaggggaa caagccagga gtttatttca ggtaatttgg gctaatagtt 960
ttaaactcc aaataacttt ttaagggtgc atataattcg atgtaagatt ggatgggaca 1020
agtaagagat ggtctgatat tttccagacg actttctgca gggctctgtg tcataatgta 1080
gtggaaaagg ctagagaata gaagttttaa aatacgagtt ctaacttaac tttgtaacta 1140
tgtaatttgg gcaatatat aaacctcctg gtggatatat atctataaaa taggattaat 1200
gccagagtgt acttacttac acagtaacaa ggtcaatct agataatgta tg 1252

```

<210> 141

<211> 721

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 4289208

<400> 141

```

ggagactgca ttccctgccc tgaaggaatg tatttctaag gcaaataggc aacttggtac 60
tatcttattc tgagtagaga gtggagaaag tattttcaga ctgaagaaaa ctttgaaaag 120
tcaggagcta agctgctcgg agctcagtgc cgcagcatgg ctgtggtgga cgcgggaaac 180
aacgggaaag ttcttgacag agtctgtgtc cgtcagtcct ctgcactttt cctttccaaa 240
tgcatctcgt tggatatgga atagatcgta gatgtttag actgagattt gggactatgt 300
tgggaccgta caggtgaatg tgccacctcc acaaatggct tctccgagtg agtcacgtca 360
cctgggtgct ggaggtggag ctgctggctgg agtaaggctt gctgtgggac gccctcgtac 420
tttgcctccc ttgctgggtg ttgctgacct gagagcattg ggatcctccc ccgactgggtg 480
gctaagtgtt tctgtctccg ggttggtctg ggaaaggggg gttgtgggtt cgggaaaaaa 540
aggttccggg gaaattcctc ctggcaaaat tccggttggt tcacattggg aacctgggta 600
acctaaattt gggtaaaagg ggtccctaata attcgcctt gggaaattcg tgggggggtt 660
ccccaaggaa cccctcggga gtcccagggg ggagaaattt gaagagcccc ttctgaaatg 720
g 721

```

<210> 142

<211> 1704

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2454013

<400> 142

```

cgcttcgcgc taacgcttgc gatgggtgaa ttcccctcct caccgccagcc taggagaaga 60
agttcgtagt cccagagggtg aggcaggagg cggcagtttc tggcgggtga gggcggagct 120
gaagtgcacg cggaggcgga agcaacggtc ggtggggcgg agaagggggc tggccccagg 180
aggaggagga aacccttccg agaaaaacagc aacaagctga gctgctgtga cagaggggaa 240
aaagatggcg gcgccgaagg ggagcctctg ggtgaggacc caactggggc tcccgcgcgt 300
gctgctgctg accatggcct tggccggagg ttccgggacc gcttcggctg aagcatttga 360
ctcgggtctt ggtgatacgg cgtcttgcca ccgggcctgt cagttgacct accccttgca 420
cacctaccct aaggaagagg agttgtacgc atgtcagaga gggtgcagga tgttttcaat 480
ttgtcagttt gtggatgatg gaattgactt aaatcgaaat aaattggaat gtgaatctgc 540
atgtacagaa gcatattccc aatctgatga gcaatatgct tgccatcttg gttgccagaa 600
tcagctgcca ttcgctgaac tgagacaaga acaacttatg tccctgatgc caaaaatgca 660
cctactcttt cctctaactc tgggtgaggtc attctggagt gacatgatgg actccgcaca 720
gagcttcata acctcttcat ggacttttta tcttcaagcc gatgacggaa aaatagttat 780
attccagttc aagccagaaa tccagtacgc accacatttg gagcaggagc ctacaaattt 840
gagagaatca tctctaagca aaatgtccta tctgcaaatg agaaattcac aagcgcacag 900
gaattttctt gaagatggag aaagtgatgg ctttttaaga tgcctctctc ttaactcttg 960
gtggatttta actacaactc ttgtcctctc ggtgatggta ttgctttgga ttgtttgtgc 1020
aactgttgct acagctgtgg agcagtatgt tccctctgag aagctgagta tctatggtga 1080
cttgaggttt atgaatgaac aaaagctaaa cagatatcca gcttctctc ttgtggttgt 1140
tagatctaaa actgaagatc atgaagaagc agggcctcta cctacaaaag tgaatcttgc 1200
tcattctgaa atttaagcat ttttctttta aaagacaagt gtaatagaca tctaaaattc 1260
cactcctcat agagctttta aaatggtttc attggatata ggccttaaga aatcactata 1320
aaatgcaaat aaagtactc aaatctgtga agactgtatt tgctataact ttattggtat 1380

```

```

tgtttttgta gtaatttaag aggtggatgt ttgggattgt attattatatt tactaatatc 1440
tgtagctatt ttgttttttg ctttggttat tgtttttttc ccttttctta gctatgagct 1500
gatcattgct ccttctcacc tccctgccatg atactgtcag ttaccttagt taacaagctg 1560
aatatttagt agaaatgatg cttctgctca ggaatggccc acaaactctgt aatttgaaat 1620
ttagcaggaa atgaccttta atgacactac attttcagga actgaaatca ttaaaatttt 1680
atttgaataa ttaaaaaaaaa aaaa 1704

```

<210> 143

<211> 964

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<223> Incyte Clone No: 2454048

<400> 143

```

cagacagcgg cgggcgagg acgtgcacta tggctcgggg ctgctgcgc cggttgctgc 60
ggctcctcgt gctggggctc tggctggcgt tgctgcgcgc cgtggccggg gagcaagcgc 120
caggcaccgc cccctgctcc cgcggcagct cctggagcgc ggacctggac aagtgcattg 180
actgcgcgtc ttgcaggggc cgaccgcaca gcgacttctg cctgggctgc gctgcagcac 240
ctcctgcccc cttccggctg ctttggccca tccttggggg cgtctgagc ctgaccttcg 300
tgctggggct gctttctggc tttttggtct ggagacgatg ccgcaggaga gagaagttca 360
ccaccccat agaggagacc ggcgagagg gctgcccagc tgtggcgctg atccagtgc 420
aatgtgcccc ctgccagcgc gggctcgcgc actcatcatt cattcatcca ttctagagcc 480
agtctctgcc tccagagcgc ggcgggagcc aagctcctcc aaccacaagg ggggtggggg 540
gcggtgaatc acctctgagg cctggggccca ggggttcaggg gaaccttcca aggtgtctgg 600
ttgcctgccc tctggctcca gaacagaaaag ggagcctcac gctggctcac aaaaaacagc 660
tgacactgac taaggaaactg cagcatttgc acaggggagg ggggtgcctt cttcctaga 720
ggccctgggg gccaggctga cttggggggc agacttgaca ctaggcccca ctactcaga 780
tgtcctgaaa ttccaccacg ggggtcacc cgggggggta gggacctatt ttaacacta 840
gggggctggc ccactaggag ggctggcctt aagatacaga ccccccaac tccccaaagc 900
ggggaggaga tatttatattt ggggagagtt tggaggggag ggagaattta ttaataaaag 960
aatc 964

```

<210> 144

<211> 1564

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2479282

<400> 144

```

ggaattgttg gaggttgtgc tgccactcgg ctgccggagg ccgaaggtcc ctgactatgg 60
ctccccagag cctgccttca tctaggatgg ctctctctgg catgctgctt gggctgctga 120
tgcccgcttg cttcaccttc tgccctcagtc atcagaacct gaaggagttt gccctgacca 180
accagagaaa gaggcagacc aaagaaacag agagaaaaga aaccaaagcc gaggaggagc 240
tggtgcccga agtcctggag gtgttccacc cgacgcata gtggcaggcc cttcagccag 300
ggcaggctgt cctgcaggga tccacgtac ggctgaatct tcagactggg gaaagagagg 360
caaaactcca atatgaggac aagttccgaa ataatttgaa aggcataaag ctggatatca 420
acaccaacac ctacacatct caggatctca agagtgcact ggcaaaattc aaggaggggg 480

```

```

cagagatgga gagttcaaag gaagacaagg caaggcaggc tgaggtaaag cggctcttcc 540
gccccattga ggaactgaag aaagactttg atgagctgaa tgttgtcatt gagactgaca 600
tgacagatcat ggtacggctg atcaacaagt tcaatagttc cagctccagt ttggaagaga 660
agattgctgc gctctttgat cttgaatatt atgtccatca gatggacaat gcgcaggacc 720
tgcttttctt tgggtggtctt caagtgggtga tcaatgggct gaacagcaca gagccccctc 780
tgaaggagta tgctgcgttt gtgctgggctg ctgccttttc cagcaacccc aaggctccagg 840
tggaggccat cgaaggggga gccctgcaga agctgctggt catcctggcc acggagcagc 900
cgctcactgc aaagaagaag gtcctgtttg cactgtgctc cctgctgcgc cacttcccc 960
atgcccagcg gcagttcctg aagctcgggg ggctgcagg cctgaggacc ctggtgcagg 1020
agaagggcac ggagtgctc gccgtgcgcg tggtcacact gctctacgac ctggtcacgg 1080
agaagatggt cgccgaggag gaggtgagc tgaccaggga gatgtcccca gagaagctgc 1140
agcagtatcg ccaggtacac ctctgccag gcctgtggga acagggtctg tgcgagatca 1200
cggcccacct cctggcgctg cccgagcatg atgccgtga gaaggtgctg cagacactgg 1260
gcgtcctcct gaccacctgc cgggaccgct accgtcagga cccccagctc ggccaggcac 1320
tggccagcct gcaggctgag taccaggtgc tggccagcct ggagctgcag gatggtgagg 1380
acgagggcta cttccaggag ctgctgggct ctgtcaacag cttgctgaag gagctgagat 1440
gaggccccac accaggactg gactgggatg ccgctagtga ggctgagggg tgccagctg 1500
ggtgggcttc tcaggcagga ggacatcttg gcagtgtggt cttggccatt aaatggaac 1560
ctgg 1564

```

<210> 145

<211> 1385

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2483432

<400> 145

```

gtccgcccgc cgctgcgtcc cggagtgcaa gtgagcttct cggctgcccc gcgggcccgg 60
gtgcccaggcc gacatgcgcc cgcttctcgg cctccttctg gtcttcgccg gctgcacctt 120
cgccttgtag ttgctgtcga cgcgactgcc ccgcggcgag agactgggct ccaccaggga 180
ggctggaggc aggtcgctgt ggttccccctc cgacttgcca gagctgcggg agctctctga 240
ggtccttcga gagtaccgga aggagcacca ggcctacgtg ttcctgctct tctgcggcgc 300
ctacctctac aaacagggtt ttgccatccc cggctccagc ttcctgaatg ttttagctgg 360
tgcccttggtt gggccatggc tggggcttct gctgtgctgt gtgttgacct cgggtgggtgc 420
cacatgctgc tacctgctct ccagtatttt tggcaaacag ttggtggtgt cctactttcc 480
tgataaagtg gccctgctgc agagaaaggt ggaggagaac agaaacagct tgtttttttt 540
cttattgttt ttgagacttt tccccatgac accaaactgg ttcttgaaac tctcgccccc 600
aattctgaac attcccatcg tgcagttctt cttctcagtt cttatcgggt tgatcccata 660
taatttcacg tgtgtgcaga cagggtccat cctgtcaacc ctaacctctc tggatgctct 720
tttctcctgg gacactgtct ttaagctgtt ggccattgcc atggtggcat taattcctgg 780
aaccctcatt aaaaaattta gtcagaaaca tctgcaattg aatgaaacaa gtactgctaa 840
tcatatacac agtagaaaag acacatgac tggattttct gtttgccaca tccctggact 900
cagttgctta tttgtgtaat ggatgtggtc ctctaaagcc cctcattgtt tttgattgcc 960
ttctataggt gatgtggaca ctgtgcatca atgtgcagtg tcttttcaga aaggacactc 1020
tgctcttgaa ggtgtattac atcaggtttt caaacagcc ctggtgtagc agacactgca 1080
acagatgcct cctagaaaat gctgtttgtg gccgggcgcg gtggctcacg cctgtaatcc 1140
cagcactttg ggaggccgag gccggtgatt cacaaggcca ggagttcaag accagcctgg 1200
ccaagatggt gaaatcctgt ctctaataaa aatacaaaaa ttagccaggc gtggtggcag 1260
gcacctgtaa tcccagctac tcgggaggct gaggcaggag aattgcttga accaagggtg 1320
cagaggttgc agtaagccaa gatcacacca ctgcactcca gcctgggtga tagagtgaga 1380
ccaca 1385

```

<210> 146
<211> 2031
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone No: 2493824

<400> 146
tgggcgggggg cccacggcgg ccactcactg agccccacgg gccgcagcgg cagtgcgta 60
gggttggcgc acggatccgt tgcggctgca gctctgcagt cgggcccgttc cttcgccgcc 120
gccaggggta gcggtgtagc tgcgcagcgt cgcgcgcgct accgcacca ggttcggccc 180
ataggcgtct ggcagcccgg cgccatcttc atcgagcgcc atggccgcag cctgcggggc 240
gggagcggcc gggtagctgt tgcctcctcg cttgcatttg tttctgctga ccgcgggccc 300
tgccctgggc tggaaacgacc ctgacagaat gttgctgcgg gatgtaaaag ctcttaccct 360
ccactatgac cgctatacca cctcccgcag gctggatccc atcccacagt tgaaatgtgt 420
tggaggcaca gctggttgtg attcttatac cccaaaagtc atacagtgtc agaacaaagg 480
ctgggatggg tatgatgtac agtgggaatg taagacggac ttagatattg catacaatt 540
tggaaaaact gtggtgagct gtgaaggcta tgagtcctct gaagaccagt atgtactaag 600
aggttcttgt ggcttggagt ataatttaga ttatacagaa cttggcctgc agaaactgaa 660
ggagtctgga aagcagcacg gctttgcctc tttctctgat tattattata agtggctctc 720
ggcggattcc tgtaacatga gtggattgat taccatcgtg gtactccttg ggatcgccct 780
tgtagtctat aagctgttcc tgagtgcagg gcagttattc cctccaccgt actctgagta 840
tcctccattt tcccaccgtt accagagatt caccaactca gcaggacctc ctccccagg 900
ctttaagtct gagttcacag gaccacagaa tactggccat ggtgcaactt ctggttttgg 960
cagtgccttt acaggacaac aaggatatga aaattcagga ccagggttct ggacaggctt 1020
gggaactggt ggaatactag gatatttgtt tggcagcaat agagcggcaa cacccttctc 1080
agactcgtgg tactaccctt cctatcctcc ctccctaccct ggcacgtgga atagggtcta 1140
ctcaccctt catggaggct cgggcagcta ttcggtatgt tcaaactcag acacgaaaa 1200
cagaactgca tcaggatatg gtggtaccag gagacgataa agtagaaagt tggagtcaaa 1260
cactggatgc agaaattttg gatttttcat cactttctct ttagaaaaaa agtactacct 1320
gttaacaatt gggaaaaggg gatattcaaa agttctgtgg tgttatgtcc agtgtagctt 1380
tttgtattct attatttgag gctaaaagtt gatgtgtgac aaaatactta tgtgttgat 1440
gtcagtgtaa catgcagatg tatattgcag tttttgaaag tgatcattac tgtggaatgc 1500
taaaaataca ttaatttcta aaacctgtga tgccctaaga agcattaaga atgaagggtg 1560
tgtactaata gaaactaagt acagaaaatt tcagtttttag gtggttgtag ctgatgagtt 1620
attacctcat agagactata atattctatt tggattata ttatttgatg tttgctgttc 1680
ttcaaacatt taaatcaagc tttggactaa ttatgctaatt ttgtgagttc tgatcacttt 1740
tgagctctga agctttgaat cattcagtggt tggagatggc cttctggtaa ctgaatatta 1800
ccttctgtag gaaaagggtg aaaataagca tctagaaggt tggttgtaat gactctgtgc 1860
tggcaaaaat gcttgaacc tctatatctt tttcgttcat aagaggtaaa ggtcaaat 1920
ttcaacaaaa gtcttttaat aacaaaagca tgcagttctc tgtgaaatct caaatattgt 1980
tgtaatatgc tgtttcaatc ttaaaaagaa tcaataaaaa caaaaaaaaa a 2031

<210> 147
<211> 1790
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone No: 2555823

<400> 147

```

gcgggaggac cggctgaccc tggatgggtga ggccgggtgc ccgcctgtgc ctggggagtg 60
tggggagggg gctgtgectg gtgtctcccc tgctttgtct cgggtgcaggt ttctctcttc 120
tgaacacgct cttcatccag cgcggccggc acgagaccac ctggaccatc ctgcggcgct 180
tcggctacag cgatgccctg gagctgactg cggactatct ctccccctctg atccacgtgc 240
cccccggtcg cagcacggag ctcaaccacc ttggctacca gtttgtgcag agagtgtttg 300
agaagcacga ccaggaccgc gacggcgccc tctcgcccgt ggagctgcaa agccttttca 360
gtgtgttccc agcagcgccc tggggccccc agctcccacg cacagtccgc acagaggccg 420
gccggttgcc cctgcacgga tacctctgcc agtggaccct ggtgacctac ctggacgtcc 480
ggagctgcct tggacaccta ggctacctgg gctacccac cctctgtgag caggaccagg 540
cccatgccat cacagtcaact cgtgagaaga ggctggacca ggagaaggga cagacgcagc 600
ggagcgtcct cctgtgcaag gtggtagggg cccgtggagt gggcaagtct gccttctctg 660
aggcctttct cggccgcgcc ctggggcacc aggacacgag ggagcagcct cccggctacg 720
ccatcgacac ggtgcaggtc aatggacagg agaagtactt gatcctctgt gaggtgggca 780
cagatggtct gctggccaca tcgctggacg ccacctgtga cgttgccctgc ttgatgtttg 840
atggcagtga cccaaagtcc tttgcacatt gtgccagcgt ctacaagcac cattacatgg 900
acgggcagac cccctgcctc tttgtctcct ccaaggccga cctgcccga ggtgtcgcg 960
tgtctggccc atcacggcc gagttttgcc gcaagcaccg gctaccgct cccgtgccgt 1020
tctcctgtgc tggcccagcc gagcccagca ccacctctt caccagctc gccaccatgg 1080
ccgccttccc acatttggtc cacgcagagc tgcattccctc ttcttcttg ctccgggggc 1140
tgctgggggt tgcggggcc gccgtggccg cagtccctag cttctcactc tacagggtcc 1200
tgggtgaagag ccagtgaggc ccctggtacc caagccccct cccctgacct ggggtgtgct 1260
cgctgctggg gctctgcagg ggcagcacag ctgggggtgca ggccaggctg ccactccggg 1320
aacgcctttg cgcggggact ttttgtttct gaaggcagtc gatctgcagc ggggccttat 1380
gctgccatgc actgccctgg ctccctgccg acccccaggg tgggcccgtg cagggtggctg 1440
agcaggagct cccaagtgc ggccaccgct gtcagggtt gccaccctc gggcatcatg 1500
tgtgtggggc cggggagcac aggtgtggga gctggtgacc ccagaccag aattctcagg 1560
gctctacccc cctttcctgg tcctaggtgg ccagtgggta tgaggagggc tggaaaggcag 1620
agctttgggc caaaagcagg cgttgggggg tccccctca agtttggagc cgtttccgtg 1680
gttgtagcag aggaccggag gttgggttcc tgattaaact tcactgtgtg ttttctatct 1740
cggatcccag tctctgaaga caacttgctt tgattcaacc taaaaaaaaa 1790

```

<210> 148

<211> 1979

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2598242

<400> 148

```

ctactcctca ctggccggga caactggtct tatcacggag gctggggcca ggagccctt 60
cgggttcgggt gggcccatgg accccagtc aacgccgagg gaataggacc atccaaaagc 120
ggaaccttcg cctcagaaaa aggggtcggg acccctctc accgtgcggc cagcgtgga 180
ccctgccagc agccaggcca tggagctctc tgatgtcacc ctcatgagg gtgtgggtaa 240
tgagggtgatg gtggtggcag gtgtggtggt gctgattcta gccttggct tagcttggct 300
ctctacctac gtagcagaca gcggtagcaa ccagctcctg ggcgctattg tgtcagcagg 360
cgacacatcc gtccctccacc tggggcatgt ggaccacctg gtggcaggcc aaggcaacc 420
cgagccaact gaactcccc atccatcaga gggtaatgat gagaaggctg aagaggcggg 480
tgaaggctcg ggagactcca ctggggaggc tggagctggg ggtggtgttg agcccagcct 540
tgagcatctc cttgacatcc aaggcctgcc caaaagacaa gcagggtgcag gcagcagcag 600
tcagagggcc cccctgagat ctgaggatag cacctgcctc cctcccagcc ctggcctcat 660
cactgtgcgg ctcaaattcc tcaatgatac cgaggagctg gctgtggcta ggccagagg 720
taccgtgggt gccctgaaga gcaaatactt ccctggacaa gaaagccaga tgaaactgat 780

```

```

ctaccagggc cgcctgctac aagaccagc cgcacactg cgttctctga acattaccga 840
caactgtgtg attcactgcc accgctcacc cccaggggtca gctgttccag gccctcagc 900
ctccttggcc ccctcggcca ctgagccacc cagccttggg gtcaatgtgg gcagcctcat 960
gggtgcctgtc tttgtgggtgc tgttgggtgt ggtctggtac tccgaatca attaccgcca 1020
attcttcaca gcacctgcca ctgtctccct ggtgggagtc accgtcttct tcagcttcct 1080
agtatttggg atgtatggac gataaggaca taggaagaaa atgaaaggca tggctcttct 1140
cctttatggc ctccccactt ttcctggcca gagctgggcc caagggccgg ggagggagg 1200
gtggaaggaa tgtgatggaa atctcctcca taggacacag gaggcaagta tgcggcctcc 1260
ccttctcatc cacaggagta cagatgtccc tcccgtgcga gcacaactca ggtagaaatg 1320
aggatgtcat ctcccttcac ttttagggtc ctctgaagga gttcaaagct gctggccaag 1380
ctcagtgggg agcctgggct ctgagattcc ctccacctg tggttctgac tcttccag 1440
gtcctgcatg tctgccccca gcaccaggg ctgctgcaa gggcagctca gcattggccc 1500
agcacaaact cgtaggaggc ctggagtatc cttccatttc tcagccaaat actcatctt 1560
tgagactgaa atcacactgg cgggaatgaa gattgtgcca gccttctct atgggcacct 1620
agccgccttc accttcttcc tctaccctt agcaggaata ggggtgctct ccttcttca 1680
aagcactttg cttgcatttt attttatttt ttaaagagtc cttcatagag ctcagtccag 1740
aaggggatgg ggcaccaagc caagcccca gcattgggag cggccaggcc acagctgctg 1800
ctcccgtagt cctcaggctg taagcaagag acagcactgg ccttggcca gcgtcctacc 1860
ctgccaact ccaaggactg ggtatggatt gctgggcctt aggtcttgc tctggggct 1920
attggagggt cagtgtctgt gactgaataa agttccattt tgtggtcaaa aaaaaaaaa 1979

```

<210> 149

<211> 1810

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<223> Incyte Clone No: 2634120

<400> 149

```

ccccctgccc gcctctccgc acaatacttg aacattcatc tgtactgaag tgttacttga 60
accgggggaa tctcggacct gggggagccg ggggtgtagg ggactggacc agcttggaact 120
gagacctgag accgggccgg tgggcgcca tttgggactg cgccaccccc aggttgttc 180
ttgttttact gtattgagcg gcggcaccgc cgggaccgcg attatggctg ggggcgccag 240
ccaagaatgg ggacctggg actcctccag cctggtctt cccactctt catcgctatg 300
gaaacttgta tccatttgc ccagggaact gccactcctg gttgccatgg aaatagcagc 360
caacggacac ctcccgatgc cagtgtctaa gctggaaatg gccccctctt agttgccatg 420
ggaacctagt aacagactct gctggccctc cttccctgcc ccttccctga gcgcggggtg 480
gggcttcggg accccgggga tgagccgggc caggtcccgc ccctccgcgc aggcctccgg 540
ggggccgggg cttaccatgt aggggagggg agatctatcc acatacctca ggtggccatg 600
gtggagggtg agctggagag tgaccacgag taccacccag gcctgctggt gcccttcagt 660
gcctgcacca cgtgctggt ggctgtgcac ctctttgcac tcatggtctc cacgtgtctg 720
ctgccccaca ttgaagctgt gagcaacatc cacaacctca actctgtcca ccagtgcgca 780
caccagagac tgcaccgcta cgtggagctg gcctggggct tctccactgc cctgggcacc 840
tttctcttcc ttgctgaagt tgcctggtt ggttgggtca agtttgtgcc cattggggct 900
cccttgagca caccgacccc catggtgccc acatcccggg tgccccggac tctggcacca 960
gtggctacct ccttagtcc agcttccaat ctcccacggt cctctgcgtc tgcagcaccg 1020
tcccaggctg agccagcctg cccaccccgg caagcctgtg gtggtggtgg ggcccatggg 1080
ccaggctggc aagcagccat ggctccaca gccatcatgg taccgtggg gctcgtgttt 1140
gtggcctttg cctgcattt ctaccgctcc ttggtggcac acaagacaga ccgtacaag 1200
caggaaactag aggaactgaa tcgcctgcag ggggagctgc aggtgtgtg agactggtgt 1260
tagccaccgc tcaactgaag cactgcctcc ctccggggtc tgtaagaggc cgcagggggc 1320
tacagacctc atcccccat cccctggctg gagccacttc cagtggccac tctcaggcag 1380
agttcagatt cctgcccgca ggtcctctg gctgggcctt ggggcagctc ccacattccc 1440

```

```

agggattttc cccatcagtc tgtcccttgg gttttgcaag ctactctgca cctgggctgg 1500
cctcagttga aggatcatgc agtagataga ggggaggcag ggagagcttg tgggaccttc 1560
agtgtctgact ttagccacca tttccattcc tatacaggat gtgaagggtca gaaggcagcc 1620
aattgttgggt ttaatttttt ttttttttga gacagtctgt ttcccaggct ggagtgtagt 1680
gatacagtca cagctcactg tagcctcgac cttccaggct caaaagatgc tcccaccaca 1740
gcctcccagg tagtgagtag ctggtactac aggtgtgtgc tgccacaccc gactaatttt 1800
ttttagagaga 1810

```

<210> 150

<211> 535

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2765411

<400> 150

```

gaggaaccag aaatttgtcc ttgaataatg tttccctgtg tgggctggat cttgatagca 60
gttggtatca tcattcttct gattttttaca tctgtcaccg gatgcctatc tccagttagt 120
tttctgcagc tgaattcttg gaaaatctat ttggaacagg agcagcagat ctttaaaagt 180
aaagccacag agcatgcaac tgaattggca aaagagaata ttaaatgttt ctttgagggc 240
tcgcacccaa aagaatataa cactccaagc atgaaagagt ggcagcaaat ttcactcactg 300
tatactttca atccgaaggg ccagtactac agcatgttgc acaaatatgt caacagaaaa 360
gagaagactc acagtatcag gtctactgaa ggagatacgg tgattcctgt tcttggcttt 420
gtagattcat ctggtataaa cagcactcct gagttatgac cttttgaatg agtagaaaaa 480
aaaattgttt tgaattattg ctttattaaa aaataaacat tggtaaaaaa aaaaa 535

```

<210> 151

<211> 891

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 2769412

<400> 151

```

gaaaagaatc cgaggcacag ataaagataa gttttactgt catgctgctt ttaacataac 60
agagcaacat cacctaggaa aaaagtgtgt aggaggattt ttaatccata tatttgtctt 120
atggctagat aaagatttct ctgaaaaaaa gaagcatgtc aggaatctct ggggtgccct 180
ttttctctcg gggacttcta gcattgttgg gcttggcttt ggttatatca ctgatcttca 240
atatttccca ctatgtggaa aagcaacgac aagataaaat gtacagctac tccagtgacc 300
acaccagggt tgatgagtat tatattgaag acacaccaat ttatggtaac ttagatgata 360
tgatttcaga accaatggat gaaaattgct atgaacaaat gaaagcccgga ccagagaaat 420
ctgtaaataa gatgcaggaa gccaccccat ctgcacaggc aaccaatgaa acacagatgt 480
gtacgcctc acttgatcac agcgtttaagg ggaagcgtag aaagcccagg aaacagaata 540
ctcatttctc agacaaggat ggagatgagc aactacatgc aatagatgcc agcgtttcta 600
agaccacctt agtagacagt ttctccccag aaagccaggc agtagaggaa aacattcatg 660
atgatcccat cagactgttt ggattgatcc gtgctaagag agaacctata aactagctgg 720
accatgatct agttcaatga tttggctcct attgaagatg gcttctaaga aaacaagatg 780
cacagaggac acagaaggac ttggcagcag ggtgatgacc tgatcatttg ttgatgggat 840
ggtggcttac ctcttattca cagcttacac ttatgcatgc caaatgtaag g 891

```

<210> 152
<211> 2311
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone No: 2842779

<400> 152
gggcgcgcca cgcagctgg atggctgggg ccgcccggat cgccgcgcgc gccgcgcgcg 60
cacgtacgtg gcatgcctgg atgtccctgc cctggctgtg gcatggcggg cccaaggctc 120
ctcttcctca ctgcccttgc cctggagctc ttgggaaggg ctgggggttc ccagccggcc 180
ctccggagcc gggggactgc gacggcctgt cgctggaca acaaggaaag cgagtcctgg 240
ggggctctgc tgagcggaga gcggctggac acctggatct gctccctcct gggttccctc 300
atggtggggc tcagtgggtt ctcccgctt cttgtcattc ccctagagat ggggacctg 360
ctgcgctcag aagctggggc ctggcgctg aagcagctgc tcagcttcgc cctgggggga 420
ctcttgggca atgtgtttct gcatctgctg ccgaaagcct gggcctacac gtgcagcgcc 480
agccctggtg gtgaggggca gacgctgcag cagcagcaac agctggggct gtgggtcatt 540
gctggcatcc tgaccttcct ggcgttggag aagatgttcc tggacagcaa ggaggagggg 600
accagccagg cccccaacaa agacccact gctgctgccg ccgcactcaa tggaggccac 660
tgtctggccc agcggctgc agagcccggc ctcggtgccg tggtcgggag catcaaagtc 720
agcggctacc tcaacctgct ggccaacacc atcgataact tcacccacgg gctggctgtg 780
gctgccagct tccttgtgag caagaagatc gggctcctga caacctggc catcctcctg 840
catgagatcc cccatgaggt gggcgacttt gccatcctgc tccgggcccg ctttgaccga 900
tggagcgcag ccaagctgca actctcaaca gcgctggggg gcctactggg cgctggcttc 960
gccatctgta cccagtcctc caagggagta gaggagacgg cagcctgggt cctgcccttc 1020
acctctggcg gctttctcta catgccttg gtgaacgtgc tccctgacct cttggaagaa 1080
gaggaccgtt ggcgtccctc gcagcagctg cttctgctct gtgcgggcat cgtggtaagt 1140
gtgctgttct cgctcttctt ggattaactt tccctgatgc cgacgcccct gccccctgca 1200
gcaataagat gctcggattc actctgtgac cgcataatgt agaggcagag agggcgagtg 1260
gctgcgagag agaagtagcc tcccgccaga caggaggag gtgcgtgtgg atgtatgtg 1320
tgtgcacatg tggccagagg tgtgtgcgcg agaccgacac tgtgatccct gtgctgggtc 1380
cggggcccag tgtagcgctt gtccccagcc atgctgtggg tacctctcct tgccgcccctg 1440
tcaccttcac ctccctggag aagcagcgag gaagagcagc actggtccca agcagaggcc 1500
ttgcctgtgt gggaccccg gagtgagagc agcccaagga tcccagggtg cagggaactc 1560
cagagctgcc cacctccac tgccccctca gcacacacac agtccccagg cggcctaggg 1620
gccaaaggctg ggggggcttt ggtccctttt cctggccctt ccttccccac ttctaagcca 1680
aagaaaggag aggcaggtgc tcctgtacct cagccccact cagcactgac agtccccagc 1740
tcctagtagt gagctgggag gcgcttccta agaccctttc ctccaggctg ccctgggagc 1800
tcattcctgg ccaacacgcc ctggcagcac cagcagctct tgccacctcc agctgccaaa 1860
cagcagcctg ccgggaggg agcagcccca ggccagagag gcctcccgtt ccagctcagg 1920
gatgctcctg ccagcacagg ggccagggac tcctggagca ggcacatagt gagcccgggc 1980
agccctgccc agctcaggcc cctttccttc cccattgagg ttggggtagg tgggggagg 2040
gagggctcca cgttgtcagc gctcaggaat gtgctccggc agagtgtgta agccataatc 2100
cccaaccatt tcccttgtct gacgcccagg tactcagctg gccactcca cagccaggcc 2160
tggccctgcc cttcaccgtg gatgttttca gaagtggcca tcgagaggctc tggatgggtt 2220
tatagcaact ttgctgtgat tccgtttgta tctgtaaata tttgttctat agataagata 2280
caaataaata ttatccacat aaaaaaaaaa a 2311

<210> 153
<211> 2169
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone No: 2966260

<400> 153
gctgcaggcg ggcacggcta caccatgggc cggctgctgc gggccgccc gctgccgccg 60
ctgctttcgc cgctgctgct tctgctgggt gggggagcgt tcctgggtgc ctgtgtggct 120
gggtctgatg agcctggccc agagggcctc acctccacct ccctgctaga cctcctgctg 180
cccactggct tggagccact ggactcagag gaggcctagt agaccatggg cctgggagct 240
gggctgggag cccctggctc aggcctcccc agcgaagaga atgaagagtc tcggattctg 300
cagccaccac agtacttctg ggaagaggag gaagagctga atgactcaag tctggacctg 360
ggaccactg cagattatgt ttttctgac ttaactgaga aggcagggtc cattgaagac 420
accagccagg ctcaagagct gccaaacctc ccctctccct tgcccaagat gaatctgggt 480
gagcctccct ggcatatgcc tcccagagag gaggaagaag aggaagagga agaggaggag 540
atggagaagg aagaggtaga gaaacaagat gtggaggaag agggaggagct gctccctgtg 600
aatggatccc aagaagaagc caagcctcag gtccgtgact tttctctcac cagcagcagc 660
cagacccagc gggccaccaa aagcaggcat gaagactccg gggaccaggc ctcatcaggt 720
gtggaaggtag agagcagcat ggggcccagc ttgctgctgc cttcagtcac cccaactata 780
gtgactccgg gggaccagga ctccaccagc caagaggcag aggccacagt gctgccagct 840
gcagggcttg gggtagagtt cgaggctcct caggaagcaa gcgaggaagc cactgcagga 900
gcagctgggt tgtctggcca gcacgaggag gtgccggcct tgccctcatt ccctcaaacc 960
acagctccca gtggggccga gcaaccagat gaagatcccc ttggctctag aacctcagcc 1020
tcttccccac tggcccttgg agacatggaa ctgacacctt cctctgctac cttgggacaa 1080
gaagatctca accagcagct cctagaaggg caggcagctg aagctcaatc caggataccc 1140
tgggattcta cgcaggtgat ctgcaaggac tggagcaatc tggctgggaa aaactacatc 1200
attctgaaca tgacagagaa catagactgt gaggtgttcc ggcagcaccg ggggccacag 1260
ctcctggccc tgggtggaaga ggtgctgccc cgccatggca gtggccacca tggggcctgg 1320
cacatctctc tgagcaagcc cagcgagaag gagcagcacc ttctcatgac actggtgggc 1380
gagcaggggg tgggtgcccac tcaagatgtc ctttccatgc tgggtgacat ccgaggagc 1440
ctggaggaga ttggcatcca gaactattcc acaaccagca gctgccaggc gcgggccagc 1500
cagggtgcga gcgactacgg cacgctcttc gtggtgctgg tggtcattgg ggccatctgc 1560
atcatcatca ttgcgcttgg cctgctctac aactgctggc agcgccggct gcccaagctc 1620
aagcacgtgt cgcacggcga ggagctgcgc ttctgtggaga acggctgcca cgacaacccc 1680
acgctggagc tggccagcga cagccagtcg gagatgcagg agaagcacc cagcctgaac 1740
ggcggcgggg ccctcaacgg cccggggagc tggggggcgc tcatgggggg caagcgggac 1800
cccaggagct cggacgtgtt cgaggaggac acgcacctgt gagcgcagcc gaggcgcagg 1860
ccgagtgggc cgccaggacc aagcgagggt gaccccgaaa cggacggccc ggagccagca 1920
caagccccga gcctaccgg gccgcccccg cggcctggcc ctcggcgcgg gctccttccc 1980
gcttcccccg acttcacacg gcggacttgc gaccaactcc ctcaactccc cccgaggggc 2040
aggcctcaaa gccgccttg gccccgcttt cccgcccctg aaccccggcc ccgcgggcgg 2100
cgggcggcgc ttctgcgcc ccgggactca attaaacccg cccggagacc acgcccgggc 2160
cagcgaataa 2169

<210> 154
<211> 1480
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone No: 2993326

<400> 154

```

ggatggggat ctttgtctgg tccctaacca acaggtatctt caccaactta ttagcccttt 60
cttgtaaaat ggccacatct cgcggtggtg caggcctccg gcccacatggg atccgcctgt 120
aattactgcc acttctctca tcccattca gatgcttggg ctttcggttt cttttgcccc 180
gggtcctggt tgtgggctcc aggtcaact gagccagata gtcatctgcc agggcctgga 240
cagcagcagc aacctgagtc tcaagggcac ttacgttggg ctgagcagag gctatcttgg 300
cctgggcccc ttggtcagca tttggagtct ggctttcagt tgcccagacc ttagtgagcag 360
ccttcagagc cctagaccct ctcttgaccc gcaggggtggc tgccagggct tggtttgtga 420
ctatctgagt ggcaagtggg gcctcagaga tctcagagac agaatttggg cccctgctgg 480
cagccttctt gcccttggtg tttttgggct tgatagccac tactgaggcc tcaatctgcc 540
tggtagctgc gtcagtgaac ttttagacct ctatatgctc agtgtcagta tttatgacct 600
tagcaattgt cttcctggct ttggaggctt tcttggttcg gatggaggct gctgtggtgt 660
ggatactggc tgtctcattg gtaatttggc cttgggtggt agctgtatgg gtggcagttg 720
cagccagcga gacctcgggt gcactagcta tggccttatt tgagccttc ttagccttgg 780
aagctttctt aggttgata gaggttatca aggccttggga actggtctgac tcattggcaa 840
ttggagcgtg aatattctgt gagatgactg gtgactttag gacctgcaag ggtgacttca 900
gctgtatagt gccaccctca tggccagttg gggattggga gccttgggct gccttggcag 960
taactctctt catcttgttg gctttcttag gctgagcagt gactgaagaa gcctgagtat 1020
tggttacctc agtggttagt aaagcctggc tgatctgggt aatgactggc aggtttaaag 1080
cctgccaaatg tattttgggc ttgttggtgg caatctcatt ggcagctggg actggagggg 1140
cagcaggtgc agccttagta atagtcttta taggggcctt cttggtcttg cttttcttag 1200
gccggttgac aactggtggg tccatggcca gggagtcctt ggttgccgcc aacaggggat 1260
gcacagcagc gacactgtcc tcttctgtgg tctcagctcg tatatctgga gggaaggga 1320
gccccaggtc ccccggggga ggcagagggc cctgaaatag aggcacccta tatccgtagt 1380
catttctcct atccatcttt ctgggaggcc gagtaacagg tgagcctcgt cttcttgaat 1440
ccagaaggcg tctgctctct ccaagtctgc tctctccaag 1480

```

<210> 155

<211> 1222

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3001124

<400> 155

```

agaaatatca tatggttact ttggtatctg acacagccat gacaccaatt gctagtgtag 60
acacaatagc tgtgtgtctt tttgcaggag cctggggagg ggccatggtg ccaatgcact 120
tactggggag actggagaag ccgcttctcc tctgtgctg cgcctccttc ctactggggc 180
tggttttgct gggcataaag acggacatca cccccgttgc ttatttcttt ctacatttgg 240
gtggttctct cttgtttgct tatctcctgg tccggtttct ggaatggggg cttcgggtccc 300
agctccaatc aatgcagact gagagccag ggcctcagg caatgcacgg gacaatgaag 360
cctttgaagt gccagtctat gaagaggccg tgggtggact agaatcccag tgccgcccc 420
aagagttgga ccaaccaccc ccctacagca ctgttggtat acccccagca cctgaggagg 480
aacaacctag ccatccagag ggggtccagga gagccaaact ggaacagagg cgaatggcct 540
cagaggggtc catggcccag gaaggaagcc ctggaagagc tccaatcaac cttcggcttc 600
ggggaccacg ggctgtgtcc actgctcctg atctgcagag cttggcggca gtccccacat 660
tagagcctct gactccaccc cctgcctatg atgtctgctt tggtcaccct gatgatgata 720
gtgtttttta tgaggacaac tgggcacccc cttaaagtac tctcccaaga tttctcttct 780
ctccacacca gacctcgttc atttgactaa cattttccag cgcctactat gtgtcagaaa 840
caagtgtttc tgcctggaca tcataaatgg ggacttggac cctgaggaga gtcaggccac 900
ggtaagccct tcccagctga gatattgggt gcataatttg agtcttcttg caacatttgg 960
tgacctaccc catatccaat atttccagcg ttagattgag gatgaggtag ggaggtgatc 1020
cagagaaggc ggagaaggaa gaagtaacct ctgagtggtg gctattgctt ctgttccagg 1080
tgctgttcga gctgttagaa cccttaggct tgacagcttt gtgagttatt attgaaaaat 1140

```

gaggattcca agagtcagag gagtttgata atgtgcacga gggcacactg ctagtaaata 1200
acattaaaaat aactcgaatg ac 1222

<210> 156
<211> 1983
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone No: 3120070

<400> 156
ggaaccgcct ccccgcggcc tcttcgcttt tgtggcggcg cccgcgctcg caggccactc 60
tctgctgtcg cccgtcccgc gcgctcctcc gaccgcctcc gctccgctcc gctcggcccc 120
gcgcgcgccg tcaacatgat ccgctgcggc ctggcctgcg agcgctgccg ctggatcctg 180
cccctgctcc tactcagcgc catcgccttc gacatcatcg cgctggccgg ccgcggtctg 240
ttgcagtcta gcgaccacgg ccagacgtcc tcgctgtggt ggaaatgctc ccaagagggg 300
ggcggcagcg ggtccctacga ggagggctgt cagagcctca tggagtacgc gtggggtaga 360
gcagcggctg ccatgctctt ctgtggcttc atcactcctg tgatctgttt catcctctcc 420
ttcttcgccc tctgtggacc ccagatgctt gtcttctctga gagtgtattg aggtctcctt 480
gccttggtgt ctgtgttcca gatcatctcc ctggtaattt acccgtgaa gtacaccag 540
accttcaccc ttcatgccaa ccctgctgtc acttacatct ataactgggc ctacggcttt 600
gggtgggag ccacgattat cctgattggc tgtgccttct tcttctgctg cctccccaac 660
tacgaagatg accttctggg caatgccaaag cccagggtact tctacacatc tgcctaactt 720
gggaatgaat gtgggagaaa atcgctgctg ctgagatgga ctccagaaga agaaactgtt 780
tctccaggcg actttgaacc catTTTTTtg cagtgttcat attattaaac tagtcaaaa 840
tgctaaaata atttgggaga aaatatTTTt taagttagtg tatagtTTTc tgtttatctt 900
ttattatggt ttgtgaagtt gtgtctTTTc actaattacc tatactatgc caatatttcc 960
ttatatctat ccataacatt tatactacat ttgtaagaga atatgcacgt gaaacttaac 1020
actttataag gtaaaaatga ggTTTccaag atttaataat ctgatcaagt tcttgttatt 1080
tccaaataga atggactcgg tctgttaagg gctaaggaga agaggaagat aaggTTaaaa 1140
gttgTTaatg accaaacatt ctaaaagaaa tgcaaaaaaa agttttattt tcaagccttc 1200
gaactatttt aggaaagcaa aatcatttcc taaatgcata tcatttTgtga gaatttctca 1260
ttaatatcct gaatcattca tttcagctaa ggcttcatgt tgactcgata tgtcatctag 1320
gaaagtacta tttcatggtc caaacctgtt gccatagttg gtaaggcttt cctttaagtg 1380
tgaaatattt agatgaaatt ttctctTTTt aagttctTTt tagggTtagg gtgtgggaaa 1440
atgctatatt aataaatctg tagtgtTTTt tgtttatatg ttcagaacca gagtagactg 1500
gattgaaaga tggactgggt ctaatttatc atgactgata gatctggTta agttgtgtag 1560
taaagcatta gggTcattcc tgtcacaaaa gtgccactaa aacagcctca ggagaataaa 1620
tgacttgctt ttctaaatct caggTTtatc tgggctctat catatagaca ggcttctgat 1680
agtttTgaac tgtaagcaga aacctacata tagTTaaaat cctggTcttt cttggTaaac 1740
agattTTaaa tgtctgatat aaaacatgcc acaggagaat tcggggattt gagtttctct 1800
gaatagcata tatatgatgc atcggatagg tcattatgat tttttacat ttcgacttac 1860
ataatgaaaa ccaattcatt ttaaatatca gattattatt ttgtaagttg tggaaaaagc 1920
taattgtagt tttcattatg aagTTTtccc aataaaccag gtatttctaaa cttgaaaaaa 1980
aaa 1983

<210> 157
<211> 1835
<212> DNA
<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3133035

<400> 157

```

accaggctgt gtaagagctg ctggagtagg caccatttta aagaaaaaat gaagaagcag 60
caataaagaa gttgtaatcg ttacctagac aaacagagaa ctggttttga cagtgtttct 120
agagtgcctt ttattatttt cctgacagtt gtgttccacc atgattactt tctccttcag 180
cgaataggct aaatgaatat gaaacagaaa agcgtgtatc agcaaacc aaagcacttctg 240
tgcaagaatt ttcttaagaa atggaggatg aaaagagaga gcttattgga atggggcctc 300
tcaatacttc taggactgtg tattgctctg ttttccagtt ccatgagaaa tgtccagttt 360
cctggaatgg ctctcagaa tctgggaagg gtagataaat ttaatagctc ttctttaatg 420
gttgtgtata caccaatatc taatttaacc cagcagataa tgaataaaac agcacttgct 480
cctcttttga aaggaacaag tgtcattggg gcacaaataa tacacacatg gacgaaatac 540
ttctggaaaa ttacatatg ctatgggaat catctttaat gaaactttct cttataagtt 600
aatatttttc cagggatata acagtccact ttggaaagaa gatttctcag gtgactttcc 660
atatcaaata tcattatgga atttttcatg ttttcaacat aaagaacaga ggaggttggg 720
caacagagat gctttcaatg acacatgaga aaacagggaag agcccatctt attgctgaac 780
ttatttcaag gtcaatcgta tgttctact acaggatgac tgcaaaaatt gtagagtcac 840
ccaacatata tgtgttgagc atgcagatgc atgtgtcaaa ggacacatga gtaaccaag 900
actgacaggc cccagcctca ggtgagattc cagggttagc gcaaagacag acattgaaca 960
attaatgaca agtacaagaa aaagtgttct atgggcactt agaccagggg ttcctaatag 1020
tgggacctag agaagtccta cctggggaaa tgatgtttaa agggagacca gaatgaatag 1080
cagggtgtgag gtgctagaag cattgtgttt cagatagaag aaaggttaatt gtgaagacc 1140
tgaggtgaga aaggacatct gttcctagat ctggaagaag agcagtatag ctgaacaagg 1200
aacatgaaaa ggaatgtaat gggagagtga agctgaagtc actcaagtgc tacctcctgt 1260
ggcatcttgt aaacctaggc aaggaatagc cactgagtca cttaatcac ggcaaaagt 1320
taattcgggt tccaaaatta ggggaacact ccagatatag cccggggaat agattgcaa 1380
gaggctatgg agaattgtcaa gaaacaagga gtccattatg gctggagcag agtgtttgct 1440
ttcatctcct tttatttttc taagactttc taagcatgct gtggtctgca agaataaaat 1500
tgctttatta aaaaactttc tttatttgct tcctttttct atgtagttaa aagtctactg 1560
tggggccagc catggtggct cacacctgta atcccagcac tttgagaggc cgaggtgcac 1620
ggatcacctg aggtcaggag ttcgagacca gcctggccaa catggtgaaa gcctgtctct 1680
actaaaaata caaaaattag ctagacaacg tggcctgtgc ctataatccc agctttggga 1740
ggctgaggta ggagaatcac ttgaaccag gaggtggagg ttgcagttag ctgagatcgc 1800
accactgcac tccagcatgg gcaacagagt gagat 1835

```

<210> 158

<211> 819

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone No: 3436879

<400> 158

```

cacgactcac tatagggaat ttggccctcg aggcaagaat tcggcacgag gtcgacacc 60
tcatcctgaa aggtattgag cacgatgcac ggccatcaag taccactttt ctcagcccat 120
ccgcttgca aacattcctt ttaatttaac caagaccata cagcaagatg agtggcacct 180
gcttcattta agaagaatca ctgctggcct cctcgcatg gccgtagccg tcttctctg 240
cggctgcatt gtggccacag tcagtttctt ctgggaggag agcttgaccc agcacgtggc 300
tggaactcctg ttctcatga caggatatt ttgcaaccatt tccctctgta cttatgccgc 360
cagtatctcg tatgatttga accggctccc aaagctaatt tatagcctgc ctgctgatgt 420
ggaacatggt tacagctggc ccatcttttg cgctgggtgc agtttaggct ttattgtggc 480

```



```
agctggaggt ctctgcatcg cttatccggt tattagccgg accaagattg cacagctaaa 540
gtctggcaga gactccacgg tatgactgtc ctcaactgggc ctgtccacag tgcgagcgac 600
tcctgagggg aacagcgcgg agttcaggag tccaagcaca aagcgggtctt ttacattcca 660
acctggtgcc tgccagccct ttctggatta ctgatagaaa atcatgcaaa acctcccaac 720
ctttctaagg acaagactac tgtggattca agtgctttaa tgactattta tgcgttgact 780
gtgagaatag ggagccatgc catgggacat ttctaggtg 819
```



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/63, C07K 14/705, 16/18, A61K 38/17, G01N 33/50		A3	(11) International Publication Number: WO 99/61471
			(43) International Publication Date: 2 December 1999 (02.12.99)
(21) International Application Number: PCT/US99/11904		(72) Inventors; and	
(22) International Filing Date: 28 May 1999 (28.05.99)		(75) Inventors/Applicants (for US only): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). GORGONE, Gina, A. [US/US]; 1253 Pinecrest Drive, Boulder Creek, CA 95006 (US). KASER, Matthew, R. [GB/US]; 4793 Ewing Road, Castro Valley, CA 94546-1017 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). AU-YOUNG, Janice [US/US]; 1419 Kains Avenue, Berkeley, CA 94702 (US).	
(30) Priority Data:			
60/087,260	29 May 1998 (29.05.98)	US	
60/091,674	2 July 1998 (02.07.98)	US	
60/102,954	2 October 1998 (02.10.98)	US	
60/109,869	24 November 1998 (24.11.98)	US	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications			
US	60/087,260 (CIP)		
Filed on	29 May 1998 (29.05.98)		
US	60/091,674 (CIP)		
Filed on	2 July 1998 (02.07.98)		
US	60/102,954 (CIP)		
Filed on	2 October 1998 (02.10.98)		
US	60/109,869 (CIP)		
Filed on	24 November 1998 (24.11.98)		
(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).		(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).	
		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
		Published	
		With international search report.	
		Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
		(88) Date of publication of the international search report: 16 March 2000 (16.03.00)	
(54) Title: HUMAN TRANSMEMBRANE PROTEINS			
(57) Abstract			
The invention provides human transmembrane proteins (HTMPN) and polynucleotides which identify and encode HTMPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HTMPN.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/11904

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12N15/63 C07K14/705 C07K16/18 A61K38/17
G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 834 563 A (SMITHKLINE BEECHAM CORP) 8 April 1998 (1998-04-08) the whole document ---	
A	LOO T.W. ET AL.: "Drug-stimulated ATPase Activity of Human P-glycoprotein Requires Movement between Transmembrane Segments 6 and 12" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 34, 22 August 1997 (1997-08-22), pages 20986-20989, XP002116312 the whole document --- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

27 September 1999

Date of mailing of the international search report

18. 1. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Schönwasser, D

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/11904

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>HILLIER L. ET AL.: "WashU-NCI human EST Project; af42e03.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 1034332 3'"</p> <p>EMBL DATABASE ENTRY AA779652; ACCESSION NO. AA779652,6 February 1998 (1998-02-06), XP002116313</p> <p>Amino acids 90-240 of SEQ ID NO:1 are identical to amino acids 1-151 of AA779652.</p>	5,6,9-11
X	<p>---</p> <p>HILLIER L. ET AL.: "WashU-Merck EST Project 1997; aal8a10.r1 Soares NhMPu S1 Homo sapiens cDNA clone 813594 5'"</p> <p>EMBL DATABASE ENTRY HS1247817; ACCESSION NO. AA447814,10 June 1997 (1997-06-10), XP002116314</p> <p>Amino acids 62 -209 of SEQ ID NO:1 are identical to amino acids 1-148 of AA447814.</p> <p>-----</p>	5,6,9-11

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/11904

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 19 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 17,18,20
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

It is not possible to carry out a meaningful search for claims 17,18 and 20, since the claimed agonists and antagonists are not sufficiently described.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-20 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box 1.2

Claims Nos.: 17,18,20

It is not possible to carry out a meaningful search for claims 17,18 and 20, since the claimed agonists and antagonists are not sufficiently described.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claim : .

Invention 1: Claims 1-20 (all partially)

A substantially purified polypeptide comprising the amino acid sequence SEQ ID NO:1 or a fragment thereof, an isolated and substantially purified polynucleotide encoding said polypeptide, a method for detecting said polynucleotide, an expression vector and a host cell comprising the polynucleotide, a method of producing the above mentioned polypeptide, a pharmaceutical composition comprising said polypeptide as well as an antibody against said polypeptide and a method for treating or preventing a disorder associated with decreased expression or activity of human transmembrane proteins.

Inventions 2-79: Claims 1-20 (all partially)

The inventions No. 2 - 79 relate to subject-matter as defined above for "subject 1", whereby each invention refers to one of the polypeptide sequences of SEQ ID NO:2 to SEQ ID NO:79 (and the respective nucleotide sequences of SEQ ID NO:80 to SEQ ID NO:158).

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 99/11904

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0834563 A	08-04-1998	JP 10179178 A	07-07-1998
		US 5824504 A	20-10-1998
